US20140088077A1 - Novel substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments - Google Patents
Novel substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments Download PDFInfo
- Publication number
- US20140088077A1 US20140088077A1 US14/094,976 US201314094976A US2014088077A1 US 20140088077 A1 US20140088077 A1 US 20140088077A1 US 201314094976 A US201314094976 A US 201314094976A US 2014088077 A1 US2014088077 A1 US 2014088077A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- compound
- formula
- combination
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C1([7*])CC2=C(C([5*])=C([4*])C(CN([1*])[2*])=C2[3*])C(*)([6*])C1N([8*])C(=O)C*CB Chemical compound *C1([7*])CC2=C(C([5*])=C([4*])C(CN([1*])[2*])=C2[3*])C(*)([6*])C1N([8*])C(=O)C*CB 0.000 description 19
- IHMXVSZXHFTOFN-ZCFIWIBFSA-N CC[C@@H]1CCCO1 Chemical compound CC[C@@H]1CCCO1 IHMXVSZXHFTOFN-ZCFIWIBFSA-N 0.000 description 4
- PBSXIUHGNJLTQH-PBZMZIQDSA-N CCC(CC)N[C@H](C)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CCC(CC)N[C@H](C)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 PBSXIUHGNJLTQH-PBZMZIQDSA-N 0.000 description 3
- IGVJVKBYWRLMJT-YTMVLYRLSA-N CC(C)(O)C1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound CC(C)(O)C1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 IGVJVKBYWRLMJT-YTMVLYRLSA-N 0.000 description 2
- UGBCFEYFODPFAD-BDYUSTAISA-N CC(C)CCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)CCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 UGBCFEYFODPFAD-BDYUSTAISA-N 0.000 description 2
- QMTAITIZNTZFQZ-BDYUSTAISA-N CC(C)CN(C)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)CN(C)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 QMTAITIZNTZFQZ-BDYUSTAISA-N 0.000 description 2
- UCOCWZUKGIRMJV-YOSQAMIOSA-N CC(C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)N1CCCC1 Chemical compound CC(C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)N1CCCC1 UCOCWZUKGIRMJV-YOSQAMIOSA-N 0.000 description 2
- YYKWXRFRJWBGIQ-XCZPVHLTSA-N CC1(CNCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CCCC1 Chemical compound CC1(CNCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CCCC1 YYKWXRFRJWBGIQ-XCZPVHLTSA-N 0.000 description 2
- RZKUREQWKAXOFY-UHFFFAOYSA-N CC1=CC=C(C)C=C1.CC1=CC=C(C)N=C1.CC1=CN=C(C)C=C1 Chemical compound CC1=CC=C(C)C=C1.CC1=CC=C(C)N=C1.CC1=CN=C(C)C=C1 RZKUREQWKAXOFY-UHFFFAOYSA-N 0.000 description 2
- FHGDOVCLULVALY-AHWVRZQESA-N CC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=NC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound CC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=NC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 FHGDOVCLULVALY-AHWVRZQESA-N 0.000 description 2
- VSUIHCVVJWJQLQ-DUDBVELDSA-N CCC1CCCOC1.OCC1CCCCO1.OCC1OCCO1.OC[C@@H]1CCCO1.OC[C@@H]1CCOC1.OC[C@H]1CCCO1.OC[C@H]1CCOC1 Chemical compound CCC1CCCOC1.OCC1CCCCO1.OCC1OCCO1.OC[C@@H]1CCCO1.OC[C@@H]1CCOC1.OC[C@H]1CCCO1.OC[C@H]1CCOC1 VSUIHCVVJWJQLQ-DUDBVELDSA-N 0.000 description 2
- YVHFYWVQSIXKHS-FZYSWFTMSA-N CCC1CCOCC1.OCC1CCCCO1.OCC1CCCOC1.OCC1CCO1.OCC1COC1.OCC1OCCO1.OC[C@@H]1CCCO1.OC[C@@H]1CCOC1.OC[C@@H]1COCO1.OC[C@H]1CCCO1.OC[C@H]1CCOC1.OC[C@H]1COCO1 Chemical compound CCC1CCOCC1.OCC1CCCCO1.OCC1CCCOC1.OCC1CCO1.OCC1COC1.OCC1OCCO1.OC[C@@H]1CCCO1.OC[C@@H]1CCOC1.OC[C@@H]1COCO1.OC[C@H]1CCCO1.OC[C@H]1CCOC1.OC[C@H]1COCO1 YVHFYWVQSIXKHS-FZYSWFTMSA-N 0.000 description 2
- DUPBOUOHQCPTPA-YTMVLYRLSA-N CCCN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)CC1CC1 Chemical compound CCCN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)CC1CC1 DUPBOUOHQCPTPA-YTMVLYRLSA-N 0.000 description 2
- WYAZRFHWZUWCAL-XICMLOBYSA-N CN1CCCC(C2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 Chemical compound CN1CCCC(C2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 WYAZRFHWZUWCAL-XICMLOBYSA-N 0.000 description 2
- BKUOSMYVUXUUKW-OICBGKIFSA-N C[C@H](NCC(C)(C)C)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound C[C@H](NCC(C)(C)C)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 BKUOSMYVUXUUKW-OICBGKIFSA-N 0.000 description 2
- OPHXGIPUJWBLJI-AHWVRZQESA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 OPHXGIPUJWBLJI-AHWVRZQESA-N 0.000 description 2
- HKSKOZRDQVKMOB-ZCYQVOJMSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCC3)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCC3)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 HKSKOZRDQVKMOB-ZCYQVOJMSA-N 0.000 description 2
- LCUGLNKPJFAERP-KLJDGLGGSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCC[C@H]3CO)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCC[C@H]3CO)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 LCUGLNKPJFAERP-KLJDGLGGSA-N 0.000 description 2
- GQEALYLFBUHXDY-AHWVRZQESA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCN4C=NN=C4C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCN4C=NN=C4C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 GQEALYLFBUHXDY-AHWVRZQESA-N 0.000 description 2
- DCRUFTKXLMXLMD-AHWVRZQESA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCSCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCSCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 DCRUFTKXLMXLMD-AHWVRZQESA-N 0.000 description 2
- REKMZNXWWKXQHD-JDXGNMNLSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCCC3=CC=CC=C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCCC3=CC=CC=C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 REKMZNXWWKXQHD-JDXGNMNLSA-N 0.000 description 2
- FXICHUCTFHAEMJ-RUZDIDTESA-N O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(C2CCCCC2)C=C1 Chemical compound O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(C2CCCCC2)C=C1 FXICHUCTFHAEMJ-RUZDIDTESA-N 0.000 description 2
- HXCDBZQTBSEKKY-FKHAVUOCSA-N O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(N2N=C3CCCC3C2=O)C=C1 Chemical compound O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(N2N=C3CCCC3C2=O)C=C1 HXCDBZQTBSEKKY-FKHAVUOCSA-N 0.000 description 2
- GGVUHSOMQRWVBL-LCQOSCCDSA-N O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(OCC(O)C(F)(F)F)C=C1 Chemical compound O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(OCC(O)C(F)(F)F)C=C1 GGVUHSOMQRWVBL-LCQOSCCDSA-N 0.000 description 2
- WZETWNXOTHFDMS-NABNVEFZSA-N [H][C@@]12CC[C@@]([H])(CN1CC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 Chemical compound [H][C@@]12CC[C@@]([H])(CN1CC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 WZETWNXOTHFDMS-NABNVEFZSA-N 0.000 description 2
- IJBDFSPDNLBVGU-PAHRNIGTSA-O C1=CC(C2CC(CN3CCOCC3)C2)=CC=C1CN1CCCC1.CC(=O)C[C@@H](CS)C(=O)O.CC(C[N+](C)(C)C)OC(N)=O.CC1=NC2=CC=C(C3=CC=C(Cl)C=C3)C=C2C(=O)N1C[C@H]1CCCN(C(C)C)C1.CC1=NC2=CC=C(OC3=CC=C(F)C=C3)C=C2C(=O)N1C[C@H]1CCCN(C(C)C)C1.CCOCCN1CCC2=C(C)C(CS(N)(=O)=O)=C(C)C(NC(=O)C(C)(C)C)=C21.COC1=C(OC)C(C(C)NC2=C(S(C)(=O)=O)C=CC(N3CCNCC3)=C2)=CC(Cl)=C1.COC1=C(OC)C(OC)=C(CN2CCN(CCOC(=O)NCCC3=CC=CC=C3)CC2)C=C1.ClC1=CC=C(C23CNCC2C3)C=C1Cl.O=C(NC1CCN(CCCCC2(C(=O)NCC(F)(F)F)C3=CC=CC=C3C3=C2C=CC=C3)CC1)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1.[2H]C.[Cl-].[H][C@@]12CCC3=CC(=O)CCC3=C1[C@@H](C1=CC=C(N(C)CCO[C@H]3CC[C@]4(C)[C@@]5([H])C[C@H](O)[C@@]6(C)[C@@]([H])(CC[C@]6([H])[C@H](C)CCC(=O)O)[C@]5([H])[C@H](O)C[C@]4([H])C3)C=C1)C[C@]1(C)[C@](O)(C#CC)CC[C@@]21[H] Chemical compound C1=CC(C2CC(CN3CCOCC3)C2)=CC=C1CN1CCCC1.CC(=O)C[C@@H](CS)C(=O)O.CC(C[N+](C)(C)C)OC(N)=O.CC1=NC2=CC=C(C3=CC=C(Cl)C=C3)C=C2C(=O)N1C[C@H]1CCCN(C(C)C)C1.CC1=NC2=CC=C(OC3=CC=C(F)C=C3)C=C2C(=O)N1C[C@H]1CCCN(C(C)C)C1.CCOCCN1CCC2=C(C)C(CS(N)(=O)=O)=C(C)C(NC(=O)C(C)(C)C)=C21.COC1=C(OC)C(C(C)NC2=C(S(C)(=O)=O)C=CC(N3CCNCC3)=C2)=CC(Cl)=C1.COC1=C(OC)C(OC)=C(CN2CCN(CCOC(=O)NCCC3=CC=CC=C3)CC2)C=C1.ClC1=CC=C(C23CNCC2C3)C=C1Cl.O=C(NC1CCN(CCCCC2(C(=O)NCC(F)(F)F)C3=CC=CC=C3C3=C2C=CC=C3)CC1)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1.[2H]C.[Cl-].[H][C@@]12CCC3=CC(=O)CCC3=C1[C@@H](C1=CC=C(N(C)CCO[C@H]3CC[C@]4(C)[C@@]5([H])C[C@H](O)[C@@]6(C)[C@@]([H])(CC[C@]6([H])[C@H](C)CCC(=O)O)[C@]5([H])[C@H](O)C[C@]4([H])C3)C=C1)C[C@]1(C)[C@](O)(C#CC)CC[C@@]21[H] IJBDFSPDNLBVGU-PAHRNIGTSA-O 0.000 description 1
- PZUUEVSCXXWJSA-GREMRMIQSA-N C1=CN=C2C=C3C(=CC2=N1)[C@H]1CNC[C@@H]3C1.CC1(C)CC(=O)C(C2C3=C(CC(C)(C)CC3=O)OC3CCCCC32)C(=O)C1.CCOC(=O)[C@H](C)CP(=O)(N[C@@H](C)C(=O)OCC)C1=CC=C(C2=C(CC(C)C)SC(N)=N2)O1.CC[C@H](C)[C@H](NC(=O)C(C)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)C(CC(C)C)NC(=O)[C@@H](NC(=O)C(CCCCN)NNC(C)(C)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C(C)C)C(=O)C(=O)[C@H](CC1=CC=CC=C1)NN[C@@H](CCC(=O)O)C(=O)C(=O)[C@H](CCCCN)NC(=O)C(C)NC(=O)[C@H](C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(=O)O)NNC(CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NC(CO)C(=O)N[C@@H](CO)C(=O)NC(C(=O)N[C@@H](CC(=O)O)C(=O)C(=O)[C@H](CO)NN[C@H](C(=O)C(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CN=CN1)NN)[C@@H](C)O)[C@@H](C)O)C(C)C.C[C@@H](CC[C@H](O)C1=CC(Cl)=CC=C1)CC1=CC=C2O[C@@H](C(=O)O)COC2=C1.C[C@H]1CNCCC2=CC=C(Cl)C=C21.N#C[C@@H]1CC[C@H](C#N)N1C(=O)CNC1(CO)CCCC1.O=C(O)C1=CC=CC(C2=CC(NCCCC[C@H](O)C3=CC=CC(Cl)=C3)=CC=C2)=C1.O=C(O)[C@H](O)[C@@H](O)C(=O)O.[H][C@]12CC[C@@]3(C)[C@@]([H])(CC[C@]3([H])[C@H](C)CC[C@@H](OS(=O)(=O)O)C(C)C)[C@]1([H])[C@H](O)C[C@@]1([H])C[C@@H](NCCCNCCCCCCCCN)CC[C@]21C Chemical compound C1=CN=C2C=C3C(=CC2=N1)[C@H]1CNC[C@@H]3C1.CC1(C)CC(=O)C(C2C3=C(CC(C)(C)CC3=O)OC3CCCCC32)C(=O)C1.CCOC(=O)[C@H](C)CP(=O)(N[C@@H](C)C(=O)OCC)C1=CC=C(C2=C(CC(C)C)SC(N)=N2)O1.CC[C@H](C)[C@H](NC(=O)C(C)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)C(CC(C)C)NC(=O)[C@@H](NC(=O)C(CCCCN)NNC(C)(C)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C(C)C)C(=O)C(=O)[C@H](CC1=CC=CC=C1)NN[C@@H](CCC(=O)O)C(=O)C(=O)[C@H](CCCCN)NC(=O)C(C)NC(=O)[C@H](C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(=O)O)NNC(CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NC(CO)C(=O)N[C@@H](CO)C(=O)NC(C(=O)N[C@@H](CC(=O)O)C(=O)C(=O)[C@H](CO)NN[C@H](C(=O)C(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CN=CN1)NN)[C@@H](C)O)[C@@H](C)O)C(C)C.C[C@@H](CC[C@H](O)C1=CC(Cl)=CC=C1)CC1=CC=C2O[C@@H](C(=O)O)COC2=C1.C[C@H]1CNCCC2=CC=C(Cl)C=C21.N#C[C@@H]1CC[C@H](C#N)N1C(=O)CNC1(CO)CCCC1.O=C(O)C1=CC=CC(C2=CC(NCCCC[C@H](O)C3=CC=CC(Cl)=C3)=CC=C2)=C1.O=C(O)[C@H](O)[C@@H](O)C(=O)O.[H][C@]12CC[C@@]3(C)[C@@]([H])(CC[C@]3([H])[C@H](C)CC[C@@H](OS(=O)(=O)O)C(C)C)[C@]1([H])[C@H](O)C[C@@]1([H])C[C@@H](NCCCNCCCCCCCCN)CC[C@]21C PZUUEVSCXXWJSA-GREMRMIQSA-N 0.000 description 1
- RWDUUBWJCMLRLM-RRCXEDSKSA-M CC#CCN1C(N2CCCC(N)C2)=NC2C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C.CC(C)(C)NC(=O)C1=C(C[C@H](O)[C@H](N)CC2=C(F)C=C(F)C(F)=C2)N=C(C(F)(F)F)C=C1.CC(C)(OC1=CC=C(C(=O)C2=CC=C(Cl)C=C2)C=C1)C(=O)[O-].CCN(CC)CC1=CC=C(C(=O)N(CCC2=C(OC)C=CC=C2)[C@@H]2CCNC2)C=C1.COC(=O)N(CC(=O)O)CC1=CC(OCC2=C(C)OC(C3=CC=C(Cl)C=C3)=N2)=CC=C1.COC(=O)N(CC(=O)O)CC1=CC(OCC2=C(C)OC(C3=CC=C(Cl)C=C3)=N2)=CC=C1F.CS(=O)C1=CC=C(OCCC2CCN(C(=O)OC(C)(C)C)CC2)C=C1F.C[N+](C)(C)CCO.N#CC1CC(F)(F)CN1C(=O)CNC1(CO)CCC2(CCOCC2)CC1.[H]N1C(=O)SC(CC2=CC=C(OCC3=NC4=CC=CC=C4C(=O)N3C)C=C2)C1=O.[H]N1C(C2=CN(C(F)F)C(=O)C=C2)N[C@](C2=CC=C(F)C=C2)(C2=CN=C(F)C=C2)[C@@H]1C.[H][C@@]1(C2=CC(CC3=CC=C(OCC)C=C3)=C(Cl)C=C2)C[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O Chemical compound CC#CCN1C(N2CCCC(N)C2)=NC2C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C.CC(C)(C)NC(=O)C1=C(C[C@H](O)[C@H](N)CC2=C(F)C=C(F)C(F)=C2)N=C(C(F)(F)F)C=C1.CC(C)(OC1=CC=C(C(=O)C2=CC=C(Cl)C=C2)C=C1)C(=O)[O-].CCN(CC)CC1=CC=C(C(=O)N(CCC2=C(OC)C=CC=C2)[C@@H]2CCNC2)C=C1.COC(=O)N(CC(=O)O)CC1=CC(OCC2=C(C)OC(C3=CC=C(Cl)C=C3)=N2)=CC=C1.COC(=O)N(CC(=O)O)CC1=CC(OCC2=C(C)OC(C3=CC=C(Cl)C=C3)=N2)=CC=C1F.CS(=O)C1=CC=C(OCCC2CCN(C(=O)OC(C)(C)C)CC2)C=C1F.C[N+](C)(C)CCO.N#CC1CC(F)(F)CN1C(=O)CNC1(CO)CCC2(CCOCC2)CC1.[H]N1C(=O)SC(CC2=CC=C(OCC3=NC4=CC=CC=C4C(=O)N3C)C=C2)C1=O.[H]N1C(C2=CN(C(F)F)C(=O)C=C2)N[C@](C2=CC=C(F)C=C2)(C2=CN=C(F)C=C2)[C@@H]1C.[H][C@@]1(C2=CC(CC3=CC=C(OCC)C=C3)=C(Cl)C=C2)C[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWDUUBWJCMLRLM-RRCXEDSKSA-M 0.000 description 1
- BZAOFEKYBJORFM-YTMVLYRLSA-N CC(=O)N1CCC(NCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound CC(=O)N1CCC(NCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 BZAOFEKYBJORFM-YTMVLYRLSA-N 0.000 description 1
- XIZPBVWABSMXJU-XCZPVHLTSA-N CC(=O)N1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound CC(=O)N1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 XIZPBVWABSMXJU-XCZPVHLTSA-N 0.000 description 1
- SDYOXDMYWWALCI-ZEJIAQGSSA-N CC(=O)NC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 Chemical compound CC(=O)NC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 SDYOXDMYWWALCI-ZEJIAQGSSA-N 0.000 description 1
- JNJZBBXFXUVTAV-AHWVRZQESA-N CC(=O)NCCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(=O)NCCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 JNJZBBXFXUVTAV-AHWVRZQESA-N 0.000 description 1
- CGZOECCGAPHPMH-KCRBBIKOSA-N CC(C)(C)C1CCCN1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)(C)C1CCCN1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 CGZOECCGAPHPMH-KCRBBIKOSA-N 0.000 description 1
- LZCHZVXJHVUVHC-JDXGNMNLSA-N CC(C)(C)C1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound CC(C)(C)C1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 LZCHZVXJHVUVHC-JDXGNMNLSA-N 0.000 description 1
- QSKCPZSGYVHFLD-XCZPVHLTSA-N CC(C)(C)CCCCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)(C)CCCCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 QSKCPZSGYVHFLD-XCZPVHLTSA-N 0.000 description 1
- LNJBRULAOXJUST-BDYUSTAISA-N CC(C)(C)CCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)(C)CCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 LNJBRULAOXJUST-BDYUSTAISA-N 0.000 description 1
- CESFPUVESOXFQU-JDXGNMNLSA-N CC(C)(C)CN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)CC1CC1 Chemical compound CC(C)(C)CN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)CC1CC1 CESFPUVESOXFQU-JDXGNMNLSA-N 0.000 description 1
- AAQGTNSDKVQTMW-UNRZKBSHSA-N CC(C)(C)CN1CCC[C@@H](C2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 Chemical compound CC(C)(C)CN1CCC[C@@H](C2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 AAQGTNSDKVQTMW-UNRZKBSHSA-N 0.000 description 1
- AAQGTNSDKVQTMW-XEVVZDEMSA-N CC(C)(C)CN1CCC[C@H](C2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 Chemical compound CC(C)(C)CN1CCC[C@H](C2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 AAQGTNSDKVQTMW-XEVVZDEMSA-N 0.000 description 1
- XBFVIKXXHVPELL-BDYUSTAISA-N CC(C)(C)CNC(C)(C)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)(C)CNC(C)(C)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 XBFVIKXXHVPELL-BDYUSTAISA-N 0.000 description 1
- BTSWZBKMBQOCKN-BDYUSTAISA-N CC(C)(C)CNCC1=CC2=C(C=C1)C[C@@H](N1CCC3=CC(OC[C@@H]4CCCO4)=CC=C3C1=O)CC2 Chemical compound CC(C)(C)CNCC1=CC2=C(C=C1)C[C@@H](N1CCC3=CC(OC[C@@H]4CCCO4)=CC=C3C1=O)CC2 BTSWZBKMBQOCKN-BDYUSTAISA-N 0.000 description 1
- KTKWRORMYBNKOJ-AHWVRZQESA-N CC(C)(C)CNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)(C)CNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 KTKWRORMYBNKOJ-AHWVRZQESA-N 0.000 description 1
- URGAZQPXTXIRPY-UPVQGACJSA-N CC(C)(C)CNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=NC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)(C)CNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=NC=C(OC[C@@H]3CCCO3)C=C1)CC2 URGAZQPXTXIRPY-UPVQGACJSA-N 0.000 description 1
- QDSYBTCZCCFEED-ZCYQVOJMSA-N CC(C)(C)NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)(C)NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 QDSYBTCZCCFEED-ZCYQVOJMSA-N 0.000 description 1
- SZONNTXPTBKOIF-XCZPVHLTSA-N CC(C)(C)OCCCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)(C)OCCCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 SZONNTXPTBKOIF-XCZPVHLTSA-N 0.000 description 1
- JGWWPBHXXKZRLE-KXESWAQBSA-N CC(C)(N)C(=O)N[C@H](C/C1=C/NC2=CC=CC=C21)C1=NN=C(CCC/C2=C/NC3=CC=CC=C32)N1CC1=CC=CC=C1.CC1=CC(OCP(=O)(O)O)=CC(C)=C1CC1=CC(C(C)C)=C(O)C=C1.CC1=CC(OC[P@@]2(=O)OCC[C@@H](C3=CC(Cl)=CC=C3)O2)=CC(C)=C1CC1=CC(C(C)C)=C(O)C=C1.CCC1=C(C2=CC=CC=C2)C(C2=CC=CC=C2)=NN1C1=CC=CC=C1C1=CC(OCC(=O)O)=CC=C1.CCCN1CCN(C(=O)[C@H](C2=CC=C(CN3C4=CC=CC=C4C4=C3N=C(C)C(CCC(=O)O)=C4C)C=C2)C2CCOCC2)CC1.COC1=CC=C(CN2C(CCC3=CC=CC=C3)=NN=C2[C@@H](C/C2=C/NC3=CC=CC=C32)NC(=O)C2=CC=CC=N2)C(OC)=C1.COC1=CC=C(CN2C(CCC3=CC=CC=C3)=NN=C2[C@@H](C/C2=C/NC3=CC=CC=C32)NC(=O)C2CCNCC2)C=C1.COC1=CC=C(CN2C(CCC3=CC=CC=C3)=NN=C2[C@@H](C/C2=C/NC3=CC=CC=C32)NC(=O)CN)C=C1.COC1=CC=C(OC2=NC=NC(N(C)CCOC3=CC=C(CC4SC(=O)NC4=O)C=C3)=C2)C=C1 Chemical compound CC(C)(N)C(=O)N[C@H](C/C1=C/NC2=CC=CC=C21)C1=NN=C(CCC/C2=C/NC3=CC=CC=C32)N1CC1=CC=CC=C1.CC1=CC(OCP(=O)(O)O)=CC(C)=C1CC1=CC(C(C)C)=C(O)C=C1.CC1=CC(OC[P@@]2(=O)OCC[C@@H](C3=CC(Cl)=CC=C3)O2)=CC(C)=C1CC1=CC(C(C)C)=C(O)C=C1.CCC1=C(C2=CC=CC=C2)C(C2=CC=CC=C2)=NN1C1=CC=CC=C1C1=CC(OCC(=O)O)=CC=C1.CCCN1CCN(C(=O)[C@H](C2=CC=C(CN3C4=CC=CC=C4C4=C3N=C(C)C(CCC(=O)O)=C4C)C=C2)C2CCOCC2)CC1.COC1=CC=C(CN2C(CCC3=CC=CC=C3)=NN=C2[C@@H](C/C2=C/NC3=CC=CC=C32)NC(=O)C2=CC=CC=N2)C(OC)=C1.COC1=CC=C(CN2C(CCC3=CC=CC=C3)=NN=C2[C@@H](C/C2=C/NC3=CC=CC=C32)NC(=O)C2CCNCC2)C=C1.COC1=CC=C(CN2C(CCC3=CC=CC=C3)=NN=C2[C@@H](C/C2=C/NC3=CC=CC=C32)NC(=O)CN)C=C1.COC1=CC=C(OC2=NC=NC(N(C)CCOC3=CC=C(CC4SC(=O)NC4=O)C=C3)=C2)C=C1 JGWWPBHXXKZRLE-KXESWAQBSA-N 0.000 description 1
- XJGHHZLCGKHWBD-GMAHTHKFSA-N CC(C)(N)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)(N)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 XJGHHZLCGKHWBD-GMAHTHKFSA-N 0.000 description 1
- NHWUNCKUSWCNHP-JDXGNMNLSA-N CC(C)(O)C1CCN(CC2=CC3=C(C=C2)C[C@@H](N2CCC4=CC(OC[C@@H]5CCCO5)=CC=C4C2=O)CC3)CC1 Chemical compound CC(C)(O)C1CCN(CC2=CC3=C(C=C2)C[C@@H](N2CCC4=CC(OC[C@@H]5CCCO5)=CC=C4C2=O)CC3)CC1 NHWUNCKUSWCNHP-JDXGNMNLSA-N 0.000 description 1
- VMGVJMCOBYPIAT-ZCYQVOJMSA-N CC(C)(O)CNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)(O)CNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 VMGVJMCOBYPIAT-ZCYQVOJMSA-N 0.000 description 1
- IMTKWKJIUVYOSU-OAQYLSRUSA-N CC(C)(O)COC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 Chemical compound CC(C)(O)COC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 IMTKWKJIUVYOSU-OAQYLSRUSA-N 0.000 description 1
- CXRDVHUGLPAAKV-GOWMWYNSSA-M CC(C)(SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1)SC1=CC(C(C)(C)C)=C(OC(=O)CCC(=O)O)C(C(C)(C)C)=C1.CC(C)C1=C(/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C(C2=CC=C(F)C=C2)=NC(N(C)C2=NC=NN2C)=N1.CC(C)CC1=C(C2=CC=C(P(=O)(O)O)O2)N=C(N)S1.CC(C)OC(=O)C1=CN(C(=O)C2=CC=C(F)C(F)=C2)CC(C)(C)C2=C1NC1=C2C=CC=C1.CCC(CC)CC1(C(=O)NC2=C(SC(=O)C(C)C)C=CC=C2)CCCCC1.CCCC1(C(N)=O)CCN(C2=NC=NC3=C2N=C(C2=CC=CC=C2Cl)N3C2=CC=C(Cl)C=C2)CC1.CCOC(=O)C(C)(C)CP(=O)(NC(C)(C)C(=O)OCC)C1=CC=C(C2=C(CC(C)C)SC(N)=N2)O1.O=S(=O)(NC1=CC=C(SC2=NC3=C(C=CC(Cl)=C3)S2)C(Cl)=C1)C1=C(Cl)C=C(C(F)(F)F)C=C1.[H]Cl.[Na+] Chemical compound CC(C)(SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1)SC1=CC(C(C)(C)C)=C(OC(=O)CCC(=O)O)C(C(C)(C)C)=C1.CC(C)C1=C(/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C(C2=CC=C(F)C=C2)=NC(N(C)C2=NC=NN2C)=N1.CC(C)CC1=C(C2=CC=C(P(=O)(O)O)O2)N=C(N)S1.CC(C)OC(=O)C1=CN(C(=O)C2=CC=C(F)C(F)=C2)CC(C)(C)C2=C1NC1=C2C=CC=C1.CCC(CC)CC1(C(=O)NC2=C(SC(=O)C(C)C)C=CC=C2)CCCCC1.CCCC1(C(N)=O)CCN(C2=NC=NC3=C2N=C(C2=CC=CC=C2Cl)N3C2=CC=C(Cl)C=C2)CC1.CCOC(=O)C(C)(C)CP(=O)(NC(C)(C)C(=O)OCC)C1=CC=C(C2=C(CC(C)C)SC(N)=N2)O1.O=S(=O)(NC1=CC=C(SC2=NC3=C(C=CC(Cl)=C3)S2)C(Cl)=C1)C1=C(Cl)C=C(C(F)(F)F)C=C1.[H]Cl.[Na+] CXRDVHUGLPAAKV-GOWMWYNSSA-M 0.000 description 1
- IYZAOLFFIYJVRG-LETIRJCYSA-N CC(C)C(O)COC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 Chemical compound CC(C)C(O)COC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 IYZAOLFFIYJVRG-LETIRJCYSA-N 0.000 description 1
- SDADUGVXAHNNED-CVYBXRIJSA-N CC(C)C1CCCCN1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)C1CCCCN1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 SDADUGVXAHNNED-CVYBXRIJSA-N 0.000 description 1
- ZVTZGKFCLAKJLQ-JDSNJFFGSA-N CC(C)CC1CCCN1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)CC1CCCN1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 ZVTZGKFCLAKJLQ-JDSNJFFGSA-N 0.000 description 1
- GOEPQJWIFCTORL-XCZPVHLTSA-N CC(C)CCCCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)CCCCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 GOEPQJWIFCTORL-XCZPVHLTSA-N 0.000 description 1
- BINYGHSRDZXVJW-XCZPVHLTSA-N CC(C)CCNCC1=CC2=C(C=C1)C[C@@H](N1CCC3=CC(OC[C@@H]4CCCO4)=CC=C3C1=O)CC2 Chemical compound CC(C)CCNCC1=CC2=C(C=C1)C[C@@H](N1CCC3=CC(OC[C@@H]4CCCO4)=CC=C3C1=O)CC2 BINYGHSRDZXVJW-XCZPVHLTSA-N 0.000 description 1
- LCGXTEIRAXQKCG-ZCYQVOJMSA-N CC(C)CCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=NC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)CCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=NC=C(OC[C@@H]3CCCO3)C=C1)CC2 LCGXTEIRAXQKCG-ZCYQVOJMSA-N 0.000 description 1
- RQLKZENHVSBJCA-LARUCZGFSA-N CC(C)CCN[C@H](C)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)CCN[C@H](C)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 RQLKZENHVSBJCA-LARUCZGFSA-N 0.000 description 1
- ZJHWKNQEFFQSRD-AVKNQKEWSA-N CC(C)CN(CC(C)C)[C@H](C)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)CN(CC(C)C)[C@H](C)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 ZJHWKNQEFFQSRD-AVKNQKEWSA-N 0.000 description 1
- XYYHKOMKANJOMO-JDXGNMNLSA-N CC(C)CN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)CC(C)C Chemical compound CC(C)CN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)CC(C)C XYYHKOMKANJOMO-JDXGNMNLSA-N 0.000 description 1
- RTPIIWIKPGBPOI-BIPIZLCXSA-N CC(C)CN1CCCC(C2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 Chemical compound CC(C)CN1CCCC(C2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 RTPIIWIKPGBPOI-BIPIZLCXSA-N 0.000 description 1
- HAMPCSDJPFCXMK-UPVQGACJSA-N CC(C)CNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=NC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)CNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=NC=C(OC[C@@H]3CCCO3)C=C1)CC2 HAMPCSDJPFCXMK-UPVQGACJSA-N 0.000 description 1
- ZXYUOBGJRMQQRG-RAHIQWLESA-N CC(C)CN[C@H](C)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)CN[C@H](C)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 ZXYUOBGJRMQQRG-RAHIQWLESA-N 0.000 description 1
- NYNWUBJWJFADSG-XCZPVHLTSA-N CC(C)N(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C(C)C Chemical compound CC(C)N(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C(C)C NYNWUBJWJFADSG-XCZPVHLTSA-N 0.000 description 1
- KRQKPBYLLAXFOR-NAUKPKSFSA-N CC(C)N1CCCC(C2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 Chemical compound CC(C)N1CCCC(C2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 KRQKPBYLLAXFOR-NAUKPKSFSA-N 0.000 description 1
- URWZCYFMIDGFDW-ZCYQVOJMSA-N CC(C)NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(C)NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 URWZCYFMIDGFDW-ZCYQVOJMSA-N 0.000 description 1
- GBQMIJYECKRRLY-DTDTVYEOSA-N CC(COC)NCc1ccc(C[C@H](CC2)NC(c(cc3)ccc3OCC3OCCC3)=O)c2c1 Chemical compound CC(COC)NCc1ccc(C[C@H](CC2)NC(c(cc3)ccc3OCC3OCCC3)=O)c2c1 GBQMIJYECKRRLY-DTDTVYEOSA-N 0.000 description 1
- PTBMMUHVMWXYTH-KWHVIBKZSA-N CC(NC1CCCCC1)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(NC1CCCCC1)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 PTBMMUHVMWXYTH-KWHVIBKZSA-N 0.000 description 1
- IUSVDOAFIQCXBQ-YOSQAMIOSA-N CC(NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C(C)(C)C Chemical compound CC(NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C(C)(C)C IUSVDOAFIQCXBQ-YOSQAMIOSA-N 0.000 description 1
- PXLHXLNEUBVRDO-HFKVKABFSA-N CC(O)CCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(O)CCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 PXLHXLNEUBVRDO-HFKVKABFSA-N 0.000 description 1
- XUTOJEAWYNLNJX-LMNIDFBRSA-N CC(O)CCOC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 Chemical compound CC(O)CCOC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 XUTOJEAWYNLNJX-LMNIDFBRSA-N 0.000 description 1
- JFCHWZPFPVNHNU-BOQFIEIISA-N CC(O)CNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC(O)CNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 JFCHWZPFPVNHNU-BOQFIEIISA-N 0.000 description 1
- CMVJXRMNVCCITM-YTMVLYRLSA-N CC1(C)CCC(NCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound CC1(C)CCC(NCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 CMVJXRMNVCCITM-YTMVLYRLSA-N 0.000 description 1
- FMUUVWKTIOEWPM-XCZPVHLTSA-N CC1(C)CCCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 Chemical compound CC1(C)CCCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 FMUUVWKTIOEWPM-XCZPVHLTSA-N 0.000 description 1
- UXPGLRURFXGQNH-XCZPVHLTSA-N CC1(C)CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound CC1(C)CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 UXPGLRURFXGQNH-XCZPVHLTSA-N 0.000 description 1
- LDBDQXYGGYUJAG-AHWVRZQESA-N CC1(C)CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=NC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound CC1(C)CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=NC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 LDBDQXYGGYUJAG-AHWVRZQESA-N 0.000 description 1
- RVXRSAICRNZLSY-BDYUSTAISA-N CC1(C)CN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CCO1 Chemical compound CC1(C)CN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CCO1 RVXRSAICRNZLSY-BDYUSTAISA-N 0.000 description 1
- IECOMPNROIBSKO-BDYUSTAISA-N CC1(C)CN(CC2=CC3=C(C=C2)C[C@@H](NCC2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C=N1 Chemical compound CC1(C)CN(CC2=CC3=C(C=C2)C[C@@H](NCC2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C=N1 IECOMPNROIBSKO-BDYUSTAISA-N 0.000 description 1
- PXUDIBHDZDGUPZ-AHWVRZQESA-N CC1(CNCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=NC=C(OC[C@@H]4CCCO4)C=C2)CC3)CCCC1 Chemical compound CC1(CNCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=NC=C(OC[C@@H]4CCCO4)C=C2)CC3)CCCC1 PXUDIBHDZDGUPZ-AHWVRZQESA-N 0.000 description 1
- VONKXTVZZIHFQW-SANMLTNESA-N CC1(COC2=CC=C(C(=O)N[C@H]3CCC4=C(C=CC(CN5CCCCCC5)=C4)C3)C=C2)COC1 Chemical compound CC1(COC2=CC=C(C(=O)N[C@H]3CCC4=C(C=CC(CN5CCCCCC5)=C4)C3)C=C2)COC1 VONKXTVZZIHFQW-SANMLTNESA-N 0.000 description 1
- IGIMCOIWKGPJMI-MDDDSFMHSA-N CC1(NCC(=O)N2[C@H](C#N)CC[C@@H]2C#N)CCN(C2=CC(C(=O)O)=CC=N2)CC1.CCOC(=O)OC[C@H]1O[C@@H](OC2=C(CC3=CC=C(OC)C=C3)C=CC=C2)[C@H](O)[C@@H](O)[C@@H]1O.CCOC1=NC2=C(C(C(=O)O)=CC=C2)N1CC1=CC=C(C2=C(C3=NC(=O)ON3)C=CC=C2)C=C1.CCOC[C@@H]1[C@@H](C2=CC=C(Cl)C(Cl)=C2)C[C@@H]2CC[C@H]1N2C.CN(C)CCC1=CNC2=CC=C(NS(=O)(=O)C3=CC=C4C(Cl)=CC=CC4=C3)C=C12.CN/C(=N\S(=O)(=O)C1=CC=C(Cl)C=C1)N1C[C@H](C2=CC=CC=C2)C(C2=CC=C(Cl)C=C2)=N1.COC1=C(CS(=O)(=O)C2=CC3=C(OC=C3)C(OC3CCNCC3)=C2)C=C(C)C=C1.COC1=C(OC)C([C@H]2O[C@H](CC(=O)N3CCC(CC(=O)O)CC3)C(=O)N(CC(C)(C)COC(C)=O)C3=CC=C(Cl)C=C32)=CC=C1.CS(=O)(=O)N(C1=CC(F)=CC(F)=C1)C1CN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)C1.C[C@H](NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1)[C@@H](CC1=CC=C(Cl)C=C1)C1=CC(C#N)=CC=C1.N[C@H]1CC(C(=O)N2CCN3C(=NN=C3C(F)(F)F)C2)=CC[C@@H]1C1=CC(F)=C(F)C=C1F Chemical compound CC1(NCC(=O)N2[C@H](C#N)CC[C@@H]2C#N)CCN(C2=CC(C(=O)O)=CC=N2)CC1.CCOC(=O)OC[C@H]1O[C@@H](OC2=C(CC3=CC=C(OC)C=C3)C=CC=C2)[C@H](O)[C@@H](O)[C@@H]1O.CCOC1=NC2=C(C(C(=O)O)=CC=C2)N1CC1=CC=C(C2=C(C3=NC(=O)ON3)C=CC=C2)C=C1.CCOC[C@@H]1[C@@H](C2=CC=C(Cl)C(Cl)=C2)C[C@@H]2CC[C@H]1N2C.CN(C)CCC1=CNC2=CC=C(NS(=O)(=O)C3=CC=C4C(Cl)=CC=CC4=C3)C=C12.CN/C(=N\S(=O)(=O)C1=CC=C(Cl)C=C1)N1C[C@H](C2=CC=CC=C2)C(C2=CC=C(Cl)C=C2)=N1.COC1=C(CS(=O)(=O)C2=CC3=C(OC=C3)C(OC3CCNCC3)=C2)C=C(C)C=C1.COC1=C(OC)C([C@H]2O[C@H](CC(=O)N3CCC(CC(=O)O)CC3)C(=O)N(CC(C)(C)COC(C)=O)C3=CC=C(Cl)C=C32)=CC=C1.CS(=O)(=O)N(C1=CC(F)=CC(F)=C1)C1CN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)C1.C[C@H](NC(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1)[C@@H](CC1=CC=C(Cl)C=C1)C1=CC(C#N)=CC=C1.N[C@H]1CC(C(=O)N2CCN3C(=NN=C3C(F)(F)F)C2)=CC[C@@H]1C1=CC(F)=C(F)C=C1F IGIMCOIWKGPJMI-MDDDSFMHSA-N 0.000 description 1
- UAHOGLSVELXMRU-XCZPVHLTSA-N CC1(O)CCN(CCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound CC1(O)CCN(CCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 UAHOGLSVELXMRU-XCZPVHLTSA-N 0.000 description 1
- USIGCHWNYHVFAB-GYNAHIMCSA-N CC1=C(CCOC2=CC=C(C[C@](C)(OC3=CC=CC=C3)C(=O)O)C=C2)N=C(C2=CC=CS2)O1.CC1=CC(SCC2=C(C)N=C(C3=CC=C(C(F)(F)F)C=C3)S2)=CC=C1OCC(=O)O.CCC(CC)CC1(C(=O)CC2=C(SC(=O)C(C)C)C=CC=C2)CCCCC1.CCOP(=O)(CC1=CC=C(C(=O)NC2=C(C#N)C=C(Br)C=C2)C=C1)OCC.CC[C@@H](C)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@@H]5CO[C@@](CSC6=NN=CN6C)(C6=CC=C(Cl)C=C6)O5)C=C4)CC3)C=C2)C1=O.COC1=CC(N2CCN(CC(=O)NC3C4=C(CC3(C)C)C(C)=CC(C)=C4O)CC2)=CC=C1.O=C(CC1CCN(CCCCC2(C(=O)CCC(F)(F)F)C3=C(C=CC=C3)C3=C2C=CC=C3)CC1)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1.[C-10] Chemical compound CC1=C(CCOC2=CC=C(C[C@](C)(OC3=CC=CC=C3)C(=O)O)C=C2)N=C(C2=CC=CS2)O1.CC1=CC(SCC2=C(C)N=C(C3=CC=C(C(F)(F)F)C=C3)S2)=CC=C1OCC(=O)O.CCC(CC)CC1(C(=O)CC2=C(SC(=O)C(C)C)C=CC=C2)CCCCC1.CCOP(=O)(CC1=CC=C(C(=O)NC2=C(C#N)C=C(Br)C=C2)C=C1)OCC.CC[C@@H](C)N1N=CN(C2=CC=C(N3CCN(C4=CC=C(OC[C@@H]5CO[C@@](CSC6=NN=CN6C)(C6=CC=C(Cl)C=C6)O5)C=C4)CC3)C=C2)C1=O.COC1=CC(N2CCN(CC(=O)NC3C4=C(CC3(C)C)C(C)=CC(C)=C4O)CC2)=CC=C1.O=C(CC1CCN(CCCCC2(C(=O)CCC(F)(F)F)C3=C(C=CC=C3)C3=C2C=CC=C3)CC1)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1.[C-10] USIGCHWNYHVFAB-GYNAHIMCSA-N 0.000 description 1
- VBEKHBLIAZXJTE-UHFFFAOYSA-N CC1=CC(C)=NN1.CC1=CC=C(C)C=C1.CC1=CC=C(C)N=C1.CC1=CC=C(C)O1.CC1=CC=C(C)S1.CC1=CC=CC(C)=C1.CC1=CN=C(C)C=C1.CC1=CN=C(C)S1.CC1=CSC(C)=C1.CC1=CSC(C)=N1 Chemical compound CC1=CC(C)=NN1.CC1=CC=C(C)C=C1.CC1=CC=C(C)N=C1.CC1=CC=C(C)O1.CC1=CC=C(C)S1.CC1=CC=CC(C)=C1.CC1=CN=C(C)C=C1.CC1=CN=C(C)S1.CC1=CSC(C)=C1.CC1=CSC(C)=N1 VBEKHBLIAZXJTE-UHFFFAOYSA-N 0.000 description 1
- WLOJOSYBRLGSCX-IGKIAQTJSA-N CC1=CC(CNCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)=NO1 Chemical compound CC1=CC(CNCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)=NO1 WLOJOSYBRLGSCX-IGKIAQTJSA-N 0.000 description 1
- OXOCKNMOQYPBQC-ZAVXWJCBSA-N CC1=CC(F)=C(CCNC(=O)C2=CC=C(N/C(=N/C3C[C@H]4C[C@@H]([C@@H]3C)C4(C)C)N3CCN[C@@H](C)C3)C=C2)C=C1.CN(C)C1=C2C=CC=CC2=NC(C[C@H]2CC[C@@H](NC(=O)C3=CC(F)=C(F)C=C3)CC2)=N1.CN(C)C[C@@H]1CCC2=C(C=CC(NC(=O)C3=CC=C(C4=CC=C(F)C=C4)C=C3)=C2)C1.COC1=C(OCCN2CCCC2)C=CC(N2C=NC3=C(SC(C4=CC=C(Cl)C=C4)=C3)C2=O)=C1.O=C(O)/C=C\C(=O)O.O=C1C=C(C(=O)CC2CCN(CC3=CC4=C(C=C3)OCO4)CC2)OC2=C1C=CC(F)=C2.O=C1C=C(NC2CCN(CC3=CC4=C(C=C3)OCO4)CC2)C2=CC(Cl)=CC=C2O1.[C+103].[C+7].[H][C@@](NC(=O)[C@H](CCCNC(=N)N)CC(=O)[C@@H](N)CC(C)C)(C(=O)C[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)C[C@@H](CS)C(=O)N[C@@H](CCCCC(N)=O)C(=O)C[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)C[C@@H](CO)C(=O)N[C@@H](CS)C(=O)CCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)C[C@@H](CC1=CC=C(O)C=C1)C(=O)O)C(C)C)C(C)C)[C@@H](C)CC Chemical compound CC1=CC(F)=C(CCNC(=O)C2=CC=C(N/C(=N/C3C[C@H]4C[C@@H]([C@@H]3C)C4(C)C)N3CCN[C@@H](C)C3)C=C2)C=C1.CN(C)C1=C2C=CC=CC2=NC(C[C@H]2CC[C@@H](NC(=O)C3=CC(F)=C(F)C=C3)CC2)=N1.CN(C)C[C@@H]1CCC2=C(C=CC(NC(=O)C3=CC=C(C4=CC=C(F)C=C4)C=C3)=C2)C1.COC1=C(OCCN2CCCC2)C=CC(N2C=NC3=C(SC(C4=CC=C(Cl)C=C4)=C3)C2=O)=C1.O=C(O)/C=C\C(=O)O.O=C1C=C(C(=O)CC2CCN(CC3=CC4=C(C=C3)OCO4)CC2)OC2=C1C=CC(F)=C2.O=C1C=C(NC2CCN(CC3=CC4=C(C=C3)OCO4)CC2)C2=CC(Cl)=CC=C2O1.[C+103].[C+7].[H][C@@](NC(=O)[C@H](CCCNC(=N)N)CC(=O)[C@@H](N)CC(C)C)(C(=O)C[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)C[C@@H](CS)C(=O)N[C@@H](CCCCC(N)=O)C(=O)C[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)C[C@@H](CO)C(=O)N[C@@H](CS)C(=O)CCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)C[C@@H](CC1=CC=C(O)C=C1)C(=O)O)C(C)C)C(C)C)[C@@H](C)CC OXOCKNMOQYPBQC-ZAVXWJCBSA-N 0.000 description 1
- WFSTYDJZBIDAEJ-RDEFILIRSA-N CC1=CC(OCC(=O)O)=CC(C)=C1CC1=CC(C(C)C)=C(O)C=C1.CCC1=C(C(=O)C(N)=O)C2=C(OCC(=O)OC)C=CC=C2N1CC1=CC=CC=C1.CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(SCC2=CC=C(F)C=C2)=NC(=O)C2=C1CCC2.O=C(NC1=C(C2=CN3C(CN4CCNCC4)=CSC3=N2)C=CC=C1)C1=CN=C2C=CC=CC2=N1.O=C(NC1=CC=CC=C1)NC1=CC=C(C2=CC=C(C(=O)[C@@H]3CCC[C@H]3C(=O)O)C=C2)C=C1.O=C(O)CCC1=CC(I)=C(OC2=CC=C(O)C=C2)C(I)=C1.O=C(OC1=C(O)C=CC=C1)C1=C(O)C=CC=C1.O=S(=O)(NC1=CC(Cl)=C(OC2=CC3=CC=CC=C3N=C2)C(Cl)=C1)C1=C(Cl)C=C(Cl)C=C1.O=S(=O)(O)C1=CC=CC=C1.O=S(=O)(O)C1=CC=CC=C1.[CH3-].[H][C@@](NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H](N)C(C)C)(C(=O)N[C@@H](CC(=O)O)C(N)=O)[C@@H](C)O.[H][C@]12CCN(CCC3(C(=O)O)CCCCC3)C[C@]1([H])[C@@H](C)C1=C(C2)NC2=CC=C(C(F)(F)F)C=C21 Chemical compound CC1=CC(OCC(=O)O)=CC(C)=C1CC1=CC(C(C)C)=C(O)C=C1.CCC1=C(C(=O)C(N)=O)C2=C(OCC(=O)OC)C=CC=C2N1CC1=CC=CC=C1.CCN(CC)CCN(CC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(=O)CN1C(SCC2=CC=C(F)C=C2)=NC(=O)C2=C1CCC2.O=C(NC1=C(C2=CN3C(CN4CCNCC4)=CSC3=N2)C=CC=C1)C1=CN=C2C=CC=CC2=N1.O=C(NC1=CC=CC=C1)NC1=CC=C(C2=CC=C(C(=O)[C@@H]3CCC[C@H]3C(=O)O)C=C2)C=C1.O=C(O)CCC1=CC(I)=C(OC2=CC=C(O)C=C2)C(I)=C1.O=C(OC1=C(O)C=CC=C1)C1=C(O)C=CC=C1.O=S(=O)(NC1=CC(Cl)=C(OC2=CC3=CC=CC=C3N=C2)C(Cl)=C1)C1=C(Cl)C=C(Cl)C=C1.O=S(=O)(O)C1=CC=CC=C1.O=S(=O)(O)C1=CC=CC=C1.[CH3-].[H][C@@](NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H](N)C(C)C)(C(=O)N[C@@H](CC(=O)O)C(N)=O)[C@@H](C)O.[H][C@]12CCN(CCC3(C(=O)O)CCCCC3)C[C@]1([H])[C@@H](C)C1=C(C2)NC2=CC=C(C(F)(F)F)C=C21 WFSTYDJZBIDAEJ-RDEFILIRSA-N 0.000 description 1
- UBRSSSAKTIATEJ-LSYYVWMOSA-N CC1=CC=C(CNCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)O1 Chemical compound CC1=CC=C(CNCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)O1 UBRSSSAKTIATEJ-LSYYVWMOSA-N 0.000 description 1
- WLDIJNFTKMXXLW-LSYYVWMOSA-N CC1=CN=C(CNCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C=N1 Chemical compound CC1=CN=C(CNCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C=N1 WLDIJNFTKMXXLW-LSYYVWMOSA-N 0.000 description 1
- GXSPIMSRZAWXTQ-LWBIIHDLSA-N CC1CC(C)CN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 Chemical compound CC1CC(C)CN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 GXSPIMSRZAWXTQ-LWBIIHDLSA-N 0.000 description 1
- VDAZSUMIFZOXED-KAITVKJSSA-N CC1CC(NCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC(C)(C)C1 Chemical compound CC1CC(NCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC(C)(C)C1 VDAZSUMIFZOXED-KAITVKJSSA-N 0.000 description 1
- KFXYPBITPLTKMN-LJNJGMTMSA-N CC1CCC(C)N1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC1CCC(C)N1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 KFXYPBITPLTKMN-LJNJGMTMSA-N 0.000 description 1
- KKJMSHYPTQZFJX-HOIOEWMKSA-N CC1CCC(NCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound CC1CCC(NCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 KKJMSHYPTQZFJX-HOIOEWMKSA-N 0.000 description 1
- FHDRXSQCJAMPPO-YOSQAMIOSA-N CC1CCCN1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CC1CCCN1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 FHDRXSQCJAMPPO-YOSQAMIOSA-N 0.000 description 1
- NVGYDXYOQCVYHM-XMMPIXPASA-N CC1CCN(C2=CC=C(C(=O)N[C@H]3COC4=C(C=CC(CN5CCCC5)=C4)C3)C=C2)CC1 Chemical compound CC1CCN(C2=CC=C(C(=O)N[C@H]3COC4=C(C=CC(CN5CCCC5)=C4)C3)C=C2)CC1 NVGYDXYOQCVYHM-XMMPIXPASA-N 0.000 description 1
- VFKJQPDNMKEBDD-YTMVLYRLSA-N CC1CCN(CC2=CC3=C(C=C2)C[C@@H](N2CCC4=CC(OC[C@@H]5CCCO5)=CC=C4C2=O)CC3)CC1 Chemical compound CC1CCN(CC2=CC3=C(C=C2)C[C@@H](N2CCC4=CC(OC[C@@H]5CCCO5)=CC=C4C2=O)CC3)CC1 VFKJQPDNMKEBDD-YTMVLYRLSA-N 0.000 description 1
- NMPVAECMGWOAOA-XCZPVHLTSA-N CC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound CC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 NMPVAECMGWOAOA-XCZPVHLTSA-N 0.000 description 1
- GIOOZTPMMOLWJZ-YTMVLYRLSA-N CC1CCN(CCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound CC1CCN(CCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 GIOOZTPMMOLWJZ-YTMVLYRLSA-N 0.000 description 1
- URISNSHBQKEWQO-RVBRUHEGSA-N CC1CCN([C@H](C)C2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound CC1CCN([C@H](C)C2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 URISNSHBQKEWQO-RVBRUHEGSA-N 0.000 description 1
- LBAXDNZIIHFBKZ-AHWVRZQESA-N CCC(C)(C)NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CCC(C)(C)NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 LBAXDNZIIHFBKZ-AHWVRZQESA-N 0.000 description 1
- TVOMTJUMMRVJHZ-HFKVKABFSA-N CCC(C)NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CCC(C)NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 TVOMTJUMMRVJHZ-HFKVKABFSA-N 0.000 description 1
- MUAHKDNQVCBJSW-BDYUSTAISA-N CCC(CC)NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CCC(CC)NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 MUAHKDNQVCBJSW-BDYUSTAISA-N 0.000 description 1
- INKBUUFUGHMWII-MIHMCVIASA-N CCC(O)C#CC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 Chemical compound CCC(O)C#CC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 INKBUUFUGHMWII-MIHMCVIASA-N 0.000 description 1
- UMFSMABKJIHDAM-QBGWGINNSA-N CCC(O)CNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CCC(O)CNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 UMFSMABKJIHDAM-QBGWGINNSA-N 0.000 description 1
- RHPFJBHLJIHTII-QGWOSTIUSA-N CCC1CCCCN1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CCC1CCCCN1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 RHPFJBHLJIHTII-QGWOSTIUSA-N 0.000 description 1
- QHPAFZYRDYJQEK-ZEJIAQGSSA-N CCC1CCCN1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CCC1CCCN1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 QHPAFZYRDYJQEK-ZEJIAQGSSA-N 0.000 description 1
- ARJAZPPLMLJCNP-WTQRLHSKSA-N CCCC(O)COC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 Chemical compound CCCC(O)COC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 ARJAZPPLMLJCNP-WTQRLHSKSA-N 0.000 description 1
- DEJGPNFSSXMIPW-JDXGNMNLSA-N CCCC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound CCCC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 DEJGPNFSSXMIPW-JDXGNMNLSA-N 0.000 description 1
- RFOKZJRBLHIJFN-JOCHJYFZSA-N CCCCC1=CN=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCC(OC)CC4)=C3)C2)C=C1 Chemical compound CCCCC1=CN=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCC(OC)CC4)=C3)C2)C=C1 RFOKZJRBLHIJFN-JOCHJYFZSA-N 0.000 description 1
- BTHMCVUROLNAAE-BDYUSTAISA-N CCCCN(C)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CCCCN(C)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 BTHMCVUROLNAAE-BDYUSTAISA-N 0.000 description 1
- PVTUAJRWVQEURF-JDXGNMNLSA-N CCCCN(CCCC)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CCCCN(CCCC)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 PVTUAJRWVQEURF-JDXGNMNLSA-N 0.000 description 1
- UTYSKLQHHJBLET-JOCHJYFZSA-N CCCCOC1=C(Cl)C=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCC(OC)CC4)=C3)C2)C=C1 Chemical compound CCCCOC1=C(Cl)C=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCC(OC)CC4)=C3)C2)C=C1 UTYSKLQHHJBLET-JOCHJYFZSA-N 0.000 description 1
- FQPBSSMJZATCOL-HSZRJFAPSA-N CCCCOC1=C(OC)C=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCC(OC)CC4)=C3)C2)C=C1 Chemical compound CCCCOC1=C(OC)C=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCC(OC)CC4)=C3)C2)C=C1 FQPBSSMJZATCOL-HSZRJFAPSA-N 0.000 description 1
- GNLNJACWYKAJQQ-HSZRJFAPSA-N CCCCOC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCC(OC)CC4)=C3)C2)C(C)=C1 Chemical compound CCCCOC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCC(OC)CC4)=C3)C2)C(C)=C1 GNLNJACWYKAJQQ-HSZRJFAPSA-N 0.000 description 1
- XLCGYLPPCHGYOP-JOCHJYFZSA-N CCCCOC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 Chemical compound CCCCOC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 XLCGYLPPCHGYOP-JOCHJYFZSA-N 0.000 description 1
- MSIAHFZCBMBACA-OAQYLSRUSA-N CCCCOC1=CN=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCC(OC)CC4)=C3)C2)C=C1 Chemical compound CCCCOC1=CN=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCC(OC)CC4)=C3)C2)C=C1 MSIAHFZCBMBACA-OAQYLSRUSA-N 0.000 description 1
- HWTUWEQZHXSPSX-AHWVRZQESA-N CCCN(C)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CCCN(C)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 HWTUWEQZHXSPSX-AHWVRZQESA-N 0.000 description 1
- IKGSJIYXSMZDMF-YTMVLYRLSA-N CCCN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)CC(C)(C)C Chemical compound CCCN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)CC(C)(C)C IKGSJIYXSMZDMF-YTMVLYRLSA-N 0.000 description 1
- JKAUCRAJBMNPBM-XCZPVHLTSA-N CCCN(CCC)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CCCN(CCC)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 JKAUCRAJBMNPBM-XCZPVHLTSA-N 0.000 description 1
- CZYRPOPMXNRNBV-NAUKPKSFSA-N CCCN1CCCC(C2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 Chemical compound CCCN1CCCC(C2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 CZYRPOPMXNRNBV-NAUKPKSFSA-N 0.000 description 1
- XURBQFOJZKBHIM-ZCYQVOJMSA-N CCN(C)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CCN(C)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 XURBQFOJZKBHIM-ZCYQVOJMSA-N 0.000 description 1
- VIURXXJGCNQVDL-BDYUSTAISA-N CCN(CC)CC1=CC2=C(C=C1)C[C@@H](N1CCC3=CC(OC[C@@H]4CCCO4)=CC=C3C1=O)CC2 Chemical compound CCN(CC)CC1=CC2=C(C=C1)C[C@@H](N1CCC3=CC(OC[C@@H]4CCCO4)=CC=C3C1=O)CC2 VIURXXJGCNQVDL-BDYUSTAISA-N 0.000 description 1
- HFNRCWSACLRICX-AHWVRZQESA-N CCN(CC)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CCN(CC)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 HFNRCWSACLRICX-AHWVRZQESA-N 0.000 description 1
- HUMYPLYKKCEFHM-BDYUSTAISA-N CCN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C(C)C Chemical compound CCN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C(C)C HUMYPLYKKCEFHM-BDYUSTAISA-N 0.000 description 1
- XTOCZUSONHEBNO-FIBWVYCGSA-N CCN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C1CCCCC1 Chemical compound CCN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C1CCCCC1 XTOCZUSONHEBNO-FIBWVYCGSA-N 0.000 description 1
- HIDAHCNGCIOOHP-XCZPVHLTSA-N CCN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)CC(C)(C)C Chemical compound CCN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)CC(C)(C)C HIDAHCNGCIOOHP-XCZPVHLTSA-N 0.000 description 1
- VAKIZERDUNHDFO-BDYUSTAISA-N CCN(CCOC)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CCN(CCOC)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 VAKIZERDUNHDFO-BDYUSTAISA-N 0.000 description 1
- OOLDVCNOIBKNKO-WNJJXGMVSA-N CCOC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound CCOC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 OOLDVCNOIBKNKO-WNJJXGMVSA-N 0.000 description 1
- GBWLLUKFBOLSDX-IGKIAQTJSA-N CCOC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=NC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound CCOC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=NC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 GBWLLUKFBOLSDX-IGKIAQTJSA-N 0.000 description 1
- JXDUPTFAKYMCIY-BDYUSTAISA-N CCOCCCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CCOCCCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 JXDUPTFAKYMCIY-BDYUSTAISA-N 0.000 description 1
- ZGGFISZPROXQSZ-BDYUSTAISA-N CCOCCNCC1=CC2=C(C=C1)C[C@@H](N1CCC3=CC(OC[C@@H]4CCCO4)=CC=C3C1=O)CC2 Chemical compound CCOCCNCC1=CC2=C(C=C1)C[C@@H](N1CCC3=CC(OC[C@@H]4CCCO4)=CC=C3C1=O)CC2 ZGGFISZPROXQSZ-BDYUSTAISA-N 0.000 description 1
- VRUDAWBZQXZEFO-AHWVRZQESA-N CCOCCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CCOCCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 VRUDAWBZQXZEFO-AHWVRZQESA-N 0.000 description 1
- VGZCGLWRYMXDKJ-FGZHOGPDSA-N CC[C@@H](O)COC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 Chemical compound CC[C@@H](O)COC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 VGZCGLWRYMXDKJ-FGZHOGPDSA-N 0.000 description 1
- VGZCGLWRYMXDKJ-YADHBBJMSA-N CC[C@H](O)COC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 Chemical compound CC[C@H](O)COC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 VGZCGLWRYMXDKJ-YADHBBJMSA-N 0.000 description 1
- JSPRWOIIVCIDEP-CLFWOEFHSA-N CC[C@H]1CC[C@H](NCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound CC[C@H]1CC[C@H](NCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 JSPRWOIIVCIDEP-CLFWOEFHSA-N 0.000 description 1
- AEJBQZBDBHBKEX-BDYUSTAISA-N CN(C(=O)C1=CC=C(OC[C@@H]2CCCO2)C=C1)[C@H]1CCC2=C(C=CC(CN3CCCC3)=C2)C1 Chemical compound CN(C(=O)C1=CC=C(OC[C@@H]2CCCO2)C=C1)[C@H]1CCC2=C(C=CC(CN3CCCC3)=C2)C1 AEJBQZBDBHBKEX-BDYUSTAISA-N 0.000 description 1
- OFQPHLMCKJZXBL-ZCYQVOJMSA-N CN(C)C(C)(C)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CN(C)C(C)(C)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 OFQPHLMCKJZXBL-ZCYQVOJMSA-N 0.000 description 1
- OYMZPNDPYDPXDO-UPVQGACJSA-N CN(C)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CN(C)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 OYMZPNDPYDPXDO-UPVQGACJSA-N 0.000 description 1
- OJAOEKQNPHAXLM-BDYUSTAISA-N CN(C)CCCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CN(C)CCCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 OJAOEKQNPHAXLM-BDYUSTAISA-N 0.000 description 1
- LIEZAGMBBXQQHT-BDYUSTAISA-N CN(C)CCN(C)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CN(C)CCN(C)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 LIEZAGMBBXQQHT-BDYUSTAISA-N 0.000 description 1
- DZKWOABOYNLEQM-LSYYVWMOSA-N CN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C1CCCC1 Chemical compound CN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C1CCCC1 DZKWOABOYNLEQM-LSYYVWMOSA-N 0.000 description 1
- KADJRJATLDDTNE-WNJJXGMVSA-N CN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C1CCCCC1 Chemical compound CN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C1CCCCC1 KADJRJATLDDTNE-WNJJXGMVSA-N 0.000 description 1
- CAQHOHNNCDXELX-BDYUSTAISA-N CN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)CC(C)(C)C Chemical compound CN(CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)CC(C)(C)C CAQHOHNNCDXELX-BDYUSTAISA-N 0.000 description 1
- SENCNCQLYGJKMI-JDXGNMNLSA-N CN(CC1=CC=CC=C1)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CN(CC1=CC=CC=C1)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 SENCNCQLYGJKMI-JDXGNMNLSA-N 0.000 description 1
- FDEWPKYSTLDYMK-YTMVLYRLSA-N CN(CC1=CC=CN=C1)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CN(CC1=CC=CN=C1)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 FDEWPKYSTLDYMK-YTMVLYRLSA-N 0.000 description 1
- CGRAATXYMYORGC-AHWVRZQESA-N CN(CCCO)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CN(CCCO)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 CGRAATXYMYORGC-AHWVRZQESA-N 0.000 description 1
- VTACLAJRKXCCEV-ZCYQVOJMSA-N CN(CCO)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CN(CCO)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 VTACLAJRKXCCEV-ZCYQVOJMSA-N 0.000 description 1
- VSPZRDRKHUFYBE-IGKIAQTJSA-N CN1C=CC(CNCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)=N1 Chemical compound CN1C=CC(CNCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)=N1 VSPZRDRKHUFYBE-IGKIAQTJSA-N 0.000 description 1
- MBZQCOBSWISVNN-OGUPFJCYSA-N CN1CCCCC1C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CN1CCCCC1C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 MBZQCOBSWISVNN-OGUPFJCYSA-N 0.000 description 1
- HDBIHBNPUKCLTF-BDYUSTAISA-N CN1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound CN1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 HDBIHBNPUKCLTF-BDYUSTAISA-N 0.000 description 1
- GGZDILWRFPIJPR-XCZPVHLTSA-N COC(=O)C1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound COC(=O)C1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 GGZDILWRFPIJPR-XCZPVHLTSA-N 0.000 description 1
- BSVIIWGPAZYVHT-UPVQGACJSA-N COC(=O)CNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound COC(=O)CNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 BSVIIWGPAZYVHT-UPVQGACJSA-N 0.000 description 1
- PAAPRRANDBNBBJ-XCZPVHLTSA-N COC1=CC=C(CNCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C=N1 Chemical compound COC1=CC=C(CNCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C=N1 PAAPRRANDBNBBJ-XCZPVHLTSA-N 0.000 description 1
- VGIGZZXFJVQQCO-IQGAQJDESA-N COC1CCCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 Chemical compound COC1CCCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 VGIGZZXFJVQQCO-IQGAQJDESA-N 0.000 description 1
- CLROLADJIXMDFY-WNJJXGMVSA-N COC1CCN(CC2=CC3=C(C=C2)C[C@@H](N2C=CC4=CC(OC[C@@H]5CCCO5)=CC=C4C2=O)CC3)CC1 Chemical compound COC1CCN(CC2=CC3=C(C=C2)C[C@@H](N2C=CC4=CC(OC[C@@H]5CCCO5)=CC=C4C2=O)CC3)CC1 CLROLADJIXMDFY-WNJJXGMVSA-N 0.000 description 1
- UGIBMISSGRTKHI-WNJJXGMVSA-N COC1CCN(CC2=CC3=C(C=C2)C[C@@H](N2CCC4=CC(OC[C@@H]5CCCO5)=CC=C4C2=O)CC3)CC1 Chemical compound COC1CCN(CC2=CC3=C(C=C2)C[C@@H](N2CCC4=CC(OC[C@@H]5CCCO5)=CC=C4C2=O)CC3)CC1 UGIBMISSGRTKHI-WNJJXGMVSA-N 0.000 description 1
- UQQUKFZAEGPTOY-RUZDIDTESA-N COC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC4CCCCCC4)C=C2)CO3)CC1 Chemical compound COC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC4CCCCCC4)C=C2)CO3)CC1 UQQUKFZAEGPTOY-RUZDIDTESA-N 0.000 description 1
- LPIIGXMPRHVLPS-JOCHJYFZSA-N COC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OCC(C)C)N=C2)CO3)CC1 Chemical compound COC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OCC(C)C)N=C2)CO3)CC1 LPIIGXMPRHVLPS-JOCHJYFZSA-N 0.000 description 1
- IRRIURCEGSCJOB-VNBODJOOSA-N COC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 Chemical compound COC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 IRRIURCEGSCJOB-VNBODJOOSA-N 0.000 description 1
- ROHUIWJKZXVODL-LSYYVWMOSA-N COC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound COC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 ROHUIWJKZXVODL-LSYYVWMOSA-N 0.000 description 1
- HHIWUWAYHIOXMV-OZXSUGGESA-N COC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=NC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound COC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=NC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 HHIWUWAYHIOXMV-OZXSUGGESA-N 0.000 description 1
- RIZJDJFNJXPJIM-WNJJXGMVSA-N COC1CCN(CCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound COC1CCN(CCC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 RIZJDJFNJXPJIM-WNJJXGMVSA-N 0.000 description 1
- GBQMIJYECKRRLY-HFKVKABFSA-N COCC(C)NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound COCC(C)NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 GBQMIJYECKRRLY-HFKVKABFSA-N 0.000 description 1
- DTBWQQFYPQDXQJ-QBGWGINNSA-N COCC(O)CNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound COCC(O)CNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 DTBWQQFYPQDXQJ-QBGWGINNSA-N 0.000 description 1
- JZFOHOMDQZFFRV-QGWOSTIUSA-N COCC1CCCCN1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound COCC1CCCCN1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 JZFOHOMDQZFFRV-QGWOSTIUSA-N 0.000 description 1
- AAXJPFWYHZFWBB-YTMVLYRLSA-N COCC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound COCC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 AAXJPFWYHZFWBB-YTMVLYRLSA-N 0.000 description 1
- WUWLBMKYKZNWEA-BDYUSTAISA-N COCCCCCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound COCCCCCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 WUWLBMKYKZNWEA-BDYUSTAISA-N 0.000 description 1
- BCZLWPAJFFVTAB-AHWVRZQESA-N COCCCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound COCCCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 BCZLWPAJFFVTAB-AHWVRZQESA-N 0.000 description 1
- NRLLBTXSTQOURQ-BDYUSTAISA-N COCCCNCCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound COCCCNCCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 NRLLBTXSTQOURQ-BDYUSTAISA-N 0.000 description 1
- AHJSVLSJFKEJRN-AHWVRZQESA-N COCCN(C)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound COCCN(C)CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 AHJSVLSJFKEJRN-AHWVRZQESA-N 0.000 description 1
- BHVLQQTXXUYMQN-ZCYQVOJMSA-N COCCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound COCCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 BHVLQQTXXUYMQN-ZCYQVOJMSA-N 0.000 description 1
- BJLOJHDWAJEZPP-OAQYLSRUSA-N COCCOC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 Chemical compound COCCOC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 BJLOJHDWAJEZPP-OAQYLSRUSA-N 0.000 description 1
- UNRGAGSZFBSGOM-REUBFRLUSA-N COC[C@H]1CCCN1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound COC[C@H]1CCCN1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 UNRGAGSZFBSGOM-REUBFRLUSA-N 0.000 description 1
- IFYNXWOTOMIQKJ-OGUPFJCYSA-N CS(=O)(=O)C1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 Chemical compound CS(=O)(=O)C1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)C1 IFYNXWOTOMIQKJ-OGUPFJCYSA-N 0.000 description 1
- AFSFNPPEIYMQTM-ZCYQVOJMSA-N CS(=O)(=O)CCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound CS(=O)(=O)CCNCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 AFSFNPPEIYMQTM-ZCYQVOJMSA-N 0.000 description 1
- IUSVDOAFIQCXBQ-RAHIQWLESA-N C[C@@H](NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C(C)(C)C Chemical compound C[C@@H](NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C(C)(C)C IUSVDOAFIQCXBQ-RAHIQWLESA-N 0.000 description 1
- PUMDYFOCOZUDCK-JPDBUEETSA-N C[C@@H](NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C1CCCCC1 Chemical compound C[C@@H](NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C1CCCCC1 PUMDYFOCOZUDCK-JPDBUEETSA-N 0.000 description 1
- RBUPXSSHTGCUCJ-LJQNWDROSA-N C[C@@H](NCC1CCCC1)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound C[C@@H](NCC1CCCC1)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 RBUPXSSHTGCUCJ-LJQNWDROSA-N 0.000 description 1
- MWLBEAXHISNZRZ-LARUCZGFSA-N C[C@@H]1CCCCN1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound C[C@@H]1CCCCN1CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 MWLBEAXHISNZRZ-LARUCZGFSA-N 0.000 description 1
- MOVIXGALSAAQIP-AVPJRLCVSA-N C[C@@]1(O)CCC[C@H]1OC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 Chemical compound C[C@@]1(O)CCC[C@H]1OC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 MOVIXGALSAAQIP-AVPJRLCVSA-N 0.000 description 1
- WSBFUJUTOOZBGO-HSARQWDWSA-N C[C@H](C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)N(CC1CCCC1)CC1CCCC1 Chemical compound C[C@H](C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)N(CC1CCCC1)CC1CCCC1 WSBFUJUTOOZBGO-HSARQWDWSA-N 0.000 description 1
- CLYGPGIXMFJWTM-RVBRUHEGSA-N C[C@H](C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)N1CCCCCC1 Chemical compound C[C@H](C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)N1CCCCCC1 CLYGPGIXMFJWTM-RVBRUHEGSA-N 0.000 description 1
- FZZWWOYCJRMNJS-YROCYRMSSA-N C[C@H](N)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound C[C@H](N)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 FZZWWOYCJRMNJS-YROCYRMSSA-N 0.000 description 1
- PTBMMUHVMWXYTH-SSKOMTKWSA-N C[C@H](NC1CCCCC1)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound C[C@H](NC1CCCCC1)C1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 PTBMMUHVMWXYTH-SSKOMTKWSA-N 0.000 description 1
- IUSVDOAFIQCXBQ-OICBGKIFSA-N C[C@H](NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C(C)(C)C Chemical compound C[C@H](NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C(C)(C)C IUSVDOAFIQCXBQ-OICBGKIFSA-N 0.000 description 1
- PUMDYFOCOZUDCK-XFHDSQNASA-N C[C@H](NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C1CCCCC1 Chemical compound C[C@H](NCC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2)C1CCCCC1 PUMDYFOCOZUDCK-XFHDSQNASA-N 0.000 description 1
- XUYWYBDRZBVAKE-NJNPRVFISA-N C[C@H](O)[C@@H](C)OC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 Chemical compound C[C@H](O)[C@@H](C)OC1=CC=C(C(=O)N[C@H]2COC3=C(C=CC(CN4CCCC4)=C3)C2)C=C1 XUYWYBDRZBVAKE-NJNPRVFISA-N 0.000 description 1
- RBFIYJRLKRIEGX-XCZPVHLTSA-N N#CC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 Chemical compound N#CC1CCN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CC1 RBFIYJRLKRIEGX-XCZPVHLTSA-N 0.000 description 1
- OPHXGIPUJWBLJI-RSXGOPAZSA-N O=C(N[C@@H]1CCC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@@H]1CCC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 OPHXGIPUJWBLJI-RSXGOPAZSA-N 0.000 description 1
- XSUFYUHTGPCRGB-BRVRNLPISA-N O=C(N[C@H]1CCC2=C(C=CC(C3CCCCN3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(C3CCCCN3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 XSUFYUHTGPCRGB-BRVRNLPISA-N 0.000 description 1
- YLFQOEBMZQWCSK-CVYBXRIJSA-N O=C(N[C@H]1CCC2=C(C=CC(C3CCCCN3CC3CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(C3CCCCN3CC3CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 YLFQOEBMZQWCSK-CVYBXRIJSA-N 0.000 description 1
- HDJHINUDLLUAFL-BIPIZLCXSA-N O=C(N[C@H]1CCC2=C(C=CC(C3CCCN(CC4CC4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(C3CCCN(CC4CC4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 HDJHINUDLLUAFL-BIPIZLCXSA-N 0.000 description 1
- MMZJZBDTZJWXIM-VNNQTNQMSA-N O=C(N[C@H]1CCC2=C(C=CC(C3CCCNC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(C3CCCNC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 MMZJZBDTZJWXIM-VNNQTNQMSA-N 0.000 description 1
- HIWILABNKXFPMO-XCZPVHLTSA-N O=C(N[C@H]1CCC2=C(C=CC(CCCC3CCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CCCC3CCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 HIWILABNKXFPMO-XCZPVHLTSA-N 0.000 description 1
- HEONJSKVAHMJIT-JDXGNMNLSA-N O=C(N[C@H]1CCC2=C(C=CC(CCCC3CCCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CCCC3CCCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 HEONJSKVAHMJIT-JDXGNMNLSA-N 0.000 description 1
- PCEZVYWMFIZKMF-YTMVLYRLSA-N O=C(N[C@H]1CCC2=C(C=CC(CCCC3CCOCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CCCC3CCOCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 PCEZVYWMFIZKMF-YTMVLYRLSA-N 0.000 description 1
- AIFHFHSBDAVXNO-OZXSUGGESA-N O=C(N[C@H]1CCC2=C(C=CC(CCN3CC(O)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CCN3CC(O)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 AIFHFHSBDAVXNO-OZXSUGGESA-N 0.000 description 1
- OYPZFXDDOOIJMW-SYFQUZJUSA-N O=C(N[C@H]1CCC2=C(C=CC(CCN3CC4CCC(C4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CCN3CC4CCC(C4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 OYPZFXDDOOIJMW-SYFQUZJUSA-N 0.000 description 1
- NVKQCANVLYDQKP-JIBYJJDDSA-N O=C(N[C@H]1CCC2=C(C=CC(CCN3CC4CCC3CC4)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CCN3CC4CCC3CC4)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 NVKQCANVLYDQKP-JIBYJJDDSA-N 0.000 description 1
- AELJJWCKEFIBAN-LSYYVWMOSA-N O=C(N[C@H]1CCC2=C(C=CC(CCN3CCC(O)CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CCN3CCC(O)CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 AELJJWCKEFIBAN-LSYYVWMOSA-N 0.000 description 1
- VZDVMJGSVWXTPL-BDYUSTAISA-N O=C(N[C@H]1CCC2=C(C=CC(CCN3CCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CCN3CCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 VZDVMJGSVWXTPL-BDYUSTAISA-N 0.000 description 1
- VWGZZUXFGLBGRW-BDYUSTAISA-N O=C(N[C@H]1CCC2=C(C=CC(CCNCC3CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CCNCC3CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 VWGZZUXFGLBGRW-BDYUSTAISA-N 0.000 description 1
- LYRQENBBCQNDLL-DZUIKGQPSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3C4CCC3C3(CC3)C4)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3C4CCC3C3(CC3)C4)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 LYRQENBBCQNDLL-DZUIKGQPSA-N 0.000 description 1
- YVEHZNMXIHPYMW-ASVGVZQUSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3C4CCC3CC(O)C4)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3C4CCC3CC(O)C4)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 YVEHZNMXIHPYMW-ASVGVZQUSA-N 0.000 description 1
- SSIWIHJSYVMKJB-DHLKQENFSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CC(O)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CC(O)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 SSIWIHJSYVMKJB-DHLKQENFSA-N 0.000 description 1
- HBYPBCUUPSRSLN-LWBIIHDLSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CC4CCC(C4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CC4CCC(C4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 HBYPBCUUPSRSLN-LWBIIHDLSA-N 0.000 description 1
- WZETWNXOTHFDMS-TUOYVSMPSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CC4CCC3C4)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CC4CCC3C4)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 WZETWNXOTHFDMS-TUOYVSMPSA-N 0.000 description 1
- SQZBJSHIRAWGIE-QORGCAQBSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CC4CCC3C4)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CC4CCC3C4)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 SQZBJSHIRAWGIE-QORGCAQBSA-N 0.000 description 1
- MMLKPXZUFVRHLK-VYUPJMSVSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CC4CCC3CC4)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CC4CCC3CC4)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 MMLKPXZUFVRHLK-VYUPJMSVSA-N 0.000 description 1
- QVSDSJIIFJMEHY-XELBMSLBSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CC4CCCC4C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CC4CCCC4C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 QVSDSJIIFJMEHY-XELBMSLBSA-N 0.000 description 1
- DGNCYYMQYJZFAM-SPSLYSOASA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CC4CCCC4C3)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CC4CCCC4C3)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 DGNCYYMQYJZFAM-SPSLYSOASA-N 0.000 description 1
- NSTMJGGUOVTABA-AHWVRZQESA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCC(F)(F)CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCC(F)(F)CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 NSTMJGGUOVTABA-AHWVRZQESA-N 0.000 description 1
- VMUZBYVAMVRAAD-BDYUSTAISA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCC(F)CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCC(F)CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 VMUZBYVAMVRAAD-BDYUSTAISA-N 0.000 description 1
- YVTBWCLSAOGTKE-IGKIAQTJSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCC(O)CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCC(O)CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 YVTBWCLSAOGTKE-IGKIAQTJSA-N 0.000 description 1
- GTBNIPCBLWXJQF-ZCYQVOJMSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 GTBNIPCBLWXJQF-ZCYQVOJMSA-N 0.000 description 1
- PGQPYKZQCFFMCC-XCZPVHLTSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCC4(CC3)CC4)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCC4(CC3)CC4)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 PGQPYKZQCFFMCC-XCZPVHLTSA-N 0.000 description 1
- XKBCZRXNPZATGF-XCZPVHLTSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCC4(CC3)OCCO4)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCC4(CC3)OCCO4)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 XKBCZRXNPZATGF-XCZPVHLTSA-N 0.000 description 1
- KBKQMJRJLVLRIN-YTMVLYRLSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCC4(CCCC4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCC4(CCCC4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 KBKQMJRJLVLRIN-YTMVLYRLSA-N 0.000 description 1
- JQLUZNREGIMBKB-BDYUSTAISA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCC4(CCCC4)C3)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCC4(CCCC4)C3)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 JQLUZNREGIMBKB-BDYUSTAISA-N 0.000 description 1
- YUKIHVWUPWXGJW-JDXGNMNLSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCC4(CCCCC4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCC4(CCCCC4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 YUKIHVWUPWXGJW-JDXGNMNLSA-N 0.000 description 1
- XMOIKIZVCBHWMD-SMCANUKXSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCC4=C(C=CC=C4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCC4=C(C=CC=C4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 XMOIKIZVCBHWMD-SMCANUKXSA-N 0.000 description 1
- IJGYLXMJUYLTAR-XICMLOBYSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCCC(F)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCCC(F)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 IJGYLXMJUYLTAR-XICMLOBYSA-N 0.000 description 1
- OAGZVTWTAXGIPW-OYLCDDCGSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCCC(O)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCCC(O)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 OAGZVTWTAXGIPW-OYLCDDCGSA-N 0.000 description 1
- ZYOLVACPHACZBV-UPVQGACJSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCCC3)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCCC3)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 ZYOLVACPHACZBV-UPVQGACJSA-N 0.000 description 1
- SIWQNNFHXLXYPE-BDYUSTAISA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 SIWQNNFHXLXYPE-BDYUSTAISA-N 0.000 description 1
- NCZIRYCCBRLALW-UIOOFZCWSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCCC3)=C2)C1)C1=CC(F)=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCCC3)=C2)C1)C1=CC(F)=C(OC[C@@H]2CCCO2)C=C1 NCZIRYCCBRLALW-UIOOFZCWSA-N 0.000 description 1
- FFPSXIADFMLZFF-BVOOQYFDSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCCC3)=C2)C1)C1=CC=C(OCC2CCCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCCC3)=C2)C1)C1=CC=C(OCC2CCCCO2)C=C1 FFPSXIADFMLZFF-BVOOQYFDSA-N 0.000 description 1
- BJUYRARLMGAADF-NDEPHWFRSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCCC3)=C2)C1)C1=CC=C(OCC2CCOCC2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCCC3)=C2)C1)C1=CC=C(OCC2CCOCC2)C=C1 BJUYRARLMGAADF-NDEPHWFRSA-N 0.000 description 1
- AXYIWAWHNRYZKZ-VWLOTQADSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCCC3)=C2)C1)C1=CC=C(OCC2OCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCCC3)=C2)C1)C1=CC=C(OCC2OCCO2)C=C1 AXYIWAWHNRYZKZ-VWLOTQADSA-N 0.000 description 1
- IIVXJALMQSZFTJ-XCZPVHLTSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 IIVXJALMQSZFTJ-XCZPVHLTSA-N 0.000 description 1
- IIVXJALMQSZFTJ-XTEPFMGCSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCCC3)=C2)C1)C1=CC=C(OC[C@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCCC3)=C2)C1)C1=CC=C(OC[C@H]2CCCO2)C=C1 IIVXJALMQSZFTJ-XTEPFMGCSA-N 0.000 description 1
- MTHSCUWKBMANMQ-AHWVRZQESA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCCC3)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCCC3)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 MTHSCUWKBMANMQ-AHWVRZQESA-N 0.000 description 1
- CGEJYQXKMILESZ-YTMVLYRLSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCCCCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 CGEJYQXKMILESZ-YTMVLYRLSA-N 0.000 description 1
- LYSONIZACIHUNW-BDYUSTAISA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCCOCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCCOCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 LYSONIZACIHUNW-BDYUSTAISA-N 0.000 description 1
- CIPYHQNAQRVWRB-AHWVRZQESA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCOCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCOCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 CIPYHQNAQRVWRB-AHWVRZQESA-N 0.000 description 1
- WILNJNMZGREWGY-AHWVRZQESA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CCS(=O)(=O)CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CCS(=O)(=O)CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 WILNJNMZGREWGY-AHWVRZQESA-N 0.000 description 1
- PCRPOFMAZNRZAM-USZFVNFHSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CC[C@@H](F)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CC[C@@H](F)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 PCRPOFMAZNRZAM-USZFVNFHSA-N 0.000 description 1
- IXDBSNJUYPZCIM-GSLIJJQTSA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CC[C@@H](O)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CC[C@@H](O)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 IXDBSNJUYPZCIM-GSLIJJQTSA-N 0.000 description 1
- PCRPOFMAZNRZAM-GNKBHMEESA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CC[C@H](F)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CC[C@H](F)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 PCRPOFMAZNRZAM-GNKBHMEESA-N 0.000 description 1
- IXDBSNJUYPZCIM-GNKBHMEESA-N O=C(N[C@H]1CCC2=C(C=CC(CN3CC[C@H](O)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN3CC[C@H](O)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 IXDBSNJUYPZCIM-GNKBHMEESA-N 0.000 description 1
- OOZGRXQBEUNWJX-DHLKQENFSA-N O=C(N[C@H]1CCC2=C(C=CC(CNC(CO)CO)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNC(CO)CO)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 OOZGRXQBEUNWJX-DHLKQENFSA-N 0.000 description 1
- NWJCCTRRLFEPRW-ZCYQVOJMSA-N O=C(N[C@H]1CCC2=C(C=CC(CNC3CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNC3CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 NWJCCTRRLFEPRW-ZCYQVOJMSA-N 0.000 description 1
- BNHZPCOHNRAPDP-ZFUGNCTFSA-N O=C(N[C@H]1CCC2=C(C=CC(CNC3CC4CCC3C4)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNC3CC4CCC3C4)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 BNHZPCOHNRAPDP-ZFUGNCTFSA-N 0.000 description 1
- QFVOKUZZJKYREI-AHWVRZQESA-N O=C(N[C@H]1CCC2=C(C=CC(CNC3CCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNC3CCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 QFVOKUZZJKYREI-AHWVRZQESA-N 0.000 description 1
- MFYXXFYOOZHTNC-DOEKRREGSA-N O=C(N[C@H]1CCC2=C(C=CC(CNC3CCC4=C3C=CC=C4)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNC3CCC4=C3C=CC=C4)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 MFYXXFYOOZHTNC-DOEKRREGSA-N 0.000 description 1
- DPOLWOGXZWATOA-BDYUSTAISA-N O=C(N[C@H]1CCC2=C(C=CC(CNC3CCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNC3CCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 DPOLWOGXZWATOA-BDYUSTAISA-N 0.000 description 1
- CPSCQUXXXCHWBY-XCZPVHLTSA-N O=C(N[C@H]1CCC2=C(C=CC(CNC3CCCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNC3CCCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 CPSCQUXXXCHWBY-XCZPVHLTSA-N 0.000 description 1
- LZBFIAJHVBEQGT-AHWVRZQESA-N O=C(N[C@H]1CCC2=C(C=CC(CNC3CCCCC3)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNC3CCCCC3)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 LZBFIAJHVBEQGT-AHWVRZQESA-N 0.000 description 1
- VBKDFOMIXLPXHI-CJYPUVKASA-N O=C(N[C@H]1CCC2=C(C=CC(CNC3CCCCC3O)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNC3CCCCC3O)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 VBKDFOMIXLPXHI-CJYPUVKASA-N 0.000 description 1
- JKZJMTCDIZVYPA-YTMVLYRLSA-N O=C(N[C@H]1CCC2=C(C=CC(CNC3CCCCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNC3CCCCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 JKZJMTCDIZVYPA-YTMVLYRLSA-N 0.000 description 1
- IXAFIIQEXZBSBU-CBYROYASSA-N O=C(N[C@H]1CCC2=C(C=CC(CNC3CCCCCC3=O)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNC3CCCCCC3=O)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 IXAFIIQEXZBSBU-CBYROYASSA-N 0.000 description 1
- GASMSPGHQDOXOI-OYLCDDCGSA-N O=C(N[C@H]1CCC2=C(C=CC(CNC3CCCOC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNC3CCCOC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 GASMSPGHQDOXOI-OYLCDDCGSA-N 0.000 description 1
- MHXQAPZBHBPPHJ-BDYUSTAISA-N O=C(N[C@H]1CCC2=C(C=CC(CNC3CCOCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNC3CCOCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 MHXQAPZBHBPPHJ-BDYUSTAISA-N 0.000 description 1
- WENFXSDCTMBKPO-GMAHTHKFSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCC(F)(F)F)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCC(F)(F)F)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 WENFXSDCTMBKPO-GMAHTHKFSA-N 0.000 description 1
- FQWNDYRJSJMDNV-GMAHTHKFSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCC(F)F)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCC(F)F)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 FQWNDYRJSJMDNV-GMAHTHKFSA-N 0.000 description 1
- GXXHPAPXSPYHHP-GXBCDIMNSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCC(O)C(F)(F)F)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCC(O)C(F)(F)F)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 GXXHPAPXSPYHHP-GXBCDIMNSA-N 0.000 description 1
- MWQNOAHMAIAAAJ-MFXHTCIWSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCC(O)CO)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCC(O)CO)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 MWQNOAHMAIAAAJ-MFXHTCIWSA-N 0.000 description 1
- LDUBWRJPBBWILD-AHWVRZQESA-N O=C(N[C@H]1CCC2=C(C=CC(CNCC3CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCC3CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 LDUBWRJPBBWILD-AHWVRZQESA-N 0.000 description 1
- RNEODSBIQGBLBI-UPVQGACJSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCC3CC3)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCC3CC3)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 RNEODSBIQGBLBI-UPVQGACJSA-N 0.000 description 1
- HTJGBKLHOXGNNI-BDYUSTAISA-N O=C(N[C@H]1CCC2=C(C=CC(CNCC3CCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCC3CCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 HTJGBKLHOXGNNI-BDYUSTAISA-N 0.000 description 1
- XKALHMZMWOOBJK-XCZPVHLTSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCC3CCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCC3CCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 XKALHMZMWOOBJK-XCZPVHLTSA-N 0.000 description 1
- UZMIUJPXNLVLMY-AHWVRZQESA-N O=C(N[C@H]1CCC2=C(C=CC(CNCC3CCCC3)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCC3CCCC3)=C2)C1)C1=NC=C(OC[C@@H]2CCCO2)C=C1 UZMIUJPXNLVLMY-AHWVRZQESA-N 0.000 description 1
- PYUKPBFTDPZKAG-YTMVLYRLSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCC3CCCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCC3CCCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 PYUKPBFTDPZKAG-YTMVLYRLSA-N 0.000 description 1
- UOKPPRZRMJTEPC-JDXGNMNLSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCC3CCCCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCC3CCCCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 UOKPPRZRMJTEPC-JDXGNMNLSA-N 0.000 description 1
- ZZXYGOBRISUTIY-VNBODJOOSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCC3CCCO3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCC3CCCO3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 ZZXYGOBRISUTIY-VNBODJOOSA-N 0.000 description 1
- UBQSKNNFMSQSBM-XCZPVHLTSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCC3CCOCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCC3CCOCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 UBQSKNNFMSQSBM-XCZPVHLTSA-N 0.000 description 1
- JPWZYSRQQOMUTR-OGUPFJCYSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCC3COCCO3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCC3COCCO3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 JPWZYSRQQOMUTR-OGUPFJCYSA-N 0.000 description 1
- PPMJMCPWEILHIG-ZCYQVOJMSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCC3OCCO3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCC3OCCO3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 PPMJMCPWEILHIG-ZCYQVOJMSA-N 0.000 description 1
- FRJBWZGLKHMJHY-JDXGNMNLSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCCC3=CCCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCCC3=CCCCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 FRJBWZGLKHMJHY-JDXGNMNLSA-N 0.000 description 1
- NKUUSNFNOCHUTE-BDYUSTAISA-N O=C(N[C@H]1CCC2=C(C=CC(CNCCC3CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCCC3CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 NKUUSNFNOCHUTE-BDYUSTAISA-N 0.000 description 1
- BDMHQWZWFOKPFI-ZCYQVOJMSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCCCC(F)(F)F)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCCCC(F)(F)F)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 BDMHQWZWFOKPFI-ZCYQVOJMSA-N 0.000 description 1
- RLASPFOZNMDUJD-YTMVLYRLSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCCCC3CCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCCCC3CCC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 RLASPFOZNMDUJD-YTMVLYRLSA-N 0.000 description 1
- DMCNVAXKXMDWTN-ZCYQVOJMSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCCCF)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCCCF)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 DMCNVAXKXMDWTN-ZCYQVOJMSA-N 0.000 description 1
- ZXUGXHAEFUKLKX-XCZPVHLTSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCCCN3C=CN=C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCCCN3C=CN=C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 ZXUGXHAEFUKLKX-XCZPVHLTSA-N 0.000 description 1
- ZHPKYUYUYWPHDC-XCZPVHLTSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCCCN3CCCC3=O)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCCCN3CCCC3=O)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 ZHPKYUYUYWPHDC-XCZPVHLTSA-N 0.000 description 1
- UKBURROYCCXFST-UPVQGACJSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCCF)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCCF)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 UKBURROYCCXFST-UPVQGACJSA-N 0.000 description 1
- KTARQQURNQHWJH-AHWVRZQESA-N O=C(N[C@H]1CCC2=C(C=CC(CNCCN3CCNC3=O)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCCN3CCNC3=O)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 KTARQQURNQHWJH-AHWVRZQESA-N 0.000 description 1
- MTKMSLPEZBBOES-FIBWVYCGSA-N O=C(N[C@H]1CCC2=C(C=CC(CNCCOC3=CC=CC=C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CNCCOC3=CC=CC=C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 MTKMSLPEZBBOES-FIBWVYCGSA-N 0.000 description 1
- GVSRPIXGBXOSRY-CYPWOGTMSA-N O=C(N[C@H]1CCC2=C(C=CC(CN[C@@H]3C4=C(C=CC=C4)C[C@H]3O)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN[C@@H]3C4=C(C=CC=C4)C[C@H]3O)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 GVSRPIXGBXOSRY-CYPWOGTMSA-N 0.000 description 1
- GVSRPIXGBXOSRY-XRCDWDDJSA-N O=C(N[C@H]1CCC2=C(C=CC(CN[C@H]3C4=C(C=CC=C4)C[C@H]3O)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN[C@H]3C4=C(C=CC=C4)C[C@H]3O)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 GVSRPIXGBXOSRY-XRCDWDDJSA-N 0.000 description 1
- KQBRCDDNEKDEQL-MNUOIFNESA-N O=C(N[C@H]1CCC2=C(C=CC(CN[C@H]3CCC[C@@H]3O)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN[C@H]3CCC[C@@H]3O)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 KQBRCDDNEKDEQL-MNUOIFNESA-N 0.000 description 1
- VVVLNQAUAGHCEO-OBXRUURASA-N O=C(N[C@H]1CCC2=C(C=CC(CN[C@H]3CC[C@H](O)CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC(CN[C@H]3CC[C@H](O)CC3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 VVVLNQAUAGHCEO-OBXRUURASA-N 0.000 description 1
- NJDHLGGAFLGTKY-PRMIEGHPSA-N O=C(N[C@H]1CCC2=C(C=CC([C@@H]3CCCN(C4CCCCC4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC([C@@H]3CCCN(C4CCCCC4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 NJDHLGGAFLGTKY-PRMIEGHPSA-N 0.000 description 1
- YWJKHVHCYHMPNL-XHWIWGEHSA-N O=C(N[C@H]1CCC2=C(C=CC([C@@H]3CCCN(C4CCOCC4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC([C@@H]3CCCN(C4CCOCC4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 YWJKHVHCYHMPNL-XHWIWGEHSA-N 0.000 description 1
- NJDHLGGAFLGTKY-OLWNVYNHSA-N O=C(N[C@H]1CCC2=C(C=CC([C@H]3CCCN(C4CCCCC4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC([C@H]3CCCN(C4CCCCC4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 NJDHLGGAFLGTKY-OLWNVYNHSA-N 0.000 description 1
- YWJKHVHCYHMPNL-QYDYLWNGSA-N O=C(N[C@H]1CCC2=C(C=CC([C@H]3CCCN(C4CCOCC4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1CCC2=C(C=CC([C@H]3CCCN(C4CCOCC4)C3)=C2)C1)C1=CC=C(OC[C@@H]2CCCO2)C=C1 YWJKHVHCYHMPNL-QYDYLWNGSA-N 0.000 description 1
- CKDZEOUIWJXKEN-XMMPIXPASA-N O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(NC(=O)C2=CCCC2)C=C1 Chemical compound O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(NC(=O)C2=CCCC2)C=C1 CKDZEOUIWJXKEN-XMMPIXPASA-N 0.000 description 1
- ALXJBNIVWVEKJG-XMMPIXPASA-N O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(NC(=O)C2CCCC2)C=C1 Chemical compound O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(NC(=O)C2CCCC2)C=C1 ALXJBNIVWVEKJG-XMMPIXPASA-N 0.000 description 1
- OSQROPHPTKSHFT-JOCHJYFZSA-N O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(OC2CCCC2)C=C1 Chemical compound O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(OC2CCCC2)C=C1 OSQROPHPTKSHFT-JOCHJYFZSA-N 0.000 description 1
- ZXEDXKXHJAGEJV-LETIRJCYSA-N O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(OC2CCCOC2)C=C1 Chemical compound O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(OC2CCCOC2)C=C1 ZXEDXKXHJAGEJV-LETIRJCYSA-N 0.000 description 1
- ZATKSXOMXANVNY-JOCHJYFZSA-N O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(OCC2CC2)C=C1 Chemical compound O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(OCC2CC2)C=C1 ZATKSXOMXANVNY-JOCHJYFZSA-N 0.000 description 1
- VQMWGTLVERFQTN-HSZRJFAPSA-N O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(OCCN2CCCC2=O)C=C1 Chemical compound O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(OCCN2CCCC2=O)C=C1 VQMWGTLVERFQTN-HSZRJFAPSA-N 0.000 description 1
- AZMBXWHYSMMXHM-ISKFKSNPSA-N O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(OC[C@H]2CCCO2)C=C1 Chemical compound O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(OC[C@H]2CCCO2)C=C1 AZMBXWHYSMMXHM-ISKFKSNPSA-N 0.000 description 1
- LFWPWEHCAMHLOM-GMKZXUHWSA-N O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(O[C@@H]2CCC[C@H]2O)C=C1 Chemical compound O=C(N[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1)C1=CC=C(O[C@@H]2CCC[C@H]2O)C=C1 LFWPWEHCAMHLOM-GMKZXUHWSA-N 0.000 description 1
- LINJWJAVEVYXNH-OGUPFJCYSA-N O=C(c(cc1)ccc1OC[C@H]1OCCC1)N[C@@H](CC1)Cc2c1cc(CNC(CCCCN1)C1=O)cc2 Chemical compound O=C(c(cc1)ccc1OC[C@H]1OCCC1)N[C@@H](CC1)Cc2c1cc(CNC(CCCCN1)C1=O)cc2 LINJWJAVEVYXNH-OGUPFJCYSA-N 0.000 description 1
- CWWFQVFUPKAATQ-FCMLDSNUSA-N O=C(c(cc1)ccc1O[C@H](C1)C11OCCC1)N[C@@H](CC1)Cc2c1cc(CCNC1CCC1)cc2 Chemical compound O=C(c(cc1)ccc1O[C@H](C1)C11OCCC1)N[C@@H](CC1)Cc2c1cc(CCNC1CCC1)cc2 CWWFQVFUPKAATQ-FCMLDSNUSA-N 0.000 description 1
- XNRMPURQVXWHMH-FYYCDXOSSA-N O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(/C=C\C(CN3CC4CCC3CC4)=C/2)C1 Chemical compound O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(/C=C\C(CN3CC4CCC3CC4)=C/2)C1 XNRMPURQVXWHMH-FYYCDXOSSA-N 0.000 description 1
- UUSUIRKKQLOJGY-BHCZWRPHSA-N O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(C=CC(CN3CC4CCC3C4)=C2)C1 Chemical compound O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(C=CC(CN3CC4CCC3C4)=C2)C1 UUSUIRKKQLOJGY-BHCZWRPHSA-N 0.000 description 1
- WDYZLWOZNVQIJW-BDYUSTAISA-N O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(C=CC(CN3CCCC3)=C2)C1 Chemical compound O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(C=CC(CN3CCCC3)=C2)C1 WDYZLWOZNVQIJW-BDYUSTAISA-N 0.000 description 1
- RSWOOWFVCGVGKK-XCZPVHLTSA-N O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(C=CC(CN3CCCCC3)=C2)C1 Chemical compound O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(C=CC(CN3CCCCC3)=C2)C1 RSWOOWFVCGVGKK-XCZPVHLTSA-N 0.000 description 1
- VZWWQGTVDXKLKJ-YTMVLYRLSA-N O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(C=CC(CNC3CCCCC3)=C2)C1 Chemical compound O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(C=CC(CNC3CCCCC3)=C2)C1 VZWWQGTVDXKLKJ-YTMVLYRLSA-N 0.000 description 1
- NSHRJSQQEYOVDN-XCZPVHLTSA-N O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(C=CC(CNC3CCOCC3)=C2)C1 Chemical compound O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(C=CC(CNC3CCOCC3)=C2)C1 NSHRJSQQEYOVDN-XCZPVHLTSA-N 0.000 description 1
- AXCHADCPEVNUHT-BDYUSTAISA-N O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(C=CC(CNCC3CC3)=C2)C1 Chemical compound O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(C=CC(CNCC3CC3)=C2)C1 AXCHADCPEVNUHT-BDYUSTAISA-N 0.000 description 1
- PHJTUZBBIMGEGN-XCZPVHLTSA-N O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(C=CC(CNCC3CCC3)=C2)C1 Chemical compound O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(C=CC(CNCC3CCC3)=C2)C1 PHJTUZBBIMGEGN-XCZPVHLTSA-N 0.000 description 1
- IEBAZJZTXTXOEB-YTMVLYRLSA-N O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(C=CC(CNCC3CCCC3)=C2)C1 Chemical compound O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(C=CC(CNCC3CCCC3)=C2)C1 IEBAZJZTXTXOEB-YTMVLYRLSA-N 0.000 description 1
- FGAZYLPZJAESIT-YTMVLYRLSA-N O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(C=CC(CNCC3CCOCC3)=C2)C1 Chemical compound O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1CCC2=C(C=CC(CNCC3CCOCC3)=C2)C1 FGAZYLPZJAESIT-YTMVLYRLSA-N 0.000 description 1
- UWWOMXIZTHMDJH-NOZRDPDXSA-N O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1 Chemical compound O=C1C2=CC=C(OC[C@@H]3CCCO3)C=C2CCN1[C@H]1COC2=C(C=CC(CN3CCCC3)=C2)C1 UWWOMXIZTHMDJH-NOZRDPDXSA-N 0.000 description 1
- CHGGKUAYMQNZMI-ZCYQVOJMSA-N O=C1CN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CCN1 Chemical compound O=C1CN(CC2=CC3=C(C=C2)C[C@@H](NC(=O)C2=CC=C(OC[C@@H]4CCCO4)C=C2)CC3)CCN1 CHGGKUAYMQNZMI-ZCYQVOJMSA-N 0.000 description 1
- XJWPVGPRISNXHP-NLALRGLNSA-N [H][C@@]12CC[C@@]([H])(CN1CCC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 Chemical compound [H][C@@]12CC[C@@]([H])(CN1CCC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 XJWPVGPRISNXHP-NLALRGLNSA-N 0.000 description 1
- OROGTFYLBIWVNA-OSWHCFOWSA-N [H][C@]12CCCC[C@]1([H])CCCN2CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound [H][C@]12CCCC[C@]1([H])CCCN2CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 OROGTFYLBIWVNA-OSWHCFOWSA-N 0.000 description 1
- OQMBHKBYLRYPDB-VXKPSODKSA-N [H][C@]12CCCC[C@]1([H])CCN(CC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 Chemical compound [H][C@]12CCCC[C@]1([H])CCN(CC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 OQMBHKBYLRYPDB-VXKPSODKSA-N 0.000 description 1
- CJAXSUKRZFJYGF-KEGBZTQNSA-N [H][C@]12CC[C@]([H])(C1)C(CCNCC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 Chemical compound [H][C@]12CC[C@]([H])(C1)C(CCNCC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 CJAXSUKRZFJYGF-KEGBZTQNSA-N 0.000 description 1
- WZETWNXOTHFDMS-HMZPFFFMSA-N [H][C@]12CC[C@]([H])(C1)N(CC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 Chemical compound [H][C@]12CC[C@]([H])(C1)N(CC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 WZETWNXOTHFDMS-HMZPFFFMSA-N 0.000 description 1
- WNLZOOCIHGVNNG-HTZNEOPZSA-N [H][C@]12CC[C@]([H])(C1)[C@@H](CCCC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 Chemical compound [H][C@]12CC[C@]([H])(C1)[C@@H](CCCC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 WNLZOOCIHGVNNG-HTZNEOPZSA-N 0.000 description 1
- WNLZOOCIHGVNNG-QIKFUENHSA-N [H][C@]12CC[C@]([H])(C1)[C@H](CCCC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 Chemical compound [H][C@]12CC[C@]([H])(C1)[C@H](CCCC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 WNLZOOCIHGVNNG-QIKFUENHSA-N 0.000 description 1
- QBCBWWBWHNLWQW-IQTZWRCFSA-N [H][C@]12CC[C@]([H])(C1)[C@H](NCC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 Chemical compound [H][C@]12CC[C@]([H])(C1)[C@H](NCC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 QBCBWWBWHNLWQW-IQTZWRCFSA-N 0.000 description 1
- WJFJLWJHHGGJHW-VAPSASEMSA-N [H][C@]12CC[C@]([H])(CC1)CN(CC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 Chemical compound [H][C@]12CC[C@]([H])(CC1)CN(CC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 WJFJLWJHHGGJHW-VAPSASEMSA-N 0.000 description 1
- HLXZIWFWGPNVRA-NAVOWQOKSA-N [H][C@]12CC[C@]([H])(CC1)N2CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 Chemical compound [H][C@]12CC[C@]([H])(CC1)N2CC1=CC2=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]3CCCO3)C=C1)CC2 HLXZIWFWGPNVRA-NAVOWQOKSA-N 0.000 description 1
- UEGYMHIVLBRONT-QFVIIZQESA-N [H][C@]12CN(C(C)=O)[C@]([H])(CN1CC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 Chemical compound [H][C@]12CN(C(C)=O)[C@]([H])(CN1CC1=CC3=C(C=C1)C[C@@H](NC(=O)C1=CC=C(OC[C@@H]4CCCO4)C=C1)CC3)C2 UEGYMHIVLBRONT-QFVIIZQESA-N 0.000 description 1
- YBKGWZWCNYGMMB-XLXZRNDBSA-N [H][C@]12CN(CC3=CC4=C(C=C3)C[C@@H](NC(=O)C3=CC=C(OC[C@@H]5CCCO5)C=C3)CC4)[C@]([H])(CN1)C2 Chemical compound [H][C@]12CN(CC3=CC4=C(C=C3)C[C@@H](NC(=O)C3=CC=C(OC[C@@H]5CCCO5)C=C3)CC4)[C@]([H])(CN1)C2 YBKGWZWCNYGMMB-XLXZRNDBSA-N 0.000 description 1
- XPAASYHCDGVJJA-DROSFRCNSA-N [H][C@]12CN(CC3=CC4=C(C=C3)C[C@@H](NC(=O)C3=CC=C(OC[C@@H]5CCCO5)C=C3)CC4)[C@]([H])(CO1)C2 Chemical compound [H][C@]12CN(CC3=CC4=C(C=C3)C[C@@H](NC(=O)C3=CC=C(OC[C@@H]5CCCO5)C=C3)CC4)[C@]([H])(CO1)C2 XPAASYHCDGVJJA-DROSFRCNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/12—Radicals substituted by oxygen atoms
Definitions
- the invention relates to substituted tetrahydronaphthalenes and derivatives thereof, and also to the physiologically compatible salts and physiologically functional derivatives thereof, to preparation thereof, to medicaments comprising at least one inventive substituted tetrahydronaphthalene or derivative thereof, and to the use of the inventive substituted tetrahydronaphthalenes and derivatives thereof as medicaments.
- the invention therefore relates to compounds of the formula I
- a 5-6-membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatom from the group of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur; q, r are each independently 0, 1, 2, 3, 4, 5, 6;
- ⁇ are each independently H, OH, F, O—(C 1 -C 6 )-alkyl, S—(C 1 -C 6 )-alkyl, O-phenyl, CN, COO(R25), N(R26)CO(C 1 -C 6 )-alkyl, N(R27)(R28), CON(R29)(R30), SO 2 (C 1 -C 6 )-alkyl, 3-12-membered mono-, bi- or spirocyclic ring which may contain one to four heteroatoms from the group of N, O and S, and the 3-12-membered ring may contain further substituents such as F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , oxo, O—(C 1 -C 6 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 8
- L1 is C(R34)(R35), C(R36)(R37)C(R38)(R39), (C 3 -C 6 )-cycloalkyl; optionally, R1 may be joined to one of the R34, R35, R36, R37, R38 or R39 radicals, so as to form a 5-6-membered ring;
- X is O, C(R43)(R43′);
- R6 and R6′, or R43 and R43′ together are optionally oxo;
- R8 is H, (C 1 -C 8 )-alkyl;
- L2 is a bond, C(R44)(R45);
- C 1 -C 8 are each independently H, (C 1 -C 8 )-alkyl;
- L3 is a bond or a linker having from 1 to 4 members, where the members are selected from the group consisting of O, S, SO 2 , N(R61), CO, C(R62)(R63), C ⁇ C, to give rise to a chemically viable radical, and the linker does not have any O—CO or COO groups;
- B is (C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 -C 6 )-alkyl, a 3 to 10-membered mono-, bi- or spirocyclic nonaromatic ring which may include from 0 to 3 heteroatom
- L3 is C(R62)(R63)O
- B is a 4- to 10-membered mono-, bi- or spirocyclic nonaromatic ring which includes from 1 to 3 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by one or more of the following substituents: F, CF 3 , (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 -C 4 )-alkyl, oxo, CO(R64), hydroxyl.
- the compounds of the formula I are notable in that they have an improved solubility in aqueous media as compared with structurally similar compounds with MCH-antagonistic action (especially in physiologically relevant buffer systems) coupled with simultaneously high activity. Moreover, preferred inventive compounds are notable for low blockage of the hERG channel. Furthermore, preferred inventive compounds have an improved metabolic stability as compared with prior art compounds.
- alkyl, alkenyl and alkynyl radicals in the substituents R1, R2, R3, R4, R5, R6, R6′′, R7, R7′, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R43′, R44, R45, R54, R55, R56, R57, R58, R59, R60, R61, R62, R63, R64 may be either straight-chain, branched and/or optionally substituted by substituents such as (C 1 -C 4 )-alkoxy or halogen.
- alkyl, alkenyl and alkynyl radicals are part of another group, for example part of an alkoxy group (such as (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl)).
- Suitable halogens are fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine and bromine, particularly preferably fluorine.
- alkyl groups are: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl and octyl. Included therein are both the n-isomers of these radicals and branched isomers such as isopropyl, isobutyl, isopentyl, sec-butyl, tert-butyl, neopentyl, 3,3-dimethylbutyl, etc.
- alkyl additionally also includes alkyl radicals which are unsubstituted or optionally substituted by one or more further radicals, for example by 1, 2, 3 or 4 identical or different radicals such as (C 1 -C 4 )-alkoxy or halogen.
- alkyl groups substituted by halogen are fluorinated alkyl groups such as CF 3 , CHF 2 , CH 2 F, 3-fluoroprop-1-yl, 2,2,1,1-tetrafluoroethyl. It is moreover possible for the additional substituents to appear in any desired position of the alkyl radical.
- the alkyl radicals are preferably unsubstituted.
- Cycloalkyl means in the context of the present application cycloalkyl and cycloalkylalkyl (alkyl which is in turn substituted by cycloalkyl), where cycloalkyl has at least 3 carbon atoms.
- cycloalkyl radicals are: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl.
- Polycyclic ring systems are also possible where appropriate, such as decalinyl, norbornanyl, bornanyl or adamantanyl.
- cycloalkyl radicals may be unsubstituted or optionally substituted by one or more further radicals as listed by way of example above for the alkyl radicals. Unless defined otherwise, the cycloalkyl radicals are preferably unsubstituted.
- alkenyl and alkynyl groups are: vinyl, 1-propenyl, 2-propenyl (allyl), 2-butenyl, 2-methyl-2-propenyl, 3-methyl-2-butenyl, ethynyl, 2-propynyl (propargyl), 2-butynyl or 3-butynyl.
- Cycloalkenyl means in the context of the present application cycloalkenyl radicals and cycloalkenylalkyl radicals (alkyl which is substituted by cycloalkenyl), which comprise at least three carbon atoms.
- Examples of cycloalkenyl are: cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.
- the alkenyl radicals and cycloalkenyl radicals may have one to three conjugated or non-conjugated double bonds (i.e. also alkadienyl and alkatrienyl radicals), preferably one double bond in a linear or branched chain. The same applies to the triple bonds for alkynyl radicals.
- the alkenyl and alkynyl radicals may be unsubstituted or optionally substituted by one or more further radicals as listed by way of example above for the alkyl radicals. Unless defined otherwise, the alkenyl and alkynyl radicals are preferably unsubstituted.
- Aryl refers in the present invention to radicals which are derived from monocyclic or bicyclic aromatic compounds comprising no ring heteroatoms. Where aryl refers to systems which are not monocyclic, the saturated form (perhydro form) or the partly unsaturated form (for example the dihydro form or tetrahydro form) is also possible for the second ring when the respective forms are known and stable.
- aryl also includes in the present invention for example bicyclic radicals in which both rings are aromatic and bicyclic radicals in which only one ring is aromatic.
- aryl examples include: phenyl, naphthyl, indanyl, 1,2-dihydronaphthenyl, 1,4-dihydronaphthenyl, indenyl or 1,2,3,4-tetrahydronaphthyl. Unless defined otherwise, the aryl radicals are preferably unsubstituted.
- Aryl is particularly preferably phenyl or naphthyl.
- Heteroaryl radicals mean radicals derived from monocyclic or bicyclic aromatic compounds which comprise ring heteroatoms, preferably N, O or S. Otherwise, the statements made about aryl radicals apply to heteroaryl radicals.
- a “tricycle” means structures having 3 rings which are linked together by more than one bond. Examples of such systems are fused systems with 3 rings and spirocycles with fused-on ring system.
- a polycyclic group means in the context of the present application a group which is derived from spiranes, fused ring systems or bridged ring systems.
- the spiranes are notable for two rings having only one carbon atom in common and the ring planes of the two rings being perpendicular to one another.
- the fused ring systems two rings are linked together in such a way that they have two atoms in common. This type of linkage involves an “ortho fusion”.
- Bridged ring systems are ring systems having a bridge of carbon atoms and/or heteroatoms between two nonadjacent atoms of a ring.
- a “chemically viable radical” means in the context of the present invention a radical which is stable at room temperature and atmospheric pressure.
- a “chemically viable radical” in the definition of group A in compounds of the formula I preferably means groups which have no heteroatom-heteroatom bonds between the individual members of the groups.
- a “nonaromatic” ring means in the context of the present application preferably a ring which is saturated or partly unsaturated.
- a partly unsaturated ring according to the present application has one or, where appropriate, a plurality of double bonds, but the partly unsaturated ring is not aromatic.
- the term “nonaromatic” in the context of the present application also includes “nonheteroaromatic” rings.
- the compounds of the formula I may have one or more centers of asymmetry.
- the compounds of the formula I may therefore exist in the form of their racemates, enantiomer-enriched mixtures, pure enantiomers, diastereomers and mixtures of diastereomers.
- the present invention encompasses all these isomeric forms of the compounds of the formula I. These isomeric forms may be obtained by known methods, even if not expressly described in some cases.
- Suitable pharmaceutically acceptable acid addition salts of the compounds of the invention are salts of inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid and sulfuric acid, and of organic acids, for example acetic acid, benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glycolic acid, isethionic acid, lactic acid, lactobionic acid, maleic acid, malic acid, methanesulfonic acid, succinic acid, p-toluenesulfonic acid and tartaric acid.
- inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid and sulfuric acid
- organic acids for example acetic acid, benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, glu
- Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts), alkaline earth metal salts (such as magnesium and calcium salts) and salts of trometamol (2-amino-2-hydroxymethyl-1,3-propanediol), diethanolamine, lysine or ethylenediamine.
- Salts with a pharmaceutically unacceptable anion for example trifluoroacetate, likewise belong within the framework of the invention as useful intermediates for the preparation or purification of pharmaceutically acceptable salts and/or for use in nontherapeutic, for example in vitro, applications.
- physiologically functional derivative refers to any physiologically tolerated derivative of a compound of the formula I of the invention, for example an ester, which on administration to a mammal, for example a human, is able to form (directly or indirectly) a compound of the formula I or an active metabolite thereof.
- Physiologically functional derivatives also include prodrugs of the compounds of the invention, as described, for example, in H. Okada et al., Chem. Pharm. Bull. 1994, 42, 57-61. Such prodrugs can be metabolized in vivo to a compound of the invention. These prodrugs may themselves be active or not.
- the compounds of the invention may also exist in various polymorphous forms, for example as amorphous and crystalline polymorphous forms. All polymorphous forms of the compounds of the invention belong within the framework of the invention and are a further aspect of the invention.
- radicals or substituents can occur more than once in the compounds of the formula I, they may each independently be defined as specified and be the same or different.
- R1 is preferably: H, (C 1 -C 8 )-alkyl, (C(R10)(R11)) q -R12, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 3 -C 8 ) alkenyl, (C 3 -C 8 )-alkynyl, CO(R9), (C(R10)(R11)) q -R12, CO(C(R13)(R14)) r -R15, CO—O(C 1 -C 8 )-alkyl, CO(C(R13)(R14)) r N(R16)(R17);
- R1 is preferably: H, (C 1 -C 8 )-alkyl, (C(R10)(R11)) q -R12, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 3 -C 8
- a 5-6-membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatom from the group of NH, N—(C 1 -C 6 )-alkyl, oxygen and sulfur; q, r are each independently 0, 1, 2, 3, 4, 5, 6; preferably 0, 1, 2, 3, 4;
- ⁇ are each independently H, OH, F, O—(C 1 -C 6 )-alkyl, S—(C 1 -C 6 )-alkyl, O-phenyl, CN, COO(R25), N(R26)CO(C 1 -C 6 )-alkyl, N(R27)(R28), CON(R29)(R30), SO 2 (C 1 -C 6 )-alkyl, 3-12-membered mono-, bi- or spirocyclic ring which may contain one to four heteroatoms from the group of N, O and S, and the 3-12-membered ring may contain further substituents such as F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , oxo, O—(C 1 -C 6 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6
- L1 is C(R34)(R35), C(R36)(R37)C(R38)(R39), (C 3 -C 6 )-cycloalkyl; preferably C(R34)(R35); optionally, R1 may be joined to one of the R34, R35, R36, R37, R38 or R39 radicals, so as to form a 5-6-membered ring;
- X is O, C(R43)(R43′);
- R8 is H, (C 1 -C 8 )-alkyl
- L2 is a bond, C(R44)(R45); preferably a bond;
- A is a 5-6-membered aromatic ring which may include up to 2 heteroatoms selected from the group of nitrogen, oxygen and sulfur, and may be substituted by one or more of the substituents H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, (C 1 -C 6 )-alkyl, N(R54)(R55), SO 2 —CH 3 , CON(R56)(R57), N(R58)CO(R59), CO(R60); preferably H, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, (C 1 -C 4 )--alkyl, (C 1 -C 4 )-
- C(O)NR8 may be joined to an ortho substituent of A via a bridge containing one or two elements from the group of carbon and nitrogen, so as to form a 9- to 10-membered bicyclic ring overall; the bridge preferably contains two carbon elements, so as to form an isoquinolinone or a dihydroisoquinolinone overall;
- L3 is a bond or a linker having from 1 to 4 members, where the members are selected from the group consisting of O, S, SO 2 , N(R61), CO, C(R62)(R63), C ⁇ C, to give rise to a chemically viable radical, and the linker does not have any O—CO or COO groups; preferably a bond or a linker having from 1 to 4 members, where the members are selected from the group consisting of O, N(R61), CO, C(R62)(R63), to give rise to a chemically viable radical, and the linker does not have any O—CO or COO groups; more preferably a bond, O, C(R62)(R63)O; B is (C
- L3 is C(R62)(R63)O
- B is a 4- to 10-membered mono-, bi- or spirocyclic nonaromatic ring which includes from 1 to 3 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by one or more of the following substituents: F, CF 3 , (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, hydroxy-(C 1 -C 4 )-alkyl, oxo, CO(R64), hydroxyl.
- a particular aspect of the invention is that of compounds of the formula II
- L3 is CH 2 O
- B is a 4- to 6-membered nonaromatic ring which includes from 1 to 2 oxygen atoms, where the ring system may additionally be substituted by one or more of the following substituents: F, (C 1 -C 6 )-alkyl, O—(C 1 -C 8 )-alkyl, (C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, oxo, hydroxyl, preferably (C 1 -C 6 )-alkyl or hydroxyl; the combined element B-L3 is preferably selected from the group of
- a further particular aspect of the invention is that of compounds of the formula IIa
- the invention relates to compounds of the formula III
- R1, R2, R3, R4, R8, A, L1, L3 and B are each as defined for formula I.
- the invention relates to compounds of the formula IV
- R1, R2, R3, R4, X, L1, L3 and B are each as defined for formula I.
- the broken line indicates an optional double bond, such that both dihydroisoquinolinones and isoquinolinones are encompassed by the formula IV.
- inventive compounds of the general formula I can be prepared analogously to processes known to those skilled in the art. Suitable processes for preparing the inventive compounds of the general formula I are mentioned below by way of example (see especially methods A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P and schemes 1 to 3).
- This invention further relates to the use of compounds of the formula I and pharmaceutical compositions thereof as MCH receptor ligands.
- the inventive MCH receptor ligands are suitable especially as modulators of the activity of MCH R1.
- MCH antagonists can have a beneficial influence on centrally related disorders such as, for example, anxiety neuroses and depressions (Borowsky, B. et al. Nature Medicine 2002, 8, 825-30; Reviews: G. Hervieu, Expert Opin. Ther. Targets 2003, 7, 495-511; Chaki, S. et al., Drug Dev. Res. 2005, 65, 278-290; Dyck, B., Drug Dev. Res. 2005, 65, 291-300; Shimazaki, T., CNS Drugs 2006, 20, 801-11; Drugs Fut. 2007, 32, 809-822).
- Compounds of this type are particularly suitable for the treatment and/or prevention of
- the amount of a compound of formula I necessary to achieve the desired biological effect depends on a number of factors, for example the specific compound chosen, the intended use, the mode of administration and the clinical condition of the patient.
- the daily dose is generally in the range from 0.001 mg to 100 mg (typically from 0.01 mg to 50 mg) per day and per kilogram of body weight, for example 0.1-10 mg/kg/day.
- An intravenous dose may be, for example, in the range from 0.001 mg to 1.0 mg/kg, which can suitably be administered as infusion of 10 ng to 100 ng per kilogram and per minute.
- Suitable infusion solutions for these purposes may contain, for example, from 0.1 ng to 10 mg, typically from 1 ng to 10 mg, per milliliter.
- Single doses may contain, for example, from 1 mg to 10 g of the active ingredient.
- ampoules for injections may contain, for example, from 1 mg to 100 mg
- single-dose formulations which can be administered orally, such as, for example, tablets or capsules may contain, for example, from 0.05 to 1000 mg, typically from 0.5 to 600 mg.
- the compounds of formula I may be used as the compound itself, but they are preferably in the form of a pharmaceutical composition with an acceptable carrier.
- the carrier must, of course, be acceptable in the sense that it is compatible with the other ingredients of the composition and is not harmful for the patient's health.
- the carrier may be a solid or a liquid or both and is preferably formulated with the compound as a single dose, for example as a tablet, which may contain from 0.05% to 95% by weight of the active ingredient.
- Other pharmaceutically active substances may likewise be present, including other compounds of formula I.
- the pharmaceutical compositions of the invention can be produced by one of the known pharmaceutical methods, which essentially consist of mixing the ingredients with pharmacologically acceptable carriers and/or excipients.
- compositions of the invention are those suitable for oral, rectal, topical, peroral (for example sublingual) and parenteral (for example subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable mode of administration depends in each individual case on the nature and severity of the condition to be treated and on the nature of the compound of formula I used in each case.
- Coated formulations and coated slow-release formulations also belong within the framework of the invention. Preference is given to acid- and gastric juice-resistant formulations. Suitable coatings resistant to gastric juice comprise cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate.
- Suitable pharmaceutical preparations for oral administration may be in the form of separate units such as, for example, capsules, cachets, suckable tablets or tablets, each of which contains a defined amount of at least one compound of formula I; as powders or granules; as solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-in-oil emulsion.
- These compositions may, as already mentioned, be prepared by any suitable pharmaceutical method which includes a step in which the active ingredient and the carrier (which may consist of one or more additional ingredients) are brought into contact.
- the compositions are generally produced by uniform and homogeneous mixing of the active ingredient with a liquid and/or finely divided solid carrier, after which the product is shaped if necessary.
- a tablet can be produced by compressing or molding a powder or granules of the compound, where appropriate with one or more additional ingredients.
- Compressed tablets can be produced by tableting the compound in free-flowing form such as, for example, a powder or granules, where appropriate mixed with a binder, glidant, inert diluent and/or one (or more) surface-active/dispersing agent(s) in a suitable machine.
- Molded tablets can be produced by molding the compound, which is in powder form and is moistened with an inert liquid diluent, in a suitable machine.
- compositions which are suitable for peroral (sublingual) administration comprise suckable tablets which contain at least one compound of formula I with a flavoring, normally sucrose and gum arabic or tragacanth, and pastilles which comprise the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic.
- compositions suitable for parenteral administration comprise preferably sterile aqueous preparations of at least one compound of formula I, which are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although administration may also take place by subcutaneous, intramuscular or intradermal injection. These preparations can preferably be produced by mixing the compound with water and making the resulting solution sterile and isotonic with blood. Injectable compositions of the invention generally contain from 0.1 to 5% by weight of the active compound.
- compositions suitable for rectal administration are preferably in the form of single-dose suppositories. These can be produced by mixing at least one compound of the formula I with one or more conventional solid carriers, for example cocoa butter, and shaping the resulting mixture.
- compositions suitable for topical use on the skin are preferably in the form of ointment, cream, lotion, paste, spray, aerosol or oil.
- Carriers which can be used are petrolatum, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances.
- the active ingredient is generally present in a concentration of from 0.1 to 15% by weight of the composition, for example from 0.5 to 2%.
- compositions suitable for transdermal uses can be in the form of single patches which are suitable for long-term close contact with the patient's epidermis. Such patches suitably contain the active ingredient in an aqueous solution which is buffered where appropriate, dissolved and/or dispersed in an adhesive or dispersed in a polymer.
- a suitable active ingredient concentration is about 1% to 35%, preferably about 3% to 15%.
- a particular possibility is for the active ingredient to be released by electrotransport or iontophoresis as described, for example, in Pharmaceutical Research, 2(6): 318 (1986).
- the compounds of the formula I are distinguished by beneficial effects on lipid metabolism, and they are particularly suitable for weight reduction and for maintaining a reduced weight after weight reduction has taken place in mammals and as anorectic agents.
- the compounds are distinguished as selective MCH1R antagonists by their low toxicity, the small effect on metabolizing enzymes and their few side effects.
- preferred compounds of the invention are notable for low blockade of the hERG channel.
- preferred compounds of the formula I are noticeably soluble in aqueous systems and thus particularly suitable for pharmaceutical development. The pharmacological effect is moreover achieved in in vivo test models after oral administration from well-tolerated vehicles.
- the compounds can be employed alone or in combination with other weight-reducing or anorectic active ingredients.
- Further anorectic active ingredients of this type are mentioned, for example, in the Rote Liste, chapter 01 under weight-reducing agents/appetite suppressants, and may also include active ingredients which increase the energy turnover of the organism and thus lead to weight reduction or else those which influence the general metabolism of the organism in such a way that an increased calorie intake does not lead to an enlargement of the fat depots and a normal calorie intake leads to a reduction of the fat depots of the organism.
- the compounds are suitable for the prophylaxis and, in particular, for the treatment of excessive weight or obesity.
- the compounds are further suitable for the prophylaxis and, in particular, for the treatment of type II diabetes, of arteriosclerosis and for normalizing lipid metabolism and for the treatment of high blood pressure.
- the compounds of the invention can be administered alone or in combination with one or more further pharmacologically active substances which have, for example, beneficial effects on metabolic disturbances or disorders frequently associated therewith.
- further pharmacologically active substances which have, for example, beneficial effects on metabolic disturbances or disorders frequently associated therewith. Examples of such medicaments are
- the active ingredient combination can be administered either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation.
- the active ingredient combination can be administered either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation. If the active ingredients are administered separately, this can be done simultaneously or successively. Most of the active ingredients mentioned hereinafter are disclosed in the USP Dictionary of USAN and International Drug Names, US Pharmacopeia, Rockville 2006.
- Antidiabetics include insulin and insulin derivatives, for example LANTUS® (insulin glargine, also see www.lantus.com) or HMR 1964 or LEVEMIR® (insulin detemir), HUMALOG® (Insulin Lispro), HUMULIN®, VIAJECTTM, SULIXEN® or those as described in WO2005005477 (Novo Nordisk), fast-acting insulins (see U.S. Pat. No.
- inhalable insulins for example EXUBERA®, NASULINTM, or oral insulins, for example IN-105 (Nobex) or ORAL-LYNTM (Generex Biotechnology), or TECHNOSPHERE® Insulin (MannKind) or COBALAMINTM oral insulin, or insulins as described in WO2007128815, WO2007128817, WO2008034881, WO2008049711, or insulins which can be administered transdermally; GLP-1 derivatives and GLP-1 agonists, for example exenatide or specific formulations thereof, as described, for example, in WO2008061355, liraglutide, taspoglutide or those which have been disclosed in WO 98/08871, WO2005027978, WO2006037811, WO2006037810 by Novo Nordisk A/S, in WO 01/04156 by Zealand or in WO 00/34331 by Beaufour-Ipsen, pramlintide
- Antidiabetics also include agonists of the glucose-dependent insulinotropic polypeptide (GIP) receptor, as described, for example, in WO2006121860. Antidiabetics also include the glucose-dependent insulinotropic polypeptide (GIP), and also analogous compounds, as described, for example, in WO2008021560.
- GIP glucose-dependent insulinotropic polypeptide
- Antidiabetics also include analogs and derivatives of fibroblast growth factor 21 (FGF-21).
- FGF-21 fibroblast growth factor 21
- the orally active hypoglycemic ingredients preferably include
- sulfonylureas biguanidines, meglitinides, oxadiazolidinediones, thiazolidinediones, PPAR and RXR modulators, glucosidase inhibitors, inhibitors of glycogen phosphorylase, glucagon receptor antagonists, glucokinase activators, inhibitors of fructose 1,6-bisphosphatase modulators of glucose transporter 4 (GLUT4), inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), GLP-1 agonists, potassium channel openers, for example pinacidil, cromakalim, diazoxide, or those as described in R. D.
- glucosidase inhibitors inhibitors of glycogen phosphorylase, glucagon receptor antagonists, glucokinase activators, inhibitors of fructose 1,6-bisphosphatase modulators of glucose transporter 4 (GLUT4), inhibitors of glut
- active ingredients which act on the ATP-dependent potassium channel of the beta cells active ingredients which act on the ATP-dependent potassium channel of the beta cells, inhibitors of dipeptidylpeptidase IV (DPP-IV), insulin sensitizers, inhibitors of liver enzymes involved in stimulating gluconeogenesis and/or glycogenolysis, modulators of glucose uptake, of glucose transport and of glucose reabsorption, modulators of sodium-dependent glucose transporter 1 or 2 (SGLT1, SGLT2), inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 (11 ⁇ -HSD1), inhibitors of protein tyrosine phosphatase 1B (PTP-1B), nicotinic acid receptor agonists, inhibitors of hormone-sensitive or endothelial lipases, inhibitors of acetyl-CoA carboxylase (ACC1 and/or ACC2) or inhibitors of GSK-3 beta.
- DPP-IV dipeptidylpeptidase IV
- insulin sensitizers inhibitors of liver
- HMGCoA reductase inhibitors HMGCoA reductase inhibitors, farnesoid X receptor (FXR) modulators, fibrates, cholesterol reabsorption inhibitors, CETP inhibitors, bile acid reabsorption inhibitors, MTP inhibitors, agonists of estrogen receptor gamma (ERR ⁇ agonists), sigma-1 receptor antagonists, antagonists of the somatostatin 5 receptor (SST5 receptor); compounds which reduce food intake, and compounds which increase thermogenesis.
- FXR farnesoid X receptor
- the compound of the formula I is administered in combination with insulin.
- the compound of the formula I is administered in combination with an active ingredient which acts on the ATP-dependent potassium channel of the beta cells, for example sulfonylureas, for example tolbutamide, glibenclamide, glipizide, gliclazide or glimepiride.
- an active ingredient which acts on the ATP-dependent potassium channel of the beta cells, for example sulfonylureas, for example tolbutamide, glibenclamide, glipizide, gliclazide or glimepiride.
- the compound of the formula I is administered in combination with a tablet which comprises both glimepiride, which is released rapidly, and metformin, which is released over a longer period (as described, for example, in US2007264331, WO2008050987).
- the compound of the formula I is administered in combination with a biguanide, for example metformin.
- a biguanide for example metformin.
- the compound of the formula I is administered in combination with a meglitinide, for example repaglinide, nateglinid or mitiglinide.
- a meglitinide for example repaglinide, nateglinid or mitiglinide.
- the compound of the formula I is administered with a combination of mitiglinide with a glitazone, e.g. pioglitazone hydrochloride. In a further embodiment, the compound of the formula I is administered with a combination of mitiglinide with an alpha-glucosidase inhibitor. In a further embodiment, the compound of the formula I is administered in combination with antidiabetic compounds, as described in WO2007095462, WO2007101060, WO2007105650.
- the compound of the formula I is administered in combination with antihypoglycemic compounds, as described in WO2007137008.
- the compound of the formula I is administered in combination with a thiazolidinedione, for example troglitazone, ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 by Dr. Reddy's Research Foundation, especially 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy]phenyl]methyl]-2,4-thiazolidinedione.
- a thiazolidinedione for example troglitazone, ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 by Dr. Reddy's Research Foundation, especially 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy]phenyl]methyl]-2,4-thiazolidinedione.
- the compound of the formula I is administered in combination with a PPAR gamma agonist, for example rosiglitazone, pioglitazone, JTT-501, GI 262570, R-483, CS-011 (rivoglitazone), DRL-17564, DRF-2593 (Balaglitazon), INT-131, T-2384, or those as described in WO2005086904, WO2007060992, WO2007100027, WO2007103252, WO2007122970, WO2007138485, WO2008006319, WO2008006969, WO2008010238, WO2008017398, WO2008028188.
- a PPAR gamma agonist for example rosiglitazone, pioglitazone, JTT-501, GI 262570, R-483, CS-011 (rivoglitazone), DRL-17564, DRF-2593 (Balaglitazon), INT-131, T-
- the compound of the formula I is administered in combination with CompetactTM, a solid combination of pioglitazone hydrochloride with metformin hydrochloride.
- the compound of the formula I is administered in combination with TandemactTM, a solid combination of pioglitazone with glimepiride.
- the compound of the formula I is administered in combination with a solid combination of pioglitazone hydrochloride with an angiotensin II agonist, for example TAK-536.
- the compound of the formula I is administered in combination with a PPAR alpha agonist or mixed PPAR alpha/PPAR delta agonist, for example GW9578, GW-590735, K-111, LY-674, KRP-101, DRF-10945, LY-518674, CP-900691, BMS-687453, BMS-711939, or those as described in WO2001040207, WO2002096894, WO2005097076, WO2007056771, WO2007087448, WO2007089667, WO2007089557, WO2007102515, WO2007103252, JP2007246474, WO2007118963, WO2007118964, WO2007126043, WO2008006043, WO2008006044, WO2008012470, WO2008035359.
- a PPAR alpha agonist or mixed PPAR alpha/PPAR delta agonist for example GW9578, GW-590735, K-111
- the compound of the formula I is administered in combination with a mixed PPAR alpha/gamma agonisn, for example naveglitazar, LY-510929, ONO-5129, E-3030, AVE 8042, AVE 8134, AVE 0847, CKD-501 (lobeglitazone sulfate), MBX-213, KY-201 or as described in WO 00/64888, WO 00/64876, WO03/020269, WO2004024726, WO2007099553, US2007276041, WO2007085135, WO2007085136, WO2007141423, WO2008016175, WO2008053331 or in J.P. Berger et al., TRENDS in Pharmacological Sciences 28(5), 244-251, 2005.
- a mixed PPAR alpha/gamma agonisn for example naveglitazar, LY-510929, ONO-5129, E-3030, AVE 8042, AVE 8134
- the compound of the formula I is administered in combination with a PPAR delta agonist, for example GW-501516, or as described in WO2006059744, WO2006084176, WO2006029699, WO2007039172-WO2007039178, WO2007071766, WO2007101864, US2007244094, WO2007119887, WO2007141423, US2008004281, WO2008016175.
- a PPAR delta agonist for example GW-501516, or as described in WO2006059744, WO2006084176, WO2006029699, WO2007039172-WO2007039178, WO2007071766, WO2007101864, US2007244094, WO2007119887, WO2007141423, US2008004281, WO2008016175.
- the compound of the formula I is administered in combination with a pan-SPPARM (selective PPAR modulator alpha, gamma, delta), for example GFT-505, or those as described in WO2008035359.
- a pan-SPPARM selective PPAR modulator alpha, gamma, delta
- the compound of the formula I is administered in combination with metaglidasen or with MBX-2044 or other partial PPAR gamma agonists/antagonists.
- the compound of the formula I is administered in combination with an ⁇ -glucosidase inhibitor, for example miglitol or acarbose, or those as described, for example, in WO2007114532, WO2007140230, US2007287674, US2008103201.
- an ⁇ -glucosidase inhibitor for example miglitol or acarbose, or those as described, for example, in WO2007114532, WO2007140230, US2007287674, US2008103201.
- the compound of the formula I is administered in combination with an inhibitor of glycogen phosphorylase, for example PSN-357 or FR-258900, or those as described in WO2003084922, WO2004007455, WO2005073229-31, WO2005067932.
- an inhibitor of glycogen phosphorylase for example PSN-357 or FR-258900, or those as described in WO2003084922, WO2004007455, WO2005073229-31, WO2005067932.
- the compound of the formula I is administered in combination with glucagon receptor antagonists, for example A-770077 or NNC-25-2504 or as described in WO2004100875, WO2005065680, WO2006086488, WO2007047177, WO2007106181, WO2007111864, WO2007120270, WO2007120284, WO2007123581, WO2007136577, WO2008042223.
- glucagon receptor antagonists for example A-770077 or NNC-25-2504 or as described in WO2004100875, WO2005065680, WO2006086488, WO2007047177, WO2007106181, WO2007111864, WO2007120270, WO2007120284, WO2007123581, WO2007136577, WO2008042223.
- the compound of the formula I is administered in combination with an antisense compound, e.g. ISIS-325568, which inhibits the production of the glucagon receptor.
- an antisense compound e.g. ISIS-325568, which inhibits the production of the glucagon receptor.
- the compound of the formula I is administered in combination with activators of glucokinase, for example LY-2121260 (WO2004063179), PSN-105, PSN-110, GKA-50, or those as described, for example, in WO2004072031, WO2004072066, WO2005080360, WO2005044801, WO2006016194, WO2006058923, WO2006112549, WO2006125972, WO2007017549, WO2007017649, WO2007007910, WO2007007040-42, WO2007006760-61, WO2007006814, WO2007007886, WO2007028135, WO2007031739, WO2007041365, WO2007041366, WO2007037534, WO2007043638, WO2007053345, WO2007051846, WO2007051845, WO2007053765, WO2007051847, WO2007061923, WO20070758
- the compound of the formula I is administered in combination with an inhibitor of gluconeogenesis, as described, for example, in FR-225654, WO2008053446.
- the compound of the formula I is administered in combination with inhibitors of fructose 1,6-bisphosphatase (FBPase), for example MB-07729, CS-917 (MB-06322) or MB-07803, or those as described in WO2006023515, WO2006104030, WO2007014619, WO2007137962, WO2008019309, WO2008037628.
- FBPase fructose 1,6-bisphosphatase
- the compound of the formula I is administered in combination with modulators of glucose transporters 4 (GLUT4), for example KST-48 (D.-O. Lee et al.: Arzneim.-Forsch. Drug Res. 54 (12), 835 (2004)).
- GLUT4 modulators of glucose transporters 4
- KST-48 D.-O. Lee et al.: Arzneim.-Forsch. Drug Res. 54 (12), 835 (2004).
- the compound of the formula I is administered in combination with inhibitors of glutamine:fructose-6-phosphate amidotransferase (GFAT), as described, for example, in WO2004101528.
- GFAT glutamine:fructose-6-phosphate amidotransferase
- the compound of the formula I is administered in combination with inhibitors of dipeptidyl peptidase IV (DPP-IV), for example vildagliptin (LAF-237), sitagliptin (MK-0431), sitagliptin phosphate, saxagliptin ((BMS-477118), GSK-823093, PSN-9301, SYR-322, SYR-619, TA-6666, TS-021, GRC-8200 (Melogliptin), GW-825964X, KRP-104, DP-893, ABT-341, ABT-279 or another salt thereof, S-40010, S-40755, PF-00734200, BI-1356, PHX-1149, alogliptin, or those compounds as described in WO2003074500, WO2003106456, WO2004037169, WO200450658, WO2005037828, WO2005058901, WO2005012312, WO
- the compound of the formula I is administered in combination with JanumetTM, a solid combination of sitagliptin phosphate with metformin hydrochloride.
- the compound of the formula I is administered in combination with Eucreas®, a solid combination of vildagliptin with metformin hydrochloride.
- the compound of the formula I is administered in combination with a solid combination of a salt of sitagliptin with metformin hydrochloride.
- the compound of the formula I is administered in combination with a combination of a DPP-IV inhibitors with omega-3 fatty acids or omega-3 fatty acid esters, as described, for example, in WO2007128801.
- the compound of the formula I is administered in combination with a substance which enhances insulin secretion, for example KCP-265 (WO2003097064), or those as described in WO2007026761, WO2008045484.
- a substance which enhances insulin secretion for example KCP-265 (WO2003097064), or those as described in WO2007026761, WO2008045484.
- the compound of the formula I is administered in combination with agonists of the glucose-dependent insulinotropic receptor (GDIR), for example APD-668.
- GDIR glucose-dependent insulinotropic receptor
- the compound of the formula I is administered in combination with an ATP citrate lyase inhibitor, for example SB-204990.
- the compound of the formula I is administered in combination with modulators of the sodium-dependent glucose transporter 1 or 2 (SGLT1, SGLT2), for example KGA-2727, T-1095, SGL-0010, AVE 2268, SAR 7226, SGL-5083, SGL-5085, SGL-5094, ISIS-388626, sergliflozin or dapagliflozin, or as described, for example, in WO2004007517, WO200452903, WO200452902, PCT/EP2005/005959, WO2005085237, JP2004359630, WO2005121161, WO2006018150, WO2006035796, WO2006062224, WO2006058597, WO2006073197, WO2006080577, WO2006087997, WO2006108842, WO2007000445, WO2007014895, WO2007080170, WO2007093610, WO2007126117, WO2007128480,
- the compound of the formula I is administered in combination with inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 (11 ⁇ -HSD1), for example BVT-2733, JNJ-25918646, INCB-13739, INCB-20817, DIO-92 (( ⁇ )-ketoconazole) or those as described, for example, in WO200190090-94, WO200343999, WO2004112782, WO200344000, WO200344009, WO2004112779, WO2004113310, WO2004103980, WO2004112784, WO2003065983, WO2003104207, WO2003104208, WO2004106294, WO2004011410, WO2004033427, WO2004041264, WO2004037251, WO2004056744, WO2004058730, WO2004065351, WO2004089367, WO2004089380, WO2004089470-71, WO20040898
- the compound of the formula I is administered in combination with inhibitors of protein tyrosine phosphatase 1B (PTP-1B), as described, for example, in WO200119830-31, WO200117516, WO2004506446, WO2005012295, WO2005116003, WO2005116003, WO2006007959, DE 10 2004 060542.4, WO2007009911, WO2007028145, WO2007067612-615, WO2007081755, WO2007115058, US2008004325, WO2008033455, WO2008033931, WO2008033932, WO2008033934.
- PTP-1B protein tyrosine phosphatase 1B
- the compound of the formula I is administered in combination with an agonist of GPR109A (HM74A receptor agonists; NAR agonists (nicotinic acid receptor agonists)), for example nicotinic acid or “extended release niacin” in conjunction with MK-0524A (laropiprant) or MK-0524, or those compounds as described in WO2004041274, WO2006045565, WO2006045564, WO2006069242, WO2006085108, WO2006085112, WO2006085113, WO2006124490, WO2006113150, WO2007017261, WO2007017262, WO2007017265, WO2007015744, WO2007027532, WO2007092364, WO2007120575, WO2007134986, WO2007150025, WO2007150026, WO2008016968, WO2008051403.
- GPR109A HM74A receptor agonists
- the compound of the formula I is administered in combination with a solid combination of niacin with simvastatin.
- the compound of the formula I is administered in combination with nicotinic acid or “extended release niacin” in conjunction with MK-0524A (laropiprant).
- the compound of the formula I is administered in combination with nicotinic acid or “extended release niacin” in conjunction with MK-0524A (laropiprant) and with simvastatin.
- the compound of the formula I is administered in combination with nicotinic acid or another nicotinic acid receptor agonist and a prostaglandin DP receptor antagonist, for example those as described in WO2008039882.
- the compound of the formula I is administered in combination with an agonist of GPR116, as described, for example, in WO2006067531, WO2006067532.
- the compound of the formula I is administered in combination with modulators of GPR40, as described, for example, in WO2007013689, WO2007033002, WO2007106469, US2007265332, WO2007123225, WO2007131619, WO2007131620, WO2007131621, US2007265332, WO2007131622, WO2007136572, WO2008001931, WO2008030520, WO2008030618, WO2008054674, WO2008054675.
- the compound of the formula I is administered in combination with modulators of GPR119 (G-protein-coupled glucose-dependent insulinotropic receptor), for example PSN-119-1, PSN-821, MBX-2982, or those as described, for example, in WO2005061489 (PSN-632408), WO2004065380, WO2007003960-62 and WO2007003964, WO2007116229, WO2007116230, WO2008005569, WO2008005576, WO2008008887, WO2008008895, WO2008025798, WO2008025799, WO2008025800, WO2007035355, WO2006083491, WO200807692, WO2008076243.
- GPR119 G-protein-coupled glucose-dependent insulinotropic receptor
- the compound of the formula I is administered in combination with modulators of GPR120, as described, for example, in EP1688138.
- the compound of the formula I is administered in combination with inhibitors of hormone-sensitive lipase (HSL) and/or phospholipases, as described, for example, in WO2005073199, WO2006074957, WO2006087309, WO2006111321, WO2007042178, WO2007119837.
- HSL hormone-sensitive lipase
- the compound of the formula I is administered in combination with inhibitors of endothelial lipase, as described, for example, in WO2006111321, WO2006131233, WO2006131232, WO2006131231, WO2007042178, WO2007045392, WO2007045393, WO2007110216, WO2007110215.
- the compound of the formula I is administered in combination with a phospholipase A2 inhibitor, for example darapladib or A-002, or those as described in WO2008048866, WO20080488867.
- a phospholipase A2 inhibitor for example darapladib or A-002, or those as described in WO2008048866, WO20080488867.
- the compound of the formula I is administered in combination with myricitrin, a lipase inhibitor (WO2007119827).
- the compound of the formula I is administered in combination with an inhibitor of glycogen synthase kinase-3 beta (GSK-3 beta), as described, for example, in US2005222220, WO2005085230, WO2005111018, WO2003078403, WO2004022544, WO2003106410, WO2005058908, US2005038023, WO2005009997, US2005026984, WO2005000836, WO2004106343, EP1460075, WO2004014910, WO2003076442, WO2005087727, WO2004046117, WO2007073117, WO2007083978, WO2007120102, WO2007122634, WO2007125109, WO2007125110, US2007281949, WO2008002244, WO2008002245, WO2008016123, WO2008023239, WO2008044700, WO2008056266, WO2008057940.
- GSK-3 beta glycogen synthase
- the compound of the formula I is administered in combination with an inhibitor of phosphoenolpyruvate carboxykinase (PEPCK), for example those as described in WO2004074288.
- PPCK phosphoenolpyruvate carboxykinase
- the compound of the formula I is administered in combination with an inhibitor of phosphoinositide kinase-3 (PI3K), for example those as described in WO2008027584.
- PI3K phosphoinositide kinase-3
- the compound of the formula I is administered in combination with an inhibitor of serum/glucocorticoid-regulated kinase (SGK), as described, for example, in WO2006072354, WO2007093264, WO2008009335.
- SGK serum/glucocorticoid-regulated kinase
- the compound of the formula I is administered in combination with a modulator of the glucocorticoid receptor, as described, for example, in WO2008057855, WO2008057856, WO2008057857, WO2008057859, WO2008057862.
- the compound of the formula I is administered in combination with an inhibitor of protein kinase C beta (PKC beta), for example ruboxistaurin.
- PLC beta protein kinase C beta
- the compound of the formula I is administered in combination with an activator of the AMP-activated protein kinase (AMPK), as described, for example, in WO2007062568, WO2008006432, WO2008016278, WO2008016730.
- AMPK AMP-activated protein kinase
- the compound of the formula I is administered in combination with an inhibitor of ceramide kinase, as described, for example, in WO2007112914, WO2007149865.
- the compound of the formula I is administered in combination with an inhibitor of MAPK-interacting kinase 1 or 2 (MNK1 or 2), as described, for example, in WO2007104053, WO2007115822, WO2008008547.
- MNK1 or 2 an inhibitor of MAPK-interacting kinase 1 or 2
- the compound of the formula I is administered in combination with inhibitors of “I-kappaB kinase” (IKK inhibitors), as described, for example, in WO2001000610, WO2001030774, WO2004022057, WO2004022553, WO2005097129, WO2005113544, US2007244140.
- IKK inhibitors inhibitors of “I-kappaB kinase”
- the compound of the formula I is administered in combination with inhibitors of NF-kappaB (NFKB) activation, for example salsalate.
- NFKB NF-kappaB
- the compound of the formula I is administered in combination with inhibitors of ASK-1 (apoptosis signal-regulating kinase 1), as described, for example, in WO2008016131.
- ASK-1 apoptosis signal-regulating kinase 1
- the compound of the formula I is administered in combination with an HMG-CoA reductase inhibitor such as simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, cerivastatin, rosuvastatin, L-659699, BMS-644950, or those as described in US2007249583.
- an HMG-CoA reductase inhibitor such as simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, cerivastatin, rosuvastatin, L-659699, BMS-644950, or those as described in US2007249583.
- the compound of the formula I is administered in combination with a farnesoid X receptor (FXR) modulator, for example WAY-362450 or those as described in WO2003099821, WO2005056554, WO2007052843, WO2007070796, WO2007092751, JP2007230909, WO2007095174, WO2007140174, WO2007140183, WO2008000643, WO2008002573, WO2008025539, WO2008025540.
- FXR farnesoid X receptor
- the compound of the formula I is administered in combination with a ligand of the liver X receptor (LXR), as described, for example, in WO2007092965, WO2008041003, WO2008049047.
- LXR liver X receptor
- the compound of the formula I is administered in combination with a fibrate, for example fenofibrate, clofibrate, bezafibrate.
- the compound of the formula I is administered in combination with fibrates, for example the choline salt of fenofibrate (SLV-348).
- fibrates for example the choline salt of fenofibrate (SLV-348).
- the compound of the formula I is administered in combination with fibrates, for example the choline salt of fenofibrate and an HMG-CoA reductase inhibitor, for example rosuvastatin.
- fibrates for example the choline salt of fenofibrate and an HMG-CoA reductase inhibitor, for example rosuvastatin.
- the compound of the formula I is administered in combination with bezafibrate and diflunisal.
- the compound of the formula I is administered in combination with a solid combination of fenofibrate or a salt thereof with simvastatin, rosuvastatin, fluvastatin, lovastatin, cerivastatin, pravastatin or atorvastatin.
- the compound of the formula I is administered in combination with Synordia®, a solid combination of fenofibrate with metformin.
- the compound of the formula I is administered in combination with a cholesterol reabsorption inhibitor, for example ezetimibe, tiqueside, pamaqueside, FM-VP4 (sitostanol/campesterol ascorbyl phosphate; Forbes Medi-Tech, WO2005042692, WO2005005453), MD-0727 (Microbia Inc., WO2005021497, WO2005021495) or with compounds as described in WO2002066464, WO2005000353 (Kotobuki Pharmaceutical Co.
- a cholesterol reabsorption inhibitor for example ezetimibe, tiqueside, pamaqueside, FM-VP4 (sitostanol/campesterol ascorbyl phosphate; Forbes Medi-Tech, WO2005042692, WO2005005453), MD-0727 (Microbia Inc., WO2005021497, WO2005021495) or with compounds as described in WO2002066464, WO2005000353 (Kotobuki Pharmaceutical
- the compound of the formula I is administered in combination with an NPC1L1 antagonist, for example those as described in WO2008033464, WO2008033465.
- the compound of the formula I is administered in combination with VytorinTM, a solid combination of ezetimibe with simvastatin.
- the compound of the formula I is administered in combination with a solid combination of ezetimibe with atorvastatin.
- the compound of the formula I is administered in combination with a solid combination of ezetimibe with fenofibrate.
- the further active ingredient is a diphenylazetidinone derivative, as described, for example, in U.S. Pat. No. 6,992,067 or U.S. Pat. No. 7,205,290.
- the further active ingredient is a diphenylazetidinone derivative, as described, for example, in U.S. Pat. No. 6,992,067 or U.S. Pat. No. 7,205,290, combined with a statin, for example simvastatin, fluvastatin, pravastatin, lovastatin, cerivastatin, atorvastatin or rosuvastatin.
- a statin for example simvastatin, fluvastatin, pravastatin, lovastatin, cerivastatin, atorvastatin or rosuvastatin.
- the compound of the formula I is administered in combination with a solid combination of lapaquistat, a squalene synthase inhibitor, with atorvastatin.
- the compound of the formula I is administered in combination with a CETP inhibitor, for example torcetrapib, anacetrapib or JTT-705 (dalcetrapib), or those as described in WO2006002342, WO2006010422, WO2006012093, WO2006073973, WO2006072362, WO2007088996, WO2007088999, US2007185058, US2007185113, US2007185154, US2007185182, WO2006097169, WO2007041494, WO2007090752, WO2007107243, WO2007120621, US2007265252, US2007265304, WO2007128568, WO2007132906, WO2008006257, WO2008009435, WO2008018529, WO2008058961, WO2008058967.
- a CETP inhibitor for example torcetrapib, anacetrapib or JTT-705 (dalcetrapib), or those as described in WO20060023
- the compound of the formula I is administered in combination with bile acid reabsorption inhibitor (see, for example, U.S. Pat. No. 6,245,744, U.S. Pat. No. 6,221,897 or WO00/61568), for example HMR 1741, or those as described in DE 10 2005 033099.1 and DE 10 2005 033100.9, DE 10 2006 053635, DE 10 2006 053637, WO2007009655-56, WO2008058628, WO2008058629, WO2008058630, WO2008058631.
- bile acid reabsorption inhibitor see, for example, U.S. Pat. No. 6,245,744, U.S. Pat. No. 6,221,897 or WO00/61568
- HMR 1741 or those as described in DE 10 2005 033099.1 and DE 10 2005 033100.9, DE 10 2006 053635, DE 10 2006 053637, WO2007009655-56, WO2008058628, WO20080586
- the compound of the formula I is administered in combination with agonists of GPBAR1 (G-protein-coupled bile acid receptor-1; TGR5), as described, for example, in WO2007110237, WO2007127505, WO2008009407.
- GPBAR1 G-protein-coupled bile acid receptor-1
- the compound of the formula I is administered in combination with a polymeric bile acid adsorber, for example cholestyramine, colesevelam hydrochloride.
- a polymeric bile acid adsorber for example cholestyramine, colesevelam hydrochloride.
- the compound of the formula I is administered in combination with colesevelam hydrochloride and metformin or a sulfonylurea or insulin.
- the compound of the formula I is administered in combination with a chewing gum comprising phytosterols (ReductolTM)
- the compound of the formula I is administered in combination with an inhibitor of the microsomal triglyceride transfer proteins (MTP inhibitor), for example implitapide, BMS-201038, R-103757, AS-1552133, SLx-4090, AEGR-733, or those as described in WO2005085226, WO2005121091, WO2006010423, WO2006113910, WO2007143164, WO2008049806, WO2008049808.
- MTP inhibitor microsomal triglyceride transfer proteins
- the compound of the formula I is administered in combination with a combination of a cholesterol absorption inhibitor, for example ezetimibe, and an inhibitor of the triglyceride transfer proteins (MTP inhibitor), for example implitapide, as described in WO2008030382.
- a cholesterol absorption inhibitor for example ezetimibe
- MTP inhibitor inhibitor of the triglyceride transfer proteins
- the compound of the formula I is administered in combination with an active antihypertriglyceridemic ingredient, for example those as described in WO2008032980.
- the compound of the formula I is administered in combination with an antagonist of the somatostatin 5 receptor (SST5 receptor), for example those as described in WO2006094682.
- SST5 receptor somatostatin 5 receptor
- the compound of the formula I is administered in combination with an ACAT inhibitor, for example avasimibe, SMP-797 or KY-382.
- an ACAT inhibitor for example avasimibe, SMP-797 or KY-382.
- the compound of the formula I is administered in combination with an inhibitor of liver carnitine palmitoyltransferase 1 (L-CPT1), as described, for example, in WO2007063012, WO2007096251 (ST-3473), WO2008015081, US2008103182.
- L-CPT1 liver carnitine palmitoyltransferase 1
- the compound of the formula I is administered in combination with a modulator of serine palmitoyltransferase (SPT), as described, for example, in WO2008031032, WO2008046071.
- SPT serine palmitoyltransferase
- the compound of the formula I is administered in combination with a squalene synthetase inhibitor, for example BMS-188494, TAK-475 (lapaquistat acetate), or as described in WO2005077907, JP2007022943, WO2008003424.
- a squalene synthetase inhibitor for example BMS-188494, TAK-475 (lapaquistat acetate), or as described in WO2005077907, JP2007022943, WO2008003424.
- the compound of the formula I is administered in combination with ISIS-301012 (mipomersen), an antisense oligonucleotide which is capable of regulating the apolipoprotein B gene.
- the compound of the formula I is administered in combination with an LDL receptor inducer (see U.S. Pat. No. 6,342,512), for example HMR1171, HMR1586, or those as described in WO2005097738, WO2008020607.
- an LDL receptor inducer see U.S. Pat. No. 6,342,512
- HMR1171, HMR1586 or those as described in WO2005097738, WO2008020607.
- the compound of the formula I is administered in combination with an HDL cholesterol-elevating agent, for example those as described in WO2008040651.
- the compound of the formula I is administered in combination with an ABCA1 expression enhancer, as described, for example, in WO2006072393.
- the compound of the formula I is administered in combination with a lipoproteinlipase modulator, for example ibrolipim (NO-1886).
- a lipoproteinlipase modulator for example ibrolipim (NO-1886).
- the compound of the formula I is administered in combination with a lipoprotein(a) antagonist, for example gemcabene (Cl-1027).
- a lipoprotein(a) antagonist for example gemcabene (Cl-1027).
- the compound of the formula I is administered in combination with a lipase inhibitor, for example orlistat or cetilistat (ATL-962).
- a lipase inhibitor for example orlistat or cetilistat (ATL-962).
- the compound of the formula I is administered in combination with an adenosine A1 receptor agonist (adenosine A1 R), as described, for example, in EP1258247, EP1375508, WO2008028590.
- an adenosine A1 receptor agonist as described, for example, in EP1258247, EP1375508, WO2008028590.
- the compound of the formula I is administered in combination with an adenosine A2B receptor agonist (adenosine A2B R), for example ATL-801.
- adenosine A2B R adenosine A2B receptor agonist
- the compound of the formula I is administered in combination with a modulator of adenosine A2A and/or adenosine A3 receptors, as described, for example, in WO2007111954, WO2007121918, WO2007121921, WO2007121923.
- the compound of the formula I is administered in combination with an adenosine A2B receptor antagonist (adenosine A2B R), as described in US2007270433, WO2008027585.
- an adenosine A2B receptor antagonist adenosine A2B R
- the compound of the formula I is administered in combination with inhibitors of acetyl-CoA carboxylase (ACC1 and/or ACC2), for example those as described in WO199946262, WO200372197, WO2003072197, WO2005044814, WO2005108370, JP2006131559, WO2007011809, WO2007011811, WO2007013691, WO2007095601-603, WO2007119833.
- ACC1 and/or ACC2 inhibitors of acetyl-CoA carboxylase
- the compound of the formula I is administered in combination with modulators of microsomal acyl-CoA:glycerol-3-phosphate acyltransferase 3 (GPAT3, described in WO2007100789) or with modulators of microsomal acyl-CoA:glycerol-3-phosphate acyltransferase 4 (GPAT4, described in WO2007100833).
- modulators of microsomal acyl-CoA:glycerol-3-phosphate acyltransferase 3 GPAT3, described in WO2007100789
- modulators of microsomal acyl-CoA:glycerol-3-phosphate acyltransferase 4 GPAT4, described in WO2007100833
- the compound of the formula I is administered in combination with modulators of xanthine oxidoreductase (XOR).
- the compound of the formula I is administered in combination with inhibitors of soluble epoxide hydrolase (sEH), as described, for example, in WO2008051873, WO2008051875.
- SEH soluble epoxide hydrolase
- the compound of the formula I is administered in combination with CART modulators (see “Cocaine-amphetamine-regulated transcript influences energy metabolism, anxiety and gastric emptying in mice” Asakawa, A. et al.: Hormone and Metabolic Research (2001), 33(9), 554-558);
- NPY antagonists for example N- ⁇ 4-[(4-aminoquinazolin-2-ylamino)methyl]-cyclohexylmethyl ⁇ naphthalene-1-sulfonamide hydrochloride (CGP 71683A);
- NPY-5 receptor antagonists such as L-152804 or the compound “NPY-5-BY” from Banyu, or as described, for example, in WO2006001318, WO2007103295, WO2007125952, WO2008026563, WO2008026564, WO2008052769;
- NPY-4 receptor antagonists as described, for example, in WO2007038942;
- NPY-2 receptor antagonists as described, for example, in WO2007038943;
- peptide YY 3-36 PYY3-36 or analogous compounds, for example CJC-1682 (PYY3-36 conjugated with human serum albumin via Cys34) or CJC-1643 (derivative of PYY3-36, which is conjugated in vivo to serum albumin), or those as described in WO2005080424, WO2006095166, WO2008003947; derivatives of the peptide obestatin, as described by WO2006096847; CB1R (cannabinoid receptor 1) antagonists, for example rimonabant, surinabant (SR147778), SLV-319 (ibipinabant), AVE-1625, taranabant (MK-0364) or salts thereof, otenabant (CP-945,598), V-24343 or those compounds as described in, for example, EP 0656354, WO 00/15609, WO2001/64632-64634, WO 02/076949, WO2005
- urocortin urocortin
- urocortin agonists agonists of the beta-3 adrenoceptor, for example 1-(4-chloro-3-methanesulfonylmethylphenyl)-2-[2-(2,3-dimethyl-1H-indol-6-yloxy)ethylamino]-ethanol hydrochloride (WO 01/83451) or solabegron (GW-427353) or N-5984 (KRP-204), or those as described in JP2006111553, WO2002038543, WO2002038544, WO2007048840-843, WO2008015558; MSH (melanocyte-stimulating hormone) agonists; MCH (melanine-concentrating hormone) receptor antagonists (for example NBI-845, A-761, A-665798, A-798, ATC-0175, T-226296, T-71 (AMG-071, AMG-076), GW-803430,
- dexfenfluramine dexfenfluramine
- mixed serotonin/dopamine reuptake inhibitors e.g. bupropion
- naltrexone or bupropion with zonisamide e.g. DOV-21947
- mixed serotoninergic and noradrenergic compounds e.g.
- 5-HT receptor agonists for example 1-(3-ethylbenzofuran-7-yl)piperazine oxalic acid salt (WO 01/09111); mixed dopamine/norepinephrine/acetylcholine reuptake inhibitors (e.g.
- tesofensine or those as described, for example, in WO2006085118; norepinephrine reuptake inhibitors, as described, for example, in US2008076724; 5-HT2A receptor antagonists, as described, for example, in WO2007138343; 5-HT2C receptor agonists (for example lorcaserine hydrochloride (APD-356) or BVT-933, or those as described in WO200077010, WO200077001-02, WO2005019180, WO2003064423, WO200242304, WO2005035533, WO2005082859, WO2006004937, US2006025601, WO2006028961, WO2006077025, WO2006103511, WO2007028132, WO2007084622, US2007249709; WO2007132841, WO2007140213, WO2008007661, WO2008007664, WO2008009125, WO2008010073); 5-HT6 receptor modulators
- growth hormone or AOD-9604 human growth hormone or AOD-9604
- growth hormone releasing compounds tert-butyl 6-benzyloxy-1-(2-diisopropylaminoethylcarbamoyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (WO 01/85695)
- growth hormone secretagogue receptor antagonists ghrelin antagonists
- growth hormone secretagogue receptor modulators for example JMV-2959, JMV-3002, JMV-2810, JMV-2951, or those as described in WO2006012577 (e.g.
- YIL-781 or YIL-870 WO2007079239
- TRH agonists see, for example, EP 0 462 884
- decoupling protein 2 or 3 modulators leptin agonists (see, for example, Lee, Daniel W.; Leinung, Matthew C.; Rozhayskaya-Arena, Marina; Grasso, Patricia. Leptin agonists as a potential approach to the treatment of obesity.
- Drugs of the Future (2001), 26(9), 873-881); DA agonists (bromocriptin, doprexin); lipase/amylase inhibitors (e.g.
- WO 00/40569 inhibitors of diacylglycerol O-acyltransferases (DGATs), for example BAY-74-4113, or as described, for example, in US2004/0224997, WO2004094618, WO200058491, WO2005044250, WO2005072740, JP2005206492, WO2005013907, WO2006004200, WO2006019020, WO2006064189, WO2006082952, WO2006120125, WO2006113919, WO2006134317, WO2007016538, WO2007060140, JP2007131584, WO2007071966, WO2007126957, WO2007137103, WO2007137107, WO2007138304, WO2007138311, WO2007141502, WO2007141517, WO2007141538, WO2007141545, WO2007144571, WO2008011130, WO2008011131, WO2008039007,
- the compound of the formula I is administered in combination with a combination of epotirome with ezetimibe.
- the compound of the formula I is administered in combination with an inhibitor of site-1 protease (S1P), for example PF-429242.
- S1P site-1 protease
- the compound of the formula I is administered in combination with an RNAi therapeutic agent directed against PCSK9 (proprotein convertase subtilisin/kexin type 9).
- the compound of the formula I is administered in combination with Omacor® or LovazaTM (omega-3 fatty acid ester; highly concentrated ethyl ester of eicosapentaenoic acid and of docosahexaenoic acid).
- Omacor® or LovazaTM omega-3 fatty acid ester; highly concentrated ethyl ester of eicosapentaenoic acid and of docosahexaenoic acid.
- the compound of the formula I is administered in combination with lycopene.
- the compound of the formula I is administered in combination with an antioxidant, for example OPC-14117, AGI-1067 (succinobucol), probucol, tocopherol, ascorbic acid, ⁇ -carotene or selenium.
- an antioxidant for example OPC-14117, AGI-1067 (succinobucol), probucol, tocopherol, ascorbic acid, ⁇ -carotene or selenium.
- the compound of the formula I is administered in combination with a vitamin, for example Vitamin B6 or Vitamin B12.
- the compound of the formula I is administered in combination with more than one of the aforementioned compounds, for example in combination with a sulfonylurea and metformin, a sulfonylurea and acarbose, repaglinide and metformin, insulin and a sulfonylurea, insulin and metformin, insulin and troglitazone, insulin and lovastatin, etc.
- the compound of the formula I is administered in combination with an inhibitor of carboanhydrase type 2 (carbonic anhydrase type 2), for example those as described in WO2007065948.
- carboanhydrase type 2 carbonic anhydrase type 2
- the compound of the formula I is administered in combination with topiramat or a derivative thereof, as described in WO2008027557.
- the compound of the formula I is administered in combination with a solid combination of topiramat with phentermin (QnexaTM)
- the compound of the formula I is administered in combination with an antisense compound, e.g. ISIS-377131, which inhibits the production of the glucocorticoid receptor.
- an antisense compound e.g. ISIS-377131
- the compound of the formula I is administered in combination with an aldosterone synthase inhibitor and an antagonist of the glucocorticoid receptor, a cortisol synthesis inhibitor and/or an antagonist of the corticotropin releasing factor, as described, for example, in EP1886695.
- the compound of the formula I is administered in combination with an agonist of the RUP3 receptor, as described, for example, in WO2007035355, WO2008005576.
- the compound of the formula I is administered in combination with an activator of the gene which codes for ataxia telangiectasia mutated (ATM) protein kinase, for example chloroquine.
- ATM telangiectasia mutated
- the compound of the formula I is administered in combination with a tau protein kinase 1 inhibitor (TPK1 inhibitor), as described, for example, in WO2007119463.
- TPK1 inhibitor tau protein kinase 1 inhibitor
- the compound of the formula I is administered in combination with a “c-Jun N-terminal kinase” inhibitor (JNK inhibitor), as described, for example, in WO2007125405, WO2008028860.
- JNK inhibitor c-Jun N-terminal kinase inhibitor
- the compound of the formula I is administered in combination with an endothelin A receptor antagonist, for example avosentan (SPP-301).
- an endothelin A receptor antagonist for example avosentan (SPP-301).
- the compound of the formula I is administered in combination with modulators of the glucocorticoid receptor (GR), for example KB-3305 or those compounds as described, for example, in WO2005090336, WO2006071609, WO2006135826, WO2007105766.
- GR glucocorticoid receptor
- the further active ingredient is varenicline tartrate, a partial agonist of the alpha 4-beta 2 nicotinic acetylcholine receptor.
- the further active ingredient is trodusquemine.
- the further active ingredient is a modulator of the enzyme SIRT1 (an NAD + -dependent protein deacetylase); this active ingredient may, for example, be resveratrol in suitable formulations, or those compounds as specified in WO2007019416 (e.g. SRT-1720).
- SIRT1 an NAD + -dependent protein deacetylase
- the further active ingredient is DM-71 (N-acetyl-L-cysteine with bethanechol).
- the compound of the formula I is administered in combination with antihypercholesterolemic compounds, as described, for example, in WO2007107587, WO2007111994.
- the compound of the formula I is administered in combination with a cyclic peptide agonist of the VPAC2 receptor, as described, for example, in WO2007101146, WO2007133828.
- the compound of the formula I is administered in combination with an agonist of the endothelin receptor, as described, for example, in WO2007112069.
- the compound of the formula I is administered in combination with AKP-020 (bis(ethylmaltolato)oxovanadium(IV)).
- the compound of the formula I is administered in combination with tissue-selective androgen receptor modulators (SARM), as described, for example, in WO2007099200, WO2007137874.
- SARM tissue-selective androgen receptor modulators
- the compound of the formula I is administered in combination with an AGE (advanced glycation end product) inhibitor, as described, for example, in JP2008024673.
- AGE advanced glycation end product
- the further active ingredient is leptin; see, for example, “Perspectives in the therapeutic use of leptin”, Salvador, Javier; Gomez-Ambrosi, Javier; Fruhbeck, Gema, Expert Opinion on Pharmacotherapy (2001), 2(10), 1615-1622.
- the further active ingredient is metreleptin (recombinant methionyl-leptin) combined with pramlintide.
- the further active ingredient is the tetrapeptide ISF-402.
- the further active ingredient is dexamphetamine or amphetamine.
- the further active ingredient is fenfluramin or dexfenfluramin.
- the further active ingredient is sibutramine or those derivatives as described in WO2008034142.
- the further active ingredient is mazindol or phentermin.
- the further active ingredient is geniposidic acid (WO2007100104) or derivatives thereof (JP2008106008).
- the further active ingredient is a nasal calcium channel blocker, for example diltiazem, or those as described in U.S. Pat. No. 7,138,107.
- the further active ingredient is an inhibitor of sodium-calcium ion exchange, for example those as described in WO2008028958.
- the further active ingredient is a blocker of calcium channels, for example of CaV3.2, as described in WO2008033431, WO2008033447, WO2008033356, WO2008033460, WO2008033464, WO2008033465, WO2008033468.
- the further active ingredient is a blocker of the “T-type calcium channel”, as described, for example, in WO2008033431.
- the further active ingredient is an inhibitor of KCNQ potassium channel 2 or 3, for example those as described in US2008027049, US2008027090.
- the further active ingredient is an inhibitor of the potassium Kv1.3 ion channel, for example those as described in WO2008040057, WO2008040058, WO2008046065.
- the further active ingredient is a modulator of the MCP-1 receptor (monocyte chemoattractant protein-1 (MCP-1)), for example those as described in WO2008014360, WO2008014381.
- MCP-1 receptor monocyte chemoattractant protein-1 (MCP-1)
- the further active ingredient is a modulator of somatostatin receptor 5 (SSTR5), for example those as described in WO2008019967, US2008064697.
- SSTR5 somatostatin receptor 5
- the further active ingredient is a modulator of somatostatin receptor 2 (SSTR2), for example those as described in WO2008051272.
- SSTR2 somatostatin receptor 2
- the further active ingredient is an erythropoietin-mimetic peptide which acts as an erythropoietin (EPO) receptor agonist.
- EPO erythropoietin
- the further active ingredient is an anorectic/a hypoglycemic compound, for example those as described in WO2008035305, WO2008035306, WO2008035686.
- the further active ingredient is an inductor of lipoic acid synthetase, for example those as described in WO2008036966, WO2008036967.
- the further active ingredient is a stimulator of endothelial nitric oxide synthase (eNOS), for example those as described in WO2008058641.
- eNOS endothelial nitric oxide synthase
- the further active ingredient is a modulator of carbohydrate and/or lipid metabolism, for example those as described in WO2008059023, WO2008059024, WO2008059025, WO2008059026.
- the further active ingredient is an angiotensin II receptor antagonist, for example those as described in WO2008062905.
- the further active ingredient is an agonist of the sphingosine-1-phosphate receptor (S1P), for example those as described in WO2008064315.
- S1P sphingosine-1-phosphate receptor
- the compound of the formula I is administered in combination with bulking agents, preferably insoluble bulking agents (see, for example, Carob/Caromax® (Zunft H J; et al., Carob pulp preparation for treatment of hypercholesterolemia, ADVANCES IN THERAPY (2001 September-October), 18(5), 230-6).
- Caromax is a carob-containing product from Nutrinova, Nutrition Specialties & Food Ingredients GmbH, Industriepark Hochst, 65926 Frankfurt/Main).
- Combination with Caromax® is possible in one preparation or by separate administration of compounds of the formula I and Caromax®.
- Caromax® can in this connection also be administered in the form of food products such as, for example, in bakery products or muesli bars.
- the compounds of the formula I are administered in combination with medicaments with effects on the cardiovascular system and the blood vessel system, for example ACE inhibitors (e.g. ramipril), medicaments which act on the angiotensin renin system, calcium antagonists, beta-blockers, etc.
- ACE inhibitors e.g. ramipril
- medicaments which act on the angiotensin renin system calcium antagonists, beta-blockers, etc.
- the compounds of the formula I are administered in combination with antiinflammatory medicaments.
- the compounds of the formula I are administered in combination with medicaments which are used for cancer treatment and cancer prevention.
- the compounds of the invention show a significant inhibition (>30%) of the signal induced by the agonist at a concentration of 100 ⁇ M, preferably at 10 ⁇ M, particularly preferably at 1 ⁇ M, very particularly preferably at 100 nM and very very particularly preferably at 10 nM.
- Preferred compounds of the invention show an IC50 of less than 1 ⁇ M, particularly preferably of less than 100 nM, very particularly preferably of less than 10 nM and very very particularly preferably of less than 1 nM.
- the anorectic effect is tested on female NMRI mice. After withdrawal of feed for 24 hours, the test substance is administered intraperitoneally or preferably orally by gavage. The animals are housed singly with free access to drinking water and, 30 minutes after administration of product, are offered condensed milk. The condensed milk consumption is determined every half hour for 7 hours, and the general condition of the animals is observed. The measured milk consumption is compared with the vehicle-treated control animals.
- Preferred tolerated vehicles for the administration are, for example, hydroxyethylcellulose (0.5% in water) or Solutol HS15 (5% in hydroxyethylcellulose (0.5% in water)).
- mice 5 weeks old are accustomed either to a standard maintenance diet or to a high-fat and thus high-energy diet.
- the normally fed, slim mice have typically reached a body weight of about 25 g, and the fat-fed mice have reached one of about 35 g.
- the animals are housed singly, and the feed intake and water intake are determined individually. There is free access to feed and water during the experiment.
- test substances are administered orally in a vehicle and always tested by comparison with the vehicle control which is included in parallel.
- vehicle itself has no influence on the feed intake, and is normally hydroxyethylcellulose (0.5% in water) or Solutol HS15 (5% in hydroxyethylcellulose (0.5% in water)).
- a corresponding group of slim mice is kept for each group of diet-induced obese mice.
- Feed consumption and water consumption are determined each day in the first week and then once per week by reweighing the offered feed and water, respectively. The body weight is measured each day.
- Blood samples are taken before and at the end of the treatment in order to determine serum parameters which provide information about changes in intermediary metabolism. It is additionally possible to determine the body fat content on the living animal by means of an impedance measurement (TOBEC method).
- TOBEC method impedance measurement
- an antagonist of MCH1R has sufficient brain penetration (for example determined as the ratio of the compound level in the brain tissue and in the blood serum attained at one time) (on this subject, see, for example, J. Pharmacol. Exp. Thera. 2008, 324, 206-213).
- Preferred compounds of the invention have a ratio of brain to serum levels of at least 0.3. Further preferred compounds have a ratio of at least 0.6. Particularly preferred compounds exhibit a ratio of at least 1.0.
- the aim of the micronucleus test is to examine whether a test compound has the potential to elicit the formation of micronuclei (small membrane-bound DNA fragments) in various cell lines or primary cultures, with or without metabolic activation by S9 liver homogenate.
- the test system allows differentiation between the clastogenic and aneugenic potential of a test compound by an immunochemical labeling of the kinetochores or by staining the DNA fragments by the FISH (fluorescence in situ hybridization) method.
- the cells are treated in a 96-well microtiter plate with the test compound.
- the treatment time is typically 3 hours with metabolic activation or 24 hours without metabolic activation.
- Twenty-four hours after the end of the treatment the cells are isolated, fixed and stained.
- the cytotoxicity of the test compound is assessed according to the relative cell growth expressed as percentage growth or taking account of the doubling time as population doubling compared with the negative control.
- the highest test concentration should show not less than 30% surviving cells, or should be the concentration at which a precipitate of the test compound is observed. Duplicate determinations should be carried out with each test concentration. An accurate detailed description of the experiment is to be found in Kirsch-Volders et al. (Mutation Res. 2003, 540, 153-163).
- a positive control must show a clear statistically significant effect by comparison with the negative control.
- Preferred compounds of the invention are negative in the micronucleus test.
- the aim of the AMES II test is to examine whether a test compound has mutagenic potential.
- a mixed bacterial strain (mixed strains, 6 different Salmonella typhimurium strains with in each case a missence point mutation in the histidine operon) and the Salmonella typhimurium strain TA98 for detecting frame shift mutations is treated in a 384-well microtiter plate with various concentrations of the test substance with or without metabolic activation through addition of S9 liver homogenate (accurate descriptions of the experiment are to be found in the literature: P. Gee, D. M. Maron, B. N. Ames; Proc. Natl. Acad. Sci. USA 1994, 91, 11606 and dieckiger-Isler et al.; Mutation Res. 2004, 558, 181 and cit. lit.). Mutagenic test compounds cause back-mutations and thus restore the functionality of endogenous histidine biosynthesis. Mutated bacteria are thus able to divide and expand to bacterial colonies.
- Preferred compounds of the invention are negative in the AMES II test.
- LDH lactate dehydrogenase
- the LDH activity which enters the cell supernatant from the cytosol due to cell damage is measured by colorimetry.
- the cells are treated with the test compound.
- Fifty microliters of the culture supernatant are removed and mixed with the reaction solution (LDH kit, Roche, Mannheim) in accordance with the manufacturer's information.
- LDH catalyzes the conversion of lactate into pyruvate.
- NAD+ is reduced to NADH/H+.
- the latter in turn reduces, under the influence of the added diaphorase, a likewise added yellow tetrazolium salt to the red formazan.
- the formazan is quantified by measuring the absorption at 492 nM (e.g. with TECAN SPECTRAFluor Plus).
- Preferred compounds of the invention show no significant increase in LDH activity at concentrations below 10 ⁇ M. Particularly preferred compounds show no increase below a concentration of 50 ⁇ M. Even further preferred compounds show no increase below a concentration of 250 ⁇ M.
- the aim of the test is to determine the total intracellular ATP content, which is a measure of the energy level and thus the vitality of a cell.
- 100 ⁇ l of cell culture medium are mixed in a well of a microtiter plate with 100 ⁇ l of the CellTiter-Glo reagent (following the manufacturer's instructions: Promega Technical Bulletin No. 228, CellTiter-Glo Luminesent Cell Viability Assay).
- the cultures are shaken at room temperature for 2 minutes and then incubated for 10 minutes until the luminescence signal has stabilized.
- Preferred compounds of the invention show no significant reduction in the ATP levels at concentrations below 10 ⁇ M. Particularly preferred compounds show no reduction below a concentration of 50 ⁇ M. Even further preferred compounds show no reduction below a concentration of 250 ⁇ M.
- the aim of the test is to measure the uptake of neutral red (NR) into the lysosomes/endosomes and vacuoles of living cells, which is a quantitative measure of the number and vitality of the cells.
- NR neutral red
- the cells are washed with 150 ⁇ l of a preheated phosphate buffer solution (PBS) and incubated with 100 ⁇ l of the NR medium at 37° C. in a humidified atmosphere with 7.5% carbon dioxide for 3 hours. After the incubation, the NR medium is removed and the cells are washed with 150 ⁇ l of PBS. Removal of the PBS is followed by addition of exactly 150 ⁇ l of an ethanol/glacial acetic acid solution. After shaking for 10 minutes, the dye is extracted from the cells to give a homogeneous dye solution. An exact description of the test is to be found in the literature (E. Borenfreund, J. A. Puerner, Toxicol. Lett. 1985, 24(2-3), 119-124).
- PBS preheated phosphate buffer solution
- the absorption of the dye solution is determined at 540 nM using a microtiter plate reader as difference from the absorption of the ethanol/glacial acetic acid solution.
- the aim of the test is to determine the concentration range in which the test compound blocks the cardiac hERG channel. Blockade of the hERG channel, which is responsible for the Ikr current in the human heart, is associated with potentially fatal arrhythmias.
- cDNA For expression of the cDNA encoding the hERG channel it was cloned into the pcDNA3 vector (Invitrogen).
- Chinese hamster oocytes (CHO, American Type Culture Collection, Rockville, Md.) were transfected using lipofectamine (GIBCO/BRL, Grand Island, N.Y.) with the hERG cDNA and selected using G418 (GIBCO/BRL, Grand Island, N.Y.; 500 ⁇ g/ml).
- CHO cells with stable expression of the hERG channel were cultured on a HAM F-12 medium which was supplemented with 10% native bovine serum, 1 ⁇ penicillin/streptomycin and 500 ⁇ g/ml G418 in an atmosphere of 95% air/5% carbon dioxide.
- the cells selected for the patch clamp experiment are seeded on a plastic support 18-24 hours before the experiment.
- HERG channel currents are recorded at room temperature by the whole-cell variant of the patch clamp technique using an Axopatch 200B amplifier (Axon Instruments, Foster City, Calif.).
- the electrodes (3-6 megaohms resistance) are prepared from TW150F glass capillaries (World Precision Instruments, Sarasota, Fla.) and filled with the pipette solution (120 mM potassium aspartate, 20 mM KCl, 4 mM Na2ATP, 5 mM HEPES, 1 mM MgCl2; adjusted to pH 7.2 with KOH).
- the hERG channel currents are induced by a positive voltage pulse (20 mV) followed by a negative pulse ( ⁇ 40 mV) and are recorded for later analysis.
- the hERG channel current of the cell flushed with the control solution 130 mM, 5 mM KCl, 2.8 mM NaOAc, 1 mM MgCl2, 10 mM HEPES; 10 mM glucose, 1 mM CaCl2; adjusted to pH 7.4 with NaOH
- the cell is perfused with the test compound dissolved in the above control solution (by dilution of a 10 or 100 mM DMSO solution of the test compound so that the DMSO content is no more than 0.1%).
- the current is followed continuously until no further changes occur.
- the same procedure is repeated with increasing concentrations of the test compound.
- the maximum amplitude of the hERG current is measured in picoAmperes (pA) for each concentration and for each cell.
- the maximum amplitude in pA for each concentration of the test compound is compared with that of the pure control solution in the same cell and calculated as % of the control value.
- test compound is tested at various concentrations in 3-5 CHO cells which express the hERG channel.
- IC50 is obtained by use of nonlinear least squares regression (GraphPAD Software, San Diego, Calif.).
- the compounds of the invention of the formula I exhibit, as selective MCH1R antagonists, selectivity factors of at least 30, preferably of 100, more preferably of 300 and even more preferably of 1000 vis à vis the affinity to other proteins.
- selectivity factors e.g. the 5-HT2a receptor
- muscarine receptor subtypes e.g. the M1 receptor
- adrenergic receptor subtypes e.g. AR alpha1a
- sodium and calcium channels e.g. the L-type calcium channel.
- Solubility in aqueous systems can be determined by various methods. Suitable examples are solution precipitation methods (“kinetic solubility”) and methods which investigate the dissolution of a solid sample until an equilibrium is set up (“thermodynamic solubility”).
- a DMSO solution of the test compound (2.5 mM; 0.5 ⁇ l) is pipetted into 200 ⁇ l of an aqueous test solution (e.g. phosphate-buffered saline, 10 ⁇ , 1M, Sigma, adjusted to 10 mM, pH 7.4) in a 96-well microtiter plate, and the turbidity is measured at the resulting theoretical concentration for the test compound of 6.25 ⁇ M using a nephelometer (e.g. Nephelostar Galaxy, BMG Labtech). The concentration of the test compound in the aqueous test solution is then raised to a theoretical 12.5 ⁇ M by adding further DMSO solution (2.5 mM; 0.5 ⁇ l), and the turbidity measurement is repeated.
- an aqueous test solution e.g. phosphate-buffered saline, 10 ⁇ , 1M, Sigma, adjusted to 10 mM, pH 7.4
- a nephelometer e.g. Nep
- Preferred compounds of the invention show a kinetic solubility in phosphate buffer (pH 7.4) of at least 12.5 ⁇ M; more preferably of at least 50 ⁇ M and even more preferably of at least 250 ⁇ M.
- the integrated UV absorption from HPLC UV measurement of serial dilutions of the test compound in DMSO shows a linear correlation with the concentration in a calibration line.
- the test compound (500 ⁇ g) is shaken together with the aqueous test solution (250 ⁇ l) in a closed vessel (capacity: 1.5 ml) for 16 hours (Eppendorf thermoshaker, 1400 rpm, 25° C., covering to protect from light).
- the sample is then centrifuged at maximum rotational speed, and the supernatant is finally filtered.
- a sample of the filtered supernatant is analyzed directly by HPLC UV measurement (see above).
- a further sample is analyzed after dilution (1 part by volume of supernatant, 39 parts by volume of test solution).
- the concentration of the test compound in the undiluted supernatant is calculated from the resulting integrated UV absorptions of the supernatant samples on the basis of the constructed calibration lines and stated as solubility of the test compound in the respective aqueous test solution.
- aqueous test solutions are deionized water or aqueous phosphate buffer with various pH values (e.g. pH 1.2; pH 4.0; pH 6.8; pH 7.4; pH 9.0) which can be prepared from the commercial solution (phosphate buffered saline, 10 ⁇ , Sigma) by dilution and adjustment with phosphoric acid or sodium hydroxide solution by standard methods.
- pH 1.2; pH 4.0; pH 6.8; pH 7.4; pH 9.0 phosphated saline, 10 ⁇ , Sigma
- Preferred compounds of the invention show a solubility in phosphate buffer (pH 7.4) of at least 12.5 ⁇ M; more preferably of at least 50 ⁇ M and even more preferably of at least 250 ⁇ M.
- the test for permeability is carried out in CACO-2/TC7 cells which have been cultured (DMEM/Glutamax I/Gibco with high glucose content, HEPES 25 mM, 1% NEAA, 10% FBS, 40 ⁇ g/ml gentamycin; 37° C. surrounding temperature; 95% humidity and 10% CO2 content) on Becton Dickinson filters (24-well, uncoated) for 21 days.
- the permeability is tested at a concentration of 20 ⁇ M for the test compound (1% DMSO in HBSS) with a pH gradient (apical: pH 6.5 and 0.5% BSA; basolateral: pH 7.4 and 5% BSA). Analysis takes place by means of LCMS/MS. Further descriptions of the test system and references for the experimental procedure are to be found in Balimane, P. V.; Drug Discovery Today 2005, 10(5), 335-343.
- CYP enzymes The inhibition of CYP enzymes is determined on recombinant enzymes (obtained from Becton Dickinson) and fluorescent substrates (BD/Gentest) as recommended by the manufacturer (see Website http://www.bdbiosciences.com). Further descriptions of the test system and references for the experimental procedure are to be found in Zlokarnik, G.; Drug Discovery Today 2005, 10(21), 1443-1450.
- the metabolic stability is determined by incubating the test compound (5 ⁇ M) with microsomal liver fractions (1 mg/ml protein with 0.1% w/v BSA; 1 mM NADPH, 0.5% DMSO) at 37° C. Analysis at an incubation time of 0 and 20 minutes takes place by means of LCMS/MS. Further descriptions of the test system and references for the experimental procedure are to be found in Plant, N.; Drug Discovery Today 2004, 9(7), 328-336 and Lau, Y. Y. et al.; Pharmaceutical Res. 2002, 19(11), 1606-1610.
- the inventive compounds of the formula I can be prepared with the aid of reactions known in principle.
- an amino acid of the structure Z1 can first be protected selectively (for example by method D with Boc2O).
- the subsequent reaction with an amine (HNR1R2) can advantageously be carried out using a commonly known coupling reagent (for example by method A-1 with HATU or by method A-2 with EDC/HOBt).
- Removal of the protecting group for example by method C with hydrochloric acid
- subsequent reduction for example by method B with lithium aluminum hydride
- the inventive compounds of the formula Ia can be obtained by reducing the amine Z2 with an acid of the structure B-L3-A-L2-CO2H (for example by method A-1 or A-2) (scheme 1).
- ketones Z3 which are commercially available, or can be prepared by known methods (see, for example, synthesis 2004, 121; J. Org. Chem. 1995, 60, 4324). Acid-catalyzed condensation of the ketones Z3 with amides (B-L3-A-L2-CONH2) and subsequent (optionally asymmetric) catalytic hydrogenation of the resulting enamides under known conditions (see, for example, Adv. Synth. Catal. 2003, 345, 230; Tetrahedron: Asymmetry 1999, 10, 3467; J. Org. Chem. 1995, 60, 4324) gives rise to the aryl bromides Z4.
- Stereochemically defined compounds of type Ib* can be formed, for example, by condensation of the intermediates Z5′ with chiral sulfinylamides (for example by method M), addition of Grignard reagents (for example by method L), hydrolysis (for example by method K) and optional reductive alkylation, for example by method H-2 (scheme 2-1).
- the intermediates Z4 can also be used to synthesize other compounds of the formula I.
- the dian ions obtained by sequential treatment of Z4 with MeLi and then n-BuLi can be reacted with ketones (R34COR35).
- the resulting tertiary alcohols can be converted under the conditions of the Ritter reaction (e.g. TMSCN, H2SO4/HOAc to amides which then, after hydrolysis and optional reductive amination, give rise to compounds of the structure Ib-1 (scheme 2-2).
- the intermediates Z4 can also be reacted by means of transition metal complexes (for example those of Pd and Ni) catalyzed with pyridyl compounds (e.g. pyridyltrialkyltin compounds, pyridylboronic acid (derivatives) or pyridine N-oxides).
- pyridyl compounds e.g. pyridyltrialkyltin compounds, pyridylboronic acid (derivatives) or pyridine N-oxides.
- suitable catalysts e.g. PtO2 in HOAc; method J-1
- optional reductive alkylation gives rise to the structures Ib-2 (scheme 2-2).
- the intermediates Z4 are reacted with allyl-metal compounds (e.g. allyltributyltin) under palladium catalysis, then the double bond is cleaved oxidatively (for example with OsO4/NaIO4), and the aldehydes thus obtained are reacted with amines HNR1R2 in the sense of a reductive amination (scheme 2-2).
- allyl-metal compounds e.g. allyltributyltin
- a further preparation process for other compounds of the formula I again consists in reacting dichlorides of the Z6 type or isochromenones of the Z7 type with amines Z8 by processes known in principle (scheme 3).
- the dichlorides Z6 required can be obtained from ortho-methylbenzoic acids by double metalation, for example with lithium diisopropylamide (LDA), scavenging of the dianion with formaldehyde (for example in the form of paraformaldehyde) and final dichlorination.
- (dihydro)isoquinolinones of the formula I it is also to possible to cleave the amide bond of the intermediates Z4 under appropriate conditions (for example with HBr/methanesulfonic acid).
- the amines thus obtained can be reacted with the dichlorides Z6 (or the isochromenones Z7).
- the bromides Z9 thus prepared can then be converted further to inventive compounds analogously to the intermediates Z4 (preferably by means of the transition metal-catalyzed reactions specified there).
- the bromides Z9 can be reductively carbonylated and the aldehydes thus obtained can be converted to compounds of the le type by means of a reductive amination (scheme 3-1).
- method A-1, B, C, D, E, F, G in example 1; method H, I in example 2; method J-1 in example 4; method K, L, M-1 in example 6; method H-2 in example 8-1; method A-2 in example 9-1; method N in example 13; method O in example 14; method P in example 15.
- inventive compounds are bases and can form salts with correspondingly strong acid.
- the compounds after HPLC purification using an eluent comprising trifluoroacetic acid, may be present in the form of hydrotrifluoroacetates. These can be converted to the free bases shown by simple treatment of a solution of the salts, for example with sodium carbonate solution.
- the unit of the molecular weights reported is “g/mol”. Peaks observed in the mass spectrum are reported as the integer quotient of the molar molecular ion mass and the charge of the molecular ion (m/z).
- the aqueous phase was basified with concentrated sodium hydroxide solution and extracted three times with dichloromethane (DCM). The combined organic phases were dried over magnesium sulfate and concentrated. The product was thus obtained with the molecular weight of 230.36 (C15H22N2); MS (ESI): 231 (M+H+).
- N—((R)-6-formyl-1,2,3,4-tetrahydronaphthalen-2-yl)-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide was prepared from N—((R)-6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide.
- N—((S)-6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-4-hydroxybenzamide was reacted with methanesulfonic acid (S)-1-(tetrahydrofuran-2-yl)methyl ester.
- the product was thus obtained with the molecular weight of 430.35 (C22H24BrNO3); MS (ESI): 430 (M+H+).
- (S)-6-bromo-1,2,3,4-tetrahydronaphthalen-2-ylamine was reacted with 5-hydroxypyridine-2-carboxylic acid.
- the amide obtained was alkylated by method F with (S)-1-(tetrahydrofuran-2-yl)methyl methanesulfonate and converted to the desired aldehyde by method I.
- the product was thus obtained with the molecular weight of 380A5 (C22H24N2O4); MS (ESI): 381 (M+H+).
- N—((S)-6-azepan-1-ylmethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-4-hydroxybenzamide was obtained by reacting 4-hydroxybenzoic acid with (S)-6-azepan-1-ylmethyl-1,2,3,4-tetrahydronaphthalen-2-ylamine.
- reaction mixture was then allowed to come to room temperature and stirred at this temperature for 4 hours.
- the reaction mixture was admixed with water, then the THF was removed under reduced pressure and then the aqueous phase was extracted with diethyl ether.
- the aqueous phase was acidified with conc. HCl, and the resulting precipitate was filtered off and washed repeatedly with water.
- the product was thus obtained with the molecular weight of 178.06 (C10H10O3); MS (ESI): 179 (M+H+).
- 6-methoxyisochroman-1-one was treated with boron tribromide.
- Table 7 lists examples with an aminochromane base skeleton, which can be prepared by the processes described above by way of example.
- inventive compounds for example, by the process described in Scheme 2 or by way of example in Example 3-1, it is possible to proceed, for example, from 7-bromochroman-3-one, which is supplied commercially (Anichem LLC; 195 Black Horse Lane; North Brunswick, N.J., 08902; USA) or by the following route:
Abstract
The invention relates to substituted tetrahydronaphthalenes and derivatives thereof, and also to the physiologically compatible salts and physiologically functional derivatives thereof, to preparation thereof, to medicaments comprising at least one inventive substituted tetrahydronaphthalene or derivative thereof, and to the use of the inventive substituted tetrahydronaphthalenes and derivatives thereof as medicaments.
Description
- This application is a divisional of U.S. application Ser. No. 12/705,140, filed Feb. 12, 2010, which is a continuation of International Application No. PCT/EP2008/006700, filed Aug. 14, 2008, which claims priority of European Patent Application No. 07291010.2, filed Aug. 15, 2007, which is incorporated herein by reference in its entirety.
- The invention relates to substituted tetrahydronaphthalenes and derivatives thereof, and also to the physiologically compatible salts and physiologically functional derivatives thereof, to preparation thereof, to medicaments comprising at least one inventive substituted tetrahydronaphthalene or derivative thereof, and to the use of the inventive substituted tetrahydronaphthalenes and derivatives thereof as medicaments.
- Compounds which have pharmacological action and whose overall structure is similar to the substituted tetrahydronaphthalenes and derivatives thereof described in the present application are already described in the prior art, for example in WO2002/064565 and WO2000/051970.
- WO2008/002575, WO2008/001160, WO2006/044293, WO2005/033063, US2005/0075324, US 2006/0247239 and Meyers K. M. et al., Bioorganic & Medicinal Chemistry Letters 17, 2007, 814-18; Meyers K. M. et al., Bioorganic & Medicinal Chemistry Letters 17, 2007, 819-22; Mendez-Andino J. L. et al., Bioorganic & Medicinal Chemistry Letters 15, 2007, 2092-2105 disclose amino-substituted tetrahydronaphthalene derivatives with MCH R1-antagonistic action for treatment of obesity.
- Further compounds with MCH-antagonistic action for treatment of obesity have been described in the prior art (examples: WO2005047293, WO2004092181, WO2005103039, WO2004024702, WO2001021577, WO2003035624, WO2002089729, WO2002006245, WO2002002744, WO2002057233, WO2003045313, WO2003097047, WO2002010146, WO2003087044, WO2003/087046, WO2001/021577). A review is given in Rokosz, L. L., Expert Opin. Drug Discov. 2007, 2, 1301-1327.
- It was an object of the invention to provide compounds which bring about weight reduction in mammals and which are suitable for prevention and treatment of obesity and diabetes and their manifold sequelae.
- Surprisingly, a series of compounds which modulate the activity of MCH receptors has been found. More particularly, the compounds feature antagonism of MCH R1.
- The invention therefore relates to compounds of the formula I
- in which
- are each independently H, (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl, CO(R9), (C(R10)(R11))q-R12, CO(C(R13)(R14))r-R15, CO—O(C1-C8)-alkyl, CO(C(R13)(R14))r—N(R16)(R17);
or
R1 and R2, together with the nitrogen atom to which they are bonded, form a 4-to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include from 0 to 3 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, (C3-C3)-cycloalkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C6)-alkyl, oxo, CO(R18), CON(R19)(R20), hydroxyl, COO(R21), N(R22)CO(C1-C6)-alkyl, N(R23)(R24) or SO2(C1-C6)-alkyl; - are each independently H, (C1-C6)-alkyl, hydroxy-(C1-C2)-alkyl, F, OH;
- are each independently H, (C1-C6)-alkyl;
or - form, optionally together with the nitrogen atom to which they are bonded, a 5-6-membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatom from the group of NH, N—(C1-C6)-alkyl, oxygen and sulfur;
q, r are each independently 0, 1, 2, 3, 4, 5, 6; - are each independently H, OH, F, O—(C1-C6)-alkyl, S—(C1-C6)-alkyl, O-phenyl, CN, COO(R25), N(R26)CO(C1-C6)-alkyl, N(R27)(R28), CON(R29)(R30), SO2(C1-C6)-alkyl, 3-12-membered mono-, bi- or spirocyclic ring which may contain one to four heteroatoms from the group of N, O and S, and the 3-12-membered ring may contain further substituents such as F, Cl, Br, OH, CF3, NO2, CN, OCF3, oxo, O—(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, S—(C1-C8)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O—(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, O—(C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, N(R31)(R32), COO(R33), SO2(C1-C6)-alkyl and COOH;
- are each independently H, (C1-C8)-alkyl; or
- each independently form, optionally together with the nitrogen atom to which they are bonded, a 5-6-membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatom from the group of NH, N—(C1-C6)-alkyl, oxygen and sulfur;
L1 is C(R34)(R35), C(R36)(R37)C(R38)(R39), (C3-C6)-cycloalkyl;
optionally, R1 may be joined to one of the R34, R35, R36, R37, R38 or R39 radicals, so as to form a 5-6-membered ring; - are each independently H, (C1-C8)-alkyl;
- are each independently H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, S—(C1-C6)-alkyl, O—(C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, CON(R40)(R41), CO(R42);
- are each independently H, (C1-C8)-alkyl;
or - each independently form, optionally together with the nitrogen atom to which they are bonded, a 5-6-membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatom from the group of NH, N—(C1-C6)-alkyl, oxygen and sulfur;
- are each independently H, F, (C1-C8)-alkyl, OH, O—(C1-C6)-alkyl; or
R6 and R6′, or R43 and R43′ together are optionally oxo;
R8 is H, (C1-C8)-alkyl;
L2 is a bond, C(R44)(R45); - are each independently H, (C1-C8)-alkyl;
A is a 5-6-membered aromatic ring which may include up to 2 heteroatoms selected from the group of nitrogen, oxygen and sulfur, and may be substituted by one or more of the substituents H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O—(C1-C8)-alkyl, O—(C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, N(R54)(R55), SO2—CH3, CON(R56)(R57), N(R58)CO(R59), CO(R60);
in the case that L2=a bond, C(O)NR8 may be joined to an ortho substituent of A via a bridge containing one or two elements from the group of carbon and nitrogen, so as to form a 9- to 10-membered bicyclic ring overall; - are each independently H, (C1-C8)-alkyl;
or - each independently form, optionally together with the nitrogen atom to which they are bonded, a 5-6-membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatom from the group of NH, N—(C1-C8)-alkyl, oxygen and sulfur;
L3 is a bond or a linker having from 1 to 4 members, where the members are selected from the group consisting of O, S, SO2, N(R61), CO, C(R62)(R63), C≡C, to give rise to a chemically viable radical, and the linker does not have any O—CO or COO groups;
B is (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C6)-alkyl, a 3 to 10-membered mono-, bi- or spirocyclic nonaromatic ring which may include from 0 to 3 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by one or more of the following substituents: F, CF3, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, oxo, CO(R64), hydroxyl; - are each independently H, (C1-C8)-alkyl; where, in the case that X═C(R43)(R43′)
- B is a 4- to 10-membered mono-, bi- or spirocyclic nonaromatic ring which includes from 1 to 3 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by one or more of the following substituents: F, CF3, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, oxo, CO(R64), hydroxyl.
- The compounds of the formula I are notable in that they have an improved solubility in aqueous media as compared with structurally similar compounds with MCH-antagonistic action (especially in physiologically relevant buffer systems) coupled with simultaneously high activity. Moreover, preferred inventive compounds are notable for low blockage of the hERG channel. Furthermore, preferred inventive compounds have an improved metabolic stability as compared with prior art compounds.
- The alkyl, alkenyl and alkynyl radicals in the substituents R1, R2, R3, R4, R5, R6, R6″, R7, R7′, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R43′, R44, R45, R54, R55, R56, R57, R58, R59, R60, R61, R62, R63, R64 may be either straight-chain, branched and/or optionally substituted by substituents such as (C1-C4)-alkoxy or halogen. This also applies when the alkyl, alkenyl and alkynyl radicals are part of another group, for example part of an alkoxy group (such as (C1-C4)-alkoxy-(C1-C4)-alkyl)). Suitable halogens are fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine and bromine, particularly preferably fluorine.
- Examples of alkyl groups are: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl and octyl. Included therein are both the n-isomers of these radicals and branched isomers such as isopropyl, isobutyl, isopentyl, sec-butyl, tert-butyl, neopentyl, 3,3-dimethylbutyl, etc. Unless stated otherwise, the term alkyl additionally also includes alkyl radicals which are unsubstituted or optionally substituted by one or more further radicals, for example by 1, 2, 3 or 4 identical or different radicals such as (C1-C4)-alkoxy or halogen. Examples of alkyl groups substituted by halogen are fluorinated alkyl groups such as CF3, CHF2, CH2F, 3-fluoroprop-1-yl, 2,2,1,1-tetrafluoroethyl. It is moreover possible for the additional substituents to appear in any desired position of the alkyl radical. Unless defined otherwise, the alkyl radicals are preferably unsubstituted.
- Cycloalkyl means in the context of the present application cycloalkyl and cycloalkylalkyl (alkyl which is in turn substituted by cycloalkyl), where cycloalkyl has at least 3 carbon atoms. Examples of cycloalkyl radicals are: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl. Polycyclic ring systems are also possible where appropriate, such as decalinyl, norbornanyl, bornanyl or adamantanyl. The cycloalkyl radicals may be unsubstituted or optionally substituted by one or more further radicals as listed by way of example above for the alkyl radicals. Unless defined otherwise, the cycloalkyl radicals are preferably unsubstituted.
- Examples of alkenyl and alkynyl groups are: vinyl, 1-propenyl, 2-propenyl (allyl), 2-butenyl, 2-methyl-2-propenyl, 3-methyl-2-butenyl, ethynyl, 2-propynyl (propargyl), 2-butynyl or 3-butynyl.
- Cycloalkenyl means in the context of the present application cycloalkenyl radicals and cycloalkenylalkyl radicals (alkyl which is substituted by cycloalkenyl), which comprise at least three carbon atoms. Examples of cycloalkenyl are: cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.
- The alkenyl radicals and cycloalkenyl radicals may have one to three conjugated or non-conjugated double bonds (i.e. also alkadienyl and alkatrienyl radicals), preferably one double bond in a linear or branched chain. The same applies to the triple bonds for alkynyl radicals. The alkenyl and alkynyl radicals may be unsubstituted or optionally substituted by one or more further radicals as listed by way of example above for the alkyl radicals. Unless defined otherwise, the alkenyl and alkynyl radicals are preferably unsubstituted.
- Aryl refers in the present invention to radicals which are derived from monocyclic or bicyclic aromatic compounds comprising no ring heteroatoms. Where aryl refers to systems which are not monocyclic, the saturated form (perhydro form) or the partly unsaturated form (for example the dihydro form or tetrahydro form) is also possible for the second ring when the respective forms are known and stable. The term aryl also includes in the present invention for example bicyclic radicals in which both rings are aromatic and bicyclic radicals in which only one ring is aromatic. Examples of aryl are: phenyl, naphthyl, indanyl, 1,2-dihydronaphthenyl, 1,4-dihydronaphthenyl, indenyl or 1,2,3,4-tetrahydronaphthyl. Unless defined otherwise, the aryl radicals are preferably unsubstituted. Aryl is particularly preferably phenyl or naphthyl.
- Heteroaryl radicals mean radicals derived from monocyclic or bicyclic aromatic compounds which comprise ring heteroatoms, preferably N, O or S. Otherwise, the statements made about aryl radicals apply to heteroaryl radicals.
- A “tricycle” means structures having 3 rings which are linked together by more than one bond. Examples of such systems are fused systems with 3 rings and spirocycles with fused-on ring system.
- A polycyclic group (bi-, tri- or spirocyclic ring structure) means in the context of the present application a group which is derived from spiranes, fused ring systems or bridged ring systems. The spiranes are notable for two rings having only one carbon atom in common and the ring planes of the two rings being perpendicular to one another. In the fused ring systems, two rings are linked together in such a way that they have two atoms in common. This type of linkage involves an “ortho fusion”. Bridged ring systems are ring systems having a bridge of carbon atoms and/or heteroatoms between two nonadjacent atoms of a ring. A “chemically viable radical” means in the context of the present invention a radical which is stable at room temperature and atmospheric pressure. In the context of the present invention, a “chemically viable radical” in the definition of group A in compounds of the formula I preferably means groups which have no heteroatom-heteroatom bonds between the individual members of the groups.
- A “nonaromatic” ring means in the context of the present application preferably a ring which is saturated or partly unsaturated. In this connection, a partly unsaturated ring according to the present application has one or, where appropriate, a plurality of double bonds, but the partly unsaturated ring is not aromatic. The term “nonaromatic” in the context of the present application also includes “nonheteroaromatic” rings.
- The compounds of the formula I may have one or more centers of asymmetry. The compounds of the formula I may therefore exist in the form of their racemates, enantiomer-enriched mixtures, pure enantiomers, diastereomers and mixtures of diastereomers. The present invention encompasses all these isomeric forms of the compounds of the formula I. These isomeric forms may be obtained by known methods, even if not expressly described in some cases.
- Pharmaceutically acceptable salts are, because their solubility in water is greater than that of the initial or basic compounds, particularly suitable for medical applications. These salts must have a pharmaceutically acceptable anion or cation. Suitable pharmaceutically acceptable acid addition salts of the compounds of the invention are salts of inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid and sulfuric acid, and of organic acids, for example acetic acid, benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glycolic acid, isethionic acid, lactic acid, lactobionic acid, maleic acid, malic acid, methanesulfonic acid, succinic acid, p-toluenesulfonic acid and tartaric acid. Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts), alkaline earth metal salts (such as magnesium and calcium salts) and salts of trometamol (2-amino-2-hydroxymethyl-1,3-propanediol), diethanolamine, lysine or ethylenediamine.
- Salts with a pharmaceutically unacceptable anion, for example trifluoroacetate, likewise belong within the framework of the invention as useful intermediates for the preparation or purification of pharmaceutically acceptable salts and/or for use in nontherapeutic, for example in vitro, applications.
- The term “physiologically functional derivative” used herein refers to any physiologically tolerated derivative of a compound of the formula I of the invention, for example an ester, which on administration to a mammal, for example a human, is able to form (directly or indirectly) a compound of the formula I or an active metabolite thereof.
- Physiologically functional derivatives also include prodrugs of the compounds of the invention, as described, for example, in H. Okada et al., Chem. Pharm. Bull. 1994, 42, 57-61. Such prodrugs can be metabolized in vivo to a compound of the invention. These prodrugs may themselves be active or not.
- The compounds of the invention may also exist in various polymorphous forms, for example as amorphous and crystalline polymorphous forms. All polymorphous forms of the compounds of the invention belong within the framework of the invention and are a further aspect of the invention.
- All references to “compound(s) of formula I” hereinafter refer to compound(s) of the formula I as described above, and their salts, solvates and physiologically functional derivatives as described herein.
- If radicals or substituents can occur more than once in the compounds of the formula I, they may each independently be defined as specified and be the same or different.
- The symbols in the formula I are preferably each independently defined as follows:
- are each independently H, (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl, CO(R9), (C(R10)(R11))q-R12, CO(C(R13)(R14))r-R15, CO—O(C1-C8)-alkyl, CO(C(R13)(R14))rN(R16)(R17);
R1 is preferably:
H, (C1-C8)-alkyl, (C(R10)(R11))q-R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8) alkenyl, (C3-C8)-alkynyl, CO—(C1-C8)-alkyl, CO—O(C1-C8)-alkyl,
CO(C(R13)(R14))rN(R16)(R17);
R2 is preferably:
(C1-C8)-alkyl, (C(R10)(R11))q-R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl;
or
R1 and R2, together with the nitrogen atom to which they bonded, form a 4- to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include from 0 to 3 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, (C3-C8)-cycloalkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C6)-alkyl, oxo, CO(R18), CON(R19)(R20), hydroxyl, COO(R21), N(R22)CO(C1-C6)-alkyl, N(R23)(R24) or SO2(C1-C6)-alkyl;
more preferably, R1, R2 are:
(C1-C8)-alkyl, (C(R10)(R11))q-R12, (C1-C4)-alkoxy-(C1-C4)-alkyl; or R1 and R2, together with the nitrogen atom to which they are bonded, form a 4- to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen, may include from 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, Br, CF3, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C3-C8)-cycloalkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C6)-alkyl, oxo, CO(R18), hydroxyl, N(R22)CO(C1-C6)-alkyl, or SO2(C1-C6)-alkyl;
most preferably, R1 and R2, together with the nitrogen atom to which they are bonded, form a 4- to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may include from 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, Br, CF3, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C3-C8)-cycloalkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C6)-alkyl, oxo, CO(R18), hydroxyl, N(R22)CO(C1-C6)-alkyl, or SO2(C1-C6)-alkyl; - are each independently H, (C1-C6)-alkyl, hydroxy-(C1-C2)-alkyl, F, OH;
- are each independently H, (C1-C6)-alkyl;
or - form, optionally together with the nitrogen atom to which they are bonded, a 5-6-membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatom from the group of NH, N—(C1-C6)-alkyl, oxygen and sulfur;
q, r are each independently 0, 1, 2, 3, 4, 5, 6; preferably 0, 1, 2, 3, 4; - are each independently H, OH, F, O—(C1-C6)-alkyl, S—(C1-C6)-alkyl, O-phenyl, CN, COO(R25), N(R26)CO(C1-C6)-alkyl, N(R27)(R28), CON(R29)(R30), SO2(C1-C6)-alkyl, 3-12-membered mono-, bi- or spirocyclic ring which may contain one to four heteroatoms from the group of N, O and S, and the 3-12-membered ring may contain further substituents such as F, Cl, Br, OH, CF3, NO2, CN, OCF3, oxo, O—(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, S—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O—(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, O—(C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, N(R31)(R32), COO(R33), SO2(C1-C6)-alkyl and COOH;
preferably H, OH, F, O—(C1-C6)-alkyl, N(R26)CO(C1-C6)-alkyl, SO2(C1-C6)-alkyl, 3-12 membered mono-, bi- or spirocyclic ring which may contain one to three heteroatoms from the group of N, O and S, and the 3-12-membered ring may contain further substituents such as F, Cl, Br, OH, CF3, NO2, CN, OCF3, oxo, O—(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, N(R31)(R32) and SO2(C1-C6)-alkyl; - are each independently H, (C1-C8)-alkyl;
or - each independently form, optionally together with the nitrogen atom to which they are bonded, a 5-6-membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatom from the group of NH, N—(C1-C6)-alkyl, oxygen and sulfur;
L1 is C(R34)(R35), C(R36)(R37)C(R38)(R39), (C3-C6)-cycloalkyl;
preferably C(R34)(R35);
optionally, R1 may be joined to one of the R34, R35, R36, R37, R38 or R39
radicals, so as to form a 5-6-membered ring; - are each independently H, (C1-C8)-alkyl;
- are each independently H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, S—(C1-C6)-alkyl, O—(C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, CON(R40)(R41),
- preferably each independently H, F, Cl, Br, CF3, CN, OCF3, O—(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, CO(C1-C6)-alkyl;
more preferably each independently H, F, Cl, Br, CF3, CN, OCF3, O—(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl;
even more preferably each independently H, F, Cl, O—(C1-C6)-alkyl, (C1-C6)-alkyl; very especially preferably H;
where preferably at least two or all R3, R4 and R5 radicals are H; - are each independently H, (C1-C8)-alkyl;
or - each independently form, optionally together with the nitrogen atom to which they are bonded, a 5-6-membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatom from the group of NH, N—(C1-C6)-alkyl, oxygen and sulfur;
- are each independently H, F, (C1-C8)-alkyl, OH, O—(C1-C6)-alkyl;
preferably H;
or
R6 and R6′, or R43 and R43′ together are optionally oxo;
R8 is H, (C1-C8)-alkyl;
L2 is a bond, C(R44)(R45);
preferably a bond; - are each independently H, (C1-C8)-alkyl;
A is a 5-6-membered aromatic ring which may include up to 2 heteroatoms selected from the group of nitrogen, oxygen and sulfur, and may be substituted by one or more of the substituents H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, O—(C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, N(R54)(R55), SO2—CH3, CON(R56)(R57), N(R58)CO(R59), CO(R60); preferably H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl; more preferably H, F, Cl, Br, CF3, CN, OCF3, O—(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl; even more preferably H, F, Cl, O—(C1-C6)-alkyl, (C1-C6)-alkyl; very especially preferably H;
the 5-6-membered aromatic ring is preferably selected from the group consisting of - more preferably
- in the case that L2=a bond, C(O)NR8 may be joined to an ortho substituent of A via a bridge containing one or two elements from the group of carbon and nitrogen, so as to form a 9- to 10-membered bicyclic ring overall;
the bridge preferably contains two carbon elements, so as to form an isoquinolinone or a dihydroisoquinolinone overall; - are each independently H, (C1-C8)-alkyl;
or - each independently form, optionally together with the nitrogen atom to which they are bonded, a 5-6-membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatom from the group of NH, N—(C1-C6)-alkyl, oxygen and sulfur;
L3 is a bond or a linker having from 1 to 4 members, where the members are selected from the group consisting of O, S, SO2, N(R61), CO, C(R62)(R63), C≡C, to give rise to a chemically viable radical, and the linker does not have any O—CO or COO groups;
preferably a bond or a linker having from 1 to 4 members, where the members are selected from the group consisting of O, N(R61), CO, C(R62)(R63), to give rise to a chemically viable radical, and the linker does not have any O—CO or COO groups;
more preferably a bond, O, C(R62)(R63)O;
B is (C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C6)alkyl, a 3- to 10-membered mono-, bi- or spirocyclic nonaromatic ring which includes from 0 to 3 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by one or more of the following substituents: F, CF3, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, oxo, CO(R64), hydroxyl;
preferably a 4- to 6-membered nonaromatic ring which includes from 1 to 2 oxygen atoms, where the ring system may additionally be substituted by one or more of the following substituents: F, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, oxo, hydroxyl, preferably (C1-C6)-alkyl or hydroxyl;
the combined element B-L3 is more preferably
selected from the group of - preferably
- more preferably
- are each independently H, (C1-C8)-alkyl;
where, in the case that X═C(R43)(R43′) - B is a 4- to 10-membered mono-, bi- or spirocyclic nonaromatic ring which includes from 1 to 3 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by one or more of the following substituents: F, CF3, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, oxo, CO(R64), hydroxyl.
- A particular aspect of the invention is that of compounds of the formula II
- in which the variables R1, R2, L1, R3, R4 and R8 are each as defined above and
- are each independently H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, O—(C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, N(R54)(R55), SO2—CH3, CON(R56)(R57), N(R58)CO(R59), CO(R60);
preferably each independently H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, 0 (C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl;
more preferably each independently H, F, Cl, Br, CF3, CN, OCF3, O—(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl;
even more preferably each independently H, F, Cl, O—(C1-C6)-alkyl, (C1-C6)-alkyl; very especially preferably H; - B is a 4- to 6-membered nonaromatic ring which includes from 1 to 2 oxygen atoms, where the ring system may additionally be substituted by one or more of the following substituents: F, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, oxo, hydroxyl, preferably (C1-C6)-alkyl or hydroxyl;
the combined element B-L3
is preferably selected from the group of - more preferably
- especially preferably
- A further particular aspect of the invention is that of compounds of the formula IIa
- in which the variables R1, R2, L1, R3, R4, R8, R′, R″, R′″, L3 and B are each as defined above.
- In a further particular aspect, the invention relates to compounds of the formula III
- in which R1, R2, R3, R4, R8, A, L1, L3 and B are each as defined for formula I.
- In another particular aspect, the invention relates to compounds of the formula IV
- in which R1, R2, R3, R4, X, L1, L3 and B are each as defined for formula I. The broken line indicates an optional double bond, such that both dihydroisoquinolinones and isoquinolinones are encompassed by the formula IV.
- The inventive compounds of the general formula I can be prepared analogously to processes known to those skilled in the art. Suitable processes for preparing the inventive compounds of the general formula I are mentioned below by way of example (see especially methods A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P and schemes 1 to 3).
- Preferred embodiments of the steps mentioned, just like the preparation of the starting substances used in the steps, are known to those skilled in the art and are mentioned by way of example in the schemes and methods mentioned, and also examples.
- This invention further relates to the use of compounds of the formula I and pharmaceutical compositions thereof as MCH receptor ligands. The inventive MCH receptor ligands are suitable especially as modulators of the activity of MCH R1.
- The role of MCH in regulating the energy balance has now been well documented (Qu, D. et al. Nature 1996, 380, 243-7; Shimada, M. et al. Nature 1998, 396, 670-4; Chen, Y et al. Endocrinology 2002, 143, 2469-77; Endocrinology 2003, 144, 4831-40; Reviews: G. Hervieu, Expert Opin. Ther. Targets 2003, 7, 495-511; Shi, Y., Peptides 2004, 25, 1605-11; Pissios, P. et al., Endocrine Rev. 2006, 27, 606-20; Luthin, D. R., Life Sci. 2007, 81, 423-440). There are also indications that MCH antagonists can have a beneficial influence on centrally related disorders such as, for example, anxiety neuroses and depressions (Borowsky, B. et al. Nature Medicine 2002, 8, 825-30; Reviews: G. Hervieu, Expert Opin. Ther. Targets 2003, 7, 495-511; Chaki, S. et al., Drug Dev. Res. 2005, 65, 278-290; Dyck, B., Drug Dev. Res. 2005, 65, 291-300; Shimazaki, T., CNS Drugs 2006, 20, 801-11; Drugs Fut. 2007, 32, 809-822).
- Compounds of this type are particularly suitable for the treatment and/or prevention of
- 1. Obesity
- 2. Diabetes mellitus, especially type 2 diabetes, including the prevention of the sequelae associated therewith.
- Particular aspects in this connection are
-
- hyperglycemia,
- improvement in insulin resistance,
- improvement in glucose tolerance,
- protection of the pancreatic β cells
- prevention of macro- and microvascular disorders
- 3. Dyslipidemias and the sequelae thereof such as, for example, atherosclerosis, coronary heart disease, cerebrovascular disorders etc., especially (but not restricted to) those which are characterized by one or more of the following factors:
- high plasma triglyceride concentrations, high postprandial plasma triglyceride concentrations
- low HDL cholesterol concentration
- 4. Fatty liver, especially nonalcoholic fatty liver and variants thereof,
- steatosis
- steatohepatitis
- cirrhosis.
- 5. Various other conditions which may be associated with the metabolic syndrome, such as:
- thromboses, hypercoagulable and prothrombotic stages (arterial and venous)
- high blood pressure
- heart failure such as, for example (but not restricted thereto), following myocardial infarction, hypertensive heart disease or cardiomyopathy
- 6. Psychiatric indications such as
- depressions
- anxiety states
- disturbances of the circadian rhythm
- affection disorders
- schizophrenia
- addictive disorders
- 7. Sleep disorders such as
- sleep apnea
- narcolepsy
- 8. Inflammation disorders such as
- inflammatory bowel disease
- Crohn's disease
- The amount of a compound of formula I necessary to achieve the desired biological effect depends on a number of factors, for example the specific compound chosen, the intended use, the mode of administration and the clinical condition of the patient. The daily dose is generally in the range from 0.001 mg to 100 mg (typically from 0.01 mg to 50 mg) per day and per kilogram of body weight, for example 0.1-10 mg/kg/day. An intravenous dose may be, for example, in the range from 0.001 mg to 1.0 mg/kg, which can suitably be administered as infusion of 10 ng to 100 ng per kilogram and per minute. Suitable infusion solutions for these purposes may contain, for example, from 0.1 ng to 10 mg, typically from 1 ng to 10 mg, per milliliter. Single doses may contain, for example, from 1 mg to 10 g of the active ingredient. Thus, ampoules for injections may contain, for example, from 1 mg to 100 mg, and single-dose formulations which can be administered orally, such as, for example, tablets or capsules, may contain, for example, from 0.05 to 1000 mg, typically from 0.5 to 600 mg. For the therapy of the abovementioned conditions, the compounds of formula I may be used as the compound itself, but they are preferably in the form of a pharmaceutical composition with an acceptable carrier. The carrier must, of course, be acceptable in the sense that it is compatible with the other ingredients of the composition and is not harmful for the patient's health. The carrier may be a solid or a liquid or both and is preferably formulated with the compound as a single dose, for example as a tablet, which may contain from 0.05% to 95% by weight of the active ingredient. Other pharmaceutically active substances may likewise be present, including other compounds of formula I. The pharmaceutical compositions of the invention can be produced by one of the known pharmaceutical methods, which essentially consist of mixing the ingredients with pharmacologically acceptable carriers and/or excipients.
- Pharmaceutical compositions of the invention are those suitable for oral, rectal, topical, peroral (for example sublingual) and parenteral (for example subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable mode of administration depends in each individual case on the nature and severity of the condition to be treated and on the nature of the compound of formula I used in each case. Coated formulations and coated slow-release formulations also belong within the framework of the invention. Preference is given to acid- and gastric juice-resistant formulations. Suitable coatings resistant to gastric juice comprise cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate.
- Suitable pharmaceutical preparations for oral administration may be in the form of separate units such as, for example, capsules, cachets, suckable tablets or tablets, each of which contains a defined amount of at least one compound of formula I; as powders or granules; as solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-in-oil emulsion. These compositions may, as already mentioned, be prepared by any suitable pharmaceutical method which includes a step in which the active ingredient and the carrier (which may consist of one or more additional ingredients) are brought into contact. The compositions are generally produced by uniform and homogeneous mixing of the active ingredient with a liquid and/or finely divided solid carrier, after which the product is shaped if necessary. Thus, for example, a tablet can be produced by compressing or molding a powder or granules of the compound, where appropriate with one or more additional ingredients. Compressed tablets can be produced by tableting the compound in free-flowing form such as, for example, a powder or granules, where appropriate mixed with a binder, glidant, inert diluent and/or one (or more) surface-active/dispersing agent(s) in a suitable machine. Molded tablets can be produced by molding the compound, which is in powder form and is moistened with an inert liquid diluent, in a suitable machine.
- Pharmaceutical compositions which are suitable for peroral (sublingual) administration comprise suckable tablets which contain at least one compound of formula I with a flavoring, normally sucrose and gum arabic or tragacanth, and pastilles which comprise the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic.
- Pharmaceutical compositions suitable for parenteral administration comprise preferably sterile aqueous preparations of at least one compound of formula I, which are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although administration may also take place by subcutaneous, intramuscular or intradermal injection. These preparations can preferably be produced by mixing the compound with water and making the resulting solution sterile and isotonic with blood. Injectable compositions of the invention generally contain from 0.1 to 5% by weight of the active compound.
- Pharmaceutical compositions suitable for rectal administration are preferably in the form of single-dose suppositories. These can be produced by mixing at least one compound of the formula I with one or more conventional solid carriers, for example cocoa butter, and shaping the resulting mixture.
- Pharmaceutical compositions suitable for topical use on the skin are preferably in the form of ointment, cream, lotion, paste, spray, aerosol or oil. Carriers which can be used are petrolatum, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances. The active ingredient is generally present in a concentration of from 0.1 to 15% by weight of the composition, for example from 0.5 to 2%.
- Transdermal administration is also possible. Pharmaceutical compositions suitable for transdermal uses can be in the form of single patches which are suitable for long-term close contact with the patient's epidermis. Such patches suitably contain the active ingredient in an aqueous solution which is buffered where appropriate, dissolved and/or dispersed in an adhesive or dispersed in a polymer. A suitable active ingredient concentration is about 1% to 35%, preferably about 3% to 15%. A particular possibility is for the active ingredient to be released by electrotransport or iontophoresis as described, for example, in Pharmaceutical Research, 2(6): 318 (1986).
- The compounds of the formula I are distinguished by beneficial effects on lipid metabolism, and they are particularly suitable for weight reduction and for maintaining a reduced weight after weight reduction has taken place in mammals and as anorectic agents. The compounds are distinguished as selective MCH1R antagonists by their low toxicity, the small effect on metabolizing enzymes and their few side effects. In particular, preferred compounds of the invention are notable for low blockade of the hERG channel. In addition, preferred compounds of the formula I are noticeably soluble in aqueous systems and thus particularly suitable for pharmaceutical development. The pharmacological effect is moreover achieved in in vivo test models after oral administration from well-tolerated vehicles.
- The compounds can be employed alone or in combination with other weight-reducing or anorectic active ingredients. Further anorectic active ingredients of this type are mentioned, for example, in the Rote Liste, chapter 01 under weight-reducing agents/appetite suppressants, and may also include active ingredients which increase the energy turnover of the organism and thus lead to weight reduction or else those which influence the general metabolism of the organism in such a way that an increased calorie intake does not lead to an enlargement of the fat depots and a normal calorie intake leads to a reduction of the fat depots of the organism. The compounds are suitable for the prophylaxis and, in particular, for the treatment of excessive weight or obesity. The compounds are further suitable for the prophylaxis and, in particular, for the treatment of type II diabetes, of arteriosclerosis and for normalizing lipid metabolism and for the treatment of high blood pressure.
- Combinations with Other Medicaments
- The compounds of the invention can be administered alone or in combination with one or more further pharmacologically active substances which have, for example, beneficial effects on metabolic disturbances or disorders frequently associated therewith. Examples of such medicaments are
-
- 1. medicaments which lower blood glucose, antidiabetics,
- 2. active ingredients for the treatment of dyslipidemias,
- 3. antiatherosclerotic medicaments,
- 4. antiobesity agents,
- 5. antiinflammatory active ingredients
- 6. active ingredients for the treatment of malignant tumors
- 7. antithrombotic active ingredients
- 8. active ingredients for the treatment of high blood pressure
- 9. active ingredients for the treatment of heart failure and
- 10. active ingredients for the treatment and/or prevention of complications caused by diabetes or associated with diabetes.
- They can be combined with the compounds of the invention of the formula I in particular for a synergistic improvement in action. The active ingredient combination can be administered either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation.
- Further suitable active ingredients for the combination preparations are:
- All antidiabetics which are mentioned in the Rote Liste 2007, chapter 12; all weight-reducing agents/appetite suppressants which are mentioned in the Rote Liste 2007, chapter 1; all diuretics which are mentioned in the Rote Liste 2007, chapter 36; all lipid-lowering agents which are mentioned in the Rote Liste 2007, chapter 58. They can be combined with the compound of the invention of the formula I in particular for a synergistic improvement in action. The active ingredient combination can be administered either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation. If the active ingredients are administered separately, this can be done simultaneously or successively. Most of the active ingredients mentioned hereinafter are disclosed in the USP Dictionary of USAN and International Drug Names, US Pharmacopeia, Rockville 2006.
- Antidiabetics include insulin and insulin derivatives, for example LANTUS® (insulin glargine, also see www.lantus.com) or HMR 1964 or LEVEMIR® (insulin detemir), HUMALOG® (Insulin Lispro), HUMULIN®, VIAJECT™, SULIXEN® or those as described in WO2005005477 (Novo Nordisk), fast-acting insulins (see U.S. Pat. No. 6,221,633), inhalable insulins, for example EXUBERA®, NASULIN™, or oral insulins, for example IN-105 (Nobex) or ORAL-LYN™ (Generex Biotechnology), or TECHNOSPHERE® Insulin (MannKind) or COBALAMIN™ oral insulin, or insulins as described in WO2007128815, WO2007128817, WO2008034881, WO2008049711, or insulins which can be administered transdermally; GLP-1 derivatives and GLP-1 agonists, for example exenatide or specific formulations thereof, as described, for example, in WO2008061355, liraglutide, taspoglutide or those which have been disclosed in WO 98/08871, WO2005027978, WO2006037811, WO2006037810 by Novo Nordisk A/S, in WO 01/04156 by Zealand or in WO 00/34331 by Beaufour-Ipsen, pramlintide acetate (Symlin; Amylin Pharmaceuticals), AVE-0010, BIM-51077 (R-1583, I™-077), PC-DAC:Exendin-4 (an exendin-4 analog which is bonded covalently to recombinant human albumin), CVX-73, CVX-98 and CVx-96 (GLP-1 analog which is bonded covalently to a monoclonal antibody which has specific binding sites for the GLP-1 peptide), CNTO-736 (a GLP-1 analog which is bonded to a domain which includes the Fc portion of an antibody), PGC-GLP-1 (GLP-1 bonded to a nanocarrier), agonists, as described, for example, in D. Chen et al., Proc. Natl. Acad. Sci. USA 104 (2007) 943, those as described in WO2006124529, WO2007124461, peptides, for example obinepitide (TM-30338), amylin receptor agonists, as described, for example, in WO2007104789, analogs of the human GLP-1, as described in WO2007120899, WO2008022015, WO2008056726, and orally active hypoglycemic ingredients.
- Antidiabetics also include agonists of the glucose-dependent insulinotropic polypeptide (GIP) receptor, as described, for example, in WO2006121860. Antidiabetics also include the glucose-dependent insulinotropic polypeptide (GIP), and also analogous compounds, as described, for example, in WO2008021560.
- Antidiabetics also include analogs and derivatives of fibroblast growth factor 21 (FGF-21).
- The orally active hypoglycemic ingredients preferably include
- sulfonylureas,
biguanidines,
meglitinides,
oxadiazolidinediones,
thiazolidinediones,
PPAR and RXR modulators,
glucosidase inhibitors,
inhibitors of glycogen phosphorylase,
glucagon receptor antagonists,
glucokinase activators,
inhibitors of fructose 1,6-bisphosphatase
modulators of glucose transporter 4 (GLUT4),
inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT),
GLP-1 agonists,
potassium channel openers, for example pinacidil, cromakalim, diazoxide, or those as described in R. D. Carr et al., Diabetes 52, 2003, 2513.2518, in J. B. Hansen et al, Current Medicinal Chemistry 11, 2004, 1595-1615, in T. M. Tagmose et al., J. Med. Chem. 47, 2004, 3202-3211 or in M. J. Coghlan et al., J. Med. Chem. 44, 2001, 1627-1653, or those which have been disclosed in WO 97/26265 and WO 99/03861 by Novo Nordisk A/S,
active ingredients which act on the ATP-dependent potassium channel of the beta cells,
inhibitors of dipeptidylpeptidase IV (DPP-IV),
insulin sensitizers,
inhibitors of liver enzymes involved in stimulating gluconeogenesis and/or
glycogenolysis,
modulators of glucose uptake, of glucose transport and of glucose reabsorption, modulators of sodium-dependent glucose transporter 1 or 2 (SGLT1, SGLT2),
inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 (11β-HSD1),
inhibitors of protein tyrosine phosphatase 1B (PTP-1B),
nicotinic acid receptor agonists,
inhibitors of hormone-sensitive or endothelial lipases,
inhibitors of acetyl-CoA carboxylase (ACC1 and/or ACC2) or
inhibitors of GSK-3 beta. - Also included are compounds which modify the metabolism, such as active antihyperlipidemic ingredients and active antilipidemic ingredients,
- HMGCoA reductase inhibitors,
farnesoid X receptor (FXR) modulators,
fibrates,
cholesterol reabsorption inhibitors,
CETP inhibitors,
bile acid reabsorption inhibitors,
MTP inhibitors,
agonists of estrogen receptor gamma (ERRγ agonists),
sigma-1 receptor antagonists,
antagonists of the somatostatin 5 receptor (SST5 receptor);
compounds which reduce food intake, and
compounds which increase thermogenesis. - In one embodiment of the invention, the compound of the formula I is administered in combination with insulin.
- In one embodiment, the compound of the formula I is administered in combination with an active ingredient which acts on the ATP-dependent potassium channel of the beta cells, for example sulfonylureas, for example tolbutamide, glibenclamide, glipizide, gliclazide or glimepiride.
- In one embodiment, the compound of the formula I is administered in combination with a tablet which comprises both glimepiride, which is released rapidly, and metformin, which is released over a longer period (as described, for example, in US2007264331, WO2008050987).
- In one embodiment, the compound of the formula I is administered in combination with a biguanide, for example metformin.
- In another embodiment, the compound of the formula I is administered in combination with a meglitinide, for example repaglinide, nateglinid or mitiglinide.
- In a further embodiment, the compound of the formula I is administered with a combination of mitiglinide with a glitazone, e.g. pioglitazone hydrochloride. In a further embodiment, the compound of the formula I is administered with a combination of mitiglinide with an alpha-glucosidase inhibitor. In a further embodiment, the compound of the formula I is administered in combination with antidiabetic compounds, as described in WO2007095462, WO2007101060, WO2007105650.
- In a further embodiment, the compound of the formula I is administered in combination with antihypoglycemic compounds, as described in WO2007137008.
- In one embodiment, the compound of the formula I is administered in combination with a thiazolidinedione, for example troglitazone, ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 by Dr. Reddy's Research Foundation, especially 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy]phenyl]methyl]-2,4-thiazolidinedione.
- In one embodiment of the invention, the compound of the formula I is administered in combination with a PPAR gamma agonist, for example rosiglitazone, pioglitazone, JTT-501, GI 262570, R-483, CS-011 (rivoglitazone), DRL-17564, DRF-2593 (Balaglitazon), INT-131, T-2384, or those as described in WO2005086904, WO2007060992, WO2007100027, WO2007103252, WO2007122970, WO2007138485, WO2008006319, WO2008006969, WO2008010238, WO2008017398, WO2008028188.
- In one embodiment of the invention, the compound of the formula I is administered in combination with Competact™, a solid combination of pioglitazone hydrochloride with metformin hydrochloride.
- In one embodiment of the invention, the compound of the formula I is administered in combination with Tandemact™, a solid combination of pioglitazone with glimepiride.
- In a further embodiment of the invention, the compound of the formula I is administered in combination with a solid combination of pioglitazone hydrochloride with an angiotensin II agonist, for example TAK-536.
- In one embodiment of the invention, the compound of the formula I is administered in combination with a PPAR alpha agonist or mixed PPAR alpha/PPAR delta agonist, for example GW9578, GW-590735, K-111, LY-674, KRP-101, DRF-10945, LY-518674, CP-900691, BMS-687453, BMS-711939, or those as described in WO2001040207, WO2002096894, WO2005097076, WO2007056771, WO2007087448, WO2007089667, WO2007089557, WO2007102515, WO2007103252, JP2007246474, WO2007118963, WO2007118964, WO2007126043, WO2008006043, WO2008006044, WO2008012470, WO2008035359.
- In one embodiment of the invention, the compound of the formula I is administered in combination with a mixed PPAR alpha/gamma agonisn, for example naveglitazar, LY-510929, ONO-5129, E-3030, AVE 8042, AVE 8134, AVE 0847, CKD-501 (lobeglitazone sulfate), MBX-213, KY-201 or as described in WO 00/64888, WO 00/64876, WO03/020269, WO2004024726, WO2007099553, US2007276041, WO2007085135, WO2007085136, WO2007141423, WO2008016175, WO2008053331 or in J.P. Berger et al., TRENDS in Pharmacological Sciences 28(5), 244-251, 2005.
- In one embodiment of the invention, the compound of the formula I is administered in combination with a PPAR delta agonist, for example GW-501516, or as described in WO2006059744, WO2006084176, WO2006029699, WO2007039172-WO2007039178, WO2007071766, WO2007101864, US2007244094, WO2007119887, WO2007141423, US2008004281, WO2008016175.
- In one embodiment of the invention, the compound of the formula I is administered in combination with a pan-SPPARM (selective PPAR modulator alpha, gamma, delta), for example GFT-505, or those as described in WO2008035359.
- In one embodiment, the compound of the formula I is administered in combination with metaglidasen or with MBX-2044 or other partial PPAR gamma agonists/antagonists.
- In one embodiment, the compound of the formula I is administered in combination with an α-glucosidase inhibitor, for example miglitol or acarbose, or those as described, for example, in WO2007114532, WO2007140230, US2007287674, US2008103201.
- In one embodiment, the compound of the formula I is administered in combination with an inhibitor of glycogen phosphorylase, for example PSN-357 or FR-258900, or those as described in WO2003084922, WO2004007455, WO2005073229-31, WO2005067932.
- In one embodiment, the compound of the formula I is administered in combination with glucagon receptor antagonists, for example A-770077 or NNC-25-2504 or as described in WO2004100875, WO2005065680, WO2006086488, WO2007047177, WO2007106181, WO2007111864, WO2007120270, WO2007120284, WO2007123581, WO2007136577, WO2008042223.
- In a further embodiment, the compound of the formula I is administered in combination with an antisense compound, e.g. ISIS-325568, which inhibits the production of the glucagon receptor.
- In one embodiment, the compound of the formula I is administered in combination with activators of glucokinase, for example LY-2121260 (WO2004063179), PSN-105, PSN-110, GKA-50, or those as described, for example, in WO2004072031, WO2004072066, WO2005080360, WO2005044801, WO2006016194, WO2006058923, WO2006112549, WO2006125972, WO2007017549, WO2007017649, WO2007007910, WO2007007040-42, WO2007006760-61, WO2007006814, WO2007007886, WO2007028135, WO2007031739, WO2007041365, WO2007041366, WO2007037534, WO2007043638, WO2007053345, WO2007051846, WO2007051845, WO2007053765, WO2007051847, WO2007061923, WO2007075847, WO2007089512, WO2007104034, WO2007117381, WO2007122482, WO2007125103, WO2007125105, US2007281942, WO2008005914, WO2008005964, WO2008043701, WO2008044777, WO2008047821, US2008096877, WO2008050117, WO2008050101, WO2008059625.
- In one embodiment, the compound of the formula I is administered in combination with an inhibitor of gluconeogenesis, as described, for example, in FR-225654, WO2008053446.
- In one embodiment, the compound of the formula I is administered in combination with inhibitors of fructose 1,6-bisphosphatase (FBPase), for example MB-07729, CS-917 (MB-06322) or MB-07803, or those as described in WO2006023515, WO2006104030, WO2007014619, WO2007137962, WO2008019309, WO2008037628.
- In one embodiment, the compound of the formula I is administered in combination with modulators of glucose transporters 4 (GLUT4), for example KST-48 (D.-O. Lee et al.: Arzneim.-Forsch. Drug Res. 54 (12), 835 (2004)).
- In one embodiment, the compound of the formula I is administered in combination with inhibitors of glutamine:fructose-6-phosphate amidotransferase (GFAT), as described, for example, in WO2004101528.
- In one embodiment, the compound of the formula I is administered in combination with inhibitors of dipeptidyl peptidase IV (DPP-IV), for example vildagliptin (LAF-237), sitagliptin (MK-0431), sitagliptin phosphate, saxagliptin ((BMS-477118), GSK-823093, PSN-9301, SYR-322, SYR-619, TA-6666, TS-021, GRC-8200 (Melogliptin), GW-825964X, KRP-104, DP-893, ABT-341, ABT-279 or another salt thereof, S-40010, S-40755, PF-00734200, BI-1356, PHX-1149, alogliptin, or those compounds as described in WO2003074500, WO2003106456, WO2004037169, WO200450658, WO2005037828, WO2005058901, WO2005012312, WO2005/012308, WO2006039325, WO2006058064, WO2006015691, WO2006015701, WO2006015699, WO2006015700, WO2006018117, WO2006099943, WO2006099941, JP2006160733, WO2006071752, WO2006065826, WO2006078676, WO2006073167, WO2006068163, WO2006085685, WO2006090915, WO2006104356, WO2006127530, WO2006111261, US2006890898, US2006803357, US2006303661, WO2007015767 (LY-2463665), WO2007024993, WO2007029086, WO2007063928, WO2007070434, WO2007071738, WO2007071576, WO2007077508, WO2007087231, WO2007097931, WO2007099385, WO2007100374, WO2007112347, WO2007112669, WO2007113226, WO2007113634, WO2007115821, WO2007116092, US2007259900, EP1852108, US2007270492, WO2007126745, WO2007136603, WO2007142253, WO2007148185, WO2008017670, US2008051452, WO2008027273, WO2008028662, WO2008029217, JP2008031064, JP2008063256, WO2008033851, WO2008040974, WO2008040995, WO2008064107.
- In one embodiment, the compound of the formula I is administered in combination with Janumet™, a solid combination of sitagliptin phosphate with metformin hydrochloride.
- In one embodiment, the compound of the formula I is administered in combination with Eucreas®, a solid combination of vildagliptin with metformin hydrochloride.
- In one embodiment, the compound of the formula I is administered in combination with a solid combination of a salt of sitagliptin with metformin hydrochloride.
- In one embodiment, the compound of the formula I is administered in combination with a combination of a DPP-IV inhibitors with omega-3 fatty acids or omega-3 fatty acid esters, as described, for example, in WO2007128801.
- In one embodiment, the compound of the formula I is administered in combination with a substance which enhances insulin secretion, for example KCP-265 (WO2003097064), or those as described in WO2007026761, WO2008045484.
- In one embodiment, the compound of the formula I is administered in combination with agonists of the glucose-dependent insulinotropic receptor (GDIR), for example APD-668.
- In one embodiment of the invention, the compound of the formula I is administered in combination with an ATP citrate lyase inhibitor, for example SB-204990.
- In one embodiment, the compound of the formula I is administered in combination with modulators of the sodium-dependent glucose transporter 1 or 2 (SGLT1, SGLT2), for example KGA-2727, T-1095, SGL-0010, AVE 2268, SAR 7226, SGL-5083, SGL-5085, SGL-5094, ISIS-388626, sergliflozin or dapagliflozin, or as described, for example, in WO2004007517, WO200452903, WO200452902, PCT/EP2005/005959, WO2005085237, JP2004359630, WO2005121161, WO2006018150, WO2006035796, WO2006062224, WO2006058597, WO2006073197, WO2006080577, WO2006087997, WO2006108842, WO2007000445, WO2007014895, WO2007080170, WO2007093610, WO2007126117, WO2007128480, WO2007129668, US2007275907, WO2007136116, WO2007143316, WO2007147478, WO2008001864, WO2008002824, WO2008013277, WO2008013280, WO2008013321, WO2008013322, WO2008016132, WO2008020011, JP2008031161, WO2008034859, WO2008042688, WO2008044762, WO2008046497, WO2008049923, WO2008055870, WO2008055940 or by A. L. Handlon in Expert Opin. Ther. Patents (2005) 15(11), 1531-1540.
- In one embodiment, the compound of the formula I is administered in combination with inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 (11β-HSD1), for example BVT-2733, JNJ-25918646, INCB-13739, INCB-20817, DIO-92 ((−)-ketoconazole) or those as described, for example, in WO200190090-94, WO200343999, WO2004112782, WO200344000, WO200344009, WO2004112779, WO2004113310, WO2004103980, WO2004112784, WO2003065983, WO2003104207, WO2003104208, WO2004106294, WO2004011410, WO2004033427, WO2004041264, WO2004037251, WO2004056744, WO2004058730, WO2004065351, WO2004089367, WO2004089380, WO2004089470-71, WO2004089896, WO2005016877, WO2005063247, WO2005097759, WO2006010546, WO2006012227, WO2006012173, WO2006017542, WO2006034804, WO2006040329, WO2006051662, WO2006048750, WO2006049952, WO2006048331, WO2006050908, WO2006024627, WO2006040329, WO2006066109, WO2006074244, WO2006078006, WO2006106423, WO2006132436, WO2006134481, WO2006134467, WO2006135795, WO2006136502, WO2006138508, WO2006138695, WO2006133926, WO2007003521, WO2007007688, US2007066584, WO2007029021, WO2007047625, WO2007051811, WO2007051810, WO2007057768, WO2007058346, WO2007061661, WO2007068330, WO2007070506, WO2007087150, WO2007092435, WO2007089683, WO2007101270, WO2007105753, WO2007107470, WO2007107550, WO2007111921, US2007207985, US2007208001, WO2007115935, WO2007118185, WO2007122411, WO2007124329, WO2007124337, WO2007124254, WO2007127688, WO2007127693, WO2007127704, WO2007127726, WO2007127763, WO2007127765, WO2007127901, US2007270424, JP2007291075, WO2007130898, WO2007135427, WO2007139992, WO2007144394, WO2007145834, WO2007145835, WO2007146761, WO2008000950, WO2008000951, WO2008003611, WO2008005910, WO2008006702, WO2008006703, WO2008011453, WO2008012532, WO2008024497, WO2008024892, WO2008032164, WO2008034032, WO2008043544, WO2008044656, WO2008046758, WO2008052638, WO2008053194.
- In one embodiment, the compound of the formula I is administered in combination with inhibitors of protein tyrosine phosphatase 1B (PTP-1B), as described, for example, in WO200119830-31, WO200117516, WO2004506446, WO2005012295, WO2005116003, WO2005116003, WO2006007959, DE 10 2004 060542.4, WO2007009911, WO2007028145, WO2007067612-615, WO2007081755, WO2007115058, US2008004325, WO2008033455, WO2008033931, WO2008033932, WO2008033934.
- In one embodiment of the invention, the compound of the formula I is administered in combination with an agonist of GPR109A (HM74A receptor agonists; NAR agonists (nicotinic acid receptor agonists)), for example nicotinic acid or “extended release niacin” in conjunction with MK-0524A (laropiprant) or MK-0524, or those compounds as described in WO2004041274, WO2006045565, WO2006045564, WO2006069242, WO2006085108, WO2006085112, WO2006085113, WO2006124490, WO2006113150, WO2007017261, WO2007017262, WO2007017265, WO2007015744, WO2007027532, WO2007092364, WO2007120575, WO2007134986, WO2007150025, WO2007150026, WO2008016968, WO2008051403.
- In another embodiment of the invention, the compound of the formula I is administered in combination with a solid combination of niacin with simvastatin.
- In another embodiment of the invention, the compound of the formula I is administered in combination with nicotinic acid or “extended release niacin” in conjunction with MK-0524A (laropiprant).
- In a further embodiment of the invention, the compound of the formula I is administered in combination with nicotinic acid or “extended release niacin” in conjunction with MK-0524A (laropiprant) and with simvastatin.
- In one embodiment of the invention, the compound of the formula I is administered in combination with nicotinic acid or another nicotinic acid receptor agonist and a prostaglandin DP receptor antagonist, for example those as described in WO2008039882.
- In another embodiment of the invention, the compound of the formula I is administered in combination with an agonist of GPR116, as described, for example, in WO2006067531, WO2006067532.
- In one embodiment, the compound of the formula I is administered in combination with modulators of GPR40, as described, for example, in WO2007013689, WO2007033002, WO2007106469, US2007265332, WO2007123225, WO2007131619, WO2007131620, WO2007131621, US2007265332, WO2007131622, WO2007136572, WO2008001931, WO2008030520, WO2008030618, WO2008054674, WO2008054675.
- In one embodiment, the compound of the formula I is administered in combination with modulators of GPR119 (G-protein-coupled glucose-dependent insulinotropic receptor), for example PSN-119-1, PSN-821, MBX-2982, or those as described, for example, in WO2005061489 (PSN-632408), WO2004065380, WO2007003960-62 and WO2007003964, WO2007116229, WO2007116230, WO2008005569, WO2008005576, WO2008008887, WO2008008895, WO2008025798, WO2008025799, WO2008025800, WO2007035355, WO2006083491, WO200807692, WO2008076243.
- In a further embodiment, the compound of the formula I is administered in combination with modulators of GPR120, as described, for example, in EP1688138.
- In one embodiment, the compound of the formula I is administered in combination with inhibitors of hormone-sensitive lipase (HSL) and/or phospholipases, as described, for example, in WO2005073199, WO2006074957, WO2006087309, WO2006111321, WO2007042178, WO2007119837.
- In one embodiment, the compound of the formula I is administered in combination with inhibitors of endothelial lipase, as described, for example, in WO2006111321, WO2006131233, WO2006131232, WO2006131231, WO2007042178, WO2007045392, WO2007045393, WO2007110216, WO2007110215.
- In one embodiment, the compound of the formula I is administered in combination with a phospholipase A2 inhibitor, for example darapladib or A-002, or those as described in WO2008048866, WO20080488867.
- In one embodiment, the compound of the formula I is administered in combination with myricitrin, a lipase inhibitor (WO2007119827).
- In one embodiment, the compound of the formula I is administered in combination with an inhibitor of glycogen synthase kinase-3 beta (GSK-3 beta), as described, for example, in US2005222220, WO2005085230, WO2005111018, WO2003078403, WO2004022544, WO2003106410, WO2005058908, US2005038023, WO2005009997, US2005026984, WO2005000836, WO2004106343, EP1460075, WO2004014910, WO2003076442, WO2005087727, WO2004046117, WO2007073117, WO2007083978, WO2007120102, WO2007122634, WO2007125109, WO2007125110, US2007281949, WO2008002244, WO2008002245, WO2008016123, WO2008023239, WO2008044700, WO2008056266, WO2008057940.
- In one embodiment, the compound of the formula I is administered in combination with an inhibitor of phosphoenolpyruvate carboxykinase (PEPCK), for example those as described in WO2004074288.
- In one embodiment, the compound of the formula I is administered in combination with an inhibitor of phosphoinositide kinase-3 (PI3K), for example those as described in WO2008027584.
- In one embodiment, the compound of the formula I is administered in combination with an inhibitor of serum/glucocorticoid-regulated kinase (SGK), as described, for example, in WO2006072354, WO2007093264, WO2008009335.
- In one embodiment, the compound of the formula I is administered in combination with a modulator of the glucocorticoid receptor, as described, for example, in WO2008057855, WO2008057856, WO2008057857, WO2008057859, WO2008057862.
- In one embodiment, the compound of the formula I is administered in combination with an inhibitor of protein kinase C beta (PKC beta), for example ruboxistaurin.
- In a further embodiment, the compound of the formula I is administered in combination with an activator of the AMP-activated protein kinase (AMPK), as described, for example, in WO2007062568, WO2008006432, WO2008016278, WO2008016730.
- In one embodiment, the compound of the formula I is administered in combination with an inhibitor of ceramide kinase, as described, for example, in WO2007112914, WO2007149865.
- In a further embodiment, the compound of the formula I is administered in combination with an inhibitor of MAPK-interacting kinase 1 or 2 (MNK1 or 2), as described, for example, in WO2007104053, WO2007115822, WO2008008547.
- In one embodiment, the compound of the formula I is administered in combination with inhibitors of “I-kappaB kinase” (IKK inhibitors), as described, for example, in WO2001000610, WO2001030774, WO2004022057, WO2004022553, WO2005097129, WO2005113544, US2007244140.
- In another embodiment, the compound of the formula I is administered in combination with inhibitors of NF-kappaB (NFKB) activation, for example salsalate.
- In a further embodiment, the compound of the formula I is administered in combination with inhibitors of ASK-1 (apoptosis signal-regulating kinase 1), as described, for example, in WO2008016131.
- In one embodiment of the invention, the compound of the formula I is administered in combination with an HMG-CoA reductase inhibitor such as simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, cerivastatin, rosuvastatin, L-659699, BMS-644950, or those as described in US2007249583.
- In a further embodiment of the invention, the compound of the formula I is administered in combination with a farnesoid X receptor (FXR) modulator, for example WAY-362450 or those as described in WO2003099821, WO2005056554, WO2007052843, WO2007070796, WO2007092751, JP2007230909, WO2007095174, WO2007140174, WO2007140183, WO2008000643, WO2008002573, WO2008025539, WO2008025540.
- In another embodiment of the invention, the compound of the formula I is administered in combination with a ligand of the liver X receptor (LXR), as described, for example, in WO2007092965, WO2008041003, WO2008049047.
- In one embodiment of the invention, the compound of the formula I is administered in combination with a fibrate, for example fenofibrate, clofibrate, bezafibrate.
- In one embodiment of the invention, the compound of the formula I is administered in combination with fibrates, for example the choline salt of fenofibrate (SLV-348).
- In one embodiment of the invention, the compound of the formula I is administered in combination with fibrates, for example the choline salt of fenofibrate and an HMG-CoA reductase inhibitor, for example rosuvastatin.
- In a further embodiment of the invention, the compound of the formula I is administered in combination with bezafibrate and diflunisal.
- In a further embodiment of the invention, the compound of the formula I is administered in combination with a solid combination of fenofibrate or a salt thereof with simvastatin, rosuvastatin, fluvastatin, lovastatin, cerivastatin, pravastatin or atorvastatin.
- In a further embodiment of the invention, the compound of the formula I is administered in combination with Synordia®, a solid combination of fenofibrate with metformin.
- In one embodiment of the invention, the compound of the formula I is administered in combination with a cholesterol reabsorption inhibitor, for example ezetimibe, tiqueside, pamaqueside, FM-VP4 (sitostanol/campesterol ascorbyl phosphate; Forbes Medi-Tech, WO2005042692, WO2005005453), MD-0727 (Microbia Inc., WO2005021497, WO2005021495) or with compounds as described in WO2002066464, WO2005000353 (Kotobuki Pharmaceutical Co. Ltd.) or WO2005044256 or WO2005062824 (Merck & Co.) or WO2005061451 and WO2005061452 (AstraZeneca AB) and WO2006017257 (Phenomix) or WO2005033100 (Lipideon Biotechnology AG), or as described in WO2002050060, WO2002050068, WO2004000803, WO2004000804, WO2004000805, WO2004087655, WO2004097655, WO2005047248, WO2006086562, WO2006102674, WO2006116499, WO2006121861, WO2006122186, WO2006122216, WO2006127893, WO2006137794, WO2006137796, WO2006137782, WO2006137793, WO2006137797, WO2006137795, WO2006137792, WO2006138163, WO2007059871, US2007232688, WO2007126358, WO2008033431, WO2008033465, WO2008052658, WO2008057336.
- In one embodiment of the invention, the compound of the formula I is administered in combination with an NPC1L1 antagonist, for example those as described in WO2008033464, WO2008033465.
- In one embodiment of the invention, the compound of the formula I is administered in combination with Vytorin™, a solid combination of ezetimibe with simvastatin.
- In one embodiment of the invention, the compound of the formula I is administered in combination with a solid combination of ezetimibe with atorvastatin.
- In one embodiment of the invention, the compound of the formula I is administered in combination with a solid combination of ezetimibe with fenofibrate.
- In one embodiment of the invention, the further active ingredient is a diphenylazetidinone derivative, as described, for example, in U.S. Pat. No. 6,992,067 or U.S. Pat. No. 7,205,290.
- In a further embodiment of the invention, the further active ingredient is a diphenylazetidinone derivative, as described, for example, in U.S. Pat. No. 6,992,067 or U.S. Pat. No. 7,205,290, combined with a statin, for example simvastatin, fluvastatin, pravastatin, lovastatin, cerivastatin, atorvastatin or rosuvastatin.
- In one embodiment of the invention, the compound of the formula I is administered in combination with a solid combination of lapaquistat, a squalene synthase inhibitor, with atorvastatin.
- In one embodiment of the invention, the compound of the formula I is administered in combination with a CETP inhibitor, for example torcetrapib, anacetrapib or JTT-705 (dalcetrapib), or those as described in WO2006002342, WO2006010422, WO2006012093, WO2006073973, WO2006072362, WO2007088996, WO2007088999, US2007185058, US2007185113, US2007185154, US2007185182, WO2006097169, WO2007041494, WO2007090752, WO2007107243, WO2007120621, US2007265252, US2007265304, WO2007128568, WO2007132906, WO2008006257, WO2008009435, WO2008018529, WO2008058961, WO2008058967.
- In one embodiment of the invention, the compound of the formula I is administered in combination with bile acid reabsorption inhibitor (see, for example, U.S. Pat. No. 6,245,744, U.S. Pat. No. 6,221,897 or WO00/61568), for example HMR 1741, or those as described in DE 10 2005 033099.1 and DE 10 2005 033100.9, DE 10 2006 053635, DE 10 2006 053637, WO2007009655-56, WO2008058628, WO2008058629, WO2008058630, WO2008058631.
- In one embodiment, the compound of the formula I is administered in combination with agonists of GPBAR1 (G-protein-coupled bile acid receptor-1; TGR5), as described, for example, in WO2007110237, WO2007127505, WO2008009407.
- In one embodiment of the invention, the compound of the formula I is administered in combination with a polymeric bile acid adsorber, for example cholestyramine, colesevelam hydrochloride.
- In one embodiment of the invention, the compound of the formula I is administered in combination with colesevelam hydrochloride and metformin or a sulfonylurea or insulin.
- In one embodiment of the invention, the compound of the formula I is administered in combination with a chewing gum comprising phytosterols (Reductol™)
- In one embodiment of the invention, the compound of the formula I is administered in combination with an inhibitor of the microsomal triglyceride transfer proteins (MTP inhibitor), for example implitapide, BMS-201038, R-103757, AS-1552133, SLx-4090, AEGR-733, or those as described in WO2005085226, WO2005121091, WO2006010423, WO2006113910, WO2007143164, WO2008049806, WO2008049808.
- In a further embodiment of the invention, the compound of the formula I is administered in combination with a combination of a cholesterol absorption inhibitor, for example ezetimibe, and an inhibitor of the triglyceride transfer proteins (MTP inhibitor), for example implitapide, as described in WO2008030382.
- In one embodiment of the invention, the compound of the formula I is administered in combination with an active antihypertriglyceridemic ingredient, for example those as described in WO2008032980.
- In another embodiment of the invention, the compound of the formula I is administered in combination with an antagonist of the somatostatin 5 receptor (SST5 receptor), for example those as described in WO2006094682.
- In one embodiment of the invention, the compound of the formula I is administered in combination with an ACAT inhibitor, for example avasimibe, SMP-797 or KY-382.
- In a further embodiment of the invention, the compound of the formula I is administered in combination with an inhibitor of liver carnitine palmitoyltransferase 1 (L-CPT1), as described, for example, in WO2007063012, WO2007096251 (ST-3473), WO2008015081, US2008103182.
- In a further embodiment of the invention, the compound of the formula I is administered in combination with a modulator of serine palmitoyltransferase (SPT), as described, for example, in WO2008031032, WO2008046071.
- In one embodiment of the invention, the compound of the formula I is administered in combination with a squalene synthetase inhibitor, for example BMS-188494, TAK-475 (lapaquistat acetate), or as described in WO2005077907, JP2007022943, WO2008003424.
- In one embodiment of the invention, the compound of the formula I is administered in combination with ISIS-301012 (mipomersen), an antisense oligonucleotide which is capable of regulating the apolipoprotein B gene.
- In one embodiment of the invention, the compound of the formula I is administered in combination with an LDL receptor inducer (see U.S. Pat. No. 6,342,512), for example HMR1171, HMR1586, or those as described in WO2005097738, WO2008020607.
- In another embodiment of the invention, the compound of the formula I is administered in combination with an HDL cholesterol-elevating agent, for example those as described in WO2008040651.
- In one embodiment of the invention, the compound of the formula I is administered in combination with an ABCA1 expression enhancer, as described, for example, in WO2006072393.
- In one embodiment of the invention, the compound of the formula I is administered in combination with a lipoproteinlipase modulator, for example ibrolipim (NO-1886).
- In one embodiment of the invention, the compound of the formula I is administered in combination with a lipoprotein(a) antagonist, for example gemcabene (Cl-1027).
- In one embodiment of the invention, the compound of the formula I is administered in combination with a lipase inhibitor, for example orlistat or cetilistat (ATL-962).
- In one embodiment of the invention, the compound of the formula I is administered in combination with an adenosine A1 receptor agonist (adenosine A1 R), as described, for example, in EP1258247, EP1375508, WO2008028590.
- In one embodiment of the invention, the compound of the formula I is administered in combination with an adenosine A2B receptor agonist (adenosine A2B R), for example ATL-801.
- In another embodiment of the invention, the compound of the formula I is administered in combination with a modulator of adenosine A2A and/or adenosine A3 receptors, as described, for example, in WO2007111954, WO2007121918, WO2007121921, WO2007121923.
- In one embodiment of the invention, the compound of the formula I is administered in combination with an adenosine A2B receptor antagonist (adenosine A2B R), as described in US2007270433, WO2008027585.
- In one embodiment, the compound of the formula I is administered in combination with inhibitors of acetyl-CoA carboxylase (ACC1 and/or ACC2), for example those as described in WO199946262, WO200372197, WO2003072197, WO2005044814, WO2005108370, JP2006131559, WO2007011809, WO2007011811, WO2007013691, WO2007095601-603, WO2007119833.
- In another embodiment, the compound of the formula I is administered in combination with modulators of microsomal acyl-CoA:glycerol-3-phosphate acyltransferase 3 (GPAT3, described in WO2007100789) or with modulators of microsomal acyl-CoA:glycerol-3-phosphate acyltransferase 4 (GPAT4, described in WO2007100833).
- In a further embodiment, the compound of the formula I is administered in combination with modulators of xanthine oxidoreductase (XOR).
- In another embodiment, the compound of the formula I is administered in combination with inhibitors of soluble epoxide hydrolase (sEH), as described, for example, in WO2008051873, WO2008051875.
- In a further embodiment, the compound of the formula I is administered in combination with CART modulators (see “Cocaine-amphetamine-regulated transcript influences energy metabolism, anxiety and gastric emptying in mice” Asakawa, A. et al.: Hormone and Metabolic Research (2001), 33(9), 554-558);
- NPY antagonists, for example N-{4-[(4-aminoquinazolin-2-ylamino)methyl]-cyclohexylmethyl}naphthalene-1-sulfonamide hydrochloride (CGP 71683A);
- NPY-5 receptor antagonists, such as L-152804 or the compound “NPY-5-BY” from Banyu, or as described, for example, in WO2006001318, WO2007103295, WO2007125952, WO2008026563, WO2008026564, WO2008052769;
- NPY-4 receptor antagonists, as described, for example, in WO2007038942;
- NPY-2 receptor antagonists, as described, for example, in WO2007038943;
- peptide YY 3-36 (PYY3-36) or analogous compounds, for example CJC-1682 (PYY3-36 conjugated with human serum albumin via Cys34) or CJC-1643 (derivative of PYY3-36, which is conjugated in vivo to serum albumin), or those as described in WO2005080424, WO2006095166, WO2008003947;
derivatives of the peptide obestatin, as described by WO2006096847;
CB1R (cannabinoid receptor 1) antagonists, for example rimonabant, surinabant (SR147778), SLV-319 (ibipinabant), AVE-1625, taranabant (MK-0364) or salts thereof, otenabant (CP-945,598), V-24343 or those compounds as described in, for example, EP 0656354, WO 00/15609, WO2001/64632-64634, WO 02/076949, WO2005080345, WO2005080328, WO2005080343, WO2005075450, WO2005080357, WO200170700, WO2003026647-48, WO200302776, WO2003040107, WO2003007887, WO2003027069, U.S. Pat. No. 6,509,367, WO200132663, WO2003086288, WO2003087037, WO2004048317, WO2004058145, WO2003084930, WO2003084943, WO2004058744, WO2004013120, WO2004029204, WO2004035566, WO2004058249, WO2004058255, WO2004058727, WO2004069838, US20040214837, US20040214855, US20040214856, WO2004096209, WO2004096763, WO2004096794, WO2005000809, WO2004099157, US20040266845, WO2004110453, WO2004108728, WO2004000817, WO2005000820, US20050009870, WO200500974, WO2004111033-34, WO200411038-39, WO2005016286, WO2005007111, WO2005007628, US20050054679, WO2005027837, WO2005028456, WO2005063761-62, WO2005061509, WO2005077897, WO2006018662, WO2006047516, WO2006060461, WO2006067428, WO2006067443, WO2006087480, WO2006087476, WO2006100208, WO2006106054, WO2006111849, WO2006113704, WO2007009705, WO2007017124, WO2007017126, WO2007018459, WO2007018460, WO2007016460, WO2007020502, WO2007026215, WO2007028849, WO2007031720, WO2007031721, WO2007036945, WO2007038045, WO2007039740, US20070015810, WO2007046548, WO2007047737, WO2007057687, WO2007062193, WO2007064272, WO2007079681, WO2007084319, WO2007084450, WO2007086080, EP1816125, US2007213302, WO2007095513, WO2007096764, US2007254863, WO2007119001, WO2007120454, WO2007121687, WO2007123949, US2007259934, WO2007131219, WO2007133820, WO2007136571, WO2007136607, WO2007136571, U.S. Pat. No. 7,297,710, WO2007138050, WO2007139464, WO2007140385, WO2007140439, WO2007146761, WO2007148061, WO2007148062, US2007293509, WO2008004698, WO2008017381, US2008021031, WO2008024284, WO2008031734, WO2008032164, WO2008034032, WO2008035356, WO2008036021, WO2008036022, WO2008039023, WO2998043544, WO2008044111, WO2008048648, EP1921072-A1, WO2008053341, WO2008056377, WO2008059207, WO2008059335;
cannabinoid receptor 1/cannabinoid receptor 2 (CB1/CB2) modulating compounds, for example delta-9-tetrahydrocannabivarin, or those as described, for example, in WO2007001939, WO2007044215, WO2007047737, WO2007095513, WO2007096764, WO2007112399, WO2007112402;
modulators of FAAH (fatty acid amide hydrolase), as described, for example, in WO2007140005, WO2008019357, WO2008021625, WO2008023720, WO2008030532;
vanilloid-1 receptor modulators (modulators of TRPV1), as described, for example, in WO2007091948, WO2007129188, WO2007133637, WO2008007780, WO2008010061, WO2008007211, WO2008010061, WO2008015335, WO2008018827, WO2008024433, WO2008024438, WO2008032204, WO2008050199, WO2008059370;
antagonists or inverse agonists of the opioid receptors, as described, for example, in WO2008021849, WO2008021851, WO2008032156;
agonists of the prostaglandin receptor, for example bimatoprost or those compounds as described in WO2007111806;
MC4 receptor agonists (melanocortin-4 receptor agonists, MC4R agonists, for example N-[2-(3a-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydropyrazolo[4,3-c]-pyridin-5-yl)-1-(4-chlorophenyl)-2-oxoethyl]-1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxamide; (WO 01/91752)) or LB53280, LB53279, LB53278 or THIQ, MB243, RY764, CHIR-785, PT-141, MK-0493, or those as described in WO2005060985, WO2005009950, WO2004087159, WO2004078717, WO2004078716, WO2004024720, US20050124652, WO2005051391, WO2004112793, WOUS20050222014, US20050176728, US20050164914, US20050124636, US20050130988, US20040167201, WO2004005324, WO2004037797, WO2005042516, WO2005040109, WO2005030797, US20040224901, WO200501921, WO200509184, WO2005000339, EP1460069, WO2005047253, WO2005047251, WO2005118573, EP1538159, WO2004072076, WO2004072077, WO2006021655-57, WO2007009894, WO2007015162, WO2007041061, WO2007041052, JP2007131570, EP-1842846, WO2007096186, WO2007096763, WO2007141343, WO2008007930, WO2008017852, WO2008039418;
orexin receptor 1 antagonists (OX1R antagonists), orexin receptor 2 antagonists (OX2R antagonists) or mixed OX1R/OX2R antagonists (e.g. 1-(2-methyl-benzoxazol-6-yl)-3-[1,5]naphthyridin-4-ylurea hydrochloride (SB-334867-A), or those as described, for example, in WO200196302, WO200185693, WO2004085403, WO2005075458, WO2006067224, WO2007085718, WO2007088276, WO2007116374; WO2007122591, WO2007126934, WO2007126935, WO2008008517, WO2008008518, WO2008008551, WO2008020405, WO2008026149, WO2008038251);
histamine H3 receptor antagonists/inverse agonists (e.g. 3-cyclohexyl-1-(4,4-dimethyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)propan-1-one oxalic acid salt (WO 00/63208), or those as described in WO200064884, WO2005082893, US2005171181 (e.g. PF-00389027), WO2006107661, WO2007003804, WO2007016496, WO2007020213, WO2007049798, WO2007055418, WO2007057329, WO2007065820, WO2007068620, WO2007068641, WO2007075629, WO2007080140, WO2007082840, WO2007088450, WO2007088462, WO2007094962, WO2007099423, WO2007100990, WO2007105053, WO2007106349, WO2007110364, WO2007115938, WO2007131907, WO2007133561, US2007270440, WO2007135111, WO2007137955, US2007281923, WO2007137968, WO2007138431, WO2007146122, WO2008005338, WO2008012010, WO2008015125, WO2008045371);
histamine H1/histamine H3 modulators, for example betahistine or its dihydrochloride;
modulators of the histamine H3 transporter or of the histamine H3/serotonin transporter, as described, for example, in WO2008002816, WO2008002817, WO2008002818, WO2008002820;
histamine H4 modulators, as described, for example, in WO2007117399;
CRF antagonists (e.g. [2-methyl-9-(2,4,6-trimethylphenyl)-9H-1,3,9-triazafluoren-4-yl]dipropylamine (WO 00/66585) or those CRF1 antagonists as described in WO2007105113, WO2007133756, WO2008036541, WO2008036579);
CRF BP antagonists (e.g. urocortin);
urocortin agonists;
agonists of the beta-3 adrenoceptor, for example 1-(4-chloro-3-methanesulfonylmethylphenyl)-2-[2-(2,3-dimethyl-1H-indol-6-yloxy)ethylamino]-ethanol hydrochloride (WO 01/83451) or solabegron (GW-427353) or N-5984 (KRP-204), or those as described in JP2006111553, WO2002038543, WO2002038544, WO2007048840-843, WO2008015558;
MSH (melanocyte-stimulating hormone) agonists;
MCH (melanine-concentrating hormone) receptor antagonists (for example NBI-845, A-761, A-665798, A-798, ATC-0175, T-226296, T-71 (AMG-071, AMG-076), GW-803430, GW-856464, NGD-4715, ATC-0453, ATC-0759 or those compounds as described in WO2005085200, WO2005019240, WO2004011438, WO2004012648, WO2003015769, WO2004072025, WO2005070898, WO2005070925, WO2004039780, WO2004092181, WO2003033476, WO2002006245, WO2002089729, WO2002002744, WO2003004027, FR2868780, WO2006010446, WO2006038680, WO2006044293, WO2006044174, JP2006176443, WO2006018280, WO2006018279, WO2006118320, WO2006130075, WO2007018248, WO2007012661, WO2007029847, WO2007024004, WO2007039462, WO2007042660, WO2007042668, WO2007042669, US2007093508, US2007093509, WO2007048802, JP2007091649, WO2007092416; WO2007093363-366, WO2007114902, WO2007114916, WO2007141200, WO2007142217, US2007299062, WO2007146758, WO2007146759, WO200800116, WO2008016811, WO2008020799, WO2008022979, WO2008038692, WO2008041090, WO2008044632, WO2008047544, JP2008088120, WO2008065021, WO2008068265, WO2008061109, WO2008076562, WO2008071646);
CCK-A (CCK-1) agonists (for example {2-[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)thiazol-2-ylcarbamoyl]-5,7-dimethylindol-1-yl}acetic acid trifluoroacetic acid salt (WO 99/15525) or SR-146131 (WO 0244150) or SSR-125180), or those as described in WO2005116034, WO2007120655, WO2007120688, WO2007120718;
serotonin reuptake inhibitors (e.g. dexfenfluramine), or those as described in WO2007148341, WO2008034142;
mixed serotonin/dopamine reuptake inhibitors (e.g. bupropion), or those as described in WO2008063673, or solid combinations of bupropion with naltrexone or bupropion with zonisamide;
mixed reuptake inhibitors, for example DOV-21947;
mixed serotoninergic and noradrenergic compounds (e.g. WO 00/71549);
5-HT receptor agonists, for example 1-(3-ethylbenzofuran-7-yl)piperazine oxalic acid salt (WO 01/09111);
mixed dopamine/norepinephrine/acetylcholine reuptake inhibitors (e.g. tesofensine), or those as described, for example, in WO2006085118;
norepinephrine reuptake inhibitors, as described, for example, in US2008076724;
5-HT2A receptor antagonists, as described, for example, in WO2007138343;
5-HT2C receptor agonists (for example lorcaserine hydrochloride (APD-356) or BVT-933, or those as described in WO200077010, WO200077001-02, WO2005019180, WO2003064423, WO200242304, WO2005035533, WO2005082859, WO2006004937, US2006025601, WO2006028961, WO2006077025, WO2006103511, WO2007028132, WO2007084622, US2007249709; WO2007132841, WO2007140213, WO2008007661, WO2008007664, WO2008009125, WO2008010073);
5-HT6 receptor modulators, for example E-6837, BVT-74316 or PRX-07034, or those as described, for example, in WO2005058858, WO2007054257, WO2007107373, WO2007108569, WO2007108742-744, WO2008003703, WO2008027073, WO2008034815, WO2008054288;
agonists of estrogen receptor gamma (ERRγ agonists), as described, for example, in WO2007131005, WO2008052709;
sigma-1 receptor antagonists, as described, for example, in WO2007098953, WO2007098961, WO2008015266, WO2008055932, WO2008055933;
muscarin 3 receptor (M3R) antagonists, as described, for example, in WO2007110782, WO2008041184;
bombesin receptor agonists (BRS-3 agonists), as described, for example, in WO2008051404, WO2008051405, WO2008051406;
galanin receptor antagonists;
growth hormone (e.g. human growth hormone or AOD-9604);
growth hormone releasing compounds (tert-butyl 6-benzyloxy-1-(2-diisopropylaminoethylcarbamoyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (WO 01/85695));
growth hormone secretagogue receptor antagonists (ghrelin antagonists), for example A-778193, or those as described in WO2005030734, WO2007127457, WO2008008286;
growth hormone secretagogue receptor modulators, for example JMV-2959, JMV-3002, JMV-2810, JMV-2951, or those as described in WO2006012577 (e.g. YIL-781 or YIL-870), WO2007079239;
TRH agonists (see, for example, EP 0 462 884);
decoupling protein 2 or 3 modulators;
leptin agonists (see, for example, Lee, Daniel W.; Leinung, Matthew C.; Rozhayskaya-Arena, Marina; Grasso, Patricia. Leptin agonists as a potential approach to the treatment of obesity. Drugs of the Future (2001), 26(9), 873-881);
DA agonists (bromocriptin, doprexin);
lipase/amylase inhibitors (e.g. WO 00/40569);
inhibitors of diacylglycerol O-acyltransferases (DGATs), for example BAY-74-4113, or as described, for example, in US2004/0224997, WO2004094618, WO200058491, WO2005044250, WO2005072740, JP2005206492, WO2005013907, WO2006004200, WO2006019020, WO2006064189, WO2006082952, WO2006120125, WO2006113919, WO2006134317, WO2007016538, WO2007060140, JP2007131584, WO2007071966, WO2007126957, WO2007137103, WO2007137107, WO2007138304, WO2007138311, WO2007141502, WO2007141517, WO2007141538, WO2007141545, WO2007144571, WO2008011130, WO2008011131, WO2008039007, WO2008048991;
inhibitors of monoacylglycerol acyltransferase (2-acylglycerol O-acyltransferase; MGAT), as described, for example, in WO2008038768;
inhibitors of fatty acid synthase (FAS), for example C75, or those as described in WO2004005277, WO2008006113;
inhibitors of stearoyl-CoA delta9 desaturase (SCD1), as described, for example, in WO2007009236, WO2007044085, WO2007046867, WO2007046868, WO20070501124, WO2007056846, WO2007071023, WO2007130075, WO2007134457, WO2007136746, WO2007143597, WO2007143823, WO2007143824, WO2008003753, WO2008017161, WO2008024390, WO2008029266, WO2008036715, WO2008043087, WO2008044767, WO2008046226, WO2008056687;
hypoglycemic/hypertriglyceridemic indoline compounds, as described in WO2008039087;
inhibitors of “adipocyte fatty acid-binding protein aP2”, for example BMS-309403; activators of adiponectin secretion, as described, for example, in WO2006082978;
promoters of adiponectin secretion, as described, for example, in WO2007125946, WO2008038712;
oxyntomodulin or analogs thereof;
oleoyl-estrone
or agonists or partial agonists of the thyroid hormone receptor (thyroid hormone receptor agonists), for example: KB-2115 (eprotirome), QRX-431 (sobetirome) or DITPA, or those as described in WO20058279, WO200172692, WO200194293, WO2003084915, WO2004018421, WO2005092316, WO2007003419, WO2007009913, WO2007039125, WO2007110225, WO2007110226, WO2007128492, WO2007132475, WO2007134864, WO2008001959
or agonists of the thyroid hormone receptor beta (TR-beta), for example MB-07811 or MB-07344. - In one embodiment of the invention, the compound of the formula I is administered in combination with a combination of epotirome with ezetimibe.
- In one embodiment of the invention, the compound of the formula I is administered in combination with an inhibitor of site-1 protease (S1P), for example PF-429242.
- In a further embodiment of the invention, the compound of the formula I is administered in combination with an RNAi therapeutic agent directed against PCSK9 (proprotein convertase subtilisin/kexin type 9).
- In one embodiment, the compound of the formula I is administered in combination with Omacor® or Lovaza™ (omega-3 fatty acid ester; highly concentrated ethyl ester of eicosapentaenoic acid and of docosahexaenoic acid).
- In one embodiment, the compound of the formula I is administered in combination with lycopene.
- In one embodiment of the invention, the compound of the formula I is administered in combination with an antioxidant, for example OPC-14117, AGI-1067 (succinobucol), probucol, tocopherol, ascorbic acid, β-carotene or selenium.
- In one embodiment of the invention, the compound of the formula I is administered in combination with a vitamin, for example Vitamin B6 or Vitamin B12.
- In one embodiment, the compound of the formula I is administered in combination with more than one of the aforementioned compounds, for example in combination with a sulfonylurea and metformin, a sulfonylurea and acarbose, repaglinide and metformin, insulin and a sulfonylurea, insulin and metformin, insulin and troglitazone, insulin and lovastatin, etc.
- In another embodiment, the compound of the formula I is administered in combination with an inhibitor of carboanhydrase type 2 (carbonic anhydrase type 2), for example those as described in WO2007065948.
- In another embodiment, the compound of the formula I is administered in combination with topiramat or a derivative thereof, as described in WO2008027557.
- In a further embodiment, the compound of the formula I is administered in combination with a solid combination of topiramat with phentermin (Qnexa™)
- In a further embodiment, the compound of the formula I is administered in combination with an antisense compound, e.g. ISIS-377131, which inhibits the production of the glucocorticoid receptor.
- In another embodiment, the compound of the formula I is administered in combination with an aldosterone synthase inhibitor and an antagonist of the glucocorticoid receptor, a cortisol synthesis inhibitor and/or an antagonist of the corticotropin releasing factor, as described, for example, in EP1886695.
- In one embodiment, the compound of the formula I is administered in combination with an agonist of the RUP3 receptor, as described, for example, in WO2007035355, WO2008005576.
- In another embodiment, the compound of the formula I is administered in combination with an activator of the gene which codes for ataxia telangiectasia mutated (ATM) protein kinase, for example chloroquine.
- In one embodiment, the compound of the formula I is administered in combination with a tau protein kinase 1 inhibitor (TPK1 inhibitor), as described, for example, in WO2007119463.
- In one embodiment, the compound of the formula I is administered in combination with a “c-Jun N-terminal kinase” inhibitor (JNK inhibitor), as described, for example, in WO2007125405, WO2008028860.
- In one embodiment, the compound of the formula I is administered in combination with an endothelin A receptor antagonist, for example avosentan (SPP-301).
- In one embodiment, the compound of the formula I is administered in combination with modulators of the glucocorticoid receptor (GR), for example KB-3305 or those compounds as described, for example, in WO2005090336, WO2006071609, WO2006135826, WO2007105766.
- In one embodiment, the further active ingredient is varenicline tartrate, a partial agonist of the alpha 4-beta 2 nicotinic acetylcholine receptor.
- In one embodiment, the further active ingredient is trodusquemine.
- In one embodiment, the further active ingredient is a modulator of the enzyme SIRT1 (an NAD+-dependent protein deacetylase); this active ingredient may, for example, be resveratrol in suitable formulations, or those compounds as specified in WO2007019416 (e.g. SRT-1720).
- In one embodiment of the invention, the further active ingredient is DM-71 (N-acetyl-L-cysteine with bethanechol).
- In one embodiment, the compound of the formula I is administered in combination with antihypercholesterolemic compounds, as described, for example, in WO2007107587, WO2007111994.
- In another embodiment, the compound of the formula I is administered in combination with a cyclic peptide agonist of the VPAC2 receptor, as described, for example, in WO2007101146, WO2007133828.
- In a further embodiment, the compound of the formula I is administered in combination with an agonist of the endothelin receptor, as described, for example, in WO2007112069.
- In a further embodiment, the compound of the formula I is administered in combination with AKP-020 (bis(ethylmaltolato)oxovanadium(IV)).
- In another embodiment, the compound of the formula I is administered in combination with tissue-selective androgen receptor modulators (SARM), as described, for example, in WO2007099200, WO2007137874.
- In a further embodiment, the compound of the formula I is administered in combination with an AGE (advanced glycation end product) inhibitor, as described, for example, in JP2008024673.
- In one embodiment of the invention, the further active ingredient is leptin; see, for example, “Perspectives in the therapeutic use of leptin”, Salvador, Javier; Gomez-Ambrosi, Javier; Fruhbeck, Gema, Expert Opinion on Pharmacotherapy (2001), 2(10), 1615-1622.
- In another embodiment of the invention, the further active ingredient is metreleptin (recombinant methionyl-leptin) combined with pramlintide.
- In a further embodiment of the invention, the further active ingredient is the tetrapeptide ISF-402.
- In one embodiment, the further active ingredient is dexamphetamine or amphetamine.
- In one embodiment, the further active ingredient is fenfluramin or dexfenfluramin.
- In another embodiment, the further active ingredient is sibutramine or those derivatives as described in WO2008034142.
- In one embodiment, the further active ingredient is mazindol or phentermin.
- In a further embodiment, the further active ingredient is geniposidic acid (WO2007100104) or derivatives thereof (JP2008106008).
- In one embodiment, the further active ingredient is a nasal calcium channel blocker, for example diltiazem, or those as described in U.S. Pat. No. 7,138,107.
- In one embodiment, the further active ingredient is an inhibitor of sodium-calcium ion exchange, for example those as described in WO2008028958.
- In a further embodiment, the further active ingredient is a blocker of calcium channels, for example of CaV3.2, as described in WO2008033431, WO2008033447, WO2008033356, WO2008033460, WO2008033464, WO2008033465, WO2008033468.
- In one embodiment, the further active ingredient is a blocker of the “T-type calcium channel”, as described, for example, in WO2008033431.
- In one embodiment, the further active ingredient is an inhibitor of KCNQ potassium channel 2 or 3, for example those as described in US2008027049, US2008027090.
- In one embodiment, the further active ingredient is an inhibitor of the potassium Kv1.3 ion channel, for example those as described in WO2008040057, WO2008040058, WO2008046065.
- In another embodiment, the further active ingredient is a modulator of the MCP-1 receptor (monocyte chemoattractant protein-1 (MCP-1)), for example those as described in WO2008014360, WO2008014381.
- In one embodiment, the further active ingredient is a modulator of somatostatin receptor 5 (SSTR5), for example those as described in WO2008019967, US2008064697.
- In one embodiment, the further active ingredient is a modulator of somatostatin receptor 2 (SSTR2), for example those as described in WO2008051272.
- In one embodiment, the further active ingredient is an erythropoietin-mimetic peptide which acts as an erythropoietin (EPO) receptor agonist. Such molecules are described, for example, in WO2008042800.
- In a further embodiment, the further active ingredient is an anorectic/a hypoglycemic compound, for example those as described in WO2008035305, WO2008035306, WO2008035686.
- In one embodiment, the further active ingredient is an inductor of lipoic acid synthetase, for example those as described in WO2008036966, WO2008036967.
- In one embodiment, the further active ingredient is a stimulator of endothelial nitric oxide synthase (eNOS), for example those as described in WO2008058641.
- In one embodiment, the further active ingredient is a modulator of carbohydrate and/or lipid metabolism, for example those as described in WO2008059023, WO2008059024, WO2008059025, WO2008059026.
- In a further embodiment, the further active ingredient is an angiotensin II receptor antagonist, for example those as described in WO2008062905.
- In one embodiment, the further active ingredient is an agonist of the sphingosine-1-phosphate receptor (S1P), for example those as described in WO2008064315.
- In one embodiment, the compound of the formula I is administered in combination with bulking agents, preferably insoluble bulking agents (see, for example, Carob/Caromax® (Zunft H J; et al., Carob pulp preparation for treatment of hypercholesterolemia, ADVANCES IN THERAPY (2001 September-October), 18(5), 230-6). Caromax is a carob-containing product from Nutrinova, Nutrition Specialties & Food Ingredients GmbH, Industriepark Hochst, 65926 Frankfurt/Main). Combination with Caromax® is possible in one preparation or by separate administration of compounds of the formula I and Caromax®. Caromax® can in this connection also be administered in the form of food products such as, for example, in bakery products or muesli bars.
- It will be appreciated that every suitable combination of the compounds of the invention with one or more of the aforementioned compounds and optionally one or more other pharmacologically active substances is regarded as falling within the protection conferred by the present invention.
- Also suitable are the following active ingredients for combination preparations:
- all antiepileptics specified in the Rote Liste 2007, chapter 15;
all antihypertensives specified in the Rote Liste 2007, chapter 17;
all hypotonics specified in the Rote Liste 2007, chapter 19;
all anticoagulants specified in the Rote Liste 2007, chapter 20;
all arteriosclerosis drugs specified in the Rote Liste 2007, chapter 25;
all beta receptors, calcium channel blockers and inhibitors of the renin angiotensin system specified in the Rote Liste 2007, chapter 27;
all diuretics and perfusion-promoting drugs specified in the Rote Liste 2007, chapter 36 and 37;
all withdrawal drugs/drugs for the treatment of addictive disorders specified in the Rote Liste 2007, chapter 39;
all coronary drugs and gastrointestinal drugs specified in the Rote Liste 2007, chapter 55 and 60;
all migraine drugs, neuropathy preparations and Parkinson's drugs specified in the Rote Liste 2007, chapter 61, 66 and 70. - In one embodiment, the compounds of the formula I are administered in combination with medicaments with effects on the cardiovascular system and the blood vessel system, for example ACE inhibitors (e.g. ramipril), medicaments which act on the angiotensin renin system, calcium antagonists, beta-blockers, etc.
- In one embodiment, the compounds of the formula I are administered in combination with antiinflammatory medicaments.
- In one embodiment, the compounds of the formula I are administered in combination with medicaments which are used for cancer treatment and cancer prevention.
- It will be appreciated that every suitable combination of the compounds of the invention with one or more of the aforementioned compounds and optionally one or more other pharmacologically active substances is regarded as falling within the protection conferred by the present invention.
- Suitability of the compounds of the invention as active pharmaceutical ingredients can be tested by means of various test models. Descriptions are given of such test models by way of example below.
- Influence on the MCH Receptor In Vitro; Determination of Functional IC50 Values of MCH1R Antagonists
- Cloning of the cDNA for the human MCH receptor, preparation of a recombinant HEK293 cell line which expresses the human MCH receptor, and functional measurements with the recombinant cell line took place in analogy to the description by Audinot et al. (J. Biol. Chem. 2001, 276, 13554-13562). A difference from the reference was, however, the use of the plasmid pEAK8 from EDGE Biosystems (USA) for the construction of the expression vector. The host used for the transfection was a transformed HEK cell line named “PEAK Stable Cells” (likewise from EDGE Biosystems). Functional measurements of the cellular calcium flux after addition of agonist (MCH) in the presence of ligand of the invention took place with the aid of the FLIPR apparatus from Molecular Devices (USA), using protocols of the apparatus manufacturer. The compounds of the invention show a significant inhibition (>30%) of the signal induced by the agonist at a concentration of 100 μM, preferably at 10 μM, particularly preferably at 1 μM, very particularly preferably at 100 nM and very very particularly preferably at 10 nM.
- Besides the functional activity it is also possible to determine the affinity for the MCH1R according to Audinot et al. (Br. J. Pharmacol. 2001, 133, 371-378).
- Preferred compounds of the invention show an IC50 of less than 1 μM, particularly preferably of less than 100 nM, very particularly preferably of less than 10 nM and very very particularly preferably of less than 1 nM.
- The anorectic effect is tested on female NMRI mice. After withdrawal of feed for 24 hours, the test substance is administered intraperitoneally or preferably orally by gavage. The animals are housed singly with free access to drinking water and, 30 minutes after administration of product, are offered condensed milk. The condensed milk consumption is determined every half hour for 7 hours, and the general condition of the animals is observed. The measured milk consumption is compared with the vehicle-treated control animals.
- The vehicle itself has no influence on feed intake. Preferred tolerated vehicles for the administration are, for example, hydroxyethylcellulose (0.5% in water) or Solutol HS15 (5% in hydroxyethylcellulose (0.5% in water)).
- As alternative to testing the anorectic effect on NMRI mice, it is also possible analogously to use female Wistar rats weighing about 220-250 g. The animals are accustomed to the experimental environment before the start of the study. In one embodiment, the animals have free access to feed and water up to the start of the experiment. In another embodiment, access of the animals to feed is withdrawn 24 hours before the administration. For the investigation of the test substance, the animals are housed singly with free access to feed and water. Feed intake and water intake are measured continuously every 30 minutes over a period of 22 hours using a computer-assisted system (TSE Drinking & Feeding Monitor). The measured feed and water consumption is compared with the vehicle-treated control animals.
- For these investigations, male C57BL6J mice 5 weeks old (weaning age) are accustomed either to a standard maintenance diet or to a high-fat and thus high-energy diet. After 12 weeks, the normally fed, slim mice have typically reached a body weight of about 25 g, and the fat-fed mice have reached one of about 35 g. The animals are housed singly, and the feed intake and water intake are determined individually. There is free access to feed and water during the experiment.
- The test substances are administered orally in a vehicle and always tested by comparison with the vehicle control which is included in parallel. The vehicle itself has no influence on the feed intake, and is normally hydroxyethylcellulose (0.5% in water) or Solutol HS15 (5% in hydroxyethylcellulose (0.5% in water)). A corresponding group of slim mice is kept for each group of diet-induced obese mice.
- Feed consumption and water consumption are determined each day in the first week and then once per week by reweighing the offered feed and water, respectively. The body weight is measured each day.
- Blood samples are taken before and at the end of the treatment in order to determine serum parameters which provide information about changes in intermediary metabolism. It is additionally possible to determine the body fat content on the living animal by means of an impedance measurement (TOBEC method).
- For the intended effects on parameters such as food uptake and body weight development, it is desirable that an antagonist of MCH1R has sufficient brain penetration (for example determined as the ratio of the compound level in the brain tissue and in the blood serum attained at one time) (on this subject, see, for example, J. Pharmacol. Exp. Thera. 2008, 324, 206-213). Preferred compounds of the invention have a ratio of brain to serum levels of at least 0.3. Further preferred compounds have a ratio of at least 0.6. Particularly preferred compounds exhibit a ratio of at least 1.0.
- The aim of the micronucleus test (in vitro) is to examine whether a test compound has the potential to elicit the formation of micronuclei (small membrane-bound DNA fragments) in various cell lines or primary cultures, with or without metabolic activation by S9 liver homogenate. The test system allows differentiation between the clastogenic and aneugenic potential of a test compound by an immunochemical labeling of the kinetochores or by staining the DNA fragments by the FISH (fluorescence in situ hybridization) method.
- Brief description: The cells are treated in a 96-well microtiter plate with the test compound. The treatment time is typically 3 hours with metabolic activation or 24 hours without metabolic activation. Twenty-four hours after the end of the treatment, the cells are isolated, fixed and stained. The cytotoxicity of the test compound is assessed according to the relative cell growth expressed as percentage growth or taking account of the doubling time as population doubling compared with the negative control. The highest test concentration should show not less than 30% surviving cells, or should be the concentration at which a precipitate of the test compound is observed. Duplicate determinations should be carried out with each test concentration. An accurate detailed description of the experiment is to be found in Kirsch-Volders et al. (Mutation Res. 2003, 540, 153-163).
- Evaluation: The structural or numerical chromosomal damage is reported as the increase in the number of cells with micronuclei in an ensemble of 1000 cells at three analyzable test concentrations. The test is regarded as positive in the following cases:
-
- a) the increase in the number of cells with micronuclei is significant by comparison with the negative control (solvent or untreated), or
- b) the number of micronuclei is increased to a biologically relevant extent, concentration-dependently by comparison with the negative control.
- A positive control must show a clear statistically significant effect by comparison with the negative control.
- Preferred compounds of the invention are negative in the micronucleus test.
- The aim of the AMES II test is to examine whether a test compound has mutagenic potential.
- Brief description: A mixed bacterial strain (mixed strains, 6 different Salmonella typhimurium strains with in each case a missence point mutation in the histidine operon) and the Salmonella typhimurium strain TA98 for detecting frame shift mutations is treated in a 384-well microtiter plate with various concentrations of the test substance with or without metabolic activation through addition of S9 liver homogenate (accurate descriptions of the experiment are to be found in the literature: P. Gee, D. M. Maron, B. N. Ames; Proc. Natl. Acad. Sci. USA 1994, 91, 11606 and Flückiger-Isler et al.; Mutation Res. 2004, 558, 181 and cit. lit.). Mutagenic test compounds cause back-mutations and thus restore the functionality of endogenous histidine biosynthesis. Mutated bacteria are thus able to divide and expand to bacterial colonies.
- Evaluation: If there is enhanced bacterial growth owing to mutations of the bacteria, then enzymes are digested in the growth medium. As a result, the pH in the medium falls and the color of the added indicator (bromocresol purple) changes from pale violet to yellow. The test is regarded as positive if the number of wells in which a color change is observed per concentration increases significantly by comparison with the control.
- Preferred compounds of the invention are negative in the AMES II test.
- The aim of the test for LDH (lactate dehydrogenase) release is to examine whether a compound damages the integrity of the cell wall and may thus cause cell death.
- Brief description: The LDH activity which enters the cell supernatant from the cytosol due to cell damage is measured by colorimetry. The cells are treated with the test compound. Fifty microliters of the culture supernatant are removed and mixed with the reaction solution (LDH kit, Roche, Mannheim) in accordance with the manufacturer's information. LDH catalyzes the conversion of lactate into pyruvate. During this, NAD+ is reduced to NADH/H+. The latter in turn reduces, under the influence of the added diaphorase, a likewise added yellow tetrazolium salt to the red formazan.
- Evaluation: The formazan is quantified by measuring the absorption at 492 nM (e.g. with TECAN SPECTRAFluor Plus).
- Preferred compounds of the invention show no significant increase in LDH activity at concentrations below 10 μM. Particularly preferred compounds show no increase below a concentration of 50 μM. Even further preferred compounds show no increase below a concentration of 250 μM.
- The aim of the test is to determine the total intracellular ATP content, which is a measure of the energy level and thus the vitality of a cell.
- Brief description: 100 μl of cell culture medium are mixed in a well of a microtiter plate with 100 μl of the CellTiter-Glo reagent (following the manufacturer's instructions: Promega Technical Bulletin No. 228, CellTiter-Glo Luminesent Cell Viability Assay). The cultures are shaken at room temperature for 2 minutes and then incubated for 10 minutes until the luminescence signal has stabilized.
- Evaluation: The luminescence is recorded, integrating over one second (e.g. with TECAN SPECTRAFluor Plus).
- Preferred compounds of the invention show no significant reduction in the ATP levels at concentrations below 10 μM. Particularly preferred compounds show no reduction below a concentration of 50 μM. Even further preferred compounds show no reduction below a concentration of 250 μM.
- The aim of the test is to measure the uptake of neutral red (NR) into the lysosomes/endosomes and vacuoles of living cells, which is a quantitative measure of the number and vitality of the cells.
- Brief description: The cells are washed with 150 μl of a preheated phosphate buffer solution (PBS) and incubated with 100 μl of the NR medium at 37° C. in a humidified atmosphere with 7.5% carbon dioxide for 3 hours. After the incubation, the NR medium is removed and the cells are washed with 150 μl of PBS. Removal of the PBS is followed by addition of exactly 150 μl of an ethanol/glacial acetic acid solution. After shaking for 10 minutes, the dye is extracted from the cells to give a homogeneous dye solution. An exact description of the test is to be found in the literature (E. Borenfreund, J. A. Puerner, Toxicol. Lett. 1985, 24(2-3), 119-124).
- Evaluation: The absorption of the dye solution is determined at 540 nM using a microtiter plate reader as difference from the absorption of the ethanol/glacial acetic acid solution.
- The aim of the test is to determine the concentration range in which the test compound blocks the cardiac hERG channel. Blockade of the hERG channel, which is responsible for the Ikr current in the human heart, is associated with potentially fatal arrhythmias.
- For expression of the cDNA encoding the hERG channel it was cloned into the pcDNA3 vector (Invitrogen). Chinese hamster oocytes (CHO, American Type Culture Collection, Rockville, Md.) were transfected using lipofectamine (GIBCO/BRL, Grand Island, N.Y.) with the hERG cDNA and selected using G418 (GIBCO/BRL, Grand Island, N.Y.; 500 μg/ml). CHO cells with stable expression of the hERG channel were cultured on a HAM F-12 medium which was supplemented with 10% native bovine serum, 1× penicillin/streptomycin and 500 μg/ml G418 in an atmosphere of 95% air/5% carbon dioxide.
- The cells selected for the patch clamp experiment are seeded on a plastic support 18-24 hours before the experiment. HERG channel currents are recorded at room temperature by the whole-cell variant of the patch clamp technique using an Axopatch 200B amplifier (Axon Instruments, Foster City, Calif.). The electrodes (3-6 megaohms resistance) are prepared from TW150F glass capillaries (World Precision Instruments, Sarasota, Fla.) and filled with the pipette solution (120 mM potassium aspartate, 20 mM KCl, 4 mM Na2ATP, 5 mM HEPES, 1 mM MgCl2; adjusted to pH 7.2 with KOH). The hERG channel currents are induced by a positive voltage pulse (20 mV) followed by a negative pulse (−40 mV) and are recorded for later analysis. As soon as the hERG channel current of the cell flushed with the control solution (130 mM, 5 mM KCl, 2.8 mM NaOAc, 1 mM MgCl2, 10 mM HEPES; 10 mM glucose, 1 mM CaCl2; adjusted to pH 7.4 with NaOH) is stable, the cell is perfused with the test compound dissolved in the above control solution (by dilution of a 10 or 100 mM DMSO solution of the test compound so that the DMSO content is no more than 0.1%). The current is followed continuously until no further changes occur. The same procedure is repeated with increasing concentrations of the test compound. The maximum amplitude of the hERG current is measured in picoAmperes (pA) for each concentration and for each cell. The maximum amplitude in pA for each concentration of the test compound is compared with that of the pure control solution in the same cell and calculated as % of the control value.
- Evaluation: The test compound is tested at various concentrations in 3-5 CHO cells which express the hERG channel. The IC50 is obtained by use of nonlinear least squares regression (GraphPAD Software, San Diego, Calif.).
- In order to minimize the risk of unwanted side effects, it is desirable to keep the nonselective effect on biologically important functional units (e.g. receptors, ion channels and enzymes; for lists, see, for example, Whitebread, S. et al.; Drug Discovery Today 2005, 10, 1421-33 and Rolland, C. et al.; J. Med. Chem. 2005, 48, 6563-6574) by an active pharmaceutical ingredient as small as possible. General selectivity tests in a large number of in vitro test systems can be carried out by various specialized services (e.g. Cerep, Panlabs).
- The compounds of the invention of the formula I exhibit, as selective MCH1R antagonists, selectivity factors of at least 30, preferably of 100, more preferably of 300 and even more preferably of 1000 vis à vis the affinity to other proteins. Examples of such proteins are serotonin receptor subtypes (e.g. the 5-HT2a receptor), muscarine receptor subtypes (e.g. the M1 receptor), adrenergic receptor subtypes (e.g. AR alpha1a), sodium and calcium channels (e.g. the L-type calcium channel).
- Adequate solubility of a substance in aqueous solvent systems is an important prerequisite for a (reproducible) pharmacological effect. Solubilities in aqueous systems can be determined by various methods. Suitable examples are solution precipitation methods (“kinetic solubility”) and methods which investigate the dissolution of a solid sample until an equilibrium is set up (“thermodynamic solubility”).
- A DMSO solution of the test compound (2.5 mM; 0.5 μl) is pipetted into 200 μl of an aqueous test solution (e.g. phosphate-buffered saline, 10×, 1M, Sigma, adjusted to 10 mM, pH 7.4) in a 96-well microtiter plate, and the turbidity is measured at the resulting theoretical concentration for the test compound of 6.25 μM using a nephelometer (e.g. Nephelostar Galaxy, BMG Labtech). The concentration of the test compound in the aqueous test solution is then raised to a theoretical 12.5 μM by adding further DMSO solution (2.5 mM; 0.5 μl), and the turbidity measurement is repeated. Further additions of DMSO solutions (1 μl, 2.5 mM; 0.5 μl, 10 mM; then 9×1 μl, 10 mM resulting in theoretical concentrations of 25 μM, 50 μM, 100 μM, 150 μM, 200 μM, 250 μM, 300 μM, 350 μM, 400 μM, 450 μM and 500 μM) with turbidity measurement in between complete the measurement process.
- Evaluation: The turbidity values from the nephelometer are plotted against the theoretical concentration of the test compound in the aqueous test solution. As soon as a significant turbidity is detected (e.g. 5 times above the control value of the aqueous test solution) at a theoretical concentration, the level of concentration below this is stated to be the solubility limit of the test compound in the test solution. Thus, the maximum possible measurement range emerges as values <6.25 μM, 6.25-500 μM and >500 μM.
- Preferred compounds of the invention show a kinetic solubility in phosphate buffer (pH 7.4) of at least 12.5 μM; more preferably of at least 50 μM and even more preferably of at least 250 μM.
- The integrated UV absorption from HPLC UV measurement of serial dilutions of the test compound in DMSO (500 μM, 100 μM, 50 μM, 10 μM and 1 μM) shows a linear correlation with the concentration in a calibration line. The test compound (500 μg) is shaken together with the aqueous test solution (250 μl) in a closed vessel (capacity: 1.5 ml) for 16 hours (Eppendorf thermoshaker, 1400 rpm, 25° C., covering to protect from light). The sample is then centrifuged at maximum rotational speed, and the supernatant is finally filtered. A sample of the filtered supernatant is analyzed directly by HPLC UV measurement (see above). A further sample is analyzed after dilution (1 part by volume of supernatant, 39 parts by volume of test solution).
- Evaluation: The concentration of the test compound in the undiluted supernatant is calculated from the resulting integrated UV absorptions of the supernatant samples on the basis of the constructed calibration lines and stated as solubility of the test compound in the respective aqueous test solution.
- Examples of aqueous test solutions are deionized water or aqueous phosphate buffer with various pH values (e.g. pH 1.2; pH 4.0; pH 6.8; pH 7.4; pH 9.0) which can be prepared from the commercial solution (phosphate buffered saline, 10×, Sigma) by dilution and adjustment with phosphoric acid or sodium hydroxide solution by standard methods.
- Preferred compounds of the invention show a solubility in phosphate buffer (pH 7.4) of at least 12.5 μM; more preferably of at least 50 μM and even more preferably of at least 250 μM.
- The test for permeability is carried out in CACO-2/TC7 cells which have been cultured (DMEM/Glutamax I/Gibco with high glucose content, HEPES 25 mM, 1% NEAA, 10% FBS, 40 μg/ml gentamycin; 37° C. surrounding temperature; 95% humidity and 10% CO2 content) on Becton Dickinson filters (24-well, uncoated) for 21 days. The permeability is tested at a concentration of 20 μM for the test compound (1% DMSO in HBSS) with a pH gradient (apical: pH 6.5 and 0.5% BSA; basolateral: pH 7.4 and 5% BSA). Analysis takes place by means of LCMS/MS. Further descriptions of the test system and references for the experimental procedure are to be found in Balimane, P. V.; Drug Discovery Today 2005, 10(5), 335-343.
- The inhibition of CYP enzymes is determined on recombinant enzymes (obtained from Becton Dickinson) and fluorescent substrates (BD/Gentest) as recommended by the manufacturer (see Website http://www.bdbiosciences.com). Further descriptions of the test system and references for the experimental procedure are to be found in Zlokarnik, G.; Drug Discovery Today 2005, 10(21), 1443-1450.
- The metabolic stability is determined by incubating the test compound (5 μM) with microsomal liver fractions (1 mg/ml protein with 0.1% w/v BSA; 1 mM NADPH, 0.5% DMSO) at 37° C. Analysis at an incubation time of 0 and 20 minutes takes place by means of LCMS/MS. Further descriptions of the test system and references for the experimental procedure are to be found in Plant, N.; Drug Discovery Today 2004, 9(7), 328-336 and Lau, Y. Y. et al.; Pharmaceutical Res. 2002, 19(11), 1606-1610.
- The examples and preparation methods adduced below serve to illustrate the invention, but without limiting it.
- The inventive compounds of the formula I can be prepared with the aid of reactions known in principle. For example, an amino acid of the structure Z1 can first be protected selectively (for example by method D with Boc2O). The subsequent reaction with an amine (HNR1R2) can advantageously be carried out using a commonly known coupling reagent (for example by method A-1 with HATU or by method A-2 with EDC/HOBt). Removal of the protecting group (for example by method C with hydrochloric acid) and subsequent reduction (for example by method B with lithium aluminum hydride) gives rise to an amine of structure Z2 (where R8=H). When one carbamate protecting group is not removed before the reduction, Z2 is obtained with R8=methyl. In a last step, the inventive compounds of the formula Ia can be obtained by reducing the amine Z2 with an acid of the structure B-L3-A-L2-CO2H (for example by method A-1 or A-2) (scheme 1).
- Further compounds of the type Ia can be obtained by reacting the intermediates Z2 with carboxylic acids of the structure HO-A-L2-COOH (for example by method A-2) and subsequent alkylation with appropriate alkylating agents (for example by method F with alkyl bromides, alkyl iodides or alkylsulfonic esters).
- Alternatively, compounds of the formula I can be obtained from the ketones Z3, which are commercially available, or can be prepared by known methods (see, for example, synthesis 2004, 121; J. Org. Chem. 1995, 60, 4324). Acid-catalyzed condensation of the ketones Z3 with amides (B-L3-A-L2-CONH2) and subsequent (optionally asymmetric) catalytic hydrogenation of the resulting enamides under known conditions (see, for example, Adv. Synth. Catal. 2003, 345, 230; Tetrahedron: Asymmetry 1999, 10, 3467; J. Org. Chem. 1995, 60, 4324) gives rise to the aryl bromides Z4. These can be converted by literature methods to the arylcarbonyl compounds Z5 (see, for example, J. Am. Chem. Soc. 2000, 122, 6935; J. Med. Chem. 2005, 48, 1948; Angew. Chem. Int. Ed. 2006, 45, 154). Final reductive amination leads to the compounds Ib (scheme 2).
- Stereochemically defined compounds of type Ib* can be formed, for example, by condensation of the intermediates Z5′ with chiral sulfinylamides (for example by method M), addition of Grignard reagents (for example by method L), hydrolysis (for example by method K) and optional reductive alkylation, for example by method H-2 (scheme 2-1).
- Further intermediates of the Z4 type can be obtained by subsequent modification of substituents. For example, methoxy groups (B-L3=MeO) can be cleaved by reagents such as hydrogen bromide or boron tribromide (for example by method N), and the resulting aromatic hydroxyl compounds can be reacted with appropriate alkylating agents (for example by method F with alkyl bromides, alkyl iodides or alkyl sulfonates).
- The intermediates Z4 can also be used to synthesize other compounds of the formula I. For this purpose, for example, the dian ions obtained by sequential treatment of Z4 with MeLi and then n-BuLi can be reacted with ketones (R34COR35). The resulting tertiary alcohols can be converted under the conditions of the Ritter reaction (e.g. TMSCN, H2SO4/HOAc to amides which then, after hydrolysis and optional reductive amination, give rise to compounds of the structure Ib-1 (scheme 2-2).
- Alternatively, the intermediates Z4 can also be reacted by means of transition metal complexes (for example those of Pd and Ni) catalyzed with pyridyl compounds (e.g. pyridyltrialkyltin compounds, pyridylboronic acid (derivatives) or pyridine N-oxides). Subsequent hydrogenation with suitable catalysts (e.g. PtO2 in HOAc; method J-1) and optional reductive alkylation gives rise to the structures Ib-2 (scheme 2-2).
- In another variant, the intermediates Z4 are reacted with allyl-metal compounds (e.g. allyltributyltin) under palladium catalysis, then the double bond is cleaved oxidatively (for example with OsO4/NaIO4), and the aldehydes thus obtained are reacted with amines HNR1R2 in the sense of a reductive amination (scheme 2-2).
- Alkylation (for example with NaH, MeI) on the amide function of the intermediates Z4, Z5 and Z5′ and further synthesis along the pathways specified above, and also analogous alkylation of the structures Ib, Ib-1, Ib-2 and Ib-3, give rise to further routes to compounds of the formula I (variation of the substituent R8).
- A further preparation process for other compounds of the formula I again consists in reacting dichlorides of the Z6 type or isochromenones of the Z7 type with amines Z8 by processes known in principle (scheme 3). The dichlorides Z6 required can be obtained from ortho-methylbenzoic acids by double metalation, for example with lithium diisopropylamide (LDA), scavenging of the dianion with formaldehyde (for example in the form of paraformaldehyde) and final dichlorination. The amines Z8 can be obtained, for example, according to scheme 1 (Z2 with R8=H) or according to scheme 2 by hydrolysis of the structures Ib.
- Alternatively, for the synthesis of (dihydro)isoquinolinones of the formula I, it is also to possible to cleave the amide bond of the intermediates Z4 under appropriate conditions (for example with HBr/methanesulfonic acid). The amines thus obtained can be reacted with the dichlorides Z6 (or the isochromenones Z7). The bromides Z9 thus prepared can then be converted further to inventive compounds analogously to the intermediates Z4 (preferably by means of the transition metal-catalyzed reactions specified there). For example, the bromides Z9 can be reductively carbonylated and the aldehydes thus obtained can be converted to compounds of the le type by means of a reductive amination (scheme 3-1).
- Descriptions of the general methods used can be found, by way of example, at the following points:
- method A-1, B, C, D, E, F, G in example 1;
method H, I in example 2;
method J-1 in example 4;
method K, L, M-1 in example 6;
method H-2 in example 8-1;
method A-2 in example 9-1;
method N in example 13;
method O in example 14;
method P in example 15. - In the structural formulae of the examples given, for clarity, preferentially only non-hydrogen atoms are shown.
- Many of the inventive compounds are bases and can form salts with correspondingly strong acid. In particular, the compounds, after HPLC purification using an eluent comprising trifluoroacetic acid, may be present in the form of hydrotrifluoroacetates. These can be converted to the free bases shown by simple treatment of a solution of the salts, for example with sodium carbonate solution.
- The unit of the molecular weights reported is “g/mol”. Peaks observed in the mass spectrum are reported as the integer quotient of the molar molecular ion mass and the charge of the molecular ion (m/z).
-
- To a solution of 4-[(S)-1-(TETRAHYDROFURAN-2-YL)METHOXY]BENZOIC ACID (3.38 g) in NMP (30 ml) were added HATU (O-(7-AZABENZOTRIAZOL-1-YL)-N,N,N′,N′-TETRAMETHYLURONIUM HEXAFLUOROPHOSPHATE; 5.78 g) and then triethylamine (2.12 ml). A solution of (S)-6-pyrrolidin-1-ylmethyl-1,2,3,4-tetrahydronaphthalen-2-ylamine (3.5 g) in NMP (20 ml) was added dropwise. After 12 hours, the reaction mixture was diluted with ethyl acetate, washed with saturated sodium carbonate solution and concentrated. The residue was purified by chromatography on silica gel (eluent: 10:1 DCM/MeOH). The product was thus obtained with the molecular weight of 434.58 (C27H34N2O3); MS (ESI): 435 (M+H+).
- A solution of ((S)-6-amino-5,6,7,8-tetrahydronaphthalen-2-yl)pyrrolidin-1-ylmethanone (0.49 g) in THF (5 ml) was added dropwise to a suspension of lithium aluminum hydride (0.60 g) in THF (10 ml). The mixture was stirred at RT for one hour. Water (0.6 ml) was cautiously added dropwise, followed by sodium hydroxide solution (16%; 2 ml) and water again (2 ml). The resulting precipitate was filtered off and the filtrate was concentrated. The residue was taken up in hydrochloric acid (1N) and the solution was washed with diethyl ether. The aqueous phase was basified with concentrated sodium hydroxide solution and extracted three times with dichloromethane (DCM). The combined organic phases were dried over magnesium sulfate and concentrated. The product was thus obtained with the molecular weight of 230.36 (C15H22N2); MS (ESI): 231 (M+H+).
- In an analogous manner, (S)-6-(4-methoxypiperidin-1-ylmethyl)-1,2,3,4-tetrahydronaphthalen-2-ylamine and (S)-6-azepan-1-ylmethyl-1,2,3,4-tetrahydronaphthalen-2-ylamine were prepared.
- To a solution of [(S)-6-(pyrrolidine-1-carbonyl)-1,2,3,4-tetrahydronaphthalen-2-yl]-carbamic acid tert-butyl ester (0.70 g) in MeOH (5 ml) was added concentrated hydrochloric acid (5 ml). After one hour, the mixture was basified with concentrated sodium hydroxide solution and extracted three times with DCM. The combined organic phases were dried over magnesium sulfate and concentrated. The product was thus obtained with the molecular weight of 244.34 (C15H20N20); MS (ESI): 245 (M+H+).
- According to method A-1, (S)-6-tert-butoxycarbonylamino-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid was reacted with pyrrolidine. The product was thus obtained with the molecular weight of 344.46 (C20H28N2O3); MS (ESI): 345 (M+H+).
- To a mixture of (S)-6-amino-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid (1.0 g), sodium hydroxide solution (32%; 1.1 g) and MeOH (20 ml) was added DI-TERT-BUTYL DICARBONATE (1.92 g). The mixture was stirred at 50° C. for 6 hours and then water (150 ml) was added. After extraction with diethyl ether, the aqueous phase was acidified slightly and extracted three times with DCM. The combined organic phases were dried over magnesium sulphate and concentrated. The product was thus obtained with the molecular weight of 291.35 (C16H21NO4); MS (ESI): 292 (M+H+).
- A mixture of 4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzoic acid methyl ester (9.8 g), sodium hydroxide solution (2 N; 80 ml) and MeOH (300 ml) was stirred for 12 hours. Organic volatile fractions were removed on a rotary evaporator. The remaining aqueous phase was extracted with methyl tert-butyl ether (MTBE) and then acidified with concentrated hydrochloric acid. The resulting precipitate was filtered off and dried. The product was thus obtained with the molecular weight of 222.24 (C12H14O4); MS (ESI): 223 (M+H+).
- A mixture of methanesulfonic acid (S)-1-(tetrahydrofuran-2-yl)methyl ester (7.6 g), 4-hydroxybenzoic acid methyl ester (6.4 g), cesium carbonate (20 g) and NMP (100 ml) was heated to 75° C. for 12 hours. The cooled reaction mixture was admixed with water and extracted with ethyl acetate. The organic phase was washed three times with water, dried over magnesium sulfate and concentrated. The product was thus obtained with the molecular weight of 236.27 (C13H16O4); MS (ESI): 237 (M+H+).
- To a solution of (S)-1-(tetrahydrofuran-2-yl)methanol (7.95 g) in pyridine (35 ml) was added, at −15° C., methanesulfonyl chloride (7.47 g), and the reaction was stirred at 0° C. for 5 hours. After the addition of water, the mixture was extracted with ethyl acetate. The organic phases were dried over magnesium sulfate and concentrated. The product was thus obtained with the molecular weight of 180.22 (C6H12O4S); MS (ESI): 181 (M+H+). Analogously, methanesulfonic acid (R)-1-(tetrahydrofuran-2-yl)methyl ester was synthesized.
-
- According to method A-1,4-[(S)-1-(TETRAHYDROFURAN-2-YL)METHOXY]-BENZOIC ACID was reacted with methyl-((S)-6-pyrrolidin-1-ylmethyl-1,2,3,4-tetrahydronaphthalen-2-yl)amine. The product was thus obtained with the molecular weight of 448.61 (C28H36N2O3); MS (ESI): 449 (M+H+).
- According to method B, [(S)-6-(pyrrolidine-1-carbonyl)-1,2,3,4-tetrahydronaphthalen-2-yl]carbamic acid tert-butyl ester was reacted with lithium aluminum hydride (10 equiv., 60° C., 2 hours). The product was thus obtained with the molecular weight of 244.38 (C16H24N2); MS (ESI): 245 (M+H+).
-
- To a mixture of N—((S)-6-formyl-1,2,3,4-tetrahydronaphthalen-2-yl)-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide (0.50 g), THF (5 ml), methanol (2 ml), isobutylmethylamine (0.23 g) and acetic acid (0.24 g) was added polymer-bound sodium cyanoborohydride (2.7 mmol), and the suspension was agitated at room temperature for 12 hours. The polymer was filtered off with suction and the filtrate was concentrated. The residue was purified by preparative HPLC. The product was thus obtained with the molecular weight of 450.63 (C28H38N2O3); MS (ESI): 451 (M+H+).
- A mixture of N—((S)-6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide (10.0 g) and THF (130 ml) was cooled to −78° C. (dry ice bath) and a solution of methyl lithium (18.9 ml; 1.6 M in diethyl ether) was added dropwise. One minute after the addition had ended, a solution of butyllithium (13.9 ml; 2.5 M in toluene) was added dropwise. One minute after the addition had ended, DMF (5.1 g) was added, and, after a further 30 seconds, acetic acid (4.5 ml). After warming to room temperature, the reaction mixture was diluted with water and extracted with ethyl acetate. The organic phases were dried over magnesium sulfate and concentrated. The product was thus obtained with the molecular weight of 379.46 (C23H25NO4); MS (ESI): 380 (M+H+). In an analogous manner, N—((R)-6-formyl-1,2,3,4-tetrahydronaphthalen-2-yl)-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide was prepared from N—((R)-6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide.
- According to method F, N—((S)-6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-4-hydroxybenzamide was reacted with methanesulfonic acid (S)-1-(tetrahydrofuran-2-yl)methyl ester. The product was thus obtained with the molecular weight of 430.35 (C22H24BrNO3); MS (ESI): 430 (M+H+).
- A mixture of N—((S)-6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-4-methoxybenzamide (3.0 g), glacial acetic acid (2 ml) and HBr (20 ml; 48% in water) was heated to 150° C. in a closed glass vessel in a microwave reactor for 25 minutes. The precipitate obtained after the cooling was filtered off. The product was thus obtained with the molecular weight of 346.23 (C17H16BrNO2); MS (ESI): 346 (M+H+). Both N—((S)-6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-4-methoxybenzamide and N—((R)-6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-4-methoxybenzamide were obtained by literature methods (J. Org. Chem. 1995, 60, 4324).
- The examples compiled in table 1 were obtained by reacting the appropriate carbonyl compounds (aldehydes or ketones) with the appropriate amines by method H-1.
-
TABLE 1 ESI- Ex. Molecular- MS No. Structure weight [M + H]+ 3-2 434.58 435 3-3 436.59 437 3-4 448.60 449 3-5 448.60 449 3-6 462.63 463 3-7 462.63 463 3-8 462.63 463 3-9 466.59 467 3-10 484.58 485 3-11 452.57 453 3-12 460.61 461 3-13 502.70 503 3-14 474.64 475 3-15 464.65 465 3-16 448.60 449 3-17 492.66 493 3-18 492.66 493 3-19 466.62 467 3-20 484.64 485 3-21 420.55 421 3-22 450.58 451 3-23 462.51 463 3-24 422.57 423 3-25 438.57 439 3-26 452.55 453 3-27 434.58 435 3-28 434.58 435 3-29 466.64 467 3-30 452.59 453 3-31 465.59 466 3-32 488.63 489 3-33 505.66 506 3-34 450.62 451 3-35 450.62 451 3-36 465.63 466 3-37 463.62 464 3-38 450.62 451 3-39 496.65 497 3-40 464.60 465 3-41 464.60 465 3-42 464.60 465 3-43 464.60 465 3-44 491.63 492 3-45 462.63 463 3-46 450.62 451 3-47 496.65 497 3-48 488.67 489 3-49 478.63 479 3-50 461.60 462 3-51 474.60 475 3-52 476.66 477 3-53 478.63 479 3-54 452.59 453 3-55 491.63 492 3-56 492.62 493 3-57 450.58 451 3-58 454.56 455 3-59 420.55 421 3-60 502.70 503 3-61 466.58 467 3-62 478.63 479 3-63 486.61 487 3-64 486.63 487 3-65 454.56 455 3-66 450.58 451 3-67 450.62 451 3-68 478.63 479 3-69 464.60 465 3-70 492.54 493 3-71 475.59 476 3-72 463.58 464 3-73 444.52 445 3-74 452.59 453 3-75 436.55 437 3-76 452.59 453 3-77 464.60 465 3-78 468.59 469 3-79 492.66 493 3-80 478.63 479 3-81 498.64 499 3-82 474.60 475 3-83 460.61 461 3-84 473.61 474 3-85 464.60 465 3-86 452.57 453 3-87 478.63 479 3-88 506.68 507 3-89 466.59 467 3-90 512.65 513 3-91 484.64 485 3-92 422.57 423 3-93 438.57 439 3-94 438.57 439 3-95 466.62 467 3-96 512.65 513 3-97 462.63 463 3-98 506.64 507 3-99 452.59 453 3-100 462.59 463 3-101 512.67 513 3-102 464.60 465 3-103 501.62 502 3-104 480.60 481 3-105 465.63 466 3-106 476.66 477 3-107 464.65 465 3-108 452.59 453 3-109 436.59 437 3-110 506.64 507 3-111 436.59 437 3-112 500.64 501 3-113 476.66 477 3-114 485.63 486 3-115 466.62 467 3-116 491.63 492 3-117 464.60 465 3-118 474.64 475 3-119 505.66 506 3-120 487.60 488 3-121 452.59 453 3-122 440.56 441 3-123 452.59 453 3-124 426.53 427 3-125 476.66 477 3-126 448.60 449 3-127 450.62 451 3-128 476.66 477 3-129 452.59 453 3-130 476.66 477 3-131 448.60 449 3-132 478.63 479 3-133 478.63 479 3-134 450.58 451 3-135 464.65 465 3-136 448.60 449 3-137 448.60 449 3-138 448.60 449 3-139 462.63 463 3-140 408.54 409 3-141 450.62 451 3-142 436.59 437 3-143 461.60 462 3-144 490.64 491 3-145 474.64 475 3-146 503.64 504 3-147 460.61 461 3-148 460.61 461 3-149 474.64 475 3-150 474.64 475 3-151 488.67 489 3-152 448.60 449 3-153 488.67 489 3-154 488.67 489 3-155 488.67 489 3-156 474.64 475 3-157 492.70 493 3-158 476.66 477 3-159 488.67 489 3-160 476.66 477 3-161 490.68 491 3-162 490.68 491 3-163 477.65 478 3-164 476.66 477 3-165 504.71 505 3-166 476.66 477 3-167 490.68 491 3-168 464.65 465 3-169 492.66 493 3-170 462.63 463 3-171 492.70 493 3-172 462.63 463 3-173 476.66 477 3-174 476.66 477 3-175 490.68 491 3-176 490.68 491 3-177 494.67 495 3-178 490.68 491 3-179 490.68 491 3-180 502.70 503 3-181 464.65 465 3-182 474.64 475 3-183 490.56 491 3-184 502.70 503 3-185 490.68 491 3-186 490.68 491 3-187 464.65 465 3-188 464.65 465 3-189 504.71 505 3-190 476.66 477 3-191 478.63 479 3-192 490.68 491 3-193 492.66 493 3-194 488.67 489 3-195 476.66 477 3-196 463.63 464 3-197 477.65 478 3-198 451.61 452 3-199 489.66 490 3-200 477.65 478 3-201 463.63 464 3-202 463.63 464 3-203 475.64 476 3-204 479.62 480 3-205 493.65 494 3-206 451.61 452 3-207 437.59 438 3-208 435.57 436 3-209 449.60 450 3-210 461.61 462 3-211 475.64 476 3-212 475.64 476 3-213 435.57 436 3-214 449.60 450 - A mixture of N—((S)-6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide (1.0 g) and THF (10 ml) was cooled to −78° C. (dry ice bath), and a solution of methyllithium (2.0 ml; 1.6 M in diethyl ether) was added dropwise. One minute after the addition had ended, a solution of butyllithium (1.4 ml; 2.5 M in toluene) was added dropwise. One minute after the addition had ended, N-methoxy-N-methylacetamide (0.24 g) was added. After warming to room temperature, the reaction mixture was diluted with water and extracted with ethyl acetate. The organic phases were dried over magnesium sulfate and concentrated. The residue was chromatographed on silica gel (eluent: 1:1 heptane/ethyl acetate). The product was thus obtained with the molecular weight of 393.49 (C24H27NO4); MS (ESI): 394 (M+H+).
- A mixture of N—((S)-6-allyl-1,2,3,4-tetrahydronaphthalen-2-yl)-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide (0.50 g), 2-propanol (50 ml) and water (50 ml) was admixed with sodium periodate (0.60 g) and osmium tetroxide (1.3 mg). After stirring vigorously for 14 hours, the reaction mixture was extracted with ethyl acetate. The organic phase was washed with sodium chloride solution, dried over sodium sulfate and concentrated. The product was thus obtained with the molecular weight of 393.49 (C24H27NO4); MS (ESI): 394 (M+H+).
- A mixture of N—((S)-6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide (1.00 g), toluene (10 ml), Pd(PPh3)4 (26.7 mg) and allyltributyltin (2.46 g) was boiled at reflux for 5 hours. The cooled reaction mixture was diluted with ethyl acetate and washed with water. The organic phase was washed with sodium chloride solution, dried over sodium sulfate and concentrated. The residue was purified by chromatography on silica gel. The product was thus obtained with the molecular weight of 391.51 (C25H29NO3); MS (ESI): 392 (M+H+).
- According to method A, (S)-6-bromo-1,2,3,4-tetrahydronaphthalen-2-ylamine was reacted with 5-hydroxypyridine-2-carboxylic acid. The amide obtained was alkylated by method F with (S)-1-(tetrahydrofuran-2-yl)methyl methanesulfonate and converted to the desired aldehyde by method I. The product was thus obtained with the molecular weight of 380A5 (C22H24N2O4); MS (ESI): 381 (M+H+).
-
- A mixture of N—((S)-6-pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-2-yl)-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide (0.60 g), glacial acetic acid (30 ml) and platinum(IV) oxide (0.10 g) was stirred vigorously under a hydrogen atmosphere (balloon) for 12 hours. The catalyst was filtered off with suction and the filtrate was concentrated. The product was thus obtained with the molecular weight of 434.58 (C27H34N2O3); MS (ESI): 435 (M+H+).
- Preparative separation on a chiral phase (Chiralpak AD-H) afforded the pure diastereomers (N—((S)—(R)-6-piperidin-3-yl-1,2,3,4-tetrahydronaphthalen-2-yl)-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide and N—((S)—(S)-6-piperidin-3-yl-1,2,3,4-tetrahydronaphthalen-2-yl)-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide).
- A mixture of N—((S)-6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide (1.00 g), toluene (10 ml) and Pd(PPh3)4 (2.69 g) was admixed with 3-pyridylboronic acid (0.28 g), ethanol (3 ml) and cesium carbonate solution (1.2 ml; 2 M in water). The mixture was boiled at reflux for 7 hours. The cooled reaction mixture was diluted with ethyl acetate and washed with water. The organic phase was washed with sodium chloride solution, dried over sodium sulfate and concentrated. The residue was purified by chromatography on silica gel. The product was thus obtained with the molecular weight of 428.54 (C27H28N2O3); MS (ESI): 429 (M+H+).
-
- According to method J-1, N—[(S)-6-(1-oxypyridin-2-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]-benzamide was hydrogenated. The product was thus obtained with the molecular weight of 434.58 (C27H34N2O3); MS (ESI): 435 (M+H+).
- A mixture of pyridine N-oxide (0.88 g), potassium carbonate (0.64 g), tri-tert-butylphosphine (0.101 g; HBF4 adduct) and palladium(II) acetate (26 mg) was admixed with a solution of N—((S)-6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide (1.00 g) in toluene (8 ml). The mixture was boiled at reflux for 5 hours. The cooled reaction mixture was diluted with ethyl acetate and washed with water. The organic phase was washed with sodium chloride solution, dried over sodium sulfate and concentrated. The residue was purified by chromatography on silica gel (eluent: 15:1 dichloromethane/methanol). The product was thus obtained with the molecular weight of 444.54 (C27H28N2O4); MS (ESI): 445 (M+H+).
-
- A mixture of N-{(S)-6-[(S)-1-((R)-2-methylpropane-2-sulfinylamino)ethyl]-1,2,3,4-tetrahydronaphthalen-2-yl}-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]-benzamide (0.12 g) and methanol (2 ml) was admixed with hydrogen chloride (2 ml; 5 M in 2-propanol). After 30 minutes, the reaction mixture was concentrated. The product was thus obtained with the molecular weight of 394.52 (C24H30N2O3); MS (ESI): 395 (M+H+).
- In an analogous manner, it is possible to prepare N—[(S)-6-((R)-1-aminoethyl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]-benzamide.
- A suspension, cooled to −45° C., of N—((S)-6-{[(E)-(R)-2-methylpropane-2-sulfinylimino]methyl}-1,2,3,4-tetrahydronaphthalen-2-yl)-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide (0.34 g), diethyl ether (15 ml) and dichloromethane (15 ml) was admixed with methylmagnesium bromide (1.1 ml; 1.4 M in toluene). After warming to room temperature, the mixture was stirred for another 5 hours. The reaction mixture was hydrolyzed cautiously with water and extracted with ethyl acetate. The organic phase was washed with sodium chloride solution, dried over sodium sulfate and concentrated. The residue was purified by chromatography on silica gel (eluent: ethyl acetate). The product was thus obtained with the molecular weight of 498.69 (C28H38N2O4S); MS (ESI): 499 (M+H+).
- A mixture of N—((S)-6-formyl-1,2,3,4-tetrahydronaphthalen-2-yl)-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide (1.0 g), (R)-2-methylpropane-2-sulfinic acid amide (0.32 g), pyridinium para-toluenesulfonate (165 mg), copper(II) sulfate (1.0 g; anhydrous) and dichloromethane (10 ml) was stirred for 24 hours. Solid fractions were filtered off and the filtrate was concentrated. The residue was purified by chromatography on silica gel. The product was thus obtained with the molecular weight of 482.65 (C27H34N2O4S); MS (ESI): 483 (M+H+).
-
- A mixture, cooled to 0° C., of N—[(S)-6-(1-hydroxy-1-methylethyl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide (0.30 g), glacial acetic acid (1 ml) and trimethylsilyl cyanide (145 mg) was admixed dropwise with sulfuric acid (1.2 ml; 96%). The cooling bath was removed and the mixture was stirred for another 12 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with sodium chloride solution, dried over sodium sulfate and concentrated. The residue was taken up in 1,4-dioxane (20 ml) and boiled at reflux with dilute hydrochloric acid for 30 minutes. The reaction mixture was washed with ethyl acetate and basified with concentrated sodium hydroxide solution. Extraction with dichloromethane gave rise to an organic phase which was dried over sodium sulfate and concentrated. (Alternatively, the hydrolysis of the intermediate formamide can also be achieved by boiling with sodium hydroxide solution.) The product was thus obtained with the molecular weight of 408.55 (C25H32N2O3); MS (ESI): 409 (M+H+).
- A mixture of N—((S)-6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide (1.0 g) and THF (10 ml) was cooled to −78° C. (dry ice bath), and a solution of methyllithium (2.0 ml; 1.6 M in diethyl ether) was added dropwise. One minute after the addition had ended, a solution of butyllithium (1.4 ml; 2.5 M in toluene) was added dropwise. One minute after the addition had ended, acetone (0.14 g) was added. After warming to room temperature, the reaction mixture was diluted with water and extracted with ethyl acetate. The organic phases were dried over magnesium sulfate and concentrated. The residue was chromatographed on silica gel (eluent: 1:2 heptane/ethyl acetate). The product was thus obtained with the molecular weight of 409.53 (C25H31NO4); MS (ESI): 410 (M+H+).
-
- To a mixture of N—[(S)-6-(1-amino-1-methylethyl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide (30 mg), THF (1 ml), methanol (0.5 ml), trimethylacetaldehyde (10 mg) and acetic acid (9 mg) was added polymer-bound sodium cyanoborohydride (0.15 mmol), and the suspension was agitated at room temperature for 12 hours. The polymer was filtered off with suction and the filtrate was concentrated. The residue was purified by preparative HPLC. The product was thus obtained with the molecular weight of 478.68 (C30H42N2O3); MS (ESI): 479 (M+H+).
- In Table 2, examples which have been obtained by reductive alkylation of the appropriate amines by method H-2 with the appropriate carbonyl compounds (aldehyde or ketone) are summarized. If N,N-dialkylations of primary amines are to be achieved by method H-2, 2-3 equivalents of the carbonyl component and correspondingly more sodium cyanoborohydride are used.
-
TABLE 2 ESI- Ex. Molecular MS No. Structure weight [M + H]+ 8-2 436.27 437 8-3 490.32 491 8-4 488.30 489 8-5 476.30 477 8-6 448.27 449 8-7 476.30 477 8-8 448.27 449 8-9 488.30 489 8-10 464.30 465 8-11 478.32 479 8-12 492.34 493 8-13 504.34 505 8-14 464.30 465 8-15 476.30 477 8-16 464.30 465 8-17 476.30 477 8-18 464.30 465 8-19 450.29 451 8-20 558.38 559 8-21 464.30 465 8-22 506.35 507 8-23 518.31 519 8-24 516.34 517 8-25 504.34 505 8-26 518.31 519 8-27 516.34 517 8-28 504.34 505 -
- According to method F, 5-hydroxypyridine-2-carboxylic acid ((S)-6-azepan-1-ylmethyl-1,2,3,4-tetrahydronaphthalen-2-yl)amide was alkylated with methanesulfonic acid (S)-1-(tetrahydrofuran-2-yl)methyl ester (DMF, 12 h, 80° C.). The product was thus obtained with the molecular weight of 463.63 (C28H37N3O3); MS (ESI): 464 (M+H+).
- A mixture of 5-hydroxypyridine-2-carboxylic acid (0.54 g) and DMF (3 ml) was admixed with (3-dimethylaminopropyl)ethylcarbodiimide (EDC; 0.80 g) and benzotriazol-1-ol (HOBt; 0.60 g), and stirred for 5 minutes. Then ethyldiisopropylamine (0.80 ml) and (S)-6-azepan-1-ylmethyl-1,2,3,4-tetrahydronaphthalen-2-ylamine (1.00 g) were added and the mixture was stirred for 12 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic phase was dried over sodium sulfate, filtered and concentrated. The product was thus obtained with the molecular weight of 379.51 (C23H29N3O2); MS (ESI): 380 (M+H+).
- In an analogous manner, N—((S)-6-azepan-1-ylmethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-4-hydroxybenzamide was obtained by reacting 4-hydroxybenzoic acid with (S)-6-azepan-1-ylmethyl-1,2,3,4-tetrahydronaphthalen-2-ylamine.
- In Table 3, examples which have been prepared by alkylating N—((S)-6-azepan-1-ylmethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-4-hydroxybenzamide according to method F with the appropriate alkylating agents (e.g. bromides, iodides or sulfonic esters) are compiled.
-
- A mixture of N—[(S)-6-(R)-1-aminoethyl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide (50 mg), 1,5-dibromo-3-methylpentane (31 mg), ethyldiisopropylamine (0.10 ml) and acetonitrile (1 ml) was heated to 40° C. for 8 hours. The cooled reaction mixture was concentrated and the residue was purified by preparative HPLC. The product was thus obtained with the molecular weight of 476.66 (C30H40N2O3); MS (ESI): 477 (M+H+).
-
- A mixture of N—[(S)-6-(R)-1-aminoethyl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzamide (50 mg), 1,6-dibromohexane (31 mg), ethyldiisopropylamine (0.10 ml) and acetonitrile (1 ml) was heated to 40° C. for 8 hours. The cooled reaction mixture was concentrated and the residue was purified by preparative HPLC. The product was thus obtained with the molecular weight of 476.66 (C30H40N2O3); MS (ESI): 477 (M+H+).
-
- According to method A-2,3-fluoro-4-[(S)-1-(tetrahydrofuran-2-yl)methoxy]benzoic acid was reacted with (S)-6-azepan-1-ylmethyl-1,2,3,4-tetrahydronaphthalen-2-ylamine. The product was thus obtained with the molecular weight of 480.63 (C29H37FN2O3); MS (ESI): 481 (M+H+).
- According to method F, 3-fluoro-4-hydroxybenzoic acid ethyl ester was alkylated with methanesulfonic acid (S)-1-(tetrahydrofuran-2-yl)methyl ester, and the reaction product was hydrolyzed by method E. The product was thus obtained with the molecular weight of 240.23 (C12H13FO4); MS (ESI): 241 (M+H+).
-
- A mixture of 6-[(S)-1-(tetrahydrofuran-2-yl)methoxy]isochromen-1-one (50 mg), NMP (0.2 ml) and (S)-6-(4-methoxypiperidin-1-ylmethyl)-1,2,3,4-tetrahydronaphthalen-2-ylamine (55 mg) was heated to 220° C. in a microwave reactor for 3×30 minutes. The cooled reaction mixture was purified by preparative HPLC. The product was thus obtained with the molecular weight of 502.66 (C31H38N2O4); MS (ESI): 503 (M+H+).
- To a solution of 6-hydroxyisochromen-1-one (2 g) in DMF (50 ml) were added methanesulfonic acid (S)-1-(tetrahydrofuran-2-yl)methyl ester (2.7 g) and cesium carbonate (12 g), and the mixture was stirred at 80° C. for 7 hours. After water had been added, the mixture was extracted with dichloromethane. The organic phases were dried over magnesium sulfate and concentrated. The product was thus obtained with the molecular weight of 246.27 (C14H1404); MS (ESI): 247 (M+H+).
- To a solution of 6-methoxyisochromen-1-one (9.3 g) in dichloromethane (300 ml) was added, at 0° C., a solution of boron tribromide (1 M in dichloromethane, 130 ml), and the mixture was stirred at room temperature for 16 hours. After sodium carbonate solution had been added, the mixture was washed with ethyl acetate. The aqueous phase was acidified with 2 N HCl and extracted with ethyl acetate. The organic phases were dried over magnesium sulfate and concentrated. The residue was chromatographed on silica gel. The product was thus obtained with the molecular weight of 162.15 (C9H6O3); MS (ESI): 163 (M+H+).
- A solution of 6-methoxyisochroman-1-one (15.1 g), N-bromosuccinimide (NBS; 27 g) and benzoyl peroxide (500 mg) in tetrachloromethane (250 ml) was heated to reflux while irradiating with light for 3 hours. The mixture was filtered and the filtrate was concentrated. The residue was dissolved in triethylamine (100 ml) and stirred at room temperature for 48 hours. The reaction mixture was partitioned between water and ethyl acetate and adjusted to pH 1 with concentrated hydrochloric acid. The organic phase was removed, dried over magnesium sulfate and concentrated. The residue was chromatographed on silica gel. The product was thus obtained with the molecular weight of 176.17 (C10H803); MS (ESI): 177 (M+H+).
- To a solution of diisopropylamine (33.5 ml) in dry THF (190 ml) was added dropwise, at −78° C., n-butyllithium (1.6 M solution in hexane, 145.9 ml). Subsequently, the reaction mixture was warmed to room temperature for 5 minutes and then cooled again to −78° C., and a solution of 4-methoxy-2-methylbenzoic acid (10 g) in dry THF (210 ml) was added dropwise. After stirring at this temperature for 10 minutes, paraformaldehyde (7 g) was added.
- The reaction mixture was then allowed to come to room temperature and stirred at this temperature for 4 hours. The reaction mixture was admixed with water, then the THF was removed under reduced pressure and then the aqueous phase was extracted with diethyl ether. The aqueous phase was acidified with conc. HCl, and the resulting precipitate was filtered off and washed repeatedly with water. The product was thus obtained with the molecular weight of 178.06 (C10H10O3); MS (ESI): 179 (M+H+).
-
- According to method F, 6-hydroxy-2-[(S)-6-(4-methoxypiperidin-1-ylmethyl)-1,2,3,4-tetrahydronaphthalen-2-yl]-3,4-dihydro-2H-isoquinolin-1-one was alkylated with methanesulfonic acid (S)-1-(tetrahydrofuran-2-yl)methyl ester. The product was thus obtained with the molecular weight of 504.68 (C31H40N2O4); MS (ESI): 505 (M+H+).
- A mixture of 6-methoxy-2-[(S)-6-(4-methoxypiperidin-1-ylmethyl)-1,2,3,4-tetrahydronaphthalen-2-yl]-3,4-dihydro-2H-isoquinolin-1-one (0.59 g), NMP (2 ml), thiophenol (150 mg) and potassium carbonate (235 mg) was heated to 210° C. in a microwave reactor for 40 minutes. The cooled reaction mixture was purified by chromatography on silica gel (eluent: 9:1 dichloromethane/methanol). The product was thus obtained with the molecular weight of 420.56 (C26H32N2O3); MS (ESI): 421 (M+H+).
- A mixture of 6-methoxyisochroman-1-one (1.30 g) and thionyl chloride (0.87 g) was admixed with one drop of DMF and heated to reflux for 5 hours. Volatile fractions were distilled off. The residue was taken up in THF (2 ml) and added dropwise to a mixture, cooled to 0° C., of (S)-6-(4-methoxypiperidin-1-ylmethyl)-1,2,3,4-tetrahydronaphthalen-2-ylamine (2.00 g), THF (20 ml) and triethylamine (1.0 ml). After 15 minutes, potassium tert-butoxide (0.82 g) was added and the cooling bath was removed after 30 minutes. After a further 12 hours at room temperature, the reaction mixture was diluted with water and extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated. The residue was purified by preparative HPLC. The product was thus obtained with the molecular weight of 434.58 (C27H34N2O3); MS (ESI): 435 (M+H+).
-
- According to method H-1, (S)-6-{1-oxo-6-[(S)-1-(tetrahydrofuran-2-yl)methoxy]-3,4-dihydro-1H-isoquinolin-2-yl}-5,6,7,8-tetrahydronaphthalene-2-carbaldehyde was reacted with pyrrolidine. The product was thus obtained with the molecular weight of 460.62 (C29H36N2O3); MS (ESI): 461 (M+H+).
- A mixture of 2-((S)-6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)-6-[(S)-1-(tetrahydrofuran-2-yl)methoxy]-3,4-dihydro-2H-isoquinolin-1-one (1.10 g), palladium(II) acetate (16.2 mg), butyldi-1-adamantylphosphine (77 mg), TMEDA (0.27 ml) and toluene (22 ml) was heated to 120° C. in an autoclave under a hydrogen/carbon monoxide atmosphere for 14 hours. The cooled reaction mixture was diluted with ethyl acetate and washed first with dilute hydrochloric acid and then with sodium hydrogen carbonate solution. The organic phase was dried over sodium sulfate and concentrated. The residue was purified by preparative HPLC. The product was thus obtained with the molecular weight of 405.50 (C25H27NO4); MS (ESI): 406 (M+H+).
- According to method 0, 6-[(S)-1-(tetrahydrofuran-2-yl)methoxy]isochroman-1-one was reacted with (S)-6-bromo-1,2,3,4-tetrahydronaphthalen-2-ylamine (J. Org. Chem. 1995, 60, 4324). The product was thus obtained with the molecular weight of 456.38 (C24H26BrNO3); MS (ESI): 456 (M+H+).
- A mixture of 6-hydroxyisochroman-1-one (332 mg), methanesulfonic acid (S)-1-(tetrahydrofuran-2-yl)methyl ester (284 mg), cesium carbonate (1.28 g) and DMF (8 ml) was heated to 70° C. for 7 hours. The cooled reaction mixture was partitioned between water and ethyl acetate. The organic phase was dried and concentrated. The crude product was purified by chromatography on silica gel. The product was thus obtained with the molecular weight of 248.28 (C14H16O4); MS (ESI): 249 (M+H+).
- According to method N, 6-methoxyisochroman-1-one was treated with boron tribromide.
- In Table 4, examples which have been obtained by reacting (S)-6-{1-oxo-6-[(S)-1-(tetrahydrofuran-2-yl)methoxy]-3,4-dihydro-1H-isoquinolin-2-yl}-5,6,7,8-tetrahydronaphthalene-2-carbaldehyde with amines according to method H-1 are compiled.
-
TABLE 4 ESI- Ex. Molecular MS No. Structure weight [M + H]+ 15-2 488.68 489 15-3 460.62 461 15-4 476.66 477 15-5 532.73 533 15-6 476.66 477 15-7 490.65 491 15-8 462.64 463 15-9 488.68 489 15-10 486.66 487 15-11 488.68 489 15-12 504.68 505 15-13 478.64 479 15-14 474.65 475 15-15 474.65 475 15-16 488.68 489 15-17 500.69 501 - In Table 5, results which have been obtained in the above-described calcium mobilization assay are summarized for illustrative purposes.
-
TABLE 5 Ex. No. IC50/μM 1 0.09 2 0.67 3-2 3.29 3-14 0.10 3-26 0.36 3-32 0.13 3-33 0.27 3-34 0.10 3-37 0.34 3-40 0.18 3-44 0.31 3-48 0.21 3-51 0.19 3-61 0.30 3-64 0.18 3-71 0.75 3-72 1.85 3-77 0.12 3-84 0.17 3-86 0.12 3-100 0.33 3-103 0.20 3-120 2.41 3-135 0.15 3-166 0.11 3-194 0.09 3-195 0.11 8-1 0.24 8-3 0.23 8-8 0.18 8-16 0.12 8-26 0.23 9-2 1.28 9-3 0.17 9-4 0.44 9-5 0.31 10 0.11 12 0.30 13 1.40 14 0.63 - In Table 6, results which have been determined in the above-described hERG inhibition assay and in the test for kinetic solubility are compiled for illustrative purposes. It is found that inventive compounds advantageously combine low hERG inhibition with a high solubility in aqueous systems at a physiologically relevant pH of 7.4. In contrast, prior art compounds frequently exhibit a lower solubility. For example, for example No. 110 ((S)-enantiomer) from US2005/0075324, a solubility of <10 μm was found. The publication Bioorg. Med. Chem. Lett. 2007, 17, 814-818 (table footnote on page 817) also describes the sparing solubility of the prior art compounds.
-
TABLE 6 hERG Inh. Neph. sol. Ex. No. IC50/μM pH 7.4/μM 1 >30 >500 3-6 >10 >500 3-34 >30 50 3-83 >30 >500 3-154 >10 >500 3-166 >10 450 14 >10 >500 - Table 7 lists examples with an aminochromane base skeleton, which can be prepared by the processes described above by way of example. In order to obtain inventive compounds, for example, by the process described in Scheme 2 or by way of example in Example 3-1, it is possible to proceed, for example, from 7-bromochroman-3-one, which is supplied commercially (Anichem LLC; 195 Black Horse Lane; North Brunswick, N.J., 08902; USA) or by the following route:
- A mixture of 4-bromo-2-hydroxybenzaldehyde (20 g), acrylonitrile (26.4 g) and DABCO (0.78 g) was heated at reflux for 8 hours. After cooling, the reaction mixture was diluted with ethyl acetate and washed with water. The organic phase was concentrated and the residue was filtered through silica gel. The 7-bromo-2H-chromene-3-carbonitrile thus obtained (7.5 g) was boiled at reflux with sodium hydroxide solution (10.2 g of sodium hydroxide in 100 ml of water) for 8 hours. The cooled reaction mixture was washed with methyl tert-butyl ether, acidified with hydrochloric acid and extracted with ethyl acetate. Concentration of the organic phase gave 7-bromo-2H-chromene-3-carboxylic acid. This acid (3.0 g) was heated to 85° C. with DPPA (3.2 g), triethylamine (1.6 ml) and toluene (30 ml) for 12 hours. Then hydrochloric acid (6 N) was added and the mixture was heated to reflux for 2 hours. The cooled reaction mixture was extracted with ethyl acetate and the organic phase was concentrated. The product was thus obtained with the molecular weight of 227.06 (C9H7BrO2); MS (ESI): 227 (M+H+).
- The examples of Table 7 serve to illustrate further possible embodiments of the invention, without restricting it.
-
TABLE 7 Ex. Molecular- Calc No. Structure weight [M + H]+ I-1 436.55 437 I-2 436.55 437 I-3 408.54 409 I-4 406.53 407 I-5 424.54 425 I-6 424.54 425 I-7 424.54 425 I-8 438.57 439 I-9 424.54 425 I-10 438.57 439 I-11 424.54 425 I-12 464.48 464 I-13 410.51 411 I-14 420.55 421 I-15 436.55 437 I-16 450.58 451 I-17 436.55 437 I-18 463.58 464 I-19 418.58 419 I-20 433.60 434 I-21 458.56 459 I-22 418.54 419 I-23 447.58 448 I-24 445.56 446 I-25 437.58 438 I-26 453.58 454 I-27 453.58 454 I-28 487.04 487 I-29 482.62 483 I-30 466.62 467 I-31 492.66 493 I-32 462.59 463
Claims (21)
1. A compound of formula I
wherein:
R1 and R2
are each independently H, (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl, CO(R9), (C(R10)(R11))q-R12, CO(C(R13)(R14))r-R15, CO—O(C1-C8)-alkyl, and CO(C(R13)(R14))r—N(R16)(R17);
R10 and R11 are each independently H, (C1-C6)-alkyl, hydroxy-(C1-C2)-alkyl, F, and OH;
R9, R13, R14, R16, and R17 are each independently H or (C1-C6)-alkyl;
or
R16 and R17, each independently taken together with the nitrogen atom to which they are attached form a 5-6-membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatom from the group of NH, N—(C1-C6)-alkyl, oxygen and sulfur;
q and r are each independently 0, 1, 2, 3, 4, 5, 6;
R12 and R15 are each independently H, OH, F, O—(C1-C6)-alkyl, S—(C1-C6)-alkyl, O-phenyl, CN, COO(R25), N(R26)CO(C1-C6)-alkyl, N(R27)(R28), CON(R29)(R30), SO2(C1-C6)-alkyl, or 3-12-membered mono-, bi- or spirocyclic ring, which may contain one to four heteroatoms from the group of N, O and S, and the 3-12-membered ring is optionally substituted by F, Cl, Br, OH, CF3, NO2, CN, OCF3, oxo, O—(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, S—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O—(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, O—(C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, N(R31)(R32), COO(R33), SO2(C1-C6)-alkyl and COOH;
R25, R26, R27, R28, R29, R30, R31, R32 and R33 are each independently H or (C1-C8)-alkyl;
or
R27 and R28, R29 and R30, and R31 and R32 each independently taken together with the nitrogen atom to which they are attached form a 5-6-membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatom from the group of NH, N—(C1-C6)-alkyl, oxygen and sulfur;
L1 is C(R34)(R35), C(R36)(R37)C(R38)(R39), or (C3-C6)-cycloalkyl;
optionally, R1 may be joined to one of R34, R35, R36, R37, R38 or R39 radicals, so as to form a 5-6-membered ring;
R34, R35, R36, R37, R38 and R39 are each independently H or (C1-C8)-alkyl;
R3, R4, and R5 are independently H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, S—(C1-C6)-alkyl, O—(C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, CON(R40)(R41), or CO(R42);
R40, R41 and R42 are each independently H or (C1-C8)-alkyl;
or
R40 and R41 taken together with the nitrogen atom to which they are attached form a 5-6-membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatom from the group consisting of NH, N—(C1-C6)-alkyl, oxygen, and sulfur;
X is O or C(R43)(R43′);
R6, R6′, R7, R7′, R43 and R43′ are each independently H, F, (C1-C8)-alkyl, OH, or O—(C1-C6)-alkyl;
or
R6 and R6′, or R43 and R43′ together are oxo;
R8 is H or (C1-C8)-alkyl;
L2 is a bond or C(R44)(R45);
R44 and R45 are each independently H or (C1-C8)-alkyl;
A is a 5-6-membered aromatic ring that may include up to 2 heteroatoms selected from the group of nitrogen, oxygen and sulfur, and is optionally substituted by one or more of the substituents selected from H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, O—(C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, N(R54)(R55), SO2—CH3, CON(R56)(R57), N(R58)CO(R59), and CO(R60);
provided that when L2 is a bond, then C(O)NR8 may be joined to an ortho substituent of A via a bridge containing one or two elements from the group of carbon and nitrogen, so as to form a 9- to 10-membered bicyclic ring overall;
R54, R55, R56, R57, R58, R59, and R60 are each independently H or (C1-C8)-alkyl;
or
R54 and R55, and R56 and R57 each independently taken together with the nitrogen atom to which they are attached form a 5-6-membered ring which, apart from the nitrogen atom, may also include 0-1 further heteroatom from the group of NH, N—(C1-C6)-alkyl, oxygen and sulfur;
L3 is a bond or a linker having from 1 to 4 members, where the members are selected from the group consisting of O, S, SO2, N(R61), CO, C(R62)(R63), and C≡C, to give rise to a chemically viable radical, and the linker does not have any O—CO or COO groups;
B is (C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C6)-alkyl, or a 3 to 10-membered mono-, bi- or spirocyclic nonaromatic ring, which may include from 0 to 3 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system is optionally substituted by one or more substituents selected from F, CF3, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, oxo, CO(R64), and hydroxyl; and
R61, R62, R63, and R64 are each independently H or (C1-C8)-alkyl;
provided that when X is C(R43)(R43′), then
L3 is C(R62)(R63)O, and
B is a 4- to 10-membered mono-, bi- or spirocyclic nonaromatic ring which includes from 1 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the ring is optionally by one or more substituents selected from F, CF3, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, oxo, CO(R64), and hydroxyl;
or a physiologically compatible salt thereof.
2. The compound according to claim 1 , wherein:
L2 is a bond;
or a physiologically compatible salt thereof.
3. The compound according to claim 1 , wherein:
A is selected from the group of
4. The compound according to claim 1 , wherein:
L3 is a bond, O, or C(R62)(R63)O;
or a physiologically compatible salt thereof.
5. The compound according to claim 1 , wherein:
B is a 4- to 6-membered nonaromatic ring which includes from 1 to 2 oxygen atoms, where the ring system is optionally substituted by one or more substituents selected from (C1-C6)-alkyl and hydroxyl;
or a physiologically compatible salt thereof.
7. The compound according to claim 1 , which is a compound of formula II
wherein:
L1, R3, R4 and R8 are each as defined in claim 1 ;
R, R′, R″ and R′″ are each independently H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, O—(C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, N(R54)(R55), SO2—CH3, CON(R56)(R57), N(R58)CO(R59), and CO(R60);
L3 is CH2O; and
B is a 4- to 6-membered nonaromatic ring which includes from 1 to 2 oxygen atoms, wherein the ring is optionally substituted by one or more substituents selected from F, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, oxo, hydroxyl, preferably (C1-C6)-alkyl and hydroxyl;
or a physiologically compatible salt thereof.
11. A pharmaceutical composition comprising the compound according to claim 1 or a physiologically compatible salt thereof, in combination with a pharmacologically acceptable carrier or excipient.
12. The pharmaceutical composition according to claim 11 , further comprising one or more active ingredients which are effective in treating a metabolic disorder or a disease associated therewith.
13. The pharmaceutical composition according to claim 11 , further comprising one or more antidiabetics.
14. The pharmaceutical composition according to claim 11 , further comprising one or more lipid modulators.
15. The pharmaceutical composition according to claim 11 , further comprising one or more antiobesity agents.
16. A pharmaceutical composition comprising the compound according to claim 7 or a physiologically compatible salt thereof, in combination with a pharmacologically acceptable carrier or excipient.
17. A pharmaceutical composition comprising the compound according to claim 8 or a physiologically compatible salt thereof, in combination with a pharmacologically acceptable carrier or excipient.
18. A pharmaceutical composition comprising the compound according to claim 9 or a physiologically compatible salt thereof, in combination with a pharmacologically acceptable carrier or excipient.
19. A pharmaceutical composition comprising the compound according to claim 10 or a physiologically compatible salt thereof, in combination with a pharmacologically acceptable carrier or excipient.
20. A method for treating a disorder of fatty acid metabolism, glucose utilization disorder, a disorder in which insulin resistance plays a role, diabetes mellitus or a sequel associated therewith, dyslipidemia or a consequence thereof, nonalcoholic fatty liver or a variant thereof, a state associated with metabolic syndrome, or obesity or a sequel associated therewith, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound according to claim 1 or a physiologically compatible salt thereof.
21. A process for preparing a pharmaceutical composition comprising the compound according to claim 1 or a physiologically compatible salt thereof, in combination with a pharmacologically acceptable carrier or excipient, comprising mixing the compound according to claim 1 or the physiologically compatible salt thereof with the pharmacologically acceptable carrier or excipient, and converting the mixture into to a form suitable for administration.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/094,976 US20140088077A1 (en) | 2007-08-15 | 2013-12-03 | Novel substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07291010A EP2025674A1 (en) | 2007-08-15 | 2007-08-15 | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
EP07291010.2 | 2007-08-15 | ||
PCT/EP2008/006700 WO2009021740A2 (en) | 2007-08-15 | 2008-08-14 | Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments |
US12/705,140 US8609731B2 (en) | 2007-08-15 | 2010-02-12 | Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments |
US14/094,976 US20140088077A1 (en) | 2007-08-15 | 2013-12-03 | Novel substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/705,140 Division US8609731B2 (en) | 2007-08-15 | 2010-02-12 | Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140088077A1 true US20140088077A1 (en) | 2014-03-27 |
Family
ID=38823517
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/705,140 Expired - Fee Related US8609731B2 (en) | 2007-08-15 | 2010-02-12 | Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments |
US14/094,976 Abandoned US20140088077A1 (en) | 2007-08-15 | 2013-12-03 | Novel substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/705,140 Expired - Fee Related US8609731B2 (en) | 2007-08-15 | 2010-02-12 | Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments |
Country Status (26)
Country | Link |
---|---|
US (2) | US8609731B2 (en) |
EP (2) | EP2025674A1 (en) |
JP (1) | JP2010535827A (en) |
KR (1) | KR20100063700A (en) |
CN (1) | CN101784536A (en) |
AR (1) | AR068059A1 (en) |
AU (1) | AU2008286316A1 (en) |
BR (1) | BRPI0815206A2 (en) |
CA (1) | CA2695955A1 (en) |
CL (1) | CL2008002414A1 (en) |
CO (1) | CO6331303A2 (en) |
CR (1) | CR11235A (en) |
DO (1) | DOP2010000059A (en) |
EC (1) | ECSP109967A (en) |
MA (1) | MA31611B1 (en) |
MX (1) | MX2010001503A (en) |
NI (1) | NI201000024A (en) |
PA (1) | PA8793401A1 (en) |
PE (1) | PE20090986A1 (en) |
RU (1) | RU2010109416A (en) |
SV (1) | SV2010003480A (en) |
TN (1) | TN2010000075A1 (en) |
TW (1) | TW200930711A (en) |
UY (1) | UY31288A1 (en) |
WO (1) | WO2009021740A2 (en) |
ZA (1) | ZA201000520B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017172505A1 (en) * | 2016-03-29 | 2017-10-05 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110015225A1 (en) * | 2008-04-01 | 2011-01-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US8383647B2 (en) | 2009-01-30 | 2013-02-26 | Takeda Pharmaceutical Company Limited | Quinoline derivative |
AR075402A1 (en) | 2009-02-13 | 2011-03-30 | Sanofi Aventis | OXYGENATE AND / OR NITROGEN HETEROCICLIC DERIVATIVES OF TETRAHYDRONAFTALENE, DRUGS THAT CONTAIN THEM AND USE OF THE SAME IN THE TREATMENT OF METABOLIC DISORDERS, SUCH AS OBESITY, AMONG OTHERS. |
JP5711151B2 (en) * | 2010-01-06 | 2015-04-30 | 武田薬品工業株式会社 | Indole derivatives |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7524882B2 (en) * | 2002-07-30 | 2009-04-28 | Merck & Co., Inc. | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
Family Cites Families (970)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3371278D1 (en) | 1982-06-14 | 1987-06-11 | Merrill Edward Wilson | Process and apparatus for measuring blood viscosity directly and rapidly |
FR2713225B1 (en) | 1993-12-02 | 1996-03-01 | Sanofi Sa | Substituted N-piperidino-3-pyrazolecarboxamide. |
US7396814B2 (en) | 1995-06-07 | 2008-07-08 | Palatin Technologies, Inc. | Metallopeptide compositions for treatment of sexual dysfunction |
KR19990077319A (en) | 1996-01-17 | 1999-10-25 | 한센 핀 베네드, 안네 제헤르 | Condensed 1,2,4-thiadiazine and condensed 1,4-thiazine derivatives, processes for their preparation and their use |
DE122010000020I1 (en) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Method for lowering the blood glucose level in mammals |
UA72181C2 (en) | 1996-08-30 | 2005-02-15 | Ново Нордіск А/С | Derivatives of glucanolike peptide-1 |
JP4339402B2 (en) | 1996-12-31 | 2009-10-07 | ドクター・レディーズ・ラボラトリーズ・リミテッド | Novel heterocyclic compounds, processes for their preparation and pharmaceutical compositions containing them, and their use in the treatment of diabetes and related diseases |
DE19726167B4 (en) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, process for its preparation and pharmaceutical preparation containing it |
WO1999003861A1 (en) | 1997-07-16 | 1999-01-28 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
AU766219B2 (en) | 1998-02-02 | 2003-10-09 | 1149336 Ontario Inc. | Method of regulating glucose metabolism, and reagents related thereto |
EE200000504A (en) | 1998-03-12 | 2002-02-15 | Teijin Limited | Benzofuryl-a-pyrone derivatives, pharmaceutical composition, lipid metabolism enhancer, triglyceride biosynthesis inhibitor, blood triglyceride lowering agent, blood HDL elevating agent, prophylaxis of arteriosclerosis |
US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
FR2783246B1 (en) | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THE MEDICINES CONTAINING THEM |
DE19845405C2 (en) | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Aryl-substituted propanolamine derivatives and their use |
BR9915961A (en) | 1998-12-07 | 2001-08-21 | Sod Conseils Rech Applic | Glp-1 analogs |
AUPP891299A0 (en) | 1999-02-26 | 1999-03-25 | Fujisawa Pharmaceutical Co., Ltd. | New 6-membered cyclic compounds |
EP1173438A1 (en) | 1999-04-16 | 2002-01-23 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
AU3957600A (en) | 1999-04-26 | 2000-11-10 | Boehringer Ingelheim International Gmbh | Piperidyl-imidazole derivatives, their preparations and therapeutic uses |
NZ515087A (en) | 1999-04-28 | 2003-11-28 | Aventis Pharma Gmbh | Tri-aryl acid derivatives as PPAR receptor ligands |
EE200100556A (en) | 1999-04-28 | 2003-02-17 | Aventis Pharma Deutschland Gmbh | A diaryl acid derivative, a pharmaceutical composition containing it, and the use of the compound in the manufacture of a medicament |
EP1175421A1 (en) | 1999-04-30 | 2002-01-30 | Neurogen Corporation | 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS |
KR100718830B1 (en) | 1999-06-23 | 2007-05-17 | 사노피-아벤티스 도이칠란트 게엠베하 | Substituted benzimidazoles and a process for their production |
US7235625B2 (en) | 1999-06-29 | 2007-06-26 | Palatin Technologies, Inc. | Multiple agent therapy for sexual dysfunction |
EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
WO2001016094A1 (en) | 1999-09-01 | 2001-03-08 | Aventis Pharma Deutschland Gmbh | Sulfonyl carboxamide derivatives, method for their production and their use as medicaments |
EP1214060A2 (en) | 1999-09-10 | 2002-06-19 | Novo Nordisk A/S | Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48 |
WO2001019830A1 (en) | 1999-09-10 | 2001-03-22 | Novo Nordisk A/S | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
EP1214325B1 (en) | 1999-09-10 | 2005-11-09 | Novo Nordisk A/S | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
WO2001021577A2 (en) | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
DE19951360A1 (en) | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituted indoles |
FR2800375B1 (en) | 1999-11-03 | 2004-07-23 | Sanofi Synthelabo | TRICYCLIC DERIVATIVES OF PYRAZOLECARBOXYLIC ACID, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
PE20011010A1 (en) | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | OXAZOLES AND THIAZOLES REPLACED AS AGONIST OF THE RECEPTOR ACTIVATED BY THE HUMAN PEROXISOMAS PROLIFERATOR |
FR2805818B1 (en) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2805817B1 (en) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND THEIR PREPARATION |
CN1205188C (en) | 2000-03-23 | 2005-06-08 | 索尔瓦药物有限公司 | 4,5-dihydro-1h-pyrazole derivatives having cbi-antagonistic activity |
KR100502876B1 (en) | 2000-04-28 | 2005-07-21 | 아사히 가세이 파마 가부시키가이샤 | Novel Bicyclic Compounds |
US6838465B2 (en) | 2000-05-11 | 2005-01-04 | Banyu Pharmaceutical Co., Ltd. | N-acyltetrahydroisoquinoline derivatives |
SE0001899D0 (en) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
AU6497701A (en) | 2000-05-30 | 2001-12-11 | Merck & Co Inc | Melanocortin receptor agonists |
JP4611608B2 (en) | 2000-06-16 | 2011-01-12 | スミスクライン ビーチャム ピー エル シー | Piperidine for use as an orexin receptor antagonist |
WO2002002744A2 (en) | 2000-07-05 | 2002-01-10 | Synaptic Pharmaceutical Corporation | Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
AU783403B2 (en) | 2000-07-05 | 2005-10-20 | H. Lundbeck A/S | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
EA200300064A1 (en) | 2000-07-31 | 2003-06-26 | Смитклайн Бичем Пи-Эл-Си | CARBOXAMIDE CONNECTIONS AND THEIR APPLICATION AS ANTAGONISTS OF HUMAN 11CBY RECEPTOR |
DE60120748T2 (en) | 2000-11-10 | 2007-05-16 | Eli Lilly And Co., Indianapolis | 3-SUBSTITUTED OXINDOLE DERIVATIVES AS BETA-3 AGONISTS |
US20030022891A1 (en) | 2000-12-01 | 2003-01-30 | Anandan Palani | MCH antagonists and their use in the treatment of obesity |
HUP0401073A2 (en) | 2000-12-21 | 2004-09-28 | Aventis Pharma Deutschland Gmbh. | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
SK7822003A3 (en) | 2000-12-21 | 2003-12-02 | Aventis Pharma Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
BR0116411A (en) | 2000-12-21 | 2003-11-11 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
IL156552A0 (en) | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
PE20020856A1 (en) | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-TETRAHYDRONAFTIL ACILATED AMINES |
TWI291957B (en) | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
RU2281941C2 (en) | 2001-03-22 | 2006-08-20 | Солвей Фармасьютикалс Б.В. | Derivatives of 4,5-dihydro-1h-pyrazole possessing cb1-antagonistic activity |
EP1392298B1 (en) | 2001-05-04 | 2009-02-18 | Amgen Inc. | Fused heterocyclic compounds |
EP1258247A1 (en) | 2001-05-14 | 2002-11-20 | Aventis Pharma Deutschland GmbH | Adenosine analogues for the treatment of insulin resistance syndrome and diabetes |
GB0113233D0 (en) | 2001-05-31 | 2001-07-25 | Glaxo Group Ltd | Chemical compounds |
DE60236006D1 (en) | 2001-06-28 | 2010-05-27 | Alonim Holding Agricultural Co | METHOD FOR ANODIZING MAGNESIUM AND MAGNESIUM ALLOYS AND FOR PRODUCING CONDUCTIVE LAYERS ON AN ANODIZED SURFACE |
AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
US7732451B2 (en) | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
JP2005504043A (en) | 2001-08-10 | 2005-02-10 | パラチン テクノロジーズ インク. | Peptidomimetics of biologically active metal peptides |
RS50889B (en) | 2001-08-31 | 2010-08-31 | Sanofi-Aventis Deutschland Gmbh. | Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators |
CA2456606C (en) | 2001-09-21 | 2010-01-26 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
MXPA03009439A (en) | 2001-09-21 | 2004-02-12 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity. |
US7109216B2 (en) | 2001-09-21 | 2006-09-19 | Solvay Pharmaceuticals B.V. | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
US6509367B1 (en) | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
JP2005532982A (en) | 2001-09-24 | 2005-11-04 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | Production and use of pyrrole derivatives for the treatment of obesity |
AR036608A1 (en) | 2001-09-24 | 2004-09-22 | Bayer Corp | IMIDAZOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF OBESITY |
CA2464981A1 (en) | 2001-10-25 | 2003-05-01 | Takeda Chemical Industries, Ltd. | Quinoline compound |
WO2003043999A1 (en) | 2001-11-22 | 2003-05-30 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
AU2002353716A1 (en) | 2001-11-22 | 2003-06-10 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
BR0214342A (en) | 2001-11-22 | 2004-09-14 | Biovitrum Ab | 11 - Beta - Hydroxy Steroid Dehydrogenase Inhibitors Type 1 |
WO2003045313A2 (en) | 2001-11-27 | 2003-06-05 | Merck & Co. Inc. | 2-aminoquinoline compounds |
CA2474168A1 (en) | 2002-02-01 | 2003-08-14 | Merck & Co., Inc. | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
US20050124652A1 (en) | 2002-02-04 | 2005-06-09 | Rustum Boyce | Guanidino compounds |
KR20040095239A (en) | 2002-02-27 | 2004-11-12 | 화이자 프로덕츠 인코포레이티드 | Acc inhibitors |
AU2003215325B8 (en) | 2002-03-05 | 2008-10-09 | Eli Lilly And Company | Purine derivatives as kinase inhibitors |
HUP0200849A2 (en) | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetyl-pyrrolidine-2-carbonitrile derivatives, pharmaceutical compositions containing them and process for producing them |
FR2836915B1 (en) | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | AMINOINDAZOLE DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES THEREOF AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME |
WO2003087037A1 (en) | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Substituted aryl amides |
AU2003226928A1 (en) * | 2002-04-09 | 2003-10-27 | 7Tm Pharma A/S | Novel aminotetraline compounds for use in mch receptor related disorders |
WO2003087044A2 (en) | 2002-04-09 | 2003-10-23 | 7Tm Pharma A/S | Novel carboxamide compounds for use in mch receptor related disorders |
IL164249A0 (en) | 2002-04-11 | 2005-12-18 | Aventis Pharma Gmbh | Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use |
FR2838438A1 (en) | 2002-04-11 | 2003-10-17 | Sanofi Synthelabo | DIPHENYLPYRIDINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2838439B1 (en) | 2002-04-11 | 2005-05-20 | Sanofi Synthelabo | TERPHENYL DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US7667053B2 (en) | 2002-04-12 | 2010-02-23 | Merck & Co., Inc. | Bicyclic amides |
EP1505968A1 (en) | 2002-05-13 | 2005-02-16 | Eli Lilly And Company | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
AU2003234929A1 (en) | 2002-05-17 | 2003-12-02 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for diabetes |
TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
US7595311B2 (en) | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
AR040241A1 (en) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGRENASE 1 FOR THE TREATMENT OF DIABETES OBESITY AND DISLIPIDEMIA |
DE10226462A1 (en) | 2002-06-13 | 2003-12-24 | Aventis Pharma Gmbh | Fluorinated cycloalkyl-derivatized benzoylguanidines, process for their preparation, their use as medicament, and medicament containing them |
HUP0202001A2 (en) | 2002-06-14 | 2005-08-29 | Sanofi-Aventis | Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity |
DE10227507A1 (en) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Cationically substituted diphenylazetidinones, processes for their preparation, medicaments containing these compounds and their use |
DE10227508A1 (en) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Acid group-substituted diphenylazetidinones, processes for their preparation, pharmaceutical compositions containing them and their use |
DE10227506A1 (en) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Ring-substituted diphenylazetidinones, processes for their preparation, pharmaceutical compositions containing them and their use |
US20040002524A1 (en) | 2002-06-24 | 2004-01-01 | Richard Chesworth | Benzimidazole compounds and their use as estrogen agonists/antagonists |
EP1375508A1 (en) | 2002-06-27 | 2004-01-02 | Aventis Pharma Deutschland GmbH | N6-substituted adenosine analogues and their use as pharmaceutical agents |
AU2003248888A1 (en) | 2002-07-09 | 2004-01-23 | Palatin Technologies, Inc. | Peptide composition for treatment of sexual dysfunction |
DE10231370B4 (en) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophene glycoside derivatives, medicaments containing these compounds and methods of making these medicaments |
JP2006502247A (en) | 2002-07-12 | 2006-01-19 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Heterocycle-substituted benzoylureas, processes for their preparation and their use as medicaments |
KR20050025189A (en) | 2002-07-27 | 2005-03-11 | 아스트라제네카 아베 | Chemical compounds |
NZ537685A (en) | 2002-07-29 | 2007-06-29 | Hoffmann La Roche | Novel benzodioxoles |
AU2003250539A1 (en) | 2002-08-07 | 2004-02-25 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds |
DE10237723A1 (en) | 2002-08-17 | 2004-07-08 | Aventis Pharma Deutschland Gmbh | Use of IKappaB kinase inhibitors in pain therapy |
DE10237722A1 (en) | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indole or benzimidazole derivatives for the modulation of IKappaB kinase |
US20040242572A1 (en) * | 2002-08-24 | 2004-12-02 | Boehringer Ingelheim International Gmbh | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture |
DE10238865A1 (en) | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | New carboxamides are melanin-concentrating hormone receptor antagonists, useful for treating e.g. metabolic diseases, diabetes, eating disorders, cardiovascular disease, emotional disorders, reproductive and memory disorders |
AU2003278249B8 (en) | 2002-09-05 | 2010-11-18 | Aventis Pharma S.A. | Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same |
CA2498272A1 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Piperazine urea derivatives as melanocortin-4 receptor agonists |
EP1539746B1 (en) | 2002-09-12 | 2006-11-15 | F. Hoffmann-La Roche Ag | N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes |
AU2003275242B2 (en) | 2002-09-27 | 2010-03-04 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
US20050256159A1 (en) | 2002-10-11 | 2005-11-17 | Astrazeneca Ab | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors |
US20040077650A1 (en) | 2002-10-18 | 2004-04-22 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
JP4352001B2 (en) | 2002-10-18 | 2009-10-28 | メルク エンド カムパニー インコーポレーテッド | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
TW200504033A (en) | 2002-10-23 | 2005-02-01 | Procter & Gamble | Melanocortin receptor ligands |
EP1556040A1 (en) | 2002-10-24 | 2005-07-27 | Sterix Limited | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2 |
AU2003291342A1 (en) | 2002-11-05 | 2004-06-07 | Arena Pharmaceuticals, Inc. | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof |
US20060058315A1 (en) | 2002-11-07 | 2006-03-16 | Astrazeneca Ab | 2-Oxo-ethanesulfonamide derivates |
FR2847253B1 (en) | 2002-11-19 | 2007-05-18 | Aventis Pharma Sa | NOVEL DERIVATIVES OF PYRIDAZINONES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM |
MY134457A (en) | 2002-11-22 | 2007-12-31 | Merck & Co Inc | Substituted amides |
GB0227813D0 (en) | 2002-11-29 | 2003-01-08 | Astrazeneca Ab | Chemical compounds |
UY28103A1 (en) | 2002-12-03 | 2004-06-30 | Boehringer Ingelheim Pharma | NEW IMIDAZO-PIRIDINONAS REPLACED, ITS PREPARATION AND ITS EMPLOYMENT AS MEDICATIONS |
DE10258008B4 (en) | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclic fluoroglycoside derivatives, medicaments containing these compounds and methods of making these medicaments |
DE10258007B4 (en) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatic fluoroglycoside derivatives, medicaments containing these compounds and methods for the preparation of these medicaments |
EP1575901B1 (en) | 2002-12-19 | 2012-10-10 | Merck Sharp & Dohme Corp. | Substituted amides |
AU2003299791A1 (en) | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity |
JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Triazole Derivatives As Inhibitors Of 11-Beta -Hydroxysteriod Dehydrogenase-1 |
WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
FR2849032B1 (en) | 2002-12-23 | 2006-04-28 | Sanofi Synthelabo | 5- (4-BROMOPHENYL) -1- (2,4-DICHLOROPHENYL) -4-ETHYL-N - (PIPERIDIN-1-YL) -1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVE, ITS PREPARATION, ITS THERAPEUTIC APPLICATION |
GB0230088D0 (en) | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
GB0230087D0 (en) | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
DK1585739T3 (en) | 2003-01-06 | 2011-06-20 | Lilly Co Eli | Substituted arylcyclopropylacetamides as glucokinase activators |
EP1599468B1 (en) | 2003-01-14 | 2007-10-03 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
JP4621198B2 (en) | 2003-02-11 | 2011-01-26 | プロシディオン・リミテッド | Tri (cyclo) substituted amide glucokinase activating compound |
PL378117A1 (en) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tri(cyclo) substituted amide compounds |
BRPI0407387A (en) | 2003-02-13 | 2006-02-07 | Aventis Pharma Gmbh | Nitrogen-substituted hexahydropyrazine [1,2-a] pyrimidin-4,7-dione derivatives, processes for their preparation and their application with medicament |
RU2005128497A (en) | 2003-02-13 | 2006-01-27 | Санофи-Авентис Дойчленд Гмбх (De) | SUBSTITUTED DERIVATIVES OF HEXAHYDROPYRAZINO (1,2-A) PYRIMIDIN-4,7-DION, METHODS FOR THEIR PRODUCTION AND THEIR APPLICATION AS MEDICINES |
KR100728425B1 (en) | 2003-02-19 | 2007-06-13 | 에프. 호프만-라 로슈 아게 | Sulfonamide substituted xanthine derivatives for use as pepck inhibitors |
WO2004078717A1 (en) | 2003-03-03 | 2004-09-16 | Merck & Co., Inc. | Acylated piperazine derivatives as melanocortin-4 receptor agonists |
EP1460069A1 (en) | 2003-03-20 | 2004-09-22 | MyoContract Ltd. | Substituted cyclohexyl and piperidinyl derivatives as melanocortin-4 receptor modulators |
EP1460075A1 (en) | 2003-03-21 | 2004-09-22 | Sanofi-Synthelabo | Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives |
JP4637089B2 (en) | 2003-03-26 | 2011-02-23 | アクテリオン ファーマシューティカルズ リミテッド | Acetamide derivatives |
CN1764458A (en) | 2003-03-26 | 2006-04-26 | 麦克公司 | Bicyclic piperidine derivatives as the melanocortin-4 receptor agonist |
DE10314610A1 (en) | 2003-04-01 | 2004-11-04 | Aventis Pharma Deutschland Gmbh | New diphenylazetidinone with improved physiological properties, process for its preparation, medicaments containing these compounds and its use |
EP1615647B1 (en) | 2003-04-11 | 2010-01-20 | High Point Pharmaceuticals, LLC | Pharmaceutical use of fused 1,2,4-triazoles |
CA2521832A1 (en) | 2003-04-11 | 2004-10-28 | Smithkline Beecham Corporation | Heterocyclic mchr1 antagonists |
EP1615698B1 (en) | 2003-04-11 | 2010-09-29 | High Point Pharmaceuticals, LLC | New amide derivatives and pharmaceutical use thereof |
EP1615637A1 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | Pharmaceutical use of substituted 1,2,4-triazoles |
WO2004089471A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US20040214856A1 (en) | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
CN100472485C (en) | 2003-04-25 | 2009-03-25 | 松下电器产业株式会社 | Multi-medium information sharing system |
US7049323B2 (en) | 2003-04-25 | 2006-05-23 | Bristol-Myers Squibb Company | Amidoheterocycles as modulators of the melanocortin-4 receptor |
JP2006525298A (en) | 2003-05-01 | 2006-11-09 | ヴァーナリス リサーチ リミテッド | Azetidine carboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders |
KR20060017763A (en) | 2003-05-01 | 2006-02-27 | 베르날리스 리서치 리미티드 | The use of azetidinecarboxamide derivatives in therapy |
US20070173486A1 (en) | 2003-05-01 | 2007-07-26 | Vernalis Research Limited | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs |
WO2004099157A1 (en) | 2003-05-07 | 2004-11-18 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
AU2004238240A1 (en) | 2003-05-09 | 2004-11-25 | Merck & Co., Inc. | Benzimidazoles, compositions containing such compounds and methods of use |
US7067529B2 (en) | 2003-05-19 | 2006-06-27 | Hoffmann-La Roche Inc. | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors |
EP1631558A1 (en) | 2003-05-21 | 2006-03-08 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i |
AU2004249120B2 (en) | 2003-05-23 | 2008-07-24 | Glaxosmithkline | Guanidino-substituted quinazolinone compounds as MC4-R agonists |
EP1638947B1 (en) | 2003-05-29 | 2010-08-04 | Merck Sharp & Dohme Corp. | Triazole derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase-1 |
WO2004106343A2 (en) | 2003-05-30 | 2004-12-09 | Ufc Limited | Agelastatin derivatives of antitumour and gsk-3beta-inhibiting alkaloids |
JP2004359630A (en) | 2003-06-06 | 2004-12-24 | Yamanouchi Pharmaceut Co Ltd | Difluorodiphenylmethane derivative and its salt |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
RU2006100298A (en) | 2003-06-11 | 2006-05-10 | Мерк энд Ко., Инк. (US) | SUBSTITUTED 3-ALKYL-AND 3-ALKENYLASETIDINE DERIVATIVES |
ATE406365T1 (en) | 2003-06-13 | 2008-09-15 | Janssen Pharmaceutica Nv | SUBSTITUTED INDAZOLYL(INDOLYL)MALEIMIDE DERIVATIVES AS KINASE INHIBITORS |
US20040259887A1 (en) | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
GB0314049D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314057D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
US20060135523A1 (en) | 2003-06-18 | 2006-06-22 | Astrazeneca Ab | 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator |
GB0314261D0 (en) | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
AU2004251616A1 (en) | 2003-06-19 | 2005-01-06 | Eli Lilly And Company | Melanocortin receptor 4(MC4) agonists and their uses |
CA2528785A1 (en) | 2003-06-20 | 2005-01-06 | Matthias Heinrich Nettekoven | 2-amidobenzothiazoles as cb1 receptor inverse agonists |
SE0301882D0 (en) | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use I |
SE0301886D0 (en) | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use V |
WO2004113310A1 (en) | 2003-06-25 | 2004-12-29 | Biovitrum Ab | Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing |
SE0301888D0 (en) | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use VII |
FR2856683A1 (en) | 2003-06-25 | 2004-12-31 | Sanofi Synthelabo | 4-CYANOPYRAZOLE-3-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
WO2005000974A2 (en) | 2003-06-27 | 2005-01-06 | Day-Glo Color Corp. | Water-based spray marking composition |
CN100555588C (en) | 2003-06-27 | 2009-10-28 | 日本电气株式会社 | The manufacture method of thin-film transistor, thin film transistor base plate, electronic equipment and polycrystalline semiconductor thin film |
JP2005015434A (en) | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | Serum cholesterol-lowering agent or prophylactic or therapeutic agent for atherosclerosis |
PL379516A1 (en) | 2003-07-09 | 2006-10-02 | Forbes Medi-Tech Inc. | Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions |
WO2005005477A2 (en) | 2003-07-11 | 2005-01-20 | Novo Nordisk A/S | Stabilised insulin compositions |
EP1644370A4 (en) | 2003-07-11 | 2008-06-04 | Bristol Myers Squibb Co | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
FR2857570A1 (en) | 2003-07-18 | 2005-01-21 | Didier Leandri | Device for suspending stemmed glasses around drinks bucket comprises clamp hooked on bucket upper edge and bracket with suspension head connected to clamp lower end enables hooking of upturned stemmed glass |
CA2532808A1 (en) | 2003-07-22 | 2005-02-03 | Merck & Co., Inc. | Piperidine derivatives as melanocortin-4 receptor agonists |
DE10333935A1 (en) | 2003-07-25 | 2005-02-24 | Aventis Pharma Deutschland Gmbh | New bicyclic cyano-heterocycles, process for their preparation and their use as pharmaceuticals |
PE20050249A1 (en) | 2003-07-25 | 2005-06-01 | Aventis Pharma Gmbh | NEW CYANOPYRROLIDES AND PROCEDURE FOR THEIR PREPARATION AS MEDICINES |
DE10334309A1 (en) | 2003-07-28 | 2005-03-03 | Aventis Pharma Deutschland Gmbh | Substituted thiazole-Benzoisothiazoldioxidderivate, processes for their preparation and their use |
US20050026984A1 (en) | 2003-07-29 | 2005-02-03 | Aventis Pharma S.A. | Substituted thieno [2,3-c] pyrazoles and their use as medicinal products |
US7008953B2 (en) | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
CA2534221A1 (en) | 2003-08-07 | 2005-02-24 | Merck & Co., Inc. | Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
WO2005021495A2 (en) | 2003-08-25 | 2005-03-10 | Microbia Inc. | Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones |
EP1660446A2 (en) | 2003-08-28 | 2006-05-31 | Microbia, Inc. | Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones |
CN1956949A (en) | 2003-09-18 | 2007-05-02 | 默克公司 | Substituted sulfonamides |
EP2932981B1 (en) | 2003-09-19 | 2021-06-16 | Novo Nordisk A/S | Albumin-binding derivatives of GLP-1 |
AR045651A1 (en) | 2003-09-19 | 2005-11-02 | Solvay Pharm Bv | THIAZOL DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS |
CA2539596A1 (en) | 2003-09-30 | 2005-04-07 | Kilian Waldemar Conde-Frieboes | Melanocortin receptor agonists |
US20060247239A1 (en) | 2003-10-01 | 2006-11-02 | Hu Xiufeng E | Melanin concentrating hormone antagonists |
MXPA06003654A (en) * | 2003-10-01 | 2006-06-05 | Procter & Gamble | Melanin concentrating hormone antagonists. |
EP1522541A1 (en) | 2003-10-07 | 2005-04-13 | Lipideon Biotechnology AG | Novel hypocholesterolemic compounds |
TW200519105A (en) | 2003-10-20 | 2005-06-16 | Lg Life Science Ltd | Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
WO2005042516A2 (en) | 2003-10-22 | 2005-05-12 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
US20050192286A1 (en) | 2003-10-22 | 2005-09-01 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
CN1870988A (en) | 2003-10-30 | 2006-11-29 | 默克公司 | 2-azetidinones as anti-hypercholesterolemic agents |
WO2005042692A2 (en) | 2003-10-31 | 2005-05-12 | Forbes Medi-Tech Inc. | A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors |
GB0325402D0 (en) | 2003-10-31 | 2003-12-03 | Astrazeneca Ab | Compounds |
BRPI0416287A (en) | 2003-11-07 | 2007-01-23 | Hoffmann La Roche | compounds, process for the manufacture thereof, pharmaceutical compositions comprising them, method for the treatment and / or prevention of diseases that are modulated by accß inhibitors and their use |
WO2005047293A1 (en) | 2003-11-07 | 2005-05-26 | Neurocrine Biosciences, Inc. | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto |
WO2005047248A1 (en) | 2003-11-10 | 2005-05-26 | Microbia, Inc. | 4-biarylyl-1-phenylazetidin-2-ones |
WO2005047251A1 (en) | 2003-11-12 | 2005-05-26 | Lg Life Sciences Ltd. | Melanocortin receptor agonists |
KR20050045927A (en) | 2003-11-12 | 2005-05-17 | 주식회사 엘지생명과학 | Melanocortin receptor agonists |
EP1686996A4 (en) | 2003-11-19 | 2008-11-12 | Novartis Vaccines & Diagnostic | Quinazolinone compounds with reduced bioaccumulation |
JP4922615B2 (en) | 2003-11-26 | 2012-04-25 | 武田薬品工業株式会社 | Receptor function regulator |
EP1538159A1 (en) | 2003-12-05 | 2005-06-08 | Santhera Pharmaceuticals (Schweiz) GmbH | Substituted N-benzyl-lactam derivatives as melanocortin-4 receptor agonists |
WO2005060985A1 (en) | 2003-12-10 | 2005-07-07 | Merck & Co., Inc. | Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists |
DE10359098A1 (en) | 2003-12-17 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel 2- (piperazin-1-yl) and 2 - ([1,4] diazepan-1-yl) imidazo [4,5-d] pyridazin-4-ones, their preparation and their use as pharmaceuticals |
TW200528455A (en) | 2003-12-19 | 2005-09-01 | Bristol Myers Squibb Co | Azabicyclic heterocycles as cannabinoid receptor modulators |
AU2004312001B2 (en) | 2003-12-19 | 2009-08-27 | Merck & Co., Inc. | Cyclic guanidines, compositions containing such compounds and methods of use |
EP1557417B1 (en) | 2003-12-19 | 2007-03-07 | Sanofi-Aventis | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives |
BRPI0417820A (en) | 2003-12-19 | 2007-03-27 | Bristol Myers Squibb Co | azabicyclic heterocycles as cannabinoid receptor modulators |
RU2006126122A (en) | 2003-12-19 | 2008-01-27 | Бристол-Маерс Сквибб Компани (Us) | ASABICYCLIC HETEROCYCLES AS MODULATORS OF A CANNABIOID RECEPTOR |
WO2005063247A1 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Aryl sulfonamide compounds and uses related thereto |
GB0329778D0 (en) | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
ATE485267T1 (en) | 2003-12-23 | 2010-11-15 | Astrazeneca Ab | DIPHENYLAZETIDINONE DERIVATIVES WITH CHOLESTERINE ABSORPTION INHIBITING EFFECT |
AU2004308332B2 (en) | 2003-12-23 | 2008-04-10 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
CA2549955A1 (en) | 2003-12-24 | 2005-07-07 | Prosidion Limited | Heterocyclic derivatives as gpcr receptor agonists |
MXPA06007715A (en) | 2004-01-06 | 2007-01-26 | Johnson & Johnson | (3-oxo-3, 4-dihydro-quinoxalin-2-yl-amino) -benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity. |
BRPI0507120A (en) | 2004-01-28 | 2007-06-19 | Hoffmann La Roche | compounds, process for the manufacture thereof, pharmaceutical compositions comprising them, method for treating and / or prophylaxis of diseases that are associated with cb1 receptor modulation and their use |
DE502005007840D1 (en) | 2004-01-31 | 2009-09-17 | Sanofi Aventis Deutschland | 7-PHENYLAMINO-4-CHINOLONE-3-CARBOXYLIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS |
WO2005080361A1 (en) | 2004-02-02 | 2005-09-01 | Pfizer Products Inc. | Histamine-3 receptor modulators |
DE102004005172A1 (en) | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazole derivatives as inhibitors of the hormone sensitive lipase |
HUP0400405A3 (en) | 2004-02-10 | 2009-03-30 | Sanofi Synthelabo | Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
DE102004006325A1 (en) | 2004-02-10 | 2005-08-25 | Bayer Healthcare Ag | New benzazepine derivatives useful for treating or preventing dyslipidemia, arteriosclerosis, restenosis and ischemia |
FR2866340B1 (en) | 2004-02-13 | 2006-11-24 | Sanofi Synthelabo | OXAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS. |
KR20060124756A (en) | 2004-02-17 | 2006-12-05 | 라보라토리오스 델 드라. 에스테브.에스.에이. | Substituted azetidine compounds, their preparation and use as medicaments |
CA2554686A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Compounds |
PT1725536E (en) | 2004-02-19 | 2009-01-22 | Solvay Pharm Bv | Imidazoline derivatives having cb1-antagonistic activity |
ATE440085T1 (en) | 2004-02-20 | 2009-09-15 | Astrazeneca Ab | 3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES SUITABLE AS CB1 MODULATORS |
GB0403780D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Therapeutic agents |
US20070244041A1 (en) | 2004-02-23 | 2007-10-18 | Reoscience A/S | Peptide Yy Analogues |
WO2005082893A2 (en) | 2004-02-25 | 2005-09-09 | Eli Lilly And Company | Histamine h3 receptor antagonists, preparation and therapeutic uses |
DE102004010194A1 (en) | 2004-03-02 | 2005-10-13 | Aventis Pharma Deutschland Gmbh | 4-Benzimidazol-2-yl-pyridazin-3-one derivatives, their preparation and use in medicaments |
BRPI0508259A (en) | 2004-03-04 | 2007-07-31 | Kissei Pharmaceutical | fused heterocyclic derivative, medicinal composition containing same, and medicinal use thereof |
JP2007527918A (en) | 2004-03-08 | 2007-10-04 | アムジェン インコーポレイテッド | Therapeutic modulation of PPAR gamma activity |
US7504400B2 (en) | 2004-03-10 | 2009-03-17 | Janssen Pharmaceutica N.V. | MTP inhibiting aryl piperydines or piperazines substituted with 5-membered heterocycles |
DE102004012068A1 (en) | 2004-03-12 | 2005-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New alkyl-containing 5-acylindolinones, their preparation and their use as pharmaceuticals |
JP2007530690A (en) | 2004-03-29 | 2007-11-01 | メルク エンド カムパニー インコーポレーテッド | Diaryltriazoles as inhibitors of 11-β-hydroxysteroid dehydrogenase-1 |
US7608627B2 (en) | 2004-04-05 | 2009-10-27 | Takeda Pharmaceutical Company Limited | 6-azaindole compound |
EP1586318A1 (en) | 2004-04-05 | 2005-10-19 | Neuropharma S.A.U. | Thiadiazolidinones as GSK-3 inhibitors |
EP1736467A4 (en) | 2004-04-06 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Novel sulfonamide derivative |
EP1734930A2 (en) | 2004-04-09 | 2006-12-27 | Smithkline Beecham Corporation | Low dose pharmaceutical products |
WO2005103039A1 (en) | 2004-04-15 | 2005-11-03 | Neurocrine Biosciences, Inc. | 2- (3-aminopyrrolidin-1-yl) pyridines as melanin-concentrating hormone receptor an tagonists |
JPWO2005108370A1 (en) | 2004-04-16 | 2008-03-21 | 味の素株式会社 | Benzene compounds |
BRPI0511029A (en) | 2004-05-12 | 2007-11-27 | Aventis Pharma Inc | 2 - {[2- (2-Methyl-amino-pyrimidin-4-yl) -1h-indol-5-carbonyl] -amino} -3- (phenyl pyridin-2-yl-amino) -propionic acid as substantially pure a kappa kinase inhibitor |
EP1604988A1 (en) | 2004-05-18 | 2005-12-14 | Sanofi-Aventis Deutschland GmbH | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals |
WO2005118573A1 (en) | 2004-05-28 | 2005-12-15 | Smithkline Beecham Corporation | Novel diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors |
DE102004026532A1 (en) | 2004-05-29 | 2006-01-05 | Sanofi-Aventis Deutschland Gmbh | Substituted Oxazole Benzoisothiazoldioxidderivate, process for their preparation and their use |
DE102004028241B4 (en) | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | New fluoroglycoside derivatives of pyrazoles, medicines containing these compounds and manufacture of these medicines |
FR2871463B1 (en) | 2004-06-11 | 2006-09-22 | Merck Sante Soc Par Actions Si | AROYL-O-PIPERIDINE-STRUCTURED DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THERAPEUTIC APPLICATIONS THEREOF |
CA2570694A1 (en) | 2004-06-24 | 2006-02-02 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
WO2006012173A1 (en) | 2004-06-24 | 2006-02-02 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
WO2006012093A1 (en) | 2004-06-24 | 2006-02-02 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
WO2006001318A1 (en) | 2004-06-24 | 2006-01-05 | Shionogi & Co., Ltd. | Sulfonamide compound |
WO2006017257A2 (en) | 2004-07-12 | 2006-02-16 | Phenomix Corporation | Azetidinone derivatives |
DE102004034697A1 (en) | 2004-07-17 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Salicylthiazoles substituted with diphenylamine or diphenylamine derivatives, process for their preparation and their use |
FR2873368B1 (en) | 2004-07-26 | 2008-01-04 | Merck Sante Soc Par Actions Si | GUANIDINE DERIVATIVES AND THEIR USES IN THERAPEUTICS |
FR2873694B1 (en) | 2004-07-27 | 2006-12-08 | Merck Sante Soc Par Actions Si | NEW AZA-INDOLES INHIBITORS OF MTP AND APOB |
WO2006010546A2 (en) | 2004-07-28 | 2006-02-02 | F. Hoffman-La Roche Ag | Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors |
FR2873693B1 (en) | 2004-07-29 | 2006-09-15 | Sanofi Synthelabo | AMINO-TROPANE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
FR2873690B1 (en) | 2004-07-29 | 2006-10-13 | Sanofi Synthelabo | OXOPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
DE102004037554A1 (en) | 2004-08-03 | 2006-03-16 | Sanofi-Aventis Deutschland Gmbh | Substituted 8-aminoalkylthio-xanthines, process for their preparation and their use as medicaments |
DE102004038268A1 (en) | 2004-08-06 | 2006-03-16 | Sanofi-Aventis Deutschland Gmbh | Substituted, bicyclic 8-pyrrolidino-xanthines, process for their preparation and their use as medicaments |
DE102004038270A1 (en) | 2004-08-06 | 2006-03-16 | Sanofi-Aventis Deutschland Gmbh | Substituted bicyclic 8-amino-xanthines, process for their preparation and their use as medicaments |
WO2006017542A1 (en) | 2004-08-06 | 2006-02-16 | Merck & Co., Inc. | Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
DE102004038269A1 (en) | 2004-08-06 | 2006-03-16 | Sanofi-Aventis Deutschland Gmbh | Substituted bicyclic 8-piperidino-xanthines, process for their preparation and their use as pharmaceuticals |
WO2006018150A1 (en) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituited cyclene, medicaments containing said compounds, use thereof and method for the production thereof |
JP2008509898A (en) | 2004-08-12 | 2008-04-03 | プロシディオン・リミテッド | Substituted phenylacetamides and their use as glucokinase activators |
DE102004039507A1 (en) | 2004-08-14 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Substituted 8-aminoalkoxi-xanthines, process for their preparation and their use as medicaments |
JP2008509982A (en) | 2004-08-16 | 2008-04-03 | プロシディオン・リミテッド | Aryl urea derivatives |
JP2008510018A (en) | 2004-08-18 | 2008-04-03 | メタバシス・セラピューティクス・インコーポレイテッド | Novel thiazole inhibitor of fructose-1,6-bisphosphatase |
UA87328C2 (en) | 2004-08-30 | 2009-07-10 | Янссен Фармацевтика Н.В. | N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
AU2005284485A1 (en) | 2004-09-11 | 2006-03-23 | Sanofi-Aventis Deutschland Gmbh | 7-azaindoles and their use as PPAR agonists |
PT1797042E (en) | 2004-09-29 | 2009-02-12 | Hoffmann La Roche | Indozolone derivatives as 11b-hsd1 inhibitors |
MX2007003785A (en) | 2004-09-29 | 2007-07-12 | Kissei Pharmaceutical | 1-( ??-d-glycopyranosyl)-3-substituted nitrogenous heterocyclic compound, medicinal composition containing the same, and medicinal use thereof. |
AU2005292134B2 (en) | 2004-10-01 | 2010-12-23 | Merck Sharp & Dohme Corp. | Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
EP1799710A2 (en) | 2004-10-07 | 2007-06-27 | Novo Nordisk A/S | Protracted glp-1 compounds |
US8030273B2 (en) | 2004-10-07 | 2011-10-04 | Novo Nordisk A/S | Protracted exendin-4 compounds |
US8138342B2 (en) | 2004-10-12 | 2012-03-20 | High Point Pharmacueticals, LLC | 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds |
CN101076524A (en) | 2004-10-12 | 2007-11-21 | 法马科皮亚药物研发公司 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders |
JP2006111553A (en) | 2004-10-13 | 2006-04-27 | Dainippon Sumitomo Pharma Co Ltd | Sulfonyloxyindole derivative and medicinal composition containing the same |
WO2006045564A1 (en) | 2004-10-22 | 2006-05-04 | Smithkline Beecham Corporation | Xanthine derivatives with hm74a receptor activity |
WO2006045565A1 (en) | 2004-10-22 | 2006-05-04 | Smithkline Beecham Corporation | Xanthine derivatives with hm74a receptor activity |
AR051596A1 (en) | 2004-10-26 | 2007-01-24 | Irm Llc | CONDENSED HETEROCICLIC COMPOUNDS NITROGENATED AS INHIBITORS OF THE ACTIVITY OF THE CANABINOID RECEIVER 1; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF FOOD DISORDERS |
PL1807072T3 (en) | 2004-10-29 | 2009-06-30 | Lilly Co Eli | Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
US20090093463A1 (en) | 2004-11-02 | 2009-04-09 | Agouron Pharmaceuticals Inc. | Novel compounds of substituted and unsubtituted adamantyl amides |
JP2006131559A (en) | 2004-11-05 | 2006-05-25 | Takeda Chem Ind Ltd | Nitrogen-containing heterocyclic compound |
EP1666467A1 (en) | 2004-11-08 | 2006-06-07 | Evotec AG | 11Beta-HSD1 Inhibitors |
EP1659113A1 (en) | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
WO2006051662A1 (en) | 2004-11-09 | 2006-05-18 | Taisho Pharmaceutical Co., Ltd. | Thiazole derivative |
JP2006160733A (en) | 2004-11-15 | 2006-06-22 | Taisho Pharmaceut Co Ltd | Medicine containing cyanofluoropyrrolidine derivative as active ingredient |
AU2005309606B2 (en) | 2004-11-29 | 2011-01-06 | Merck Sharp & Dohme Corp. | Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
WO2007024993A2 (en) | 2005-08-26 | 2007-03-01 | Merck & Co., Inc. | Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2006059744A1 (en) | 2004-11-30 | 2006-06-08 | Nippon Chemiphar Co., Ltd. | ACTIVATOR OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR δ |
AU2005311930B9 (en) | 2004-12-03 | 2009-09-10 | Merck Sharp & Dohme Corp. | Substituted piperazines as CB1 antagonists |
JP2008521864A (en) | 2004-12-03 | 2008-06-26 | トランステック・ファーマ、インコーポレイテッド | Heteroaromatic glucokinase activator |
DE102004058449A1 (en) | 2004-12-03 | 2006-06-14 | Merck Patent Gmbh | tetrahydropyran |
JP2008007405A (en) | 2004-12-07 | 2008-01-17 | Takeda Chem Ind Ltd | Carboxamide derivative |
WO2006065826A2 (en) | 2004-12-15 | 2006-06-22 | Merck & Co., Inc. | Process to chiral beta amino acid derivatives by asymmetric hydrogenation |
DE102004060542A1 (en) | 2004-12-16 | 2006-07-06 | Sanofi-Aventis Deutschland Gmbh | Hydroxybiphenyl carboxylic acids and derivatives, process for their preparation and their use |
EP1888544A2 (en) | 2004-12-17 | 2008-02-20 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
JP2008524137A (en) | 2004-12-18 | 2008-07-10 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | (5S) -3-[(S) -Fluoro (4-trifluoromethylphenyl) methyl-5,6,7,8-tetrahydroquinolin-5-ol derivatives and their use as CETP inhibitors |
WO2006067224A2 (en) | 2004-12-23 | 2006-06-29 | Biovitrum Ab (Publ) | Spiro-benzodioxole and spiro-benzodioxane compounds as orexin receptor antagonists |
US20080146614A1 (en) | 2004-12-23 | 2008-06-19 | Leifeng Cheng | Therapeutic Agents |
PE20060949A1 (en) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | FUSED DERIVATIVES OF PIRAZOLE AS NIACIN RECEPTOR AGONISTS |
JP2008525401A (en) | 2004-12-23 | 2008-07-17 | アストラゼネカ アクチボラグ | Remedy |
JP4980928B2 (en) | 2004-12-24 | 2012-07-18 | プロシディオン・リミテッド | G protein-coupled receptor (GPR116) agonist and use thereof for the treatment of obesity and diabetes |
BRPI0518651A2 (en) | 2004-12-24 | 2008-12-02 | Dainippon Sumitomo Pharma | compound, a prodrug thereof, or a pharmaceutically acceptable compound or prodrug salt, pharmaceutical composition, dipeptidyl peptidase iv inhibitor, use of a compound, a prodrug thereof or a compound or prodrug salt pharmaceutically acceptable method of treating diabetes |
EP1838706A1 (en) | 2004-12-24 | 2007-10-03 | Prosidion Limited | G-protein coupled receptor agonists |
US7635699B2 (en) | 2004-12-29 | 2009-12-22 | Bristol-Myers Squibb Company | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
EP1848430B1 (en) | 2004-12-31 | 2017-08-02 | Dr. Reddy's Laboratories Ltd. | Novel benzylamine derivatives as cetp inhibitors |
DE102005000666B3 (en) | 2005-01-04 | 2006-10-05 | Sanofi-Aventis Deutschland Gmbh | Sulfonylpyrrolidines, process for their preparation and their use as pharmaceuticals |
AU2006204017B2 (en) | 2005-01-05 | 2011-10-06 | Abbvie Inc. | Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
WO2006073167A1 (en) | 2005-01-07 | 2006-07-13 | Ono Pharmaceutical Co., Ltd. | Pyrrolidine derivatives |
DE102005001053A1 (en) | 2005-01-07 | 2006-07-20 | Merck Patent Gmbh | Square acid derivatives |
TW200637839A (en) | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
DE102005002130A1 (en) | 2005-01-17 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | New substituted aminomethylene sulfonamides useful as hormone sensitive lipase inhibitors in medicaments for treatment and/or prevention of non-insulin dependent diabetes mellitus, diabetic syndrome or obesity |
EP1841770B1 (en) | 2005-01-19 | 2009-11-11 | Merck & Co., Inc. | Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
JP2008100916A (en) | 2005-01-24 | 2008-05-01 | Dainippon Sumitomo Pharma Co Ltd | Indoles and pharmaceutical formulation containing the same |
AR053329A1 (en) | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | INDOL DERIVATIVES USEFUL AS INHIBITORS OF GLUCOSE CONVEYORS DEPENDENT ON SODIUM (SGLT) |
US7750032B2 (en) | 2005-02-03 | 2010-07-06 | Irm Llc | Compounds and compositions as PPAR modulators |
US20090156582A1 (en) | 2005-02-09 | 2009-06-18 | Tetsuya Tsukamoto | Pyrazole Compound |
US20090005321A1 (en) | 2005-02-09 | 2009-01-01 | Microbia, Inc. | Phenylazetidinone Derivatives |
PL1856090T3 (en) | 2005-02-11 | 2010-02-26 | Lilly Co Eli | Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses |
GB0503053D0 (en) | 2005-02-14 | 2005-03-23 | Smithkline Beecham Corp | Chemical compounds |
US20080221108A1 (en) | 2005-02-14 | 2008-09-11 | Richard Hatley | Anthranilic Acid Derivatives As Hm74A Receptor Agonists |
GB0503056D0 (en) | 2005-02-14 | 2005-03-23 | Smithkline Beecham Corp | Chemical compounds |
CA2597269A1 (en) | 2005-02-15 | 2006-08-24 | Kissei Pharmaceutical Co., Ltd. | 1-substituted-7-(beta-d-glycopyranosyloxy)(aza)indole compound and pharmaceutical containing the same |
KR20070107000A (en) | 2005-02-15 | 2007-11-06 | 노보 노르디스크 에이/에스 | 3,4-dihydro-1h-isoquinoline-2-carboxylic acid 5-aminopyridin-2-yl esters |
FR2882054B1 (en) | 2005-02-17 | 2007-04-13 | Sanofi Aventis Sa | 1,5-DIARYLPYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
FR2882365B1 (en) | 2005-02-21 | 2007-09-07 | Sanofi Aventis Sa | 2- (1,5-DIPHENYL-1H-PYRAZOL-3-YL) -1,3,4-OXADIAZOLE DERIVATIVES AND THEIR PREPARATION AND THERAPEUTIC USE |
ZA200708144B (en) | 2005-02-25 | 2008-11-26 | Takeda Pharmaceutical | Pyridyl acetic acid compounds |
GB0504857D0 (en) | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
CN101137660B (en) | 2005-03-09 | 2011-06-15 | 霍夫曼-拉罗奇有限公司 | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives as antidiabetic compounds |
WO2006096847A1 (en) | 2005-03-09 | 2006-09-14 | The Board Of Trustees Of The Leland Stanford Junior University | Obestatin and its uses |
FR2883000B1 (en) | 2005-03-14 | 2007-06-01 | Merck Sante Soc Par Actions Si | TRIFLUOROMETHYLBENZAMIDE DERIVATIVES AND THEIR USES IN THERAPEUTICS |
DE102005012873B4 (en) | 2005-03-19 | 2007-05-03 | Sanofi-Aventis Deutschland Gmbh | Aminocarbonyl-substituted 8-N-benzimidazoles, process for their preparation and their use as pharmaceuticals |
DE102005012874A1 (en) | 2005-03-19 | 2006-09-21 | Sanofi-Aventis Deutschland Gmbh | Amide-substituted 8-N-benzimidazoles, process for their preparation and their use as pharmaceuticals |
TW200700387A (en) | 2005-03-21 | 2007-01-01 | Akzo Nobel Nv | 1-benzylindole-2-carboxamide derivatives |
WO2006102674A2 (en) | 2005-03-24 | 2006-09-28 | Microbia, Inc. | Diphenylheterocycle cholesterol absorption inhibitors |
WO2006104030A1 (en) | 2005-03-25 | 2006-10-05 | Daiichi Sankyo Company, Limited | Thiazole compound |
TWI357902B (en) | 2005-04-01 | 2012-02-11 | Lg Life Science Ltd | Dipeptidyl peptidase-iv inhibiting compounds, meth |
CA2602234C (en) | 2005-04-01 | 2014-01-14 | Eli Lilly And Company | Histamine h3 receptor agents, preparation and therapeutic uses |
DK1868999T3 (en) | 2005-04-06 | 2009-08-17 | Hoffmann La Roche | Pyridine-3-carboxamide derivatives as reverse CB1 agonists |
WO2006106423A2 (en) | 2005-04-07 | 2006-10-12 | Pfizer Inc. | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase |
WO2006113150A1 (en) | 2005-04-13 | 2006-10-26 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
WO2006108842A1 (en) | 2005-04-15 | 2006-10-19 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors |
DE102005017605B4 (en) | 2005-04-16 | 2007-03-15 | Sanofi-Aventis Deutschland Gmbh | Substituted 2-aminoalkylthio-benzimidazoles, process for their preparation and their use as medicaments |
CA2606288A1 (en) | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
SG164371A1 (en) | 2005-04-19 | 2010-09-29 | Surface Logix Inc | Inhibitors of microsomal triglyceride transfer protein and apo-b secretion |
EP2308839B1 (en) | 2005-04-20 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
DE102005018389A1 (en) | 2005-04-20 | 2006-10-26 | Sanofi-Aventis Deutschland Gmbh | Azole derivatives as inhibitors of lipases and phospholipases |
CA2605479A1 (en) | 2005-04-20 | 2006-10-26 | Pfizer Products Inc. | Acylaminobicyclic heteroaromatic compounds and uses thereof |
JP2008539255A (en) | 2005-04-26 | 2008-11-13 | マイクロビア インコーポレーテッド | 4-Bialyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia |
EP1877373A2 (en) | 2005-05-05 | 2008-01-16 | Microbia, Inc. | Biphenylazetidinone cholesterol absorption inhibitors |
WO2006121860A2 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use |
FR2885627B3 (en) | 2005-05-10 | 2007-06-22 | Espace Production Internationa | METHOD FOR MANUFACTURING SOIL COATING BLADES AND BLADES THEREOF, DECORATED SHEET FOR FLOOR COVERING PANELS |
WO2006122186A2 (en) | 2005-05-10 | 2006-11-16 | Microbia, Inc. | 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia |
AU2006244043A1 (en) | 2005-05-11 | 2006-11-16 | Microbia, Inc. | Processes for production of phenolic 4-biphenylylazetidin-2-ones |
PT1881850E (en) | 2005-05-13 | 2010-11-26 | Lilly Co Eli | Glp-1 pegylated compounds |
BRPI0610133A2 (en) | 2005-05-17 | 2010-06-01 | Schering Corp | heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia |
CN101222950A (en) | 2005-05-25 | 2008-07-16 | 迈克罗比亚公司 | Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids |
JP5069678B2 (en) | 2005-05-25 | 2012-11-07 | メルク・シャープ・エンド・ドーム・コーポレイション | Aminocyclohexane as a dipeptidyl peptidase IV inhibitor for the treatment or prevention of diabetes |
TW200714597A (en) | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
AU2006255944B2 (en) | 2005-06-08 | 2010-03-04 | Japan Tobacco Inc. | Heterocyclic compound |
DE102005026808A1 (en) | 2005-06-09 | 2006-12-14 | Sanofi-Aventis Deutschland Gmbh | Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases |
DE102005026762A1 (en) | 2005-06-09 | 2006-12-21 | Sanofi-Aventis Deutschland Gmbh | Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases |
US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
DE102005026809A1 (en) | 2005-06-09 | 2006-12-14 | Sanofi-Aventis Deutschland Gmbh | Benzothiazol-2-one derivatives as inhibitors of lipases and phospholipases |
JP2008543837A (en) | 2005-06-15 | 2008-12-04 | メルク エンド カムパニー インコーポレーテッド | Anti-hypercholesterolemic compound |
AU2006257646A1 (en) | 2005-06-16 | 2006-12-21 | Pfizer Inc. | N-(pyridin-2-YL)-sulfonamide derivatives |
WO2006134481A1 (en) | 2005-06-16 | 2006-12-21 | Pfizer Inc. | Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1 |
US7572808B2 (en) | 2005-06-17 | 2009-08-11 | Bristol-Myers Squibb Company | Triazolopyridine cannabinoid receptor 1 antagonists |
US7605289B2 (en) | 2005-06-17 | 2009-10-20 | Amgen, Inc. | Benzamide derivatives and uses related thereto |
EP1928859A1 (en) | 2005-06-17 | 2008-06-11 | Carex SA | Pyrazole derivates as cannabinoid receptor modulators |
UY29607A1 (en) | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
AR057380A1 (en) | 2005-06-22 | 2007-11-28 | Astrazeneca Ab | CHEMICAL COMPOUNDS DERIVED FROM 2-AZETIDINONE AND THERAPEUTIC USE OF THE SAME |
AR057383A1 (en) | 2005-06-22 | 2007-12-05 | Astrazeneca Ab | CHEMICAL COMPOUNDS DERIVED FROM 2-AZETIDINONE, PHARMACEUTICAL FORMULATION AND A COMPOUND PREPARATION PROCESS |
MY148538A (en) | 2005-06-22 | 2013-04-30 | Astrazeneca Ab | Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
MX2007015779A (en) | 2005-06-22 | 2008-02-22 | Hoffmann La Roche | ( 6-FLU0R0-BENZ0[l, 3] DIOXOLYL) -MORPHOLIN-4-YL-METHANONES AND THEIR USE AS CBl LIGANDS. |
SA06270191B1 (en) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | Novel 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors for the Treatment of Hyperlipidaemic Conditions |
AR054482A1 (en) | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | DERIVATIVES OF AZETIDINONE FOR THE TREATMENT OF HYPERLIPIDEMIAS |
AR056866A1 (en) | 2005-06-22 | 2007-10-31 | Astrazeneca Ab | CHEMICAL COMPOUNDS DERIVED FROM 2-AZETIDINONE, A PHARMACEUTICAL FORMULATION AND A COMPOSITE PREPARATION PROCESS |
WO2007001939A1 (en) | 2005-06-27 | 2007-01-04 | Janssen Pharmaceutica N.V. | Tetrahydro-pyranopyrazole compounds displaying cannabinoid modulating activities |
WO2007000445A1 (en) | 2005-06-29 | 2007-01-04 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
AU2006264649A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | GPCR agonists |
US20090325924A1 (en) | 2005-06-30 | 2009-12-31 | Stuart Edward | GPCR Agonists |
AU2006264651A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | G-protein coupled receptor agonists |
PL1904455T3 (en) | 2005-07-05 | 2012-01-31 | Hoffmann La Roche | Pyridazine derivatives |
ES2382815T3 (en) | 2005-07-08 | 2012-06-13 | Novo Nordisk A/S | Dicycloalkylcarbamoyl ureas as glucokinase activators |
JPWO2007007688A1 (en) | 2005-07-08 | 2009-01-29 | 持田製薬株式会社 | 3,5-diamino-1,2,4-triazole derivative |
CA2614518A1 (en) | 2005-07-08 | 2007-01-18 | Novo-Nordisk A/S | Dicycloalkyl urea glucokinase activators |
WO2007007040A1 (en) | 2005-07-09 | 2007-01-18 | Astrazeneca Ab | 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes |
US20080234273A1 (en) | 2005-07-09 | 2008-09-25 | Mckerrecher Darren | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes |
AU2006268406C1 (en) | 2005-07-09 | 2011-02-24 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
KR100965040B1 (en) | 2005-07-11 | 2010-06-21 | 미쓰비시 타나베 파마 코퍼레이션 | An oxime derivative and preparations thereof |
CA2614544C (en) | 2005-07-13 | 2013-09-10 | Banyu Pharmaceutical Co., Ltd. | Heterocycle-substituted benzimidazole derivative |
JP2007022943A (en) | 2005-07-13 | 2007-02-01 | Dai Ichi Seiyaku Co Ltd | Squalene synthesis enzyme inhibitor |
CA2615938C (en) | 2005-07-14 | 2014-04-29 | Novo-Nordisk A/S | Urea glucokinase activators |
DE102005033100B3 (en) | 2005-07-15 | 2007-01-25 | Sanofi-Aventis Deutschland Gmbh | Novel 1,4-benzothiazepine-1,1-dioxide derivative with improved properties, drugs containing this compound and methods for their preparation |
EP1757587A1 (en) | 2005-07-15 | 2007-02-28 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
WO2007009705A1 (en) | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A. | (rac)-n-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydr0-1h-pyrazole-3-carboxamide hydrates |
DE102005033099A1 (en) | 2005-07-15 | 2007-01-18 | Sanofi-Aventis Deutschland Gmbh | Novel 1,4-benzothiazepine 1,1-dioxide derivative with improved properties, process for its preparation, medicines containing it and its use |
MX2007016024A (en) | 2005-07-18 | 2008-03-10 | Novo Nordisk As | Peptides for use in the treatment of obesity. |
WO2007011811A1 (en) | 2005-07-19 | 2007-01-25 | Merck & Co., Inc. | Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors |
WO2007015767A1 (en) | 2005-07-20 | 2007-02-08 | Eli Lilly And Company | Pyridine derivatives as dipeptedyl peptidase inhibitors |
WO2007015744A1 (en) | 2005-07-21 | 2007-02-08 | Incyte Corporation | Disubstituted thienyl compounds and their use as pharmaceuticals |
ATE449097T1 (en) | 2005-07-21 | 2009-12-15 | Hoffmann La Roche | PYRIDOÄ2,3-DÜPYRIMIDINE-2,4-DIAMINE COMPOUNDS AS PTPIB INHIBITORS |
UY29694A1 (en) | 2005-07-28 | 2007-02-28 | Boehringer Ingelheim Int | METHODS TO PREVENT AND TREAT METABOLIC AND NEW DISORDERS DERIVED FROM PIRAZOL-O-GLUCOSIDO |
JP5084503B2 (en) | 2005-07-29 | 2012-11-28 | 武田薬品工業株式会社 | Cyclopropanecarboxylic acid compound |
WO2007017124A1 (en) | 2005-07-29 | 2007-02-15 | Laboratorios Del Dr. Esteve, S.A. | Amorphous phase of a substituted pyrazoline, its preparation and use as medicament |
WO2007017126A2 (en) | 2005-07-29 | 2007-02-15 | Laboratorios Del Dr. Esteve, S.A. | POLYMORPH OF N-PIPERIDINYL-5- (4-CHLOROPHENYL) -1- (2, 4-DICHLOROPHENYL) -4, 5-DIHYDRO-lH-PYRAZOLE- 3 -CARBOXAMIDE AND ITS USE AS A CAMNABINOID RECEPTOR MODULATOR |
WO2007016460A2 (en) | 2005-07-29 | 2007-02-08 | Mayo Foundation For Medical Education And Research | Skin pressure reduction by partial magnetic levitation |
CA2617042A1 (en) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | Spiro-cyclic compound |
FR2889190A1 (en) | 2005-08-01 | 2007-02-02 | Merck Sante Soc Par Actions Si | New imidazole carboxamides, useful to treat e.g. pathologies associated with the insulin resistance syndrome, are fructose-1,6-biphosphatase inhibitors |
EP1909797A4 (en) | 2005-08-02 | 2013-02-27 | Neurogen Corp | Dipiperazinyl ketones and related analogues |
EP1912968A1 (en) | 2005-08-04 | 2008-04-23 | Pfizer Limited | Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds |
ES2267400B1 (en) | 2005-08-04 | 2008-03-01 | Universitat De Valencia | PIGMENTARY COMPOSITIONS IN WATER BASED FOR POLYCHROMATIC MARKING OF INORGANIC MATERIALS WITH LASER. |
EP1915356A1 (en) | 2005-08-08 | 2008-04-30 | AstraZeneca AB | Therapeutic agents |
US20080306087A1 (en) | 2005-08-08 | 2008-12-11 | Astrazeneca Ab | Therapeutic Agents |
WO2007017649A1 (en) | 2005-08-09 | 2007-02-15 | Astrazeneca Ab | Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes |
GB0516462D0 (en) | 2005-08-10 | 2005-09-14 | Smithkline Beecham Corp | Novel compounds |
JP2009504592A (en) | 2005-08-10 | 2009-02-05 | スミスクライン・ビーチャム・コーポレイション | Xanthine derivatives as selective HM74A agonists |
WO2007020502A2 (en) | 2005-08-16 | 2007-02-22 | Pharmacia & Upjohn Company Llc | Cannabinoid receptor ligands and uses thereof |
ATE430744T1 (en) | 2005-08-18 | 2009-05-15 | Hoffmann La Roche | THIAZOLYLPIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS |
WO2007026215A1 (en) | 2005-08-29 | 2007-03-08 | Glenmark Pharmaceuticals S.A. | Pyrazole derivatives as cannabinoid receptor ligands, pharmaceutical compositions containing? them, and processes for their preparation |
WO2007027532A2 (en) | 2005-08-29 | 2007-03-08 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
AU2006285834A1 (en) | 2005-08-31 | 2007-03-08 | Astellas Pharma Inc. | Thiazole derivative |
JP2007063225A (en) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | Imidazopyridine compound |
WO2007028145A2 (en) | 2005-09-02 | 2007-03-08 | Dara Biosciences, Inc. | Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system |
WO2007029086A2 (en) | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors |
GB2429975A (en) | 2005-09-08 | 2007-03-14 | Univ Edinburgh | 1,5-substituted-1H-tetrazole 11beta-hydroxysteroid dehydrogenase type 1 inhibitors |
MXPA05009633A (en) | 2005-09-08 | 2007-03-07 | Silanes Sa De Cv Lab | Stable pharmaceutical composition comprising immediate-release glimepiride and delayed-release metformin. |
ES2289888B1 (en) | 2005-09-08 | 2008-12-16 | Consejo Superior Investig. Cientificas | DERIVATIVES OF PIRAZOLCARBOXAMIDA, ITS PROCESSING PROCEDURE AND ITS APPLICATIONS AS INVESTED ANTAGONISTS / AGONISTS OF THE CANNABINOID CB1 AND OPIOID MU. |
AU2006291234A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
GB0518817D0 (en) | 2005-09-15 | 2005-10-26 | Astrazeneca Ab | Therapeutic agents |
GB0518819D0 (en) | 2005-09-15 | 2005-10-26 | Astrazeneca Ab | Therapeutic agents |
JP2009508832A (en) | 2005-09-16 | 2009-03-05 | アストラゼネカ アクチボラグ | Heterobicyclic compounds as glucokinase activators |
RS20080112A (en) | 2005-09-16 | 2009-05-06 | Arena Pharmaceuticals Inc., | Modulators of metabolism and the treatment of disorders related thereto |
EP1931652A2 (en) | 2005-09-21 | 2008-06-18 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
CA2623088A1 (en) | 2005-09-21 | 2007-04-12 | 7Tm Pharma A/S | Y4 selective receptor agonists for therapeutic interventions |
US7851590B2 (en) | 2005-09-21 | 2010-12-14 | 7Tm Pharma A/S | Y2 selective receptor agonists for therapeutic interventions |
MY148863A (en) | 2005-09-23 | 2013-06-14 | Janssen Pharmaceutica Nv | Hexahydro-cyclooctyl pyrazole cannabinoid modulators |
CA2623525A1 (en) | 2005-09-23 | 2007-04-05 | Janssen Pharmaceutica N.V. | Tetrahydro-indazolyl cannabinoid modulators |
US8293900B2 (en) | 2005-09-29 | 2012-10-23 | Merck Sharp & Dohme Corp | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
CA2624105C (en) | 2005-09-29 | 2014-02-18 | Sanofi-Aventis | Phenyl-[1,2,4]-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals |
GT200600429A (en) | 2005-09-30 | 2007-04-30 | ORGANIC COMPOUNDS | |
CA2623958C (en) | 2005-09-30 | 2013-05-28 | Banyu Pharmaceutical Co., Ltd. | 2-heteroaryl-substituted indole derivative |
JP2009513573A (en) | 2005-09-30 | 2009-04-02 | メルク エンド カムパニー インコーポレーテッド | Cholesteryl ester transfer protein inhibitor |
EP1933836A2 (en) | 2005-09-30 | 2008-06-25 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
GT200600428A (en) | 2005-09-30 | 2007-05-21 | ORGANIC COMPOUNDS | |
EP1934256A2 (en) | 2005-09-30 | 2008-06-25 | Compugen Ltd. | Hepatocyte growth factor receptor splice variants and methods of using same |
AR056560A1 (en) | 2005-10-06 | 2007-10-10 | Astrazeneca Ab | PIRROLOPIRIDINONES AS MODULATORS CB1 |
DE102005048897A1 (en) | 2005-10-12 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | Diacylindazole derivatives as inhibitors of lipases and phospholipases |
TW200745031A (en) | 2005-10-13 | 2007-12-16 | Merck & Co Inc | Acyl indoles, compositions containing such compounds and methods of use |
JP2009013065A (en) | 2005-10-14 | 2009-01-22 | Astellas Pharma Inc | Condensed heterocyclic compound |
US20070105819A1 (en) | 2005-10-17 | 2007-05-10 | Roger Olsson | CB-1 modulating compounds and their use |
DE102005049954A1 (en) | 2005-10-19 | 2007-05-31 | Sanofi-Aventis Deutschland Gmbh | Triazolopyridine derivatives as inhibitors of lipases and phospholipases |
DE102005049953A1 (en) | 2005-10-19 | 2007-04-26 | Sanofi-Aventis Deutschland Gmbh | Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases |
RU2008119842A (en) | 2005-10-20 | 2009-12-10 | Мерк энд Ко., Инк. (US) | TRIAZOLE DERIVATIVES AS 11-BETA-HYDROXISTEROID-DEHYDROHENASE-1 INHIBITORS |
AR056876A1 (en) | 2005-10-21 | 2007-10-31 | Tanabe Seiyaku Co | PIRAZOLO COMPOUNDS [1-5-A] PYRIMIDINE, CB1 CANABINOID RECEPTORS ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING AND USES IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES, SUCH AS PSYCHOTIC AND NEIGHBORHOODS |
EP1944301A4 (en) | 2005-10-27 | 2012-01-04 | Msd Kk | Novel benzoxathiin derivative |
DE102005052101A1 (en) | 2005-10-28 | 2007-05-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New beta-agonists, process for their preparation and their use as medicines |
KR20080069189A (en) | 2005-11-01 | 2008-07-25 | 트랜스테크 파르마, 인크. | Pharmaceutical use of substituted amides |
JP2009513720A (en) | 2005-11-01 | 2009-04-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Substituted cycloalkyl pyrrolones as allosteric modulators of glucokinase |
WO2007051810A2 (en) | 2005-11-01 | 2007-05-10 | Transtech Pharma | Pharmaceutical use of substituted amides |
ES2372540T3 (en) | 2005-11-01 | 2012-01-23 | Array Biopharma, Inc. | GLUCOCINASE ACTIVATORS. |
BRPI0618067A2 (en) | 2005-11-03 | 2011-08-16 | Prosidion Ltd | compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and use and process for the preparation of a compound or a pharmaceutically acceptable salt thereof |
US20080293741A1 (en) | 2005-11-03 | 2008-11-27 | Matthew Colin Thor Fyfe | Tricyclo Substituted Amides as Glucokinase Modulators |
US20090005391A1 (en) | 2005-11-03 | 2009-01-01 | Matthew Colin Thor Fyfe | Tricyclo Substituted Amides |
WO2007052843A1 (en) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | Heterocyclic amide compound and use thereof |
JP2007131570A (en) | 2005-11-09 | 2007-05-31 | Mitsubishi Pharma Corp | Novel aminopyrrolidine derivative |
UA95613C2 (en) | 2005-11-09 | 2011-08-25 | Уеллстат Терепьютикс Корпорейшн | Compounds for the treatment of metabolic disorders |
JP4371164B2 (en) | 2005-11-10 | 2009-11-25 | 萬有製薬株式会社 | Aza-substituted spiro derivatives |
JP5198280B2 (en) | 2005-11-17 | 2013-05-15 | イーライ リリー アンド カンパニー | Glucagon receptor antagonists and their preparation and therapeutic use |
EP1951661B1 (en) | 2005-11-17 | 2012-08-08 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
EP1966199B1 (en) | 2005-11-18 | 2010-10-20 | F. Hoffmann-La Roche AG | Azaindole-2-carboxamide derivatives |
EP1948614A2 (en) | 2005-11-18 | 2008-07-30 | Takeda San Diego, Inc. | Glucokinase activators |
WO2007057768A2 (en) | 2005-11-18 | 2007-05-24 | Pfizer Products Inc. | Sulfonyl derivatives |
GB0523609D0 (en) | 2005-11-19 | 2005-12-28 | Vernalis R&D Ltd | Piperazine derivatives |
CA2630665C (en) | 2005-11-21 | 2011-03-15 | Shionogi & Co., Ltd. | Heterocyclic compound having inhibitory activity on 11-.beta.-hydroxysteroid dehydrogenase type i |
BRPI0618140A2 (en) | 2005-11-22 | 2011-08-16 | Lilly Co Eli | pharmaceutically acceptable compound or salt thereof, pharmaceutical composition, and use of a compound or salt thereof |
EP1951696A2 (en) | 2005-11-22 | 2008-08-06 | Amgen Inc. | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
DE102005055726A1 (en) | 2005-11-23 | 2007-08-30 | Sanofi-Aventis Deutschland Gmbh | Hydroxy-substituted diphenylazetidinones, processes for their preparation, medicaments containing these compounds and their use |
DK1957484T3 (en) | 2005-11-23 | 2010-05-10 | Lilly Co Eli | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses |
WO2007060992A1 (en) | 2005-11-25 | 2007-05-31 | Kaneka Corporation | Agent for preventing or improving metabolic syndrome or insulin-resistance syndrome |
AR058199A1 (en) | 2005-11-28 | 2008-01-23 | Merck & Co Inc | DERIVATIVES OF 3- RENTED ALQUILAZETIDINA WITH HETEROCICLOS |
WO2007064272A1 (en) | 2005-11-29 | 2007-06-07 | Astrazeneca Ab | Benzhydryl amide derivatives as cannabinoid receptor antagonists or inverse agonists |
WO2007063928A1 (en) | 2005-11-30 | 2007-06-07 | Toray Industries, Inc. | Novel noncyclic amine carboxamide derivative and salt thereof |
DE602006011363D1 (en) | 2005-12-01 | 2010-02-04 | Hoffmann La Roche | Heteroaryl-substituted steroid derivatives as L-CPT1 inhibitors |
CN1978445B (en) | 2005-12-02 | 2010-09-01 | 中国科学院上海药物研究所 | Compound serving as human-derived adenoside mononucleoside activated protein kinase activator, and its preparing method and use |
UA94921C2 (en) | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
UA94724C2 (en) | 2005-12-08 | 2011-06-10 | Новартис Аг | Thiadiazolidinone derivatives as antidiabetic agents |
CN101321761A (en) | 2005-12-09 | 2008-12-10 | 霍夫曼-拉罗奇有限公司 | Tricyclic amide derivatives useful for treating obesity |
AU2006326564B2 (en) | 2005-12-14 | 2011-06-23 | Merck Sharp & Dohme Corp. | Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes |
CA2632027A1 (en) | 2005-12-14 | 2007-06-21 | Amgen Inc. | Diaza heterocyclic sulfonamide derivatives and their uses |
EP1963318B1 (en) | 2005-12-15 | 2009-11-25 | F. Hoffmann-la Roche AG | Pyrrolo[2,3-c]pyridine derivatives |
CA2633243C (en) | 2005-12-15 | 2014-05-27 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
EP1801098A1 (en) | 2005-12-16 | 2007-06-27 | Merck Sante | 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors |
AU2006326067A1 (en) | 2005-12-16 | 2007-06-21 | F. Hoffmann-La Roche Ag | Pyrrolo [2 , 3-b] pyridine derivatives as H3 receptor modulators |
CN101379069A (en) | 2005-12-19 | 2009-03-04 | 塔夫茨大学信托人 | Soft protease inhibitors and pro-soft forms thereof |
JP2009520825A (en) | 2005-12-20 | 2009-05-28 | 武田薬品工業株式会社 | Glucokinase activator |
CN101341148A (en) | 2005-12-21 | 2009-01-07 | 霍夫曼-拉罗奇有限公司 | New salt and polymorph of DPP-IV inhibitor |
WO2007075629A2 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists |
US20090227612A1 (en) | 2005-12-22 | 2009-09-10 | Boonsaeng Park | Aminopyrimidine Derivatives Inhibiting Protein Kinase Activity, Method For The Preparation Thereof And Pharmaceutical Composition Containing Same |
CA2631390C (en) | 2005-12-22 | 2014-03-11 | Per Sauerberg | Phenoxy acetic acids as ppar delta activators |
JP2009520763A (en) | 2005-12-23 | 2009-05-28 | ノバルティス アクチエンゲゼルシャフト | Fused heterocyclic compounds useful as DPP-IV inhibitors |
US20090156465A1 (en) | 2005-12-30 | 2009-06-18 | Sattigeri Jitendra A | Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors |
WO2007081755A2 (en) | 2006-01-09 | 2007-07-19 | Metabasis Therapeutics, Inc. | Indole-benzimidazole and indazole inhibitors of tyrosine phosphatases |
UY30082A1 (en) | 2006-01-11 | 2007-08-31 | Boehringer Ingelheim Int | CRYSTAL FORM OF 1- (1-METHYLETHYL) -4` - ((2-FLUORO-4-METOXIFENIL) METHYL) -5`- METHYL-1H-PIRAZOL-3`-OBD-GLUCOPYRANOSIDE, A METHOD FOR PREPARATION AND USE OF THE SAME TO PREPARE MEDICATIONS |
CN100999517B (en) | 2006-01-11 | 2010-12-15 | 北京摩力克科技有限公司 | Pyrazole formylamine derivate, its pharmaceutical composition and preparation process |
EP1976840A1 (en) | 2006-01-13 | 2008-10-08 | F.Hoffmann-La Roche Ag | Cyclohexyl piperazinyl methanone derivatives and their use as histamine h3 receptor modulators |
EP1987000A2 (en) | 2006-01-13 | 2008-11-05 | Schering Corporation | Diaryl piperidines as cb1 modulators |
CA2635211A1 (en) | 2006-01-13 | 2007-08-02 | Merck & Co., Inc. | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
JP2009523781A (en) | 2006-01-18 | 2009-06-25 | エヴォルヴァ エスアー | PPAR regulator |
PE20071320A1 (en) | 2006-01-18 | 2007-12-29 | Schering Corp | CANNABINOID RECEPTOR MODULATORS |
WO2007133820A2 (en) | 2006-01-19 | 2007-11-22 | Neurogen Corporation | Diaryl triazolones as cb1 antagonists |
US20090069302A1 (en) | 2006-01-20 | 2009-03-12 | Smithkline Beecham Corporation | Chemical compounds |
US20090170847A1 (en) | 2006-01-23 | 2009-07-02 | Seung Chul Lee | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same |
CN101370779B (en) | 2006-01-23 | 2011-07-20 | 霍夫曼-拉罗奇有限公司 | Cyclohexyl sulfonamide derivatives having H3 receptor activity |
CN101007798B (en) | 2006-01-24 | 2011-01-26 | 中国人民解放军军事医学科学院毒物药物研究所 | Benzodioxole derivatives and their preparation method and medicinal uses |
CN101007804B (en) | 2006-01-25 | 2011-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 1,3-benzodioxole-2,2-dicarboxylic acid derivatives and their preparation method and medicinal uses |
CA2636757A1 (en) | 2006-01-25 | 2007-08-02 | Tesfaye Biftu | Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
FR2896798A1 (en) | 2006-01-27 | 2007-08-03 | Sanofi Aventis Sa | SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
JP5236499B2 (en) | 2006-01-27 | 2013-07-17 | アレイ バイオファーマ、インコーポレイテッド | Glucokinase activator |
CA2627692A1 (en) | 2006-01-30 | 2007-08-02 | Irm Llc | Spiro imidazole derivatives as ppar modulators |
JP2009525275A (en) | 2006-01-30 | 2009-07-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Polycyclic 1,2,3,4-tetrahydro-isoquinoline derivatives and compositions containing them as PPAR modulators |
US20090088368A1 (en) | 2006-01-30 | 2009-04-02 | Irm Llc | Compositions comprising them as ppar modulators |
WO2007086080A2 (en) | 2006-01-30 | 2007-08-02 | Glenmark Pharmaceuticals Limited | NOVEL IMIDAZO[1,2-a]PYRIDINE CANNABINOID RECEPTOR LIGANDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
BRPI0707408A2 (en) | 2006-01-31 | 2011-05-03 | Incyte Corp | starch compounds and their use as pharmaceuticals |
UY30117A1 (en) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | AMIS TRISUSTITUDED COMPOUND |
PE20071025A1 (en) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | TRISUSTITUTED AMINE COMPOUND |
WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
EP1816125A1 (en) | 2006-02-02 | 2007-08-08 | Ranbaxy Laboratories, Ltd. | Novel crystalline forms of an antagonist of CB1 cannabinoid receptor and preparation method thereof |
FR2896799B1 (en) | 2006-02-02 | 2008-03-28 | Sanofi Aventis Sa | SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
ES2452031T3 (en) | 2006-02-03 | 2014-03-31 | Eli Lilly & Company | Compounds and procedures to modulate FX receivers |
US7691876B2 (en) | 2006-02-07 | 2010-04-06 | Hoffmann-La Roche Inc. | Heterobicyclic amide compounds |
EP2007726B1 (en) | 2006-02-07 | 2011-03-02 | F. Hoffmann-La Roche AG | Benzamide and heteroarene derivatives as cetp inhibitors |
EP1983993A4 (en) | 2006-02-07 | 2010-09-22 | Merck Sharp & Dohme | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
WO2007091948A2 (en) | 2006-02-07 | 2007-08-16 | Astrazeneca Ab | Novel spiro [imidazolidine-4, 3´-indole] 2, 2´,5´(1h) triones for treatment of conditions associated with vanilloid receptor 1 |
US7572823B2 (en) | 2006-02-07 | 2009-08-11 | Hoffmann-La Roche Inc. | Heteroaryl carboxamide compounds |
US7678818B2 (en) | 2006-02-07 | 2010-03-16 | Hoffmann-La Roche Inc. | Anthranilamide and 2-amino-heteroarene-carboxamide compounds |
BRPI0707537A2 (en) | 2006-02-07 | 2011-05-03 | Wyeth Corp | 11-beta hsd1 inhibitors |
US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
ATE525072T1 (en) | 2006-02-09 | 2011-10-15 | Athersys Inc | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISEASES |
EP1993696A4 (en) | 2006-02-10 | 2010-04-07 | Gunderboom Inc | Filter cartridges for fluid intake systems |
CA2637884A1 (en) | 2006-02-13 | 2007-08-23 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
EP1987051A2 (en) | 2006-02-14 | 2008-11-05 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions |
DE102006006648A1 (en) | 2006-02-14 | 2007-08-23 | Merck Patent Gmbh | Mandelsäurehydrazide |
WO2007095513A1 (en) | 2006-02-14 | 2007-08-23 | Janssen Pharmaceutica, Nv | Tetrahydr0-2h-indaz0le derivatives for use as cannabinoid modulators |
EP1996567B1 (en) | 2006-02-15 | 2013-09-18 | AbbVie Inc. | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
KR20080102395A (en) | 2006-02-15 | 2008-11-25 | 베링거 인겔하임 인터내셔날 게엠베하 | Glycopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
WO2007095603A2 (en) | 2006-02-15 | 2007-08-23 | Abbott Laboratories | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
WO2007097931A2 (en) | 2006-02-15 | 2007-08-30 | Merck & Co., Inc. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
ITRM20060090A1 (en) | 2006-02-22 | 2007-08-23 | Sigma Tau Ind Farmaceuti | NEW COMPOUNDS CPT INHIBITORS AT LEVEL OF THE SNC AS ANTI-DIABETIC AND OR ANTI-BESIDE DRUGS |
ES2402581T3 (en) | 2006-02-23 | 2013-05-06 | Pfizer Limited | Piperidinoylpyrrolidines as type 4 melanocortin receptor agonists |
WO2007096186A1 (en) | 2006-02-23 | 2007-08-30 | Santhera Pharmaceuticals (Schweiz) Ag | Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators |
US7728031B2 (en) | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
WO2007100789A2 (en) | 2006-02-24 | 2007-09-07 | Wyeth | Gpat3 encodes a mammalian, microsomal acyl-coa:glycerol 3-phosphate acyltransferase |
WO2007100833A2 (en) | 2006-02-24 | 2007-09-07 | Wyeth | Gpat4 encodes a mammalian, microsomal acyl-coa:glycerol 3-phosphate acyltransferase |
WO2007099553A2 (en) | 2006-02-27 | 2007-09-07 | Cadila Healthcare Limited | 1,3-dioxane carboxylic acids |
WO2007096764A2 (en) | 2006-02-27 | 2007-08-30 | Glenmark Pharmaceuticals S.A. | Bicyclic heteroaryl derivatives as cannabinoid receptor modulators |
KR20080098615A (en) | 2006-02-28 | 2008-11-11 | 웰스태트 테러퓨틱스 코포레이션 | Compounds for the treatment of metabolic disorders |
WO2007099385A1 (en) | 2006-03-01 | 2007-09-07 | Glenmark Pharmaceuticals S.A. | Dipeptidyl peptidase iv inhibitor compounds and compositions |
US7834178B2 (en) | 2006-03-01 | 2010-11-16 | Bristol-Myers Squibb Company | Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors |
JP2007230909A (en) | 2006-03-01 | 2007-09-13 | Univ Of Tokyo | Substituted isoxazole derivative |
TW200808807A (en) | 2006-03-02 | 2008-02-16 | Incyte Corp | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
TW200745099A (en) | 2006-03-02 | 2007-12-16 | Sankyo Co | Optically active thiazolidinedione derivatives |
WO2007103719A2 (en) | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
EP1993543A2 (en) | 2006-03-03 | 2008-11-26 | Merck & Co., Inc. | Novel crystalline forms of antidiabetic compounds |
US20080051452A1 (en) | 2006-03-06 | 2008-02-28 | Avestha Gengraine Technologies Pvt. Ltd. | Hexanoic acid derivatives as dipeptidyl peptidase inhibitors |
US20070270492A1 (en) | 2006-03-06 | 2007-11-22 | Avestha Gengraine Technologies Pvt. Ltd. | Nananoic acid derivatives as dipeptidyl peptidase inhibitors |
TW200800979A (en) | 2006-03-07 | 2008-01-01 | Lundbeck & Co As H | Halogenated sulfonamide derivatives |
JP2009132620A (en) | 2006-03-07 | 2009-06-18 | Astellas Pharma Inc | Phenylthiazole derivative |
WO2007104034A2 (en) | 2006-03-08 | 2007-09-13 | Takeda San Diego, Inc. | Glucokinase activators |
US7943612B2 (en) | 2006-03-09 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds that modulate PPAR activity, their preparation and use |
ZA200807715B (en) | 2006-03-09 | 2009-11-25 | Pharmacopeia Inc | 9-Heteroarylpurine MNK2 inhibitors for treating metabolic disorders |
WO2007105650A1 (en) | 2006-03-10 | 2007-09-20 | Ajinomoto Co., Inc. | 4-hydroxyisoleucine derivative and process for producing the derivative |
DE602007011904D1 (en) | 2006-03-10 | 2011-02-24 | Neurogen Corp | PIPERAZINYL OXOALKYL TETRAHYDROISOCHINOLINE AND RELATED ANALOGUE |
CN101437398A (en) | 2006-03-10 | 2009-05-20 | 詹里恩探索公司 | Cannabinoid receptor antagonists/inverse agonists useful fortreating obesity |
JP2009539762A (en) | 2006-03-13 | 2009-11-19 | ファイザー・プロダクツ・インク | Tetralin antagonist of H3 receptor |
CA2646430A1 (en) | 2006-03-14 | 2007-09-20 | Amgen Inc. | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders |
JP5252435B2 (en) | 2006-03-15 | 2013-07-31 | ノボ・ノルデイスク・エー/エス | Amylin derivatives |
EP1834641A1 (en) | 2006-03-16 | 2007-09-19 | Sanofi-Aventis | Use of CRF1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia |
EP1995243A4 (en) | 2006-03-16 | 2009-07-22 | Astellas Pharma Inc | Triazole derivative or salt thereof |
JP5243696B2 (en) | 2006-03-17 | 2013-07-24 | 田辺三菱製薬株式会社 | Benzene derivatives |
DE102006012548A1 (en) | 2006-03-18 | 2007-09-20 | Bayer Healthcare Ag | Substituted chromanol derivatives and their use |
WO2007107550A1 (en) | 2006-03-21 | 2007-09-27 | High Point Pharmaceuticals, Llc | Adamantane derivatives for the treatment of the metabolic syndrome |
RU2470016C2 (en) | 2006-03-22 | 2012-12-20 | Ф.Хоффманн-Ля Рош Аг | Bipirazole derivative |
EP2004619A1 (en) | 2006-03-23 | 2008-12-24 | Amgen Inc. | 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
US7666912B2 (en) | 2006-03-23 | 2010-02-23 | Massachusetts Eye And Ear Infirmary | Compositions and methods for reducing body fat |
AU2007229850A1 (en) | 2006-03-23 | 2007-10-04 | Merck & Co., Inc. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
MX2008012185A (en) | 2006-03-23 | 2008-10-02 | Inotek Pharmaceuticals Corp | Purine compounds and methods of use thereof. |
CN101437816B (en) | 2006-03-24 | 2013-08-14 | 阿雷生物药品公司 | 2-aminopyridine analogs as glucokinase activators |
FR2898892A1 (en) | 2006-03-24 | 2007-09-28 | Genfit Sa | New poly-substituted N-(phenethyl)benzamide derivatives are peroxisome proliferator activated receptor activators useful to treat e.g. type-2 diabetes, insulin-resistance, metabolic disorders, atherosclerosis and cardiovascular diseases |
FR2898894B1 (en) | 2006-03-24 | 2008-06-06 | Genfit Sa | SUBSTITUTED N- (PHENETHYL) BENZAMIDE DERIVATIVE COMPOUNDS, PREPARATION AND USES |
US20070254911A1 (en) | 2006-03-27 | 2007-11-01 | Mingde Xia | Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators |
JP2007291075A (en) | 2006-03-27 | 2007-11-08 | Sankyo Co Ltd | New compound sterenin and method for producing the same |
WO2007112402A1 (en) | 2006-03-27 | 2007-10-04 | Janssen Pharmaceutica N.V. | Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators |
DE102006014688A1 (en) | 2006-03-28 | 2007-10-04 | Sanofi-Aventis | New bicyclic pyrazolone or isoxazolone derivatives useful as endothelial lipase inhibitors, e.g. for treating disorders of fat metabolism or glucose utilization |
TW200806669A (en) | 2006-03-28 | 2008-02-01 | Merck & Co Inc | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
US20100261758A1 (en) | 2006-03-28 | 2010-10-14 | Novartis Ag | Heterocyclic amides for use as pharmaceuticals |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
JP2009531376A (en) | 2006-03-28 | 2009-09-03 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | Benzothiazole having histamine H3 receptor activity |
DE102006014685A1 (en) | 2006-03-28 | 2007-10-04 | Sanofi-Aventis | New bicyclic imidazolone derivatives useful as endothelial lipase inhibitors, e.g. for treating disorders of fat metabolism or glucose utilization |
WO2007126934A2 (en) | 2006-03-29 | 2007-11-08 | Merck & Co., Inc. | Amidoethylthioether orexin receptor antagonists |
US8685961B2 (en) | 2006-03-29 | 2014-04-01 | Merck Sharp & Dohme Corp. | Diazepan orexin receptor antagonists |
GB0606429D0 (en) | 2006-03-30 | 2006-05-10 | Novartis Ag | Organic compounds |
MX2008012400A (en) | 2006-03-30 | 2008-10-10 | Irm Llc | Azolopyrimidines as inhibitors of cannabinoid 1 activity. |
EP2038267A2 (en) | 2006-03-31 | 2009-03-25 | Novartis AG | Thiadiazolidinone inhibitors of ptpase |
EP2004643A1 (en) | 2006-03-31 | 2008-12-24 | Novartis AG | Organic compounds |
EA016264B1 (en) | 2006-03-31 | 2012-03-30 | Янссен Фармацевтика Н.В. | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine hreceptor |
US7851654B2 (en) | 2006-04-03 | 2010-12-14 | Industry-Academic Cooperation Foundation Gyeongsang National University | Chalcone derivatives, pharmaceutically acceptable salt, method for preparation and uses thereof |
EP2004601B1 (en) | 2006-04-03 | 2011-03-02 | Matrix Laboratories Limited | Novel dipeptidyl peptidase iv inhibitors and processes for their preparation and pharmaceutical compositions containing them |
US7645748B2 (en) | 2006-04-03 | 2010-01-12 | Forbes Medi-Tech Inc. | Sterol/stanol phosphorylnitroderivatives and use thereof |
CN101050194B (en) | 2006-04-05 | 2013-08-21 | 上海恒瑞医药有限公司 | Derivative of bicyclo-octanes class, preparation method, and application of medicine |
JP2009532453A (en) | 2006-04-06 | 2009-09-10 | プロシディオン・リミテッド | Heterocyclic GPCR agonist |
US8053447B2 (en) | 2006-04-07 | 2011-11-08 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
EP1842846A1 (en) | 2006-04-07 | 2007-10-10 | Santhera Pharmaceuticals (Schweiz) AG | Phenylpiperidine derivatives as melanocortin-4 receptor modulators |
US7435833B2 (en) | 2006-04-07 | 2008-10-14 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
JP5302883B2 (en) | 2006-04-07 | 2013-10-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Thienopyrimidine having MNK1 / MNK2 inhibitory activity for pharmaceutical composition |
US20100029716A1 (en) | 2006-04-10 | 2010-02-04 | Concert Pharmaceuticals, Inc. | Novel 1,2,3,4- tetrahydroquinoline derivatives |
CA2646917A1 (en) | 2006-04-11 | 2007-10-18 | Actelion Pharmaceuticals Ltd | Novel sulfonamide compounds |
GB0607196D0 (en) | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
CA2648642A1 (en) | 2006-04-11 | 2007-10-25 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
TW200806627A (en) | 2006-04-11 | 2008-02-01 | Novartis Ag | Organic compounds |
JP2009533393A (en) | 2006-04-12 | 2009-09-17 | プロビオドルグ エージー | Enzyme inhibitor |
CN101421235A (en) | 2006-04-12 | 2009-04-29 | 霍夫曼-拉罗奇有限公司 | 5-amido-2-carboxamide indoles |
WO2007120593A1 (en) | 2006-04-12 | 2007-10-25 | Wyeth | Anilino-pyrimidine phenyl and benzothiophene analogs |
EP2015769A4 (en) | 2006-04-13 | 2013-12-25 | Ipsen Pharma | Pharmaceutical compositions of hglp-1, exendin-4 and analogs thereof |
FR2899899A1 (en) | 2006-04-14 | 2007-10-19 | Sanofi Aventis Sa | AMINOMETHYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF |
US20090281097A1 (en) | 2006-04-14 | 2009-11-12 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
JP2007284090A (en) | 2006-04-14 | 2007-11-01 | Dic Plastics Inc | Lid locking structure and container |
WO2007119837A1 (en) | 2006-04-14 | 2007-10-25 | Ajinomoto Co., Inc. | Lipase inhibitor |
PE20080188A1 (en) | 2006-04-18 | 2008-03-10 | Janssen Pharmaceutica Nv | DERIVATIVES OF BENZOAZEPINE-OXY-ACETIC ACID AS PPAR-DELTA AGONISTS USED TO INCREASE HDL-C, REDUCE LDL-C AND REDUCE CHOLESTEROL |
CN102643248A (en) | 2006-04-18 | 2012-08-22 | 日本化学医药株式会社 | Activating agent for peroxisome proliferator activated receptor |
WO2007120102A1 (en) | 2006-04-19 | 2007-10-25 | Astrazeneca Ab | New substituted oxindole derivatives |
ES2487967T3 (en) | 2006-04-20 | 2014-08-25 | Pfizer Products Inc. | Heterocyclic amido compounds condensed with phenyl for the prevention and treatment of glucokinase mediated diseases |
EP2573111A1 (en) | 2006-04-20 | 2013-03-27 | Amgen Inc. | GLP-1 compounds |
WO2007122970A1 (en) | 2006-04-20 | 2007-11-01 | Osaka University | Ligand capable of binding to nuclear receptor |
US20070254952A1 (en) | 2006-04-21 | 2007-11-01 | Yuguang Wang | Cannabinoid receptor modulators |
GB0607953D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
AU2007240450B2 (en) | 2006-04-21 | 2011-12-22 | Eli Lilly And Company | Cyclohexylimidazole lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
EP2016047B1 (en) | 2006-04-21 | 2013-08-28 | Eli Lilly And Company | Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1 |
GB0607951D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
EA015675B1 (en) | 2006-04-21 | 2011-10-31 | Эли Лилли Энд Компани | Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
GB0607954D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
AU2007244955B2 (en) | 2006-04-24 | 2011-12-08 | Eli Lilly And Company | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
EA016415B1 (en) | 2006-04-24 | 2012-04-30 | Эли Лилли Энд Компани | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
BRPI0710262A2 (en) | 2006-04-24 | 2011-08-09 | Lilly Co Eli | compound, pharmaceutical composition, and intermediate |
WO2007122634A2 (en) | 2006-04-24 | 2007-11-01 | Jubilant Biosys Limited | Pyrimidinediones as tyrosine kinase inhibitors |
CN101432277B (en) | 2006-04-25 | 2013-12-25 | 伊莱利利公司 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
PT2035379E (en) | 2006-04-25 | 2010-07-13 | Lilly Co Eli | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
ES2336849T3 (en) | 2006-04-25 | 2010-04-16 | Eli Lilly And Company | INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGENASE 1. |
US7659281B2 (en) | 2006-04-25 | 2010-02-09 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors |
WO2007121687A1 (en) | 2006-04-26 | 2007-11-01 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament |
EP2013209B1 (en) | 2006-04-26 | 2011-01-19 | Actelion Pharmaceuticals Ltd. | Pyrazolo-tetrahydropyridine derivatives as orexin receptor antagonists |
WO2007122411A1 (en) | 2006-04-26 | 2007-11-01 | Astrazeneca Ab | Diazepan-1-yl-sulfonyl derivatives for the treatment of metabolic syndrome |
WO2007126043A1 (en) | 2006-04-27 | 2007-11-08 | Mitsubishi Tanabe Pharma Corporation | Use as drugs of carboxylic acid derivatives having thiazole rings |
AR060623A1 (en) | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | COMPOUNDS DERIVED FROM 2-AZETIDINONE AND A PREPARATION METHOD |
US20070254863A1 (en) | 2006-04-27 | 2007-11-01 | Jochen Antel | Use of CBx cannabinoid receptor modulators as potassium channel modulators |
MX2008013844A (en) | 2006-04-28 | 2008-11-10 | Lilly Co Eli | Pieridinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1. |
EP2019824A2 (en) | 2006-04-28 | 2009-02-04 | Transtech Pharma, Inc. | Benzamide glucokinase activators |
EP1849785A1 (en) | 2006-04-28 | 2007-10-31 | Neuropharma, S.A. | N-(2-Thiazolyl)-amide derivatives as GSK-3 inhibitors |
EP2019823B1 (en) | 2006-04-28 | 2010-11-24 | TransTech Pharma, Inc. | Benzamide glucokinase activators |
MX2008013511A (en) | 2006-04-28 | 2008-10-28 | Shionogi & Co | Amine derivative having npy y5 receptor antagonist activity. |
JP2009535420A (en) | 2006-05-01 | 2009-10-01 | インサイト・コーポレイション | Tetra-substituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1 |
JP2009167103A (en) | 2006-05-02 | 2009-07-30 | Taisho Pharmaceutical Co Ltd | Pyrazolyl 5-thioglycoside compound |
JP2009167104A (en) | 2006-05-02 | 2009-07-30 | Taisho Pharmaceutical Co Ltd | Phenyl 5-thio glycoside compound |
EP1854806A1 (en) | 2006-05-02 | 2007-11-14 | MPG Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Thioglycosides as pharmaceutically active agents |
MX2008014024A (en) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Polymorphs. |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
ES2389569T3 (en) | 2006-05-05 | 2012-10-29 | Jenrin Discovery | Inverse antagonists / agonists of cannabinoid receptors |
US20090326042A1 (en) | 2006-05-05 | 2009-12-31 | Isis Pharmaceuticals, Inc | Compounds and methods for modulating expression of crp |
US20080247964A1 (en) | 2006-05-08 | 2008-10-09 | Yuelian Xu | Substituted azaspiro derivatives |
WO2007128801A1 (en) | 2006-05-08 | 2007-11-15 | Novartis Ag | Combination of organic compounds |
ES2553154T3 (en) | 2006-05-09 | 2015-12-04 | Novo Nordisk A/S | Insulin derivative |
MX2008014061A (en) | 2006-05-09 | 2008-11-14 | Novo Nordisk As | Insulin derivative. |
WO2007129188A1 (en) | 2006-05-10 | 2007-11-15 | Pfizer Japan Inc. | Cyclopropanecarboxamide compound |
US20120088746A1 (en) | 2006-05-10 | 2012-04-12 | Pfizer Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
AU2007247385B2 (en) | 2006-05-10 | 2011-07-14 | Novartis Ag | Bicyclic derivatives as CETP inhibitors |
CA2650515A1 (en) | 2006-05-11 | 2007-11-22 | Novartis Ag | Benzylamine derivatives as cetp inhibitors |
DE102006021874B4 (en) | 2006-05-11 | 2008-03-27 | Sanofi-Aventis | 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, process for their preparation and their use as medicaments |
DE502007001453D1 (en) | 2006-05-11 | 2009-10-15 | Sanofi Aventis | 4,5-Diphenyl-pyrimidine-substituted carboxylic acids, process for their preparation and their use as medicament |
DE102006021872B4 (en) | 2006-05-11 | 2008-04-17 | Sanofi-Aventis | 4,5-Diphenyl-pyrimidinyl-oxy or -mercapto substituted carboxylic acids, process for their preparation and their use as medicaments |
WO2007134149A2 (en) | 2006-05-11 | 2007-11-22 | Janssen Pharmaceutica N.V. | 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as cetp inhibitors |
DE102006021878A1 (en) | 2006-05-11 | 2007-11-15 | Sanofi-Aventis | Phenylamino-benzoxazole substituted carboxylic acids, process for their preparation and their use as medicaments |
CA2651942A1 (en) | 2006-05-11 | 2008-07-03 | Janssen Pharmaceutica N.V. | 1,2,3,4-tetrahydro-quinoline derivatives as cetp inhibitors |
WO2007133756A2 (en) | 2006-05-15 | 2007-11-22 | Neurogen Corporation | Crf1 receptor ligands comprising heteroaryl fused bicycles |
US7851468B2 (en) | 2006-05-15 | 2010-12-14 | Cephalon, Inc. | Substituted pyrazolo[3,4-d]pyrimidines |
PE20080069A1 (en) | 2006-05-15 | 2008-02-22 | Merck & Co Inc | BICYCLE COMPOUNDS AS AGONISTS OF THE RECEPTOR 40 COUPLED TO PROTEIN G (GPR40) |
CA2651777A1 (en) | 2006-05-15 | 2007-11-29 | Merck & Co., Inc. | Pro-drugs of tertiary alcohols |
JP2009537525A (en) | 2006-05-16 | 2009-10-29 | メルク エンド カムパニー インコーポレーテッド | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
US7432255B2 (en) | 2006-05-16 | 2008-10-07 | Hoffmann-La Roche Inc. | 1H-indol-5-yl-piperazin-1-yl-methanone derivatives |
WO2007136603A2 (en) | 2006-05-16 | 2007-11-29 | Merck & Co., Inc. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
JP2009537564A (en) | 2006-05-17 | 2009-10-29 | インサイト・コーポレイション | Heterocyclic inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods using the same |
EP2024334A4 (en) | 2006-05-18 | 2009-09-30 | Merck & Co Inc | Substituted esters as cannabinoid-1 receptor modulators |
WO2007137008A2 (en) | 2006-05-18 | 2007-11-29 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
WO2007134958A1 (en) | 2006-05-18 | 2007-11-29 | F. Hoffmann-La Roche Ag | Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists |
ATE533744T1 (en) | 2006-05-19 | 2011-12-15 | Wyeth Llc | N-BENZOYPYRROLIDINE-3-YLAMINE AS HISTAMINE-3 ANTAGONISTS |
RU2437876C2 (en) | 2006-05-19 | 2011-12-27 | Тайсо Фармасьютикал Ко., Лтд. | C-phenyl glycitol compound for treating diabetes |
JP5230613B2 (en) | 2006-05-23 | 2013-07-10 | テラコス・インコーポレイテッド | Glucose transporter inhibitor and method of use thereof |
WO2007135111A1 (en) | 2006-05-23 | 2007-11-29 | High Point Pharmaceuticals, Llc | 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament |
WO2007135427A1 (en) | 2006-05-23 | 2007-11-29 | Astrazeneca Ab | 1,4-disubstituted piperazine and 1,4-disubstituted azepane as 11 -beta-hydroxysteroid dehydrogenase 1 inhibitors |
WO2007134986A1 (en) | 2006-05-23 | 2007-11-29 | F. Hoffmann-La Roche Ag | Pyridopyrimidinone derivatives |
CA2651378C (en) | 2006-05-24 | 2012-08-28 | Eli Lilly And Company | Fxr agonists |
EP2029558B1 (en) | 2006-05-24 | 2010-03-10 | Eli Lilly And Company | Compounds and methods for modulating fxr |
JP5105297B2 (en) | 2006-05-25 | 2012-12-26 | 味の素株式会社 | PPAR activity regulator |
US20100292266A1 (en) | 2006-05-26 | 2010-11-18 | Richard Apodaca | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase |
TW200806625A (en) | 2006-05-26 | 2008-02-01 | Astrazeneca Ab | Therapeutic compounds |
EP2029604A2 (en) | 2006-05-26 | 2009-03-04 | Novartis AG | Aldosterone synthase and/or 11beta-hydroxylase inhibitors |
US8815312B2 (en) | 2006-05-26 | 2014-08-26 | Nestec S.A. | Methods of use and nutritional compositions of Touchi Extract |
NZ571972A (en) | 2006-05-29 | 2011-09-30 | High Point Pharmaceuticals Llc | 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist |
CA2652158A1 (en) | 2006-05-30 | 2007-12-06 | Matthias Heinrich Nettekoven | Piperidinyl pyrimidine derivatives |
NZ573028A (en) | 2006-05-30 | 2011-11-25 | Janssen Pharmaceutica Nv | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
ATE522518T1 (en) | 2006-05-31 | 2011-09-15 | Takeda San Diego Inc | INDAZOLE AND ISOINDOLE DERIVATIVES AS GLUCOKINASE ACTIVATE SUBSTANCES |
WO2007140385A2 (en) | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Thiazole compounds as cannabinoid receptor ligands and uses thereof |
WO2007140439A2 (en) | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
WO2007138050A1 (en) | 2006-05-31 | 2007-12-06 | Solvay Pharmaceuticals B.V. | Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists |
WO2007137962A1 (en) | 2006-06-01 | 2007-12-06 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
US20080241869A1 (en) | 2006-06-02 | 2008-10-02 | San Diego State University Research Foundation | Compositions and methods for ameliorating hyperlipidemia |
FR2901792A1 (en) | 2006-06-06 | 2007-12-07 | Negma Lerads Soc Par Actions S | PPAR ACTIVATOR DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC APPLICATION |
JP2009190971A (en) | 2006-06-06 | 2009-08-27 | Mitsubishi Tanabe Pharma Corp | 2-cyanopyrrolidine derivative |
TW200808695A (en) | 2006-06-08 | 2008-02-16 | Amgen Inc | Benzamide derivatives and uses related thereto |
US20070287674A1 (en) | 2006-06-08 | 2007-12-13 | Hej Research Institute Of Chemistry | New treatment of diabetes mellitus |
AU2007259143A1 (en) | 2006-06-08 | 2007-12-21 | Amgen Inc. | Benzamide derivatives and uses related thereto |
EP2035373B1 (en) | 2006-06-09 | 2011-05-04 | Action Pharma A/S | Phenyl pyrrole aminoguanidine derivatives |
US20080051387A1 (en) | 2006-06-09 | 2008-02-28 | Yuelian Xu | Tetrahydropyrido[3,4-d]pyrimidines and related analogues |
WO2008035359A2 (en) | 2006-06-12 | 2008-03-27 | Cadila Healthcare Limited | Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives |
WO2007146761A2 (en) | 2006-06-12 | 2007-12-21 | Neurogen Corporation | Diaryl pyrimidinones and related compounds |
WO2007144394A2 (en) | 2006-06-16 | 2007-12-21 | High Point Pharmaceuticals, Llc. | Pharmaceutical use of substituted piperidine carboxamides |
WO2007149865A2 (en) | 2006-06-19 | 2007-12-27 | University Of Utah Research Foundation | Methods and compositions related to inhibition of ceramide synthesis |
US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
JP2009541283A (en) | 2006-06-20 | 2009-11-26 | アストラゼネカ アクチボラグ | Remedy |
CN101472896A (en) | 2006-06-20 | 2009-07-01 | 阿斯利康(瑞典)有限公司 | Therapeutic agents |
WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
EP2044074A2 (en) | 2006-06-23 | 2009-04-08 | Incyte Corporation | Purinone derivatives as hm74a agonists |
WO2008001160A1 (en) | 2006-06-23 | 2008-01-03 | The Procter & Gamble Company | Melanin concentrating hormone antagonists |
DE602007010312D1 (en) | 2006-06-23 | 2010-12-16 | Incyte Corp | PURINONE DERIVATIVES AS HM74A AGONISTS |
DE102006028862A1 (en) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-amino-imidazo [1,2-a] pyridine |
US20070299062A1 (en) | 2006-06-26 | 2007-12-27 | The Procter & Gamble Company | Melanin concentrating hormone antagonists |
TW200811170A (en) | 2006-06-27 | 2008-03-01 | Sanofi Aventis | Urea derivatives of tropane, their preparation and their therapeutic application |
TW200811158A (en) | 2006-06-27 | 2008-03-01 | Sanofi Aventis | Piperidine or pyrrolidine urea derivatives, their preparation and their therapeutic application |
CN102731451B (en) | 2006-06-27 | 2015-07-29 | 武田药品工业株式会社 | Fused ring compound |
CN101096363B (en) | 2006-06-27 | 2011-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 2,4,5-three-substituted thiazole compound, preparation method, medicament composition and pharmacy use thereof |
TW200815417A (en) | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds II |
PL2040713T3 (en) | 2006-06-27 | 2014-11-28 | Intercept Pharmaceuticals Inc | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions |
TW200815418A (en) | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
US20080004281A1 (en) | 2006-06-28 | 2008-01-03 | Kalypsys, Inc. | Methods for the modulation of crp by the selective modulation of ppar delta |
CN101479249B (en) | 2006-06-29 | 2012-10-10 | 霍夫曼-拉罗奇有限公司 | Benzimidazole derivatives, method for the production thereof, their use as FXR agonists and pharmaceutical preparations containing the same |
EP2038269A1 (en) | 2006-06-29 | 2009-03-25 | Janssen Pharmaceutica N.V. | Substituted benzamide modulators of the histamine h3 receptor |
WO2008002817A1 (en) | 2006-06-29 | 2008-01-03 | Janssen Pharmaceutica N.V. | Butyl and butynyl benzyl amine compounds |
CN101511790A (en) | 2006-06-29 | 2009-08-19 | 詹森药业有限公司 | Substituted aminomethyl benzamide compounds |
JP2009542673A (en) | 2006-06-29 | 2009-12-03 | アリーナ ファーマシューティカルズ, インコーポレイテッド | Histamine H3-receptor modulator useful for the treatment of histamine H3-receptor related disorders |
CA2656089A1 (en) | 2006-06-29 | 2008-01-03 | Janssen Pharmaceutica N.V. | Substituted benzyl amine compounds |
US8115017B2 (en) | 2006-06-29 | 2012-02-14 | Taisho Pharmaceutical Co., Ltd | C-phenyl 1-thioglucitol compound |
US20080004325A1 (en) | 2006-06-29 | 2008-01-03 | Wyeth | PTP1B inhibitors |
GB0613196D0 (en) | 2006-07-03 | 2006-08-09 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
AR061793A1 (en) | 2006-07-05 | 2008-09-24 | Mitsubishi Tanabe Pharma Corp | PIRAZOLO COMPOUND [1,5-A] PYRIMIDINE AND PHARMACEUTICAL COMPOSITION |
CA2655692C (en) | 2006-07-05 | 2012-01-03 | F. Hoffmann-La Roche Ag | Alkyl-pyridazine derivatives as inhibitors of 11 beta hydroxysteroid dehydrogenase type 1(11b-hsd 1) |
DE102006031176A1 (en) | 2006-07-06 | 2008-01-10 | Bayer Healthcare Ag | Substituted benzoxepinoisoxazoles and their use |
US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
US7888504B2 (en) | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
TW200811140A (en) | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
EP2046753A2 (en) | 2006-07-06 | 2009-04-15 | Brystol-Myers Squibb Company | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
JP5194588B2 (en) | 2006-07-06 | 2013-05-08 | 大正製薬株式会社 | Diabetes preventive or therapeutic agent containing 1-thio-D-glucitol derivative as an active ingredient |
TW200811147A (en) | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
US20080009534A1 (en) | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US7795291B2 (en) | 2006-07-07 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method |
US7803799B2 (en) | 2006-07-07 | 2010-09-28 | National Health Research Institutes | Selenophene compounds |
CN101100458A (en) | 2006-07-07 | 2008-01-09 | 上海艾力斯医药科技有限公司 | Bibenzimidazole derivative with PPARgamma exciting agent activity and application thereof |
FR2903404B1 (en) | 2006-07-10 | 2008-08-22 | Servier Lab | NOVEL TETRACYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
CA2656875C (en) | 2006-07-11 | 2011-09-06 | Pfizer Inc. | Substituted n-bicyclicalkyl bicyclic carboxyamide compounds |
US7297710B1 (en) | 2006-07-12 | 2007-11-20 | Sanofi-Aventis | Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide, their preparation and their application in therapeutics |
WO2008008887A2 (en) | 2006-07-13 | 2008-01-17 | Smithkline Beecham Corporation | Gpr119 agonists for treating metabolic disorders |
CA2657078A1 (en) | 2006-07-13 | 2008-01-17 | High Point Pharmaceuticals, Llc | 11beta-hydroxysteroid dehydrogenase type 1 active compounds |
FR2903695B1 (en) | 2006-07-13 | 2008-10-24 | Merck Sante Soc Par Actions Si | USE OF AMPAP ACTIVATOR IMIDAZOLE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
EP1878721A1 (en) | 2006-07-13 | 2008-01-16 | Novo Nordisk A/S | 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors |
CN101489989A (en) | 2006-07-13 | 2009-07-22 | 协和发酵麒麟株式会社 | Pentadienamide derivatives |
CA2657787A1 (en) | 2006-07-14 | 2008-01-17 | Merck And Co., Inc. | 2-substituted proline bis-amide orexin receptor antagonists |
JP5372318B2 (en) | 2006-07-14 | 2013-12-18 | パナソニック株式会社 | Method for manufacturing electrochemical capacitor |
JP2009543785A (en) | 2006-07-14 | 2009-12-10 | メルク エンド カムパニー インコーポレーテッド | Cross-linked diazepan orexin receptor antagonist |
SI2049529T1 (en) | 2006-07-14 | 2010-11-30 | Merck Sharp & Dohme | Substituted diazepan orexin receptor antagonists |
WO2008008547A2 (en) | 2006-07-14 | 2008-01-17 | Ams Research Corporation | Balloon dilation for implantable prosthesis |
TWI332501B (en) | 2006-07-14 | 2010-11-01 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
CN101490077A (en) | 2006-07-17 | 2009-07-22 | 诺瓦提斯公司 | Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators |
WO2008010061A2 (en) | 2006-07-17 | 2008-01-24 | Glenmark Pharmaceuticals S.A. | 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation |
DE102006033140A1 (en) | 2006-07-18 | 2008-01-24 | Merck Patent Gmbh | Aminoindazolharnstoffderivate |
CA2659155A1 (en) | 2006-07-20 | 2008-01-24 | Amgen Inc. | Substituted azole aromatic heterocycles as inhibitors of 11.beta.-hsd-1 |
JP5042311B2 (en) | 2006-07-20 | 2012-10-03 | ノバルティス アーゲー | Aminopiperidine derivatives as CETP inhibitors |
GB2454615A (en) | 2006-07-21 | 2009-05-13 | Lupin Ltd | Antidiabetic azabicyclo (3.1.0) hexan compounds |
FR2903984B1 (en) | 2006-07-24 | 2008-10-03 | Genfit Sa | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES |
TWI418556B (en) | 2006-07-27 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | Indole derivatives |
TWI432446B (en) | 2006-07-27 | 2014-04-01 | Chugai Pharmaceutical Co Ltd | Fused ring spiroketal derivative and use thereof as anti-diabetic drug |
US20100022589A1 (en) | 2006-07-27 | 2010-01-28 | Mccoull William | Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase |
JP2008031064A (en) | 2006-07-27 | 2008-02-14 | Astellas Pharma Inc | Diacylpiperazine derivative |
EP2049548A1 (en) | 2006-07-27 | 2009-04-22 | UCB Pharma, S.A. | Fused oxazoles & thiazoles as histamine h3- receptor ligands |
TWI403516B (en) | 2006-07-27 | 2013-08-01 | Chugai Pharmaceutical Co Ltd | To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes |
US20080027014A1 (en) | 2006-07-28 | 2008-01-31 | Tanabe Seiyaku Co., Ltd. | Novel SGLT inhibitors |
FR2904316B1 (en) | 2006-07-31 | 2008-09-05 | Sanofi Aventis Sa | N- (AMINO-HETEROARYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE. |
WO2008016730A2 (en) | 2006-08-02 | 2008-02-07 | Targeted Molecular Diagnostics, Llc | Compositions and methods for reducing cellular fat |
KR20090034969A (en) | 2006-08-02 | 2009-04-08 | 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. | Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors |
WO2008016123A1 (en) | 2006-08-03 | 2008-02-07 | Takeda Pharmaceutical Company Limited | GSK-3β INHIBITOR |
US7514433B2 (en) | 2006-08-03 | 2009-04-07 | Hoffmann-La Roche Inc. | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives |
JP5270545B2 (en) | 2006-08-03 | 2013-08-21 | タフツ ユニバーシティー/トラスティーズ オブ タフツ カレッジ | Flushing-free niacin analogs and their use |
WO2008016175A1 (en) | 2006-08-03 | 2008-02-07 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator activated receptor |
EP2058309A4 (en) | 2006-08-04 | 2010-12-22 | Takeda Pharmaceutical | Fused heterocyclic compound |
TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
WO2008019309A1 (en) | 2006-08-04 | 2008-02-14 | Metabasis Therapeutics, Inc. | Novel inhibitors of fructose 1,6-bisphosphatase |
KR100826108B1 (en) | 2006-08-04 | 2008-04-29 | 한국화학연구원 | Furan-2-carboxylic acid?derivatives and process for the preparation thereof |
EP1887006A1 (en) | 2006-08-07 | 2008-02-13 | Krka | Polymorphic forms of rosiglitazone base |
JP5406716B2 (en) | 2006-08-07 | 2014-02-05 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | Indole compounds |
RU2009108280A (en) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Arylamino-arylalkyl-substituted imidazolidine-2,4-dione, methods for their preparation containing these compounds and their use |
WO2008017670A1 (en) | 2006-08-08 | 2008-02-14 | Boehringer Ingelheim International Gmbh | Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus |
CN103980151A (en) | 2006-08-09 | 2014-08-13 | 史密丝克莱恩比彻姆公司 | Novel compounds as antagonists or inverse agonists at opioid receptors |
JP2010500372A (en) | 2006-08-09 | 2010-01-07 | スミスクライン ビーチャム コーポレーション | Novel compounds as antagonists or inverse agonists for opioid receptors |
WO2008017852A1 (en) | 2006-08-11 | 2008-02-14 | Palatin Technologies, Inc. | Diamine-containing, tetra- substituted piperazine compounds as melanocortin receptor modulators |
US7750019B2 (en) | 2006-08-11 | 2010-07-06 | Kowa Company, Ltd. | Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same |
WO2008022015A2 (en) | 2006-08-11 | 2008-02-21 | Trustees Of Tufts College | Retro-inverso incretin analogues, and methods of use thereof |
TWI433839B (en) | 2006-08-11 | 2014-04-11 | Neomed Inst | New benzimidazole derivatives 290 |
JP5384343B2 (en) | 2006-08-15 | 2014-01-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and methods for their preparation |
BRPI0715893A2 (en) | 2006-08-15 | 2013-09-17 | Actelion Pharmaceuticals Ltd | azetidine compound and use for the preparation of a medicament for the prevention or treatment of dysthymic or sleep disorders |
JP5399244B2 (en) | 2006-08-17 | 2014-01-29 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー | DPP-IV resistant GIP hybrid polypeptide with selectable properties |
JP2009256208A (en) | 2006-08-17 | 2009-11-05 | Dainippon Sumitomo Pharma Co Ltd | Phthalide derivative or pharmaceutically acceptable salt of the same |
US20080045513A1 (en) | 2006-08-18 | 2008-02-21 | N.V. Organon | Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent |
US20090247499A1 (en) | 2006-08-21 | 2009-10-01 | Fletcher Joan M | Sulfonylated piperazines as cannabinoid-1 receptor modulators |
CA2661334C (en) | 2006-08-23 | 2011-11-29 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
WO2008023720A1 (en) | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | Urea compound or salt thereof |
ZA200901163B (en) | 2006-08-23 | 2010-08-25 | Neurogen Corp | 2-Phenoxy pyrimidinone analogues |
WO2008024433A2 (en) | 2006-08-23 | 2008-02-28 | Neurogen Corporation | Haloalkyl-substituted pyrimidinone derivatives |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
EP2064187A2 (en) | 2006-08-25 | 2009-06-03 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
CA2659352A1 (en) | 2006-08-28 | 2008-03-06 | Actelion Pharmaceuticals Ltd | 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives as orexin receptor antagonists |
EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
WO2008029217A2 (en) | 2006-08-29 | 2008-03-13 | Orchid Research Laboratories Limited | Dipeptidyl peptidase iv inhibitors |
EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
US20080103123A1 (en) | 2006-08-30 | 2008-05-01 | Biovitrum | New compounds |
JP5187901B2 (en) | 2006-08-30 | 2013-04-24 | 塩野義製薬株式会社 | Hydrazine amide derivatives |
CL2007002499A1 (en) | 2006-08-30 | 2008-03-14 | Phenomix Corp | SALES CITRATE AND TARTRATE OF COMPOUNDS DERIVED FROM PIRROLIDINILAMINOACETILPIRROLIDINBORONICO ACID, DPP-IV INHIBITORS; PREPARATION METHOD; SOLID FORM; PHARMACEUTICAL COMBINATION, USEFUL FOR THE TREATMENT OF DIABETES. |
US8088777B2 (en) | 2006-08-30 | 2012-01-03 | Shionogi & Co., Ltd. | Urea derivative |
AU2007290359B2 (en) | 2006-09-01 | 2012-09-20 | Vertex Pharmaceuticals Incorporated | 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase |
WO2008028188A2 (en) | 2006-09-01 | 2008-03-06 | The Ticket Reserve | Demand aggregation for future items contingent upon threshold demand |
US7470697B2 (en) | 2006-09-01 | 2008-12-30 | Adenosine Therapeutics, Llc | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors |
JP2010502702A (en) | 2006-09-05 | 2010-01-28 | シェーリング コーポレイション | Pharmaceutical composition for use in lipid management and therapeutic treatment of atherosclerosis and fatty liver |
JP2008063256A (en) | 2006-09-06 | 2008-03-21 | Astellas Pharma Inc | beta-AMINO ACID DERIVATIVE |
AU2007292816B2 (en) | 2006-09-07 | 2011-11-17 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
US20080096799A1 (en) | 2006-09-07 | 2008-04-24 | Forbes Medi-Tech (Research), Inc. | Compounds for and methods of treating insulin resistance and inflammation |
WO2008028662A1 (en) | 2006-09-07 | 2008-03-13 | Santhera Pharmaceuticals (Schweiz) Ag | N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide and related compounds as dpp-iv inhibitors for the treatment of type 2 diabetes mellitus |
US7714008B2 (en) | 2006-09-07 | 2010-05-11 | Amgen Inc. | Heterocyclic GPR40 modulators |
DE102006042143A1 (en) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Novel substituted bipyridine derivatives and their use |
WO2008032156A1 (en) | 2006-09-08 | 2008-03-20 | Pfizer Products Inc. | Diaryl ether derivatives and uses thereof |
AU2007293040A1 (en) | 2006-09-08 | 2008-03-13 | The Scripps Research Institute | Substituted oxazole ketone modulators of fatty acid amide hydrolase |
CA2663189A1 (en) | 2006-09-12 | 2008-03-20 | Pfizer Products Inc. | Benzimidazolone derivatives |
KR100886466B1 (en) | 2006-09-12 | 2009-03-04 | (주)한국씨엔에스팜 | New stigmasterol derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and composition comprising the same for inhibiting obesity or for preventing and treating hyperlipidemia |
WO2008033934A1 (en) | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Substituted heteroaryl carboxylic acid derivatives as ptb-1b inhibitors |
WO2008033455A2 (en) | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors |
WO2008033932A2 (en) | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors |
WO2008033931A1 (en) | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Para-xylylene carboxylic acids and isothiazolones useful as protein tyrosine phosphatases (ptps) in particular ptp-ib |
CA2663279C (en) | 2006-09-13 | 2016-05-17 | Takeda Pharmaceutical Company Limited | Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection |
US20100016274A1 (en) | 2006-09-14 | 2010-01-21 | Koppel Gary A | Beta-lactam cannabinoid receptor modulators |
US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
EP2069302B1 (en) | 2006-09-15 | 2010-08-25 | Pfizer Inc. | Substituted pyridylmethyl bicyclocarboxyamide compounds |
CN101528746A (en) | 2006-09-15 | 2009-09-09 | 先灵公司 | Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders |
EP2091534A1 (en) | 2006-09-15 | 2009-08-26 | Schering Corporation | Azetidinone derivatives and methods of use thereof |
WO2008033464A2 (en) | 2006-09-15 | 2008-03-20 | Schering Corporation | Azetidinone derivatives for the treatment of disorders of the lipid metabolism |
WO2008035356A2 (en) | 2006-09-20 | 2008-03-27 | Glenmark Pharmaceuticals Limited | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
WO2008036021A1 (en) | 2006-09-20 | 2008-03-27 | Astrazeneca Ab | Tetrahydro-lh-pyrido [3,4 -b] indole derivatives as cbl receptor ligands |
WO2008036022A1 (en) | 2006-09-20 | 2008-03-27 | Astrazeneca Ab | Tetrahydro-lh-pyrido[3,4-b] indole derivatives as cb1 receptor ligands |
WO2008036541A1 (en) | 2006-09-20 | 2008-03-27 | Eli Lilly And Company | Thiophene pyrazolopyrimidine compounds |
KR101088239B1 (en) | 2006-09-20 | 2011-11-30 | 일라이 릴리 앤드 캄파니 | Thiazole pyrazolopyrimidines as crf1 receptor antagonists |
US7858587B2 (en) | 2006-09-21 | 2010-12-28 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture |
EP2074141B1 (en) | 2006-09-22 | 2016-08-10 | Novo Nordisk A/S | Protease resistant insulin analogues |
CA2664245A1 (en) | 2006-09-27 | 2008-04-03 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor modulators |
TWI499414B (en) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | Inhibitors of sodium glucose co-transporter 2 and methods of their use |
WO2008039023A1 (en) | 2006-09-29 | 2008-04-03 | Green Cross Corporation | Heteroaryl-pyrazole derivatives as cannabinoid cb1 receptor antagonists |
KR20090077051A (en) | 2006-09-29 | 2009-07-14 | 액테리온 파마슈티칼 리미티드 | 3-aza-bicyclo[3.1.0]hexane derivatives |
WO2008037628A1 (en) | 2006-09-29 | 2008-04-03 | F. Hoffmann-La Roche Ag | Sulfonamide derivatives |
WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
TW200821284A (en) | 2006-10-03 | 2008-05-16 | Merck & Co Inc | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
BRPI0717845A2 (en) | 2006-10-04 | 2015-06-16 | Hoffmann La Roche | Use of compounds, pharmaceutical compositions and methods for the treatment and / or prophylaxis of diseases that can be treated with HDL-cholesterol elevating agents and compounds. |
PE20081152A1 (en) | 2006-10-06 | 2008-08-10 | Wyeth Corp | N-SUBSTITUTED AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS |
WO2008044656A1 (en) | 2006-10-06 | 2008-04-17 | Taisho Pharmaceutical Co., Ltd. | Imidazolidinone derivative |
GB0619860D0 (en) | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
AR063028A1 (en) | 2006-10-06 | 2008-12-23 | Banyu Pharma Co Ltd | HETEROCICLIC DERIVATIVES OF PIRIDIN-2-CARBOXAMIDE GLUCOKINASE ACTIVATORS, USEFUL FOR THE TREATMENT OF DIABETES AND OBESITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
WO2008040974A1 (en) | 2006-10-07 | 2008-04-10 | Peakdale Molecular Limited | Indoles for use as dpp-iv inhibitors |
US8022061B2 (en) | 2006-10-10 | 2011-09-20 | Amgen Inc. | N-aryl pyrazole compounds, compositions, and methods for their use |
EP1911747A1 (en) | 2006-10-11 | 2008-04-16 | Laboratorios del Dr. Esteve S.A. | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators |
WO2008044700A1 (en) | 2006-10-11 | 2008-04-17 | Takeda Pharmaceutical Company Limited | GSK-3β INHIBITOR |
WO2008046071A2 (en) | 2006-10-12 | 2008-04-17 | Transition Therapeutics Inc. | Compounds and methods of treating metabolic syndrome and inflammation |
US20080107725A1 (en) | 2006-10-13 | 2008-05-08 | Albano Antonio A | Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers |
WO2008044111A1 (en) | 2006-10-13 | 2008-04-17 | Pfizer Products Inc. | Pharmaceutical formulation tablet |
EP2072522A4 (en) | 2006-10-13 | 2010-01-06 | Chugai Pharmaceutical Co Ltd | Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes |
US7705005B2 (en) | 2006-10-13 | 2010-04-27 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
AU2007311178A1 (en) | 2006-10-16 | 2008-04-24 | Vidyo, Inc. | Systems and methods for signaling and performing temporal level switching in scalable video coding |
DE102006048728A1 (en) | 2006-10-16 | 2008-04-17 | Merck Patent Gmbh | 3-amino-imidazo {1,2-a] pyridine |
WO2008048648A2 (en) | 2006-10-17 | 2008-04-24 | Acadia Pharmaceuticals Inc. | Cb1-modulating compounds and their use |
TW200825054A (en) | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
CA2666489C (en) | 2006-10-19 | 2012-10-02 | F. Hoffmann-La Roche Ag | Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes |
US8410087B2 (en) | 2006-10-19 | 2013-04-02 | Takeda Pharmaceutical Company Limited | Indole compound |
JP2010506915A (en) | 2006-10-20 | 2010-03-04 | メルク エンド カムパニー インコーポレーテッド | Niacin receptor agonists, compositions comprising such compounds, and therapeutic methods |
TW200825072A (en) | 2006-10-20 | 2008-06-16 | Arete Therapeutics Inc | Soluble epoxide hydrolase inhibitors |
WO2008051875A2 (en) | 2006-10-20 | 2008-05-02 | Arete Therapeutics, Inc. | Adamantylurea compounds as soluble epoxide hydrolase inhibitors |
TW200825063A (en) | 2006-10-23 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
JP2010512305A (en) | 2006-10-23 | 2010-04-22 | ファイザー株式会社 | Substituted phenylmethylbicyclocarboxamide compounds |
KR100812538B1 (en) | 2006-10-23 | 2008-03-11 | 한올제약주식회사 | Controlled release complex formulation comprising metformin and glimepiride |
KR101387459B1 (en) | 2006-10-24 | 2014-05-14 | 얀센 파마슈티카 엔.브이. | Mtp inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives |
JO2653B1 (en) | 2006-10-24 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Piperidine Or Piperazine Substituted Tetrahydro-Naphthalene-1-Carboxylic Acid Mtp Inhibiting Compounds.apoB |
US20080103201A1 (en) | 2006-10-26 | 2008-05-01 | Wijayabandara Mirihanage Don J | Novel alpha-Glucosidase inhibitor from Tabernaemontana dichotoma |
SA07280576B1 (en) | 2006-10-26 | 2011-06-22 | استرازينيكا ايه بي | Benzoyl amino heterocyclyl compounds as glucokinase (GLK) activators |
CA2667550A1 (en) | 2006-10-27 | 2008-05-02 | Boehringer Ingelheim International Gmbh | Crystalline form of 4-(.beta.-d-glucopyranos-1-yl)-1-methyl-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
WO2008049711A1 (en) | 2006-10-27 | 2008-05-02 | Novo Nordisk A/S | Peptide extended insulins |
WO2008054674A2 (en) | 2006-10-31 | 2008-05-08 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
AU2007314405A1 (en) | 2006-10-31 | 2008-05-08 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
US7858645B2 (en) | 2006-11-01 | 2010-12-28 | Hoffmann-La Roche Inc. | Indazole derivatives |
US8067447B2 (en) | 2006-11-01 | 2011-11-29 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
JP2010508358A (en) | 2006-11-01 | 2010-03-18 | ブリストル−マイヤーズ スクイブ カンパニー | Glucocorticoid receptor, AP-1 and / or modulator of NF-κB activity, and use thereof |
CN101535238A (en) | 2006-11-01 | 2009-09-16 | 普罗诺瓦生物医药挪威公司 | Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR) |
EP2089355A2 (en) | 2006-11-01 | 2009-08-19 | Brystol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof |
ATE550337T1 (en) | 2006-11-01 | 2012-04-15 | Bristol Myers Squibb Co | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPA-B ACTIVITY AND THEIR USE |
WO2008057855A2 (en) | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | Heterocyclic compounds as modulators of glucocorticoid receptor, ap-i, and/or np-kappa-b activity |
EP1918281A1 (en) | 2006-11-02 | 2008-05-07 | Laboratorios del Dr. Esteve S.A. | Phenylamino-substituted piperidine compounds, their preparation and use as medicaments |
WO2008057336A2 (en) | 2006-11-02 | 2008-05-15 | Merck & Co., Inc. | Heterocyclyl-substituted anti-hypercholesterolemic compounds |
CN101535249A (en) | 2006-11-02 | 2009-09-16 | 塞诺菲-安万特德国有限公司 | Novel diphenylazetidinone substituted by piperazine-1-sulfonic acid having improved pharmacological properties |
EP2086965B1 (en) | 2006-11-02 | 2010-02-10 | Vertex Pharmaceuticals, Inc. | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
WO2008053446A2 (en) | 2006-11-02 | 2008-05-08 | Piramal Life Sciences Limited | Benzoxazepine compounds, their preparation and use |
TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
EP1918285A1 (en) | 2006-11-03 | 2008-05-07 | Merck Sante | Diazepane-acetamide derivatives as selective 11beta-HSD1 inhibitors |
AU2007315848A1 (en) | 2006-11-03 | 2008-05-08 | Glenmark Pharmaceuticals S.A. | Bridged bicyclic indazoles as cannabinoid receptor ligands |
EP2079753A1 (en) | 2006-11-06 | 2009-07-22 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
WO2008056377A2 (en) | 2006-11-06 | 2008-05-15 | Cadila Healthcare Limited | Polymorphic forms of rimonabant |
EP1921080B1 (en) | 2006-11-07 | 2009-08-05 | Sanofi-Aventis | Subsitituted 8-piperidinyl-2-pyridinyl-pyrimido(1,2-a)pyrimidin-6-one and 8-piperidinyl-2-pyrimidinyl-pyrimido(1,2-a)pyrimidin-6-one derivatives |
JP5337040B2 (en) | 2006-11-09 | 2013-11-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination therapy with SGLT-2 inhibitors and pharmaceutical compositions thereof |
JP2010043001A (en) | 2006-11-09 | 2010-02-25 | Sanwa Kagaku Kenkyusho Co Ltd | Glp-1 derivative and use thereof |
EP1921072A1 (en) | 2006-11-10 | 2008-05-14 | Laboratorios del Dr. Esteve S.A. | 1,2,3-Triazole derivatives as cannabinoid-receptor modulators |
GB0622569D0 (en) | 2006-11-11 | 2006-12-20 | 7Tm Pharma As | Cannabinoid receptor modulators |
JP2010509392A (en) | 2006-11-13 | 2010-03-25 | ファイザー・プロダクツ・インク | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof |
DE102006053637B4 (en) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Novel fluorine-substituted 1,4-benzothiepine-1,1-dioxide derivatives, pharmaceutical compositions containing them and their use |
DE102006053635B4 (en) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Novel benzyl-substituted 1,4-benzothiepine-1,1-dioxide derivatives, drugs containing these compounds and their use |
WO2008058631A1 (en) | 2006-11-14 | 2008-05-22 | Sanofi-Aventis Deutschland Gmbh | Novel 1,4-benzothiepin-1,1-dioxide derivatives with improved properties, method for producing the same, drugs containing said compounds and use thereof |
DE102006053636B4 (en) | 2006-11-14 | 2008-09-18 | Sanofi-Aventis Deutschland Gmbh | New cyclohexyl substituted 1,4-benzothiepine 1,1-dioxide derivatives and their use |
EP2086961A1 (en) | 2006-11-15 | 2009-08-12 | Novartis AG | Heterocyclic derivatives as cetp inhibitors |
BRPI0718809A2 (en) | 2006-11-15 | 2013-12-03 | Novartis Ag | ORGANIC COMPOUNDS |
US7964732B2 (en) | 2006-11-17 | 2011-06-21 | Pfizer Inc. | Substituted bicyclocarboxyamide compounds |
EP2111865B1 (en) | 2006-11-17 | 2019-10-02 | National University Corporation Kagawa University | Utilization of the function of rare sugar as promoter for the migration of glucokinase from nucleus to cytoplasm |
WO2008064107A2 (en) | 2006-11-20 | 2008-05-29 | Bristol-Myers Squibb Company | 7,8-dihydro-1,6-naphthyridin-5(6h)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase iv and methods |
WO2008061355A1 (en) | 2006-11-24 | 2008-05-29 | Matregen Corp. | Glp-1 depot systems, and methods of manufacture and uses thereof |
WO2008076243A2 (en) | 2006-12-14 | 2008-06-26 | Merck & Co., Inc. | Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment |
-
2007
- 2007-08-15 EP EP07291010A patent/EP2025674A1/en not_active Withdrawn
-
2008
- 2008-08-13 UY UY31288A patent/UY31288A1/en not_active Application Discontinuation
- 2008-08-13 TW TW097130748A patent/TW200930711A/en unknown
- 2008-08-13 PE PE2008001371A patent/PE20090986A1/en not_active Application Discontinuation
- 2008-08-13 AR ARP080103527A patent/AR068059A1/en unknown
- 2008-08-14 PA PA20088793401A patent/PA8793401A1/en unknown
- 2008-08-14 BR BRPI0815206 patent/BRPI0815206A2/en not_active Application Discontinuation
- 2008-08-14 WO PCT/EP2008/006700 patent/WO2009021740A2/en active Application Filing
- 2008-08-14 RU RU2010109416/04A patent/RU2010109416A/en not_active Application Discontinuation
- 2008-08-14 JP JP2010520492A patent/JP2010535827A/en active Pending
- 2008-08-14 MX MX2010001503A patent/MX2010001503A/en not_active Application Discontinuation
- 2008-08-14 AU AU2008286316A patent/AU2008286316A1/en not_active Abandoned
- 2008-08-14 KR KR1020107003293A patent/KR20100063700A/en not_active Application Discontinuation
- 2008-08-14 CA CA2695955A patent/CA2695955A1/en not_active Abandoned
- 2008-08-14 CL CL2008002414A patent/CL2008002414A1/en unknown
- 2008-08-14 CN CN200880103619A patent/CN101784536A/en active Pending
- 2008-08-14 EP EP08827286.9A patent/EP2188273B1/en active Active
-
2010
- 2010-01-22 ZA ZA201000520A patent/ZA201000520B/en unknown
- 2010-01-25 CR CR11235A patent/CR11235A/en not_active Application Discontinuation
- 2010-02-05 NI NI201000024A patent/NI201000024A/en unknown
- 2010-02-12 SV SV2010003480A patent/SV2010003480A/en unknown
- 2010-02-12 EC EC2010009967A patent/ECSP109967A/en unknown
- 2010-02-12 TN TNP2010000075A patent/TN2010000075A1/en unknown
- 2010-02-12 DO DO2010000059A patent/DOP2010000059A/en unknown
- 2010-02-12 US US12/705,140 patent/US8609731B2/en not_active Expired - Fee Related
- 2010-02-12 MA MA32620A patent/MA31611B1/en unknown
- 2010-02-15 CO CO10016564A patent/CO6331303A2/en not_active Application Discontinuation
-
2013
- 2013-12-03 US US14/094,976 patent/US20140088077A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7524882B2 (en) * | 2002-07-30 | 2009-04-28 | Merck & Co., Inc. | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017172505A1 (en) * | 2016-03-29 | 2017-10-05 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US10676458B2 (en) | 2016-03-29 | 2020-06-09 | Merch Sharp & Dohne Corp. Rahway | Antidiabetic bicyclic compounds |
Also Published As
Publication number | Publication date |
---|---|
TN2010000075A1 (en) | 2011-09-26 |
JP2010535827A (en) | 2010-11-25 |
TW200930711A (en) | 2009-07-16 |
CL2008002414A1 (en) | 2009-07-17 |
KR20100063700A (en) | 2010-06-11 |
ZA201000520B (en) | 2010-10-27 |
MA31611B1 (en) | 2010-08-02 |
AR068059A1 (en) | 2009-11-04 |
WO2009021740A2 (en) | 2009-02-19 |
EP2025674A1 (en) | 2009-02-18 |
CR11235A (en) | 2010-05-19 |
CN101784536A (en) | 2010-07-21 |
AU2008286316A1 (en) | 2009-02-19 |
MX2010001503A (en) | 2010-03-10 |
PE20090986A1 (en) | 2009-08-14 |
BRPI0815206A2 (en) | 2015-03-31 |
DOP2010000059A (en) | 2010-02-28 |
EP2188273A2 (en) | 2010-05-26 |
UY31288A1 (en) | 2009-03-31 |
US20100249097A1 (en) | 2010-09-30 |
WO2009021740A3 (en) | 2009-05-14 |
ECSP109967A (en) | 2010-03-31 |
EP2188273B1 (en) | 2014-10-22 |
CA2695955A1 (en) | 2009-02-19 |
SV2010003480A (en) | 2010-05-26 |
NI201000024A (en) | 2010-07-29 |
RU2010109416A (en) | 2011-09-20 |
US8609731B2 (en) | 2013-12-17 |
CO6331303A2 (en) | 2011-10-20 |
PA8793401A1 (en) | 2009-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8530413B2 (en) | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments | |
US9156796B2 (en) | Benzoimidazole-carboxylic acid amide derivatives as APJ receptor modulators | |
US8822495B2 (en) | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | |
US8648038B2 (en) | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments | |
US8841290B2 (en) | Substituted tetrahydronaphthalenes, method for the production thereof, and use thereof as drugs | |
US8859494B2 (en) | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament | |
US8501771B2 (en) | Aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | |
US20110059910A1 (en) | Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof | |
US8933024B2 (en) | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases | |
US20140088077A1 (en) | Novel substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments | |
JP2011503127A (en) | Novel crystalline diphenylazetidinone hydrates, drugs containing these compounds and their use | |
US8552199B2 (en) | Substituted indanes, method for the production thereof, and use thereof as drugs | |
US8809324B2 (en) | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof | |
US8901114B2 (en) | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof | |
US8828995B2 (en) | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof | |
US8809325B2 (en) | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SANOFI, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHWINK, LOTHAR;STENGELIN, SIEGFRIED;GOSSEL, MATTHIAS;AND OTHERS;SIGNING DATES FROM 20131114 TO 20131115;REEL/FRAME:031704/0005 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |